Annual Research Report

For the fiscal year ended
June 30, 2005
Medical University of South Carolina  
Office of Research and Sponsored Programs

Summary of Grant and Contract Activity  
July 2004 – June 2005

<table>
<thead>
<tr>
<th>Source</th>
<th>Number</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal</td>
<td>503</td>
<td>$150,848,907</td>
</tr>
<tr>
<td>Federal Direct</td>
<td>384</td>
<td>$136,197,225</td>
</tr>
<tr>
<td>Federal Flow-Down</td>
<td>119</td>
<td>$14,651,682</td>
</tr>
<tr>
<td>Corporate</td>
<td>304</td>
<td>$19,950,018</td>
</tr>
<tr>
<td>Foundation</td>
<td>70</td>
<td>$5,794,554</td>
</tr>
<tr>
<td>State of South Carolina</td>
<td>45</td>
<td>$3,225,225</td>
</tr>
<tr>
<td>Other Support</td>
<td>19</td>
<td>$799,063</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>941</td>
<td><strong>$180,617,767</strong></td>
</tr>
</tbody>
</table>
Executive Summary

For the 2005 fiscal year, 526 faculty members submitted 1,288 grant applications to 323 different agencies and were awarded 941 awards for $180.6 million. While the number of awards decreased by 2, MUSC eked out a $5.5 million increase. This is a 3.2% increase over last fiscal year. This gain is consistent with the 3.1% research and development budget increase granted to NIH.

During the last five years, MUSC has targeted federal funding agencies for extramural research support. In FY2000, 487 federal applications comprised 47% of the 1,042 total applications submitted. In FY2005, 1,288 applications were submitted and 702 were federal (55%).

Chart 1 - Ten Year Summary

The report format has been amended to capture and identify federal flow-down dollars which must be included in the University’s Schedule of Federal Financial Assistance reports. The majority of these funds were transferred from the Other Support category, consisting of sub-contracts from other universities. Now Other Support represents mainly awards from universities and other agencies whose primary support is nonfederal.

Direct Federal funding increased by 3%. With the revised format, which identifies federal flow-down dollars, overall federal support is $150.8 million. MUSC attracted a more diversified federal portfolio with increased funding from CDC, HRSA, and Department of Education. Federal funds now constitute 84% of MUSC’s extramural research base.
Although the number of NIH awards increased by 3, the dollar level declined by $2 million. MUSC gained 1 R01 grant, 3 fellowships and 2 cooperative agreements, but these awards did not fill the void left by the completion of 2 construction grants and the loss of a program grant.

Table 1 - NIH Funding by Activity Type

<table>
<thead>
<tr>
<th>NIH Awards</th>
<th>Number</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>224</td>
<td>$52,647,609</td>
</tr>
<tr>
<td>Program Projects &amp; Centers</td>
<td>20</td>
<td>$24,454,893</td>
</tr>
<tr>
<td>Training</td>
<td>12</td>
<td>$2,739,393</td>
</tr>
<tr>
<td>Fellowships</td>
<td>11</td>
<td>$368,380</td>
</tr>
<tr>
<td>Cooperative Agreements</td>
<td>13</td>
<td>$5,012,051</td>
</tr>
<tr>
<td>Construction</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Contracts, Agreements &amp; Other</td>
<td>8</td>
<td>$2,875,882</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>$88,098,208</strong></td>
</tr>
</tbody>
</table>

NIH now comprises 48.8% of university research and 53% of all federal research. On a positive note, MUSC made modest to significant gains from the National Cancer Institute (NCI) and the Institutes of Mental Health (NIMH), Dental and Craniofacial Research (NIDCR), and Child Health and Human Development (NICHD).

Chart 2 - NIH funding by Institute
Chart 3 - Federal Funding by Agency

Federal Funding by Agency

- NIH 52.60%
- BHP 20.76%
- VAMC 1.56%
- SAMHSA 0.60%
- AHCPR 1.92%
- DOD 1.97%

Other agencies

- PHS 0.37%
- DOE 0.36%
- NSF 0.25%
- US Army 0.22%
- NASA 0.22%
- Commerce 0.21%
- FDA 0.20%
- NOAA 0.16%
- NNLM 0.08%
- Justice 0.06%
- ONR 0.05%
- Park Service 0.02%
- EPA 0.02%
- Interior 0.01%

Chart 3 - Federal Funding by Agency

Annual Report for Research FY2005
Nonfederal sources of support are all on the decrease as MUSC focuses on federal mission agencies. Some of the decreases are a result of fewer applications as is case with Foundations. The number of corporate applications increased but the market conditions are in a decline the second half of the year. State funding remained stable in number of applications but amounts of awards decreased over 25%.

The national trend for corporate clinical research and clinical trials was down 10% and funding down 11%. MUSC did not fare as well. The number of awards increased from 291 to 304 but sustained a decline of 13% in support from $23 million to $20 million. The average size of each grant has declined from $80,000 to under $66,000. Corporate clinical research and clinical trials peaked at $26.4 million in 2000.

**FY05 Funding by Source**

![Pie chart showing funding sources]

Chart 4 - Funding Pie Chart

For the third straight year private foundation grants declined both in number and dollars. There were 143 grant submissions, three less than the previous year. The number of awards dropped 34% from 106 to 70 and funding declined 32% from $8.5 to $5.8M.

State agencies awarded 45 grants, one less than FY04 and the amount of the awards decreased 26.5% from $4.4M to $3.2M. DHEC constitutes 16 awards (36%) and $1.8M (56%) of State awards.
# Summary of Agency Support by Fund Source

## Corporate

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Labs</td>
<td>2</td>
<td>13,000</td>
<td>15,500</td>
<td>Forest Labs, Inc.</td>
<td>3</td>
<td>25,109</td>
<td>29,511</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals</td>
<td>3</td>
<td>21,314</td>
<td>26,642</td>
<td>Forest Research Institute</td>
<td>2</td>
<td>130,696</td>
<td>163,370</td>
</tr>
<tr>
<td>Aderis Pharmaceuticals</td>
<td>1</td>
<td>35,159</td>
<td>51,332</td>
<td>Fujisawa Healthcare, Inc.</td>
<td>2</td>
<td>12,800</td>
<td>16,000</td>
</tr>
<tr>
<td>Advanced Medical Optics, Inc.</td>
<td>2</td>
<td>70,952</td>
<td>88,690</td>
<td>Galen Holdings PLC</td>
<td>1</td>
<td>22,916</td>
<td>28,645</td>
</tr>
<tr>
<td>Aga Medical Corp.</td>
<td>2</td>
<td>81,435</td>
<td>101,794</td>
<td>Genentech, Inc.</td>
<td>5</td>
<td>271,557</td>
<td>339,334</td>
</tr>
<tr>
<td>Alcon, Inc.</td>
<td>4</td>
<td>146,159</td>
<td>182,699</td>
<td>General Electric</td>
<td>1</td>
<td>117,657</td>
<td>147,071</td>
</tr>
<tr>
<td>Amgen</td>
<td>5</td>
<td>288,220</td>
<td>346,507</td>
<td>Genentronics, Inc.</td>
<td>2</td>
<td>165,202</td>
<td>206,502</td>
</tr>
<tr>
<td>Amylin Pharmaceuticals</td>
<td>2</td>
<td>72,420</td>
<td>90,525</td>
<td>Genphar, Inc.</td>
<td>1</td>
<td>34,934</td>
<td>51,004</td>
</tr>
<tr>
<td>Argolyn Bioscience, Inc.</td>
<td>1</td>
<td>21,740</td>
<td>25,000</td>
<td>Gilead Sciences, Inc.</td>
<td>1</td>
<td>12,000</td>
<td>12,000</td>
</tr>
<tr>
<td>Aspreva Pharmaceuticals Corp.</td>
<td>1</td>
<td>15,500</td>
<td>19,375</td>
<td>GlaxoSmithKline</td>
<td>9</td>
<td>756,410</td>
<td>941,920</td>
</tr>
<tr>
<td>Astellas Pharma US, Inc.</td>
<td>1</td>
<td>434,640</td>
<td>543,300</td>
<td>Glenveigh Research, LLC</td>
<td>1</td>
<td>32,000</td>
<td>40,000</td>
</tr>
<tr>
<td>Astra Pharmaceuticals, L.P.</td>
<td>1</td>
<td>53,234</td>
<td>65,478</td>
<td>Guidant</td>
<td>6</td>
<td>146,320</td>
<td>182,900</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>7</td>
<td>340,140</td>
<td>424,110</td>
<td>Hoffman-Laroche, Inc.</td>
<td>1</td>
<td>89,000</td>
<td>111,250</td>
</tr>
<tr>
<td>Auris Medical AG</td>
<td>1</td>
<td>9,007</td>
<td>11,259</td>
<td>Hovmedica, Inc.</td>
<td>1</td>
<td>4,802</td>
<td>7,010</td>
</tr>
<tr>
<td>Aventis Pharmaceutical, Inc.</td>
<td>3</td>
<td>162,800</td>
<td>202,250</td>
<td>INC Research, Inc.</td>
<td>1</td>
<td>51,123</td>
<td>63,900</td>
</tr>
<tr>
<td>Avicena</td>
<td>1</td>
<td>49,150</td>
<td>61,929</td>
<td>Icon Clinical Research, Inc.</td>
<td>4</td>
<td>172,693</td>
<td>214,966</td>
</tr>
<tr>
<td>Axonyx USA</td>
<td>1</td>
<td>408,630</td>
<td>562,100</td>
<td>Ingenerx Therapeutics</td>
<td>1</td>
<td>39,023</td>
<td>48,779</td>
</tr>
<tr>
<td>Bayer Pharmaceuticals</td>
<td>1</td>
<td>19,626</td>
<td>24,532</td>
<td>Ino Therapeutics, Inc.</td>
<td>1</td>
<td>62,584</td>
<td>78,230</td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td>1</td>
<td>44,000</td>
<td>50,000</td>
<td>Intermune, Inc.</td>
<td>1</td>
<td>94,053</td>
<td>117,566</td>
</tr>
<tr>
<td>Berlex Laboratories</td>
<td>2</td>
<td>215,850</td>
<td>269,812</td>
<td>Janssen Pharmaceutica</td>
<td>5</td>
<td>120,446</td>
<td>153,330</td>
</tr>
<tr>
<td>Biomet, Inc.</td>
<td>1</td>
<td>25,531</td>
<td>37,183</td>
<td>Johnson and Johnson</td>
<td>1</td>
<td>67,525</td>
<td>74,575</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>1</td>
<td>133,120</td>
<td>166,400</td>
<td>Knoll Pharmaceutical</td>
<td>1</td>
<td>3,577</td>
<td>4,400</td>
</tr>
<tr>
<td>Boston Scientific Corp.</td>
<td>2</td>
<td>167,496</td>
<td>201,500</td>
<td>Kyowa Pharmaceuticals</td>
<td>1</td>
<td>27,000</td>
<td>33,750</td>
</tr>
<tr>
<td>Bracco Diagnostics, Inc.</td>
<td>1</td>
<td>101,600</td>
<td>127,000</td>
<td>Lexogen, Inc.</td>
<td>1</td>
<td>175,389</td>
<td>192,928</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>2</td>
<td>55,000</td>
<td>68,750</td>
<td>Lilly Research Laboratories</td>
<td>1</td>
<td>6,940</td>
<td>8,675</td>
</tr>
<tr>
<td>CV Therapeutics, Inc.</td>
<td>1</td>
<td>164,694</td>
<td>222,050</td>
<td>Lineberry Research Associates</td>
<td>1</td>
<td>6,200</td>
<td>7,750</td>
</tr>
<tr>
<td>CardioMEMS, Inc.</td>
<td>1</td>
<td>20,116</td>
<td>25,145</td>
<td>Lupus Clinical Trials Consortium</td>
<td>1</td>
<td>100,000</td>
<td>100,000</td>
</tr>
<tr>
<td>Cardiovascular Clinical Studies</td>
<td>3</td>
<td>35,972</td>
<td>44,965</td>
<td>MDC Research Associates</td>
<td>1</td>
<td>100,000</td>
<td>100,000</td>
</tr>
<tr>
<td>Carolinas Healthcare</td>
<td>1</td>
<td>7,969</td>
<td>12,019</td>
<td>MST Group, LLC</td>
<td>4</td>
<td>138,159</td>
<td>172,789</td>
</tr>
<tr>
<td>Celgene Corp.</td>
<td>1</td>
<td>56</td>
<td>70</td>
<td>MUSC Hospital Authority</td>
<td>1</td>
<td>100,000</td>
<td>100,000</td>
</tr>
<tr>
<td>Cell Factor Technologies</td>
<td>1</td>
<td>13,927</td>
<td>20,333</td>
<td>Marine Polymer Technologies</td>
<td>1</td>
<td>530</td>
<td>773</td>
</tr>
<tr>
<td>Cell Therapeutics, Inc.</td>
<td>1</td>
<td>194,219</td>
<td>242,774</td>
<td>Mary Kirkland Ctr. For Lupus Res.</td>
<td>1</td>
<td>60,000</td>
<td>60,000</td>
</tr>
<tr>
<td>CellzDirect, Inc.</td>
<td>1</td>
<td>50,000</td>
<td>62,500</td>
<td>Medi-Physics</td>
<td>1</td>
<td>86,020</td>
<td>107,525</td>
</tr>
<tr>
<td>Centocor, Inc.</td>
<td>1</td>
<td>48,280</td>
<td>60,350</td>
<td>Medimmune, Inc.</td>
<td>2</td>
<td>177,180</td>
<td>221,475</td>
</tr>
<tr>
<td>Cephalon, Inc.</td>
<td>2</td>
<td>96,641</td>
<td>120,802</td>
<td>Medrad, Inc.</td>
<td>1</td>
<td>24,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Cepheid</td>
<td>1</td>
<td>7,500</td>
<td>7,500</td>
<td>Medtronic, Inc.</td>
<td>6</td>
<td>183,572</td>
<td>213,725</td>
</tr>
<tr>
<td>Chiron, Inc.</td>
<td>2</td>
<td>32,634</td>
<td>40,793</td>
<td>Merck</td>
<td>5</td>
<td>634,626</td>
<td>764,346</td>
</tr>
<tr>
<td>Codman and Shurtleff, Inc.</td>
<td>1</td>
<td>7,200</td>
<td>9,000</td>
<td>Microvia, Inc.</td>
<td>1</td>
<td>15,222</td>
<td>19,028</td>
</tr>
<tr>
<td>Coram Healthcare, Inc.</td>
<td>1</td>
<td>9,206</td>
<td>11,508</td>
<td>Millennium Pharmaceuticals</td>
<td>3</td>
<td>306,573</td>
<td>383,216</td>
</tr>
<tr>
<td>Conixa Corp.</td>
<td>1</td>
<td>4,480</td>
<td>5,600</td>
<td>Myogen, Inc.</td>
<td>1</td>
<td>400</td>
<td>500</td>
</tr>
<tr>
<td>Corus Pharma</td>
<td>1</td>
<td>41,416</td>
<td>51,770</td>
<td>NMT Medical, Inc.</td>
<td>1</td>
<td>5,200</td>
<td>6,500</td>
</tr>
<tr>
<td>Covance, Inc.</td>
<td>1</td>
<td>3,150</td>
<td>3,937</td>
<td>Neogenix Oncology, Inc.</td>
<td>1</td>
<td>85,000</td>
<td>124,100</td>
</tr>
<tr>
<td>CureSource, Inc.</td>
<td>1</td>
<td>9,600</td>
<td>12,000</td>
<td>Neurochem, Inc.</td>
<td>1</td>
<td>193,514</td>
<td>241,892</td>
</tr>
<tr>
<td>Cyberonics, Inc.</td>
<td>3</td>
<td>20,268</td>
<td>24,930</td>
<td>Novartis Corp.</td>
<td>11</td>
<td>596,344</td>
<td>745,429</td>
</tr>
<tr>
<td>Dialysis Clinics, Inc.</td>
<td>7</td>
<td>669,260</td>
<td>669,260</td>
<td>Novo Nordisk Pharmaceuticals</td>
<td>1</td>
<td>26,779</td>
<td>33,474</td>
</tr>
<tr>
<td>Digene Corp.</td>
<td>6</td>
<td>123,828</td>
<td>154,954</td>
<td>Omni Care</td>
<td>2</td>
<td>293,533</td>
<td>366,916</td>
</tr>
<tr>
<td>Duramed Research, Inc.</td>
<td>1</td>
<td>70,700</td>
<td>88,375</td>
<td>Ono Pharmaceutical</td>
<td>1</td>
<td>8,242</td>
<td>10,303</td>
</tr>
<tr>
<td>Ekos Corp.</td>
<td>1</td>
<td>27,681</td>
<td>34,878</td>
<td>Ophthalmic Research Assoc.</td>
<td>1</td>
<td>30,000</td>
<td>37,500</td>
</tr>
<tr>
<td>Elan Pharmaceuticals</td>
<td>2</td>
<td>56,256</td>
<td>70,320</td>
<td>Orexigen Therapeutics</td>
<td>1</td>
<td>162,841</td>
<td>203,551</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>6</td>
<td>337,923</td>
<td>420,154</td>
<td>Organ Recovery Systems</td>
<td>1</td>
<td>1,888</td>
<td>2,756</td>
</tr>
<tr>
<td>Exet Corp.</td>
<td>2</td>
<td>71,958</td>
<td>105,059</td>
<td>Orijis Medical</td>
<td>1</td>
<td>55,600</td>
<td>69,500</td>
</tr>
</tbody>
</table>

Annual Report for Research FY2005
### Summary

| Ortho Biotech | 2 | 10,498 | 10,622 | Schering-Plough Corp. | 2 | 88,200 | 110,250 |
| Otsuka Medical Research Inst. | 1 | 20,896 | 26,120 | Scios, Inc. | 1 | 42,056 | 52,570 |
| PPD Development | 10 | 384,895 | 481,119 | Seahorse Biosciences, Inc. | 1 | 46,599 | 68,034 |
| Parexel Intl. Corp. | 1 | 194,330 | 242,913 | Serono Laboratories | 2 | 19,900 | 24,000 |
| Perlegen Sciences, Inc. | 1 | 8,000 | 10,000 | Shire Pharmaceutical Development | 1 | 3,000 | 3,000 |
| Pfizer, Inc. | 4 | 234,470 | 257,713 | Shrimp Improvement Systems | 1 | 8,580 | 8,580 |
| Pharma Link FHI, Inc. | 1 | 35,956 | 44,945 | Siements Medical Solutions USA | 2 | 204,966 | 225,000 |
| Pharmaceutical Research Assoc. | 1 | 63,742 | 79,678 | St. Jude Medical, Inc. | 9 | 135,760 | 169,700 |
| Pharmacia Upjohn | 1 | 1,382 | 1,700 | Stereotaxis, Inc. | 2 | 91,600 | 114,500 |
| Pharmanet | 1 | 159,340 | 200,768 | Striker Orthopeadics | 1 | 23,568 | 34,409 |
| Predix Pharmaceuticals, Inc. | 2 | 156,780 | 209,199 | Tercica, Inc. | 1 | 34,008 | 42,510 |
| Presutti Laboratories | 1 | 36,100 | 45,125 | Trine Pharmaceuticals | 1 | 28,732 | 35,915 |
| Procter and Gamble | 2 | 6,191 | 6,548 | UCB Secteur Pharmacetique | 3 | 126,929 | 158,662 |
| Q-Med AB | 1 | 82,039 | 102,549 | Ventana Medical Systems | 1 | 8,714 | 10,892 |
| Quidel Corp. | 2 | 33,950 | 42,438 | Vitatron | 2 | 6,460 | 8,075 |
| Quintiles Pacific, Inc. | 6 | 432,552 | 539,668 | Voyager Pharmaceutical Corp. | 1 | 9,902 | 12,377 |
| Roche Laboratories | 5 | 220,572 | 275,716 | World Medical Manufacturing | 2 | 7,683 | 9,450 |
| Rockey Biomed, Inc. | 1 | 21,080 | 26,350 | Wyeth, Inc. | 3 | 550,896 | 688,620 |
| SCIL Technology | 1 | 359 | 525 | Wyeth-Ayerst | 2 | 141,200 | 176,500 |
| SFBC Intl. | 1 | 17,920 | 22,400 | Z-Tech Corporation | 2 | 111,212 | 139,015 |
| Sangstat Medical Corp. | 1 | 2,000 | 2,500 | **Corporate** | 304 | 16,175,237 | 19,950,018 |
| Sanofi Research | 1 | 24,800 | 31,000 | | | | |
| Sanofi Synthelabo, Inc. | 7 | 908,739 | 1,135,926 | | | | |

#### Federal

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIAAA</td>
<td>19</td>
<td>4,643,645</td>
<td>6,363,853</td>
</tr>
<tr>
<td>NIH/NAID</td>
<td>4</td>
<td>814,299</td>
<td>1,148,697</td>
</tr>
<tr>
<td>NIH/NIAMs</td>
<td>11</td>
<td>2,087,167</td>
<td>2,725,544</td>
</tr>
<tr>
<td>NIH/NICHD</td>
<td>8</td>
<td>2,357,361</td>
<td>3,067,486</td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>31</td>
<td>7,144,294</td>
<td>9,580,633</td>
</tr>
<tr>
<td>NIH/NIDCD</td>
<td>5</td>
<td>1,719,689</td>
<td>2,426,564</td>
</tr>
<tr>
<td>NIH/NIDCR</td>
<td>9</td>
<td>1,868,598</td>
<td>2,626,193</td>
</tr>
<tr>
<td>NIH/NIDDK</td>
<td>23</td>
<td>3,314,920</td>
<td>4,369,299</td>
</tr>
<tr>
<td>NIH/NIEHS</td>
<td>6</td>
<td>646,703</td>
<td>849,858</td>
</tr>
<tr>
<td>NIH/NIGMS</td>
<td>12</td>
<td>1,933,567</td>
<td>2,589,923</td>
</tr>
<tr>
<td>NIH/NIMH</td>
<td>23</td>
<td>4,352,081</td>
<td>5,626,702</td>
</tr>
<tr>
<td>NIH/NINDS</td>
<td>21</td>
<td>3,272,611</td>
<td>4,668,623</td>
</tr>
<tr>
<td>NIH/NINLM</td>
<td>1</td>
<td>456,789</td>
<td>490,967</td>
</tr>
<tr>
<td>USDA</td>
<td>4</td>
<td>216,862</td>
<td>274,306</td>
</tr>
<tr>
<td>National Library of Medicine</td>
<td>3</td>
<td>129,335</td>
<td>139,682</td>
</tr>
<tr>
<td>National Park Service</td>
<td>1</td>
<td>34,777</td>
<td>40,043</td>
</tr>
<tr>
<td>NIST</td>
<td>2</td>
<td>15,702,684</td>
<td>15,702,684</td>
</tr>
<tr>
<td>SAMHSA/CMHS</td>
<td>1</td>
<td>482,141</td>
<td>599,909</td>
</tr>
<tr>
<td>SAMHSA/CSAT</td>
<td>1</td>
<td>273,972</td>
<td>400,000</td>
</tr>
<tr>
<td>USDA</td>
<td>4</td>
<td>634,157</td>
<td>766,976</td>
</tr>
<tr>
<td>VAMC</td>
<td>20</td>
<td>2,606,666</td>
<td>2,606,666</td>
</tr>
<tr>
<td><strong>Federal</strong></td>
<td>384</td>
<td>108,984,862</td>
<td>136,197,225</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIA</td>
<td>10</td>
<td>2,095,760</td>
<td>2,765,350</td>
</tr>
</tbody>
</table>

---

**Federal (48 Agencies)**
### Federal Flow-Down

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAMC</td>
<td>2</td>
<td>602,221</td>
<td>835,019</td>
<td>SCUREF</td>
<td>8</td>
<td>2,311,263</td>
<td>2,398,016</td>
</tr>
<tr>
<td>Advanced Cochlear Systems</td>
<td>1</td>
<td>33,737</td>
<td>49,256</td>
<td>Scripps Research Inst.</td>
<td>1</td>
<td>45,205</td>
<td>66,000</td>
</tr>
<tr>
<td>Ambulatory Pediatric Assoc.</td>
<td>1</td>
<td>67,123</td>
<td>77,191</td>
<td>Tennessee State Univ.</td>
<td>1</td>
<td>47,619</td>
<td>60,000</td>
</tr>
<tr>
<td>Amer. Medical Assoc.</td>
<td>1</td>
<td>170,475</td>
<td>188,856</td>
<td>ThinkFirst Foundation</td>
<td>1</td>
<td>21,061</td>
<td>21,061</td>
</tr>
<tr>
<td>Assoc. Teachers of Prev. Med.</td>
<td>1</td>
<td>314,432</td>
<td>383,903</td>
<td>Univ. of Alabama</td>
<td>1</td>
<td>85,600</td>
<td>85,600</td>
</tr>
<tr>
<td>Audiology, Inc.</td>
<td>1</td>
<td>57,082</td>
<td>83,340</td>
<td>Univ. of Alabama, Birmingham</td>
<td>1</td>
<td>21,843</td>
<td>31,235</td>
</tr>
<tr>
<td>Benaroya Research Inst.</td>
<td>2</td>
<td>93,377</td>
<td>136,330</td>
<td>Univ. of California</td>
<td>1</td>
<td>51,276</td>
<td>59,133</td>
</tr>
<tr>
<td>Boston Univ.</td>
<td>1</td>
<td>20,863</td>
<td>22,532</td>
<td>Univ. of Cincinnati</td>
<td>1</td>
<td>21,904</td>
<td>31,980</td>
</tr>
<tr>
<td>COG</td>
<td>1</td>
<td>21,462</td>
<td>25,754</td>
<td>Univ. of Colorado</td>
<td>2</td>
<td>58,338</td>
<td>75,174</td>
</tr>
<tr>
<td>Children's Hosp. Medical Center</td>
<td>1</td>
<td>75,475</td>
<td>110,193</td>
<td>Univ. of Connecticut</td>
<td>1</td>
<td>8,406</td>
<td>12,273</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>1</td>
<td>5,101</td>
<td>5,611</td>
<td>Univ. of Florida</td>
<td>1</td>
<td>41,750</td>
<td>60,955</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>5</td>
<td>153,684</td>
<td>206,700</td>
<td>Univ. of Georgia</td>
<td>1</td>
<td>47,945</td>
<td>70,000</td>
</tr>
<tr>
<td>Emory Univ.</td>
<td>2</td>
<td>123,394</td>
<td>180,155</td>
<td>Univ. of Illinois, Chicago</td>
<td>1</td>
<td>18,374</td>
<td>26,826</td>
</tr>
<tr>
<td>General Electric</td>
<td>1</td>
<td>298,301</td>
<td>430,000</td>
<td>Univ. of Indiana</td>
<td>2</td>
<td>50,000</td>
<td>73,000</td>
</tr>
<tr>
<td>Geo-Centers, Inc.</td>
<td>2</td>
<td>2,294,945</td>
<td>2,906,195</td>
<td>Univ. of Maryland</td>
<td>2</td>
<td>47,188</td>
<td>49,963</td>
</tr>
<tr>
<td>Greenwood Genetic Center</td>
<td>4</td>
<td>145,798</td>
<td>195,225</td>
<td>Univ. of Miami</td>
<td>2</td>
<td>71,222</td>
<td>104,684</td>
</tr>
<tr>
<td>Jordon and Howard Tech.</td>
<td>2</td>
<td>45,286</td>
<td>49,815</td>
<td>Univ. of North Carolina</td>
<td>6</td>
<td>374,086</td>
<td>534,234</td>
</tr>
<tr>
<td>Life Point</td>
<td>1</td>
<td>155,603</td>
<td>227,180</td>
<td>Univ. of Oklahoma</td>
<td>1</td>
<td>8,102</td>
<td>11,292</td>
</tr>
<tr>
<td>Lowcountry Childrens Center</td>
<td>1</td>
<td>30,000</td>
<td>30,000</td>
<td>Univ. of Pennsylvania</td>
<td>1</td>
<td>8,855</td>
<td>12,663</td>
</tr>
<tr>
<td>Mass. Inst. of Technology</td>
<td>2</td>
<td>13,698</td>
<td>20,000</td>
<td>Univ. of Pittsburgh</td>
<td>4</td>
<td>156,530</td>
<td>226,142</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>3</td>
<td>172,117</td>
<td>251,291</td>
<td>Univ. of South Alabama</td>
<td>1</td>
<td>35,195</td>
<td>51,385</td>
</tr>
<tr>
<td>Medical Coll. of Georgia</td>
<td>2</td>
<td>71,300</td>
<td>101,959</td>
<td>Univ. of South Carolina</td>
<td>7</td>
<td>408,830</td>
<td>565,626</td>
</tr>
<tr>
<td>NSABP</td>
<td>2</td>
<td>10,588</td>
<td>11,270</td>
<td>Univ. of South Florida</td>
<td>1</td>
<td>113,879</td>
<td>162,847</td>
</tr>
<tr>
<td>New Jersey Medical School</td>
<td>3</td>
<td>166,438</td>
<td>242,999</td>
<td>Univ. of Southern California</td>
<td>1</td>
<td>8,219</td>
<td>12,000</td>
</tr>
<tr>
<td>Organ Recovery Systems</td>
<td>4</td>
<td>166,458</td>
<td>241,447</td>
<td>Univ. of Tennessee</td>
<td>4</td>
<td>114,211</td>
<td>164,092</td>
</tr>
<tr>
<td>Physician Micro Systems, Inc.</td>
<td>1</td>
<td>168,881</td>
<td>246,566</td>
<td>Univ. of Texas</td>
<td>1</td>
<td>7,957</td>
<td>11,617</td>
</tr>
<tr>
<td>Res. Fdn. For Mental Hygiene</td>
<td>1</td>
<td>129,477</td>
<td>185,152</td>
<td>Virginia Commonwealth Univ.</td>
<td>2</td>
<td>56,252</td>
<td>72,439</td>
</tr>
<tr>
<td>Research Triangle Inst.</td>
<td>1</td>
<td>25,367</td>
<td>36,274</td>
<td>Wake Forest University</td>
<td>2</td>
<td>12,595</td>
<td>18,390</td>
</tr>
<tr>
<td>SC Dept. of Natural Resources</td>
<td>1</td>
<td>142,857</td>
<td>180,000</td>
<td>Wayne State Univ.</td>
<td>1</td>
<td>26,204</td>
<td>37,472</td>
</tr>
<tr>
<td>SC Research Authority</td>
<td>4</td>
<td>1,404,508</td>
<td>1,643,434</td>
<td>Yale Univ.</td>
<td>2</td>
<td>140,411</td>
<td>202,138</td>
</tr>
<tr>
<td>SC Sea Grant Consortium</td>
<td>1</td>
<td>10,000</td>
<td>14,600</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC Office of Victim Assistance</td>
<td>1</td>
<td>3,850</td>
<td>4,158</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC State Univ.</td>
<td>1</td>
<td>14,742</td>
<td>21,523</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Foundation

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha-1 Fdn.</td>
<td>1</td>
<td>261,666</td>
<td>261,666</td>
<td>Donald W. Reynolds Fdn.</td>
<td>1</td>
<td>2,311,263</td>
<td>2,398,016</td>
</tr>
<tr>
<td>Alzheimers Assoc.</td>
<td>1</td>
<td>72,728</td>
<td>80,000</td>
<td>Duke Endowment</td>
<td>9</td>
<td>1,177,012</td>
<td>1,177,012</td>
</tr>
<tr>
<td>Amer. Assoc. for Dental Research</td>
<td>1</td>
<td>2,400</td>
<td>2,400</td>
<td>Geneva Fdn.</td>
<td>1</td>
<td>49,424</td>
<td>61,780</td>
</tr>
<tr>
<td>Amer. Coll. of Radiology</td>
<td>6</td>
<td>1,044,874</td>
<td>1,221,459</td>
<td>Greenville Hospital System</td>
<td>1</td>
<td>7,500</td>
<td>7,500</td>
</tr>
<tr>
<td>Amer. Coll. of Gastroenterology</td>
<td>1</td>
<td>35,000</td>
<td>35,000</td>
<td>Institute For Cancer Prevention</td>
<td>1</td>
<td>5,850</td>
<td>5,850</td>
</tr>
<tr>
<td>Amer. Fdn. for Pharmaceutical Ed.</td>
<td>1</td>
<td>6,000</td>
<td>6,000</td>
<td>Juvenile Diabetes Fdn.</td>
<td>2</td>
<td>279,557</td>
<td>297,296</td>
</tr>
<tr>
<td>Amer. Federation for Aging</td>
<td>1</td>
<td>5,000</td>
<td>5,000</td>
<td>Leukemia and Lymphoma Society</td>
<td>1</td>
<td>47,000</td>
<td>50,000</td>
</tr>
<tr>
<td>Amer. Health Assistance Fdn.</td>
<td>2</td>
<td>85,000</td>
<td>85,000</td>
<td>March of Dimes</td>
<td>3</td>
<td>118,500</td>
<td>118,500</td>
</tr>
<tr>
<td>Amer. Heart Assoc.</td>
<td>5</td>
<td>218,182</td>
<td>236,000</td>
<td>NSABP</td>
<td>1</td>
<td>22,799</td>
<td>23,466</td>
</tr>
<tr>
<td>Amer. Heart Assoc./Mid-Atlantic</td>
<td>1</td>
<td>35,000</td>
<td>35,000</td>
<td>National Childhood Cancer Fdn.</td>
<td>2</td>
<td>26,439</td>
<td>31,727</td>
</tr>
<tr>
<td>Amer. Lung Assoc.</td>
<td>1</td>
<td>40,000</td>
<td>40,000</td>
<td>Natl. Env. Educ. and Training Fdn.</td>
<td>2</td>
<td>13,542</td>
<td>16,250</td>
</tr>
<tr>
<td>Amer. Medical Student Assoc.</td>
<td>1</td>
<td>38,164</td>
<td>41,217</td>
<td>New Morning Foundation</td>
<td>2</td>
<td>183,524</td>
<td>201,876</td>
</tr>
<tr>
<td>Amer. Board of Internal Medicine</td>
<td>1</td>
<td>17,500</td>
<td>17,500</td>
<td>Radiological Soc. of No. America</td>
<td>1</td>
<td>3,000</td>
<td>3,000</td>
</tr>
<tr>
<td>Arthritis Fdn.</td>
<td>4</td>
<td>319,142</td>
<td>341,129</td>
<td>Research to Prevent Blindness</td>
<td>1</td>
<td>110,000</td>
<td>110,000</td>
</tr>
<tr>
<td>Avon Foundation</td>
<td>1</td>
<td>150,909</td>
<td>166,000</td>
<td>Robert Wood Johnson Fdn.</td>
<td>2</td>
<td>128,101</td>
<td>139,629</td>
</tr>
<tr>
<td>Burroughs Wellcome Fdn.</td>
<td>2</td>
<td>81,000</td>
<td>81,000</td>
<td>SC Research Authority</td>
<td>1</td>
<td>15,080</td>
<td>15,080</td>
</tr>
<tr>
<td>Cystic Fibrosis Fdn.</td>
<td>2</td>
<td>93,476</td>
<td>96,676</td>
<td>SCUREF</td>
<td>2</td>
<td>99,517</td>
<td>125,392</td>
</tr>
</tbody>
</table>
### Other Support

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornell Univ. Med. Center</td>
<td>1</td>
<td>78,528</td>
<td>154,595</td>
<td>Univ. of Maryland</td>
<td>1</td>
<td>26,730</td>
<td>29,136</td>
</tr>
<tr>
<td>Dartmouth Coll.</td>
<td>1</td>
<td>6,424</td>
<td>8,030</td>
<td>Univ. of North Carolina</td>
<td>1</td>
<td>13,200</td>
<td>16,500</td>
</tr>
<tr>
<td>George Washington Univ.</td>
<td>1</td>
<td>28,616</td>
<td>31,478</td>
<td>Univ. of Pennsylvania</td>
<td>1</td>
<td>38,728</td>
<td>56,543</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>2</td>
<td>54,728</td>
<td>63,160</td>
<td>Univ. of Rochester</td>
<td>1</td>
<td>94,572</td>
<td>118,215</td>
</tr>
<tr>
<td>Judge Baker Childrens Center</td>
<td>1</td>
<td>15,000</td>
<td>15,000</td>
<td>Wake Forest University</td>
<td>2</td>
<td>11,302</td>
<td>12,205</td>
</tr>
<tr>
<td>Northwestern Univ.</td>
<td>2</td>
<td>26,477</td>
<td>28,860</td>
<td>Wayne State Univ.</td>
<td>1</td>
<td>18,964</td>
<td>27,688</td>
</tr>
<tr>
<td>Oklahoma Univ. Health Sc. Center</td>
<td>2</td>
<td>107,051</td>
<td>122,501</td>
<td>Other Support</td>
<td>19</td>
<td>606,571</td>
<td>799,063</td>
</tr>
<tr>
<td>Univ. of California, San Diego</td>
<td>1</td>
<td>61,644</td>
<td>90,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univ. of Colorado</td>
<td>1</td>
<td>24,607</td>
<td>25,152</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### State of South Carolina

<table>
<thead>
<tr>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
<th>Agency</th>
<th># Awards</th>
<th>Direct</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clemson Univ.</td>
<td>2</td>
<td>62,530</td>
<td>71,242</td>
<td>SC Energy Office</td>
<td>1</td>
<td>10,292</td>
<td>10,292</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>1</td>
<td>13,619</td>
<td>19,883</td>
<td>SC Research Authority</td>
<td>2</td>
<td>64,847</td>
<td>64,847</td>
</tr>
<tr>
<td>SC AHEC</td>
<td>1</td>
<td>10,000</td>
<td>10,000</td>
<td>SC Spinal Cord Injury Fund</td>
<td>4</td>
<td>292,592</td>
<td>292,592</td>
</tr>
<tr>
<td>SC DHEC</td>
<td>17</td>
<td>1,808,733</td>
<td>1,841,595</td>
<td>SC State Univ.</td>
<td>1</td>
<td>34,111</td>
<td>34,111</td>
</tr>
<tr>
<td>SC Dept. of Education</td>
<td>2</td>
<td>14,001</td>
<td>14,841</td>
<td>Univ. of South Carolina</td>
<td>3</td>
<td>198,180</td>
<td>198,180</td>
</tr>
<tr>
<td>SC Dept. of Natural Resources</td>
<td>3</td>
<td>49,715</td>
<td>59,995</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC Dept. of Public Safety</td>
<td>3</td>
<td>162,255</td>
<td>162,255</td>
<td>State of South Carolina</td>
<td>45</td>
<td>3,166,267</td>
<td>3,225,225</td>
</tr>
<tr>
<td>SC EPSCOR</td>
<td>5</td>
<td>445,392</td>
<td>445,392</td>
<td>(13 Agencies)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**GRAND TOTALS:** 941 $145,953,965 $180,617,767
**College and Departmental Summary**

The College of Medicine realized an $8.2 million gain for a 5.1% increase. MUSC exceeded the national research and development budget increase rate of 4.4%. The source of the increase is in federal and federal flow-down dollars. State and Corporate support remained stable and the largest decline is attributable to foundation support which dropped by $1.8 million.

The College of Dental Medicine (CODM) posted an all time high in extramural research support with awards totaling $4.3 million. CODM attracted a cooperative agreement for oral health infrastructure development. The seeds for this grant date back to the Healthy South Carolina Initiative. Congratulations to the College of Dental Medicine for its additional $1.7 million over FY04 and a 65% increase in support.

The College of Nursing experienced an $8.3% decline in research support. The loss was from corporate and federal flow-down sources. Nursing made gains in foundation support.
The College of Health Professions (CHP) sustained an overall 8.2% decrease in support. The loss is in corporate and state support. On a positive note, CHP increased it federal support by $220,000.

The College of Pharmacy experienced a similar situation to the College of Health Professions and Nursing in that it increased its federal funding but the gains did not offset the losses from corporate and foundation support. Extramural research support declined 16% from $1.72 million to $1.48 million.

### Funding by College and Department

<table>
<thead>
<tr>
<th>College</th>
<th># PIs</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHEC</td>
<td>1</td>
<td>2</td>
<td>448,798</td>
<td>459,808</td>
</tr>
<tr>
<td>Engineering &amp; Facilities</td>
<td>1</td>
<td>2</td>
<td>17,792</td>
<td>17,792</td>
</tr>
<tr>
<td>Library</td>
<td>5</td>
<td>12</td>
<td>694,818</td>
<td>897,371</td>
</tr>
<tr>
<td>President's Office</td>
<td>2</td>
<td>2</td>
<td>557,060</td>
<td>799,079</td>
</tr>
<tr>
<td><strong>Total for Administration</strong></td>
<td><strong>9</strong></td>
<td><strong>18</strong></td>
<td><strong>1,718,468</strong></td>
<td><strong>2,174,050</strong></td>
</tr>
<tr>
<td>College of Dental Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biochemistry and Molecular Biology</td>
<td>1</td>
<td>1</td>
<td>180,000</td>
<td>257,400</td>
</tr>
<tr>
<td>Microbiology and Immunology</td>
<td>2</td>
<td>4</td>
<td>2,715,608</td>
<td>3,741,621</td>
</tr>
<tr>
<td>Pediatric Dentistry and Orthodontics</td>
<td>1</td>
<td>4</td>
<td>322,277</td>
<td>327,689</td>
</tr>
<tr>
<td><strong>Total for College of Dental Medicine</strong></td>
<td><strong>4</strong></td>
<td><strong>9</strong></td>
<td><strong>3,217,885</strong></td>
<td><strong>4,326,710</strong></td>
</tr>
<tr>
<td>College of Graduate Studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graduate Studies</td>
<td>1</td>
<td>1</td>
<td>209,498</td>
<td>221,135</td>
</tr>
<tr>
<td><strong>Total for College of Graduate Studies</strong></td>
<td><strong>1</strong></td>
<td><strong>1</strong></td>
<td><strong>209,498</strong></td>
<td><strong>221,135</strong></td>
</tr>
<tr>
<td>College of Health Professions</td>
<td># PI's</td>
<td># AWARDS</td>
<td>DIRECT COSTS</td>
<td>TOTAL COSTS</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------</td>
<td>----------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Clinical Services</td>
<td>4</td>
<td>12</td>
<td>499,287</td>
<td>603,565</td>
</tr>
<tr>
<td>Health Administration and Policy</td>
<td>8</td>
<td>13</td>
<td>853,236</td>
<td>1,142,188</td>
</tr>
<tr>
<td>Health Professions</td>
<td>1</td>
<td>1</td>
<td>42,976</td>
<td>42,976</td>
</tr>
<tr>
<td>Rehabilitation Sciences</td>
<td>4</td>
<td>7</td>
<td>861,481</td>
<td>1,020,719</td>
</tr>
<tr>
<td><strong>Total for College of Health Professions</strong></td>
<td><strong>17</strong></td>
<td><strong>33</strong></td>
<td><strong>2,256,980</strong></td>
<td><strong>2,809,448</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Medicine</th>
<th># PI's</th>
<th># AWARDS</th>
<th>DIRECT COSTS</th>
<th>TOTAL COSTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anesthesiology</td>
<td>1</td>
<td>1</td>
<td>84,503</td>
<td>105,629</td>
</tr>
<tr>
<td>Biochemistry and Molecular Biology</td>
<td>15</td>
<td>43</td>
<td>8,243,843</td>
<td>11,321,809</td>
</tr>
<tr>
<td>Biostatistics, Bioinformatics and Epidemiology</td>
<td>13</td>
<td>33</td>
<td>5,649,469</td>
<td>7,460,598</td>
</tr>
<tr>
<td>Cell Biology and Anatomy</td>
<td>21</td>
<td>39</td>
<td>5,981,870</td>
<td>7,879,126</td>
</tr>
<tr>
<td>Cell and Molecular Pharmacology</td>
<td>9</td>
<td>17</td>
<td>3,386,450</td>
<td>4,554,236</td>
</tr>
<tr>
<td>Comparative Medicine</td>
<td>3</td>
<td>5</td>
<td>399,281</td>
<td>495,349</td>
</tr>
<tr>
<td>Dean's Office</td>
<td>4</td>
<td>5</td>
<td>5,163,347</td>
<td>5,879,521</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>10</td>
<td>11</td>
<td>2,603,293</td>
<td>3,005,343</td>
</tr>
<tr>
<td>Medicine</td>
<td>90</td>
<td>252</td>
<td>50,401,501</td>
<td>56,965,517</td>
</tr>
<tr>
<td>Microbiology and Immunology</td>
<td>11</td>
<td>26</td>
<td>3,522,277</td>
<td>3,932,926</td>
</tr>
<tr>
<td>Neurosciences</td>
<td>32</td>
<td>67</td>
<td>8,957,019</td>
<td>12,000,272</td>
</tr>
<tr>
<td>Obstetrics and Gynecology</td>
<td>7</td>
<td>15</td>
<td>545,302</td>
<td>657,878</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>11</td>
<td>20</td>
<td>1,450,732</td>
<td>1,974,063</td>
</tr>
<tr>
<td>Orthopaedic Surgery</td>
<td>2</td>
<td>10</td>
<td>292,058</td>
<td>420,395</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>7</td>
<td>12</td>
<td>2,016,827</td>
<td>2,796,054</td>
</tr>
<tr>
<td>Pathology and Laboratory Medicine</td>
<td>14</td>
<td>21</td>
<td>4,088,786</td>
<td>5,567,747</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>37</td>
<td>90</td>
<td>7,759,654</td>
<td>9,851,553</td>
</tr>
<tr>
<td>Psychiatry and Behavioral Sciences</td>
<td>46</td>
<td>117</td>
<td>18,202,384</td>
<td>23,772,567</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>2</td>
<td>6</td>
<td>288,974</td>
<td>343,377</td>
</tr>
<tr>
<td>Radiology</td>
<td>10</td>
<td>22</td>
<td>2,250,619</td>
<td>2,770,434</td>
</tr>
<tr>
<td>Surgery</td>
<td>14</td>
<td>33</td>
<td>3,711,193</td>
<td>4,998,404</td>
</tr>
<tr>
<td>Urology</td>
<td>2</td>
<td>3</td>
<td>125,165</td>
<td>156,456</td>
</tr>
<tr>
<td><strong>Total for College of Medicine</strong></td>
<td><strong>362</strong></td>
<td><strong>848</strong></td>
<td><strong>135,064,547</strong></td>
<td><strong>166,909,254</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Nursing</th>
<th># PI's</th>
<th># AWARDS</th>
<th>DIRECT COSTS</th>
<th>TOTAL COSTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nursing</td>
<td>9</td>
<td>14</td>
<td>2,400,003</td>
<td>2,693,334</td>
</tr>
<tr>
<td><strong>Total for College of Nursing</strong></td>
<td><strong>9</strong></td>
<td><strong>14</strong></td>
<td><strong>2,400,003</strong></td>
<td><strong>2,693,334</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Pharmacy</th>
<th># PI's</th>
<th># AWARDS</th>
<th>DIRECT COSTS</th>
<th>TOTAL COSTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical Sciences</td>
<td>11</td>
<td>16</td>
<td>1,049,376</td>
<td>1,438,576</td>
</tr>
<tr>
<td>Pharmacy and Clinical Services</td>
<td>2</td>
<td>2</td>
<td>37,208</td>
<td>45,260</td>
</tr>
<tr>
<td><strong>Total for College of Pharmacy</strong></td>
<td><strong>13</strong></td>
<td><strong>18</strong></td>
<td><strong>1,086,584</strong></td>
<td><strong>1,483,836</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GRAND TOTALS:</th>
<th># PI's</th>
<th># AWARDS</th>
<th>DIRECT COSTS</th>
<th>TOTAL COSTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>415</td>
<td>941</td>
<td>$145,953,965</td>
<td>$180,617,767</td>
</tr>
</tbody>
</table>
# Proposal Award Comparison

<table>
<thead>
<tr>
<th>Colleges</th>
<th>Departments</th>
<th># Submitted</th>
<th>$ Submitted</th>
<th># Funded</th>
<th>$ Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Administration</td>
<td>18</td>
<td>$6,295,839</td>
<td>18</td>
<td>$2,174,050</td>
</tr>
<tr>
<td></td>
<td>Dental Medicine</td>
<td>16</td>
<td>$4,143,263</td>
<td>9</td>
<td>$4,326,710</td>
</tr>
<tr>
<td></td>
<td>Biochemistry</td>
<td>3</td>
<td>987,362</td>
<td>1</td>
<td>257,400</td>
</tr>
<tr>
<td></td>
<td>Microbiology &amp; Immunology</td>
<td>3</td>
<td>2,043,851</td>
<td>4</td>
<td>3,741,621</td>
</tr>
<tr>
<td></td>
<td>Pediatric Dentistry</td>
<td>1</td>
<td>25,000</td>
<td>4</td>
<td>327,689</td>
</tr>
<tr>
<td></td>
<td>Stomatology</td>
<td>9</td>
<td>1,087,050</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Graduate Studies</td>
<td></td>
<td></td>
<td>1</td>
<td>221,135</td>
</tr>
<tr>
<td></td>
<td>Health Professions</td>
<td>46</td>
<td>$7,632,049</td>
<td>33</td>
<td>$2,809,448</td>
</tr>
<tr>
<td></td>
<td>Clinical Services</td>
<td>12</td>
<td>944,226</td>
<td>12</td>
<td>603,565</td>
</tr>
<tr>
<td></td>
<td>Dean's Office</td>
<td>1</td>
<td>9,865</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Health Admin. And Policy</td>
<td>15</td>
<td>3,038,278</td>
<td>13</td>
<td>1,142,188</td>
</tr>
<tr>
<td></td>
<td>Health Professions</td>
<td>2</td>
<td>600,773</td>
<td>1</td>
<td>42,976</td>
</tr>
<tr>
<td></td>
<td>Rehabilitation Sciences</td>
<td>16</td>
<td>3,038,907</td>
<td>7</td>
<td>1,020,719</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>1,151</td>
<td>$262,330,556</td>
<td>848</td>
<td>$166,909,254</td>
</tr>
<tr>
<td></td>
<td>Anesthesiology</td>
<td>2</td>
<td>152,128</td>
<td>1</td>
<td>105,629</td>
</tr>
<tr>
<td></td>
<td>Biochemistry</td>
<td>57</td>
<td>15,092,024</td>
<td>43</td>
<td>11,321,809</td>
</tr>
<tr>
<td></td>
<td>Biostatistics, Bioinformatics &amp; Epidemiology</td>
<td>64</td>
<td>13,039,158</td>
<td>33</td>
<td>7,460,598</td>
</tr>
<tr>
<td></td>
<td>Cell Biology &amp; Anatomy</td>
<td>74</td>
<td>18,640,567</td>
<td>39</td>
<td>7,879,126</td>
</tr>
<tr>
<td></td>
<td>Cell &amp; Molecular Pharmacology</td>
<td>35</td>
<td>6,579,047</td>
<td>17</td>
<td>4,554,236</td>
</tr>
<tr>
<td></td>
<td>Comparative Medicine</td>
<td>8</td>
<td>1,024,188</td>
<td>5</td>
<td>495,349</td>
</tr>
<tr>
<td></td>
<td>Dean's Office</td>
<td>3</td>
<td>4,713,164</td>
<td>5</td>
<td>5,879,521</td>
</tr>
<tr>
<td></td>
<td>Dermatology</td>
<td>1</td>
<td>11,905</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Family Medicine</td>
<td>16</td>
<td>5,439,402</td>
<td>11</td>
<td>3,005,343</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>260</td>
<td>74,015,202</td>
<td>252</td>
<td>56,965,917</td>
</tr>
<tr>
<td></td>
<td>Microbiology &amp; Immunology</td>
<td>51</td>
<td>9,244,825</td>
<td>26</td>
<td>3,932,926</td>
</tr>
<tr>
<td></td>
<td>Neurosciences</td>
<td>131</td>
<td>23,013,444</td>
<td>67</td>
<td>12,000,272</td>
</tr>
<tr>
<td></td>
<td>Obstetrics &amp; Gynecology</td>
<td>20</td>
<td>2,687,805</td>
<td>15</td>
<td>657,878</td>
</tr>
<tr>
<td></td>
<td>Ophthalmology</td>
<td>27</td>
<td>6,648,271</td>
<td>20</td>
<td>1,974,063</td>
</tr>
<tr>
<td></td>
<td>Orthopaedic Surgery</td>
<td>10</td>
<td>621,533</td>
<td>10</td>
<td>420,395</td>
</tr>
<tr>
<td></td>
<td>Otolaryngology</td>
<td>16</td>
<td>3,704,737</td>
<td>12</td>
<td>2,796,054</td>
</tr>
<tr>
<td></td>
<td>Pathology</td>
<td>40</td>
<td>9,823,718</td>
<td>21</td>
<td>5,567,747</td>
</tr>
<tr>
<td></td>
<td>Pediatrics</td>
<td>119</td>
<td>19,250,013</td>
<td>90</td>
<td>9,851,553</td>
</tr>
<tr>
<td></td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>148</td>
<td>37,058,600</td>
<td>117</td>
<td>23,772,567</td>
</tr>
<tr>
<td></td>
<td>Radiation Oncology</td>
<td>4</td>
<td>617,306</td>
<td>6</td>
<td>343,377</td>
</tr>
<tr>
<td></td>
<td>Radiology</td>
<td>14</td>
<td>1,767,099</td>
<td>22</td>
<td>2,770,434</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>46</td>
<td>8,977,689</td>
<td>33</td>
<td>4,998,404</td>
</tr>
<tr>
<td></td>
<td>Urology</td>
<td>5</td>
<td>208,731</td>
<td>3</td>
<td>156,456</td>
</tr>
<tr>
<td></td>
<td>Nursing</td>
<td>19</td>
<td>3,123,037</td>
<td>14</td>
<td>2,693,334</td>
</tr>
<tr>
<td></td>
<td>Pharmacy</td>
<td>53</td>
<td>9,303,153</td>
<td>18</td>
<td>1,483,836</td>
</tr>
<tr>
<td></td>
<td>Pharmaceutical Sciences</td>
<td>49</td>
<td>9,198,897</td>
<td>16</td>
<td>1,438,576</td>
</tr>
<tr>
<td></td>
<td>Pharmacy &amp; Clinical Services</td>
<td>4</td>
<td>104,256</td>
<td>2</td>
<td>45,260</td>
</tr>
<tr>
<td></td>
<td>1,303</td>
<td>$292,827,897</td>
<td>941</td>
<td>$180,617,767</td>
<td></td>
</tr>
</tbody>
</table>

Annual Report for Research FY2005
Faculty Activity

Investigators and Projects
### AHEC

**Garr, David**  
Principal Investigator  

**Model State Supported AHEC**  
Sponsor: HRSA/BHP/Medicine  
Award: 2 U77 HP03019-11-00 (04061502)  
Budget Dates: 09/30/04 - 08/31/05  
Direct: $335,162  
F & A: $11,010  

**Building Coalitions to Increase the Diversity of the South Carolina Health Care Workforce**  
Sponsor: Duke Endowment  
Award: 5556-SP (05011881)  
Budget Dates: 06/07/05 - 07/01/06  
Direct: $113,636  
F & A: 0

### Academic Affairs / Provost

**Starmer, Frank**  
Co-Investigator  
National Heart, Lung and Blood Institute Proteomics Administrative Center  
Pl: Margaret Schachte  
Dept: Library  
Award: N01 HV 28181 (03042202-3)  

### Engineering & Facilities

**Malmrose, John**  
Principal Investigator  

**FY 2005 Collegiate Recycling Grant**  
Sponsor: SC DHEC  
Award: 10.1CR5 (04091601)  
Budget Dates: 11/05/04 - 06/30/05  
Direct: $7,500  
F & A: 0  

**Rewards for Higher Education Energy Efficiency Projects**  
Sponsor: SC Energy Office  
Award: (04110337)  
Budget Dates: 05/01/04 - 12/15/05  
Direct: $10,292  
F & A: 0

**Von Kolnitz, Christine**  
Co-Investigator  

**FY 2005 Collegiate Recycling Grant**  
Sponsor: SC DHEC  
Dept: Engineering & Facilities  
Award: 10.1CR5 (04091601-1)  
Total: $7,500  

**Rewards for Higher Education Energy Efficiency Projects**  
Sponsor: SC Energy Office  
Dept: Engineering & Facilities  
Award: (04110337-1)  
Total: $10,292

### Library

**Carlson, Barbara**  
Principal Investigator  

**REACH 2010 Faith-in Health Initiative**  
Sponsor: National Network of Libraries Of Medicine  
Award: P.O. S01872 (04052401)  
Budget Dates: 09/01/04 - 02/28/06  
Direct: $36,991  
F & A: 2,959  

**REACH 2010 Rural Health eAccess Project**  
Sponsor: National Network of Libraries Of Medicine  
Award: NO1-LM-1-3521 (04062402)  
Budget Dates: 09/01/04 - 02/28/06  
Direct: $46,294  
F & A: 3,704

**McKeehan, Nancy**  
Principal Investigator  

**Hands-On-Health for South Carolinians**  
Sponsor: Univ. of Maryland  
Award: P. O. S01871 (04052804)  
Budget Dates: 10/01/04 - 09/30/05  
Direct: $25,000  
F & A: 0  

**Allendale on the Move**  
Sponsor: National Network of Libraries Of Medicine  
Award: N01-LM-1-3521 (04062310)  
Budget Dates: 09/01/04 - 02/28/06  
Direct: $46,050  
F & A: 3,684  

**Improving Access to Health: A Go Local System for South Carolina**  
Sponsor: Univ. of Maryland  
Award: N01-LM-1-3522 (04062311)  
Budget Dates: 02/01/05 - 04/30/06  
Direct: $22,188  
F & A: 1,775
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Total:</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riley, Ruth</td>
<td>Co-Investigator</td>
<td>Improving Access to Health: A Go Local System for South Carolina</td>
<td>PIs: Nancy McKeehan Sponsors: Univ. of Maryland</td>
<td>$22,188</td>
<td>$12,381</td>
<td>$9,807</td>
</tr>
<tr>
<td>Rivers, David</td>
<td>Principal Investigator</td>
<td>National Environmental Policy Commission and Community Leaders Institute</td>
<td>Sponsor: Tennessee State Univ.</td>
<td>$47,619</td>
<td>$25,875</td>
<td>$21,744</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Community Leaders Workshop</td>
<td>Sponsor: SCUREF</td>
<td>$99,517</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Support - National Environmental Policy Institute</td>
<td>Sponsor: SC State Univ.</td>
<td>$34,111</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-PI or Project Leader</td>
<td>EXPORT Center for Metabolic Syndrome and Minority Health: Outreach Core</td>
<td>$94,613</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schachte, Margaret</td>
<td>Principal Investigator</td>
<td>National Heart, Lung and Blood Institute Proteomics Administrative Center</td>
<td>Sponsor: NIH/NHLBI</td>
<td>$330,814</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sullivan, Joann</td>
<td>Principal Investigator</td>
<td>South Carolina Space Grant Consortium</td>
<td>Sponsor: Coll. of Charleston</td>
<td>$2,500</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FY2005 SC EPSCoR Travel</td>
<td>Sponsor: SC Research Authority</td>
<td>$3,734</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td>National Heart, Lung and Blood Institute Proteomics Administrative Center</td>
<td>$330,814</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coleman, III, Walker</td>
<td>Principal Investigator</td>
<td>Administrative Core</td>
<td>Sponsor: SC Spinal Cord Injury Fund</td>
<td>$30,931</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slaughter, Sabra</td>
<td>Principal Investigator</td>
<td>EXPORT Center for Metabolic Syndrome and Minority Health</td>
<td>Sponsor: NIH/NCMHD</td>
<td>$526,129</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stroke Belt Elimination Initiative/Community Initiatives to Eliminate Stroke</td>
<td>Sponsor: DHHS/PHS</td>
<td>$421,972</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**President’s Office**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Total:</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coleman, III, Walker</td>
<td>Principal Investigator</td>
<td>Administrative Core</td>
<td>Sponsor: SC Spinal Cord Injury Fund</td>
<td>$30,931</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Biochemistry and Molecular Biology

**Schwabe, Christian**  
Principal Investigator  
**Relaxin-Like Factor in Male Gonadal Development**  
Sponsor: NIH/NICHD  
Award: 5 RO1 HD040406-05 (05011997)  
**Budget Dates:** 04/01/05 - 03/10/06  
**Direct:** $180,000  
**Project Dates:** 04/01/01 - 03/31/06  
**F & A:** $77,400

### Microbiology and Immunology - CODM

**Balish, Edward**  
Principal Investigator  
**Lethal Oroesophageal Candidiasis: Immunotherapy**  
Sponsor: NIH/NIDCR  
Award: 5 RO1 DE013968-06 (04052103)  
**Budget Dates:** 08/01/04 - 07/31/06  
**Direct:** $170,000  
**Project Dates:** 09/29/00 - 07/31/06  
**F & A:** $73,100

Co-PI or Project Leader  
**SC Cobre in Lipidomics & Pathobiology: Core C - Animal Pathobiology Core**  
Pl: Lina Obeid  
Sponsor: NIH/NCRR  
**Award:** 5 P20 RR017677-03 (03071704-22)

### London, Steven

**Principal Investigator**  
**Oral Health Infrastructure Development at MUSC**  
Sponsor: NIH/NIDCR  
Award: 1 U24 DE016508-01 (04051902)  
**Budget Dates:** 09/27/04 - 08/31/05  
**Direct:** $1,000,000  
**Project Dates:** 09/27/04 - 08/31/06  
**F & A:** $423,201

**South Carolina COBRE for Oral Health**  
Sponsor: NIH/NCRR  
Award: 5 P20 RR017696-03 (04052806)  
**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $1,511,150  
**Project Dates:** 09/30/02 - 09/29/07  
**F & A:** $526,955

**College of Dental Medicine Summer Research Program**  
Sponsor: NIH/NIDCR  
Award: 5 T35 DE007337-05 (05022884)  
**Budget Dates:** 03/01/05 - 02/28/06  
**Direct:** $34,458  
**Project Dates:** 03/31/01 - 02/28/06  
**F & A:** $2,757

### Pediatric Dentistry and Orthodontics

**Salinas, Carlos**  
Principal Investigator  
**Dental Program for the Diagnosis and Treatment of Children with Special Health Care Needs**  
Sponsor: Duke Endowment  
Award: 5260-SP (02081303)  
**Budget Dates:** 08/01/04 - 07/01/05  
**Direct:** $252,689  
**Project Dates:** 08/01/02 - 07/01/05  
**F & A:** $0

**More Smiling Faces in Beautiful Places**  
Sponsor: SC DHEC  
Award: HS-03-128 (03081904)  
**Budget Dates:** 04/15/03 - 11/30/05  
**Direct:** $46,440  
**Project Dates:** 04/15/03 - 11/30/05  
**F & A:** $3,560

**Craniofacial Anomalies and Cleft Lip and Palate Team**  
Sponsor: SC DHEC  
Award: CR-5-562 (05030973)  
**Budget Dates:** 04/15/05 - 04/14/06  
**Direct:** $23,148  
**Project Dates:** 04/15/05 - 04/14/06  
**F & A:** $1,852

Co-PI or Project Leader  
**South Carolina COBRE for Oral Health - Core A: Administration Core (Renovations)**  
Pl: Steven London  
Sponsor: NIH/NCRR  
**Award:** 5 P20 RR017696-03 (04052806-7)  
**Total:** $560,845

**South Carolina COBRE for Oral Health - Core C: CLinical Core**  
Pl: Steven London  
Sponsor: NIH/NCRR  
**Award:** 5 P20 RR017696-03 (04052806-9)  
**Total:** $347,311

### Stomatology

**Reed, Susan**  
Co-PI or Project Leader  
**South Carolina COBRE for Oral Health - Project 12: Oral Cancer Prevention by Dietary Flavonoids - Role of Salivary B-glucosidase**  
Pl: Steven London  
Sponsor: NIH/NCRR  
**Award:** 5 P20 RR017696-03 (04052806-6)  
**Total:** $33,684  
**Dept:** Microbiology and Immunology - CODM
Ries, William  
**Co-Investigator**  
*Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis*  
**PI:** L. Key  
**Dept:** Pediatrics  
**Sponsor:** FDA  
**Total:** $234,434  
**Award:** FD-R-001847-04 (04062308-1)

Westwater, Caroline  
**Co-PI or Project Leader**  
*South Carolina COBRE for Oral Health - Project 11: Candida Albicans-Associated Oral Biofilms*  
**PI:** Steven London  
**Dept:** Microbiology and Immunology - CODM  
**Sponsor:** NIH/NCRR  
**Total:** $79,326  
**Award:** 5 P20 RR017696-03 (04052806-5)
Graduate Studies

Cook, Lana

Principal Investigator

Medical University of South Carolina MBRS IMSD Program

Sponsor: NIH/NIGMS

Award: 1 R25 GM072643-01 (04020903)

Budget Dates: 03/01/05 - 02/28/06

Direct: $209,498

Project Dates: 03/01/05 - 02/28/09

F & A: $11,637
Clinical Services

Geils, Karen

Principal Investigator

A Comparison Study of Two HPV DNA Tests, Hybrid Capture 2 and AMPLICOR, for Detection of Cervical Precancer and Cancer, Protocol #30
Sponsor: NIH/NCI
Award: PROTOCOL #30 (04091403)

Clinical PAP Specimen Acquisition Protocol
Sponsor: Becton Dickinson
Award: 05C2-006-PAP (05032961)

SurePath Specimen Procurement for Digene Corporation, Protocol #32
Sponsor: Digene Corp.
Total: $2,400
Dept: Clinical Services
Award: PROTOCOL #32 (04091703-1)

Holladay, E.

Principal Investigator

Clinical Evaluation of Novel Markers as an Adjunct to High-Risk HPV DNA Testing by HC2 and HC2-Plus
Sponsor: Digene Corp.
Award: PROTOCOL #22 (04012709)

Comparison of Sensitivity and Specificity of P16 Protein and Novel Markers for Progressive Cervical Disease with Hybrid Capture II
Sponsor: Digene Corp.
Award: PROTOCOL #29 (04052716)

Comparison of Inform HPV with Digene HCII and Polymerase Chain Reaction for Pathologists Medical Associates
Sponsor: Ventana Medical Systems
Award: Protocol #31 (04081902)

Digene Hybrid Capture 2 CT-ID & GC-ID DNA Test: Validation of Cytyc PreservCyt Solution as an Alternate Specimen Type for Hybrid Capture 2 CT-ID & GC-ID DNA Test
Sponsor: Digene Corp.
Award: C04-CGC-001 (05012849)

Liquid Based Specimen Assessment, Protocol #34
Sponsor: Digene Corp.
Award: Protocol #34 (05021015)

Jacques, Paul

Principal Investigator

PA Master's Degree: Meeting the Health Care Needs of South Carolina
Sponsor: HRSA/BHP/Medicine
Award: 5 D57 HP10169-02-00 (02111402)

Enhancement of Pediatric Emergency Medicine Curricula for Physician Assistants
Sponsor: DHHS
Award: 1 H3MC04369-01-00 (04110965)

Reed, Sarah

Co-Investigator

Digene Hybrid Capture 2 CT-ID & GC-ID DNA Test: Validation of Cytyc PreservCyt Solution as an Alternate Specimen Type for Hybrid Capture 2 CT-ID & GC-ID DNA Test
PI: E. Holladay
Dept: Clinical Services
Sponsor: Digene Corp.
Total: $59,346
Award: C04-CGC-001 (05012849-1)

Liquid Based Specimen Assessment, Protocol #34
PI: E. Holladay
Dept: Clinical Services
Sponsor: Digene Corp.
Total: $44,000
Award: Protocol #34 (05021015-1)
## Medical University of South Carolina Research Faculty Activity

### College of Health Professions Clinical Services

<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>Title</th>
<th>Sponsor/Institution</th>
<th>Project Dates</th>
<th>Direct/Indirect</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Truver, Lawrence</strong></td>
<td><strong>Principal Investigator</strong></td>
<td><strong>Nurse Anesthetist Traineeship</strong></td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
<td>Direct: $18,006</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: HRSA/BHP/Nursing</td>
<td>Project Dates: 07/01/04 - 06/30/05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 2 A22 HP00023-05-00 (03102801)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dean’s Office - CHP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Coker, Jennifer</strong></td>
<td><strong>Co-Investigator</strong></td>
<td>A 6-year Longitudinal Study of Community Reintegration, Subjective Well Being, and Health after Spinal Cord Injury: Relationship with Gender, Race/Ethnicity, and Environmental Factors</td>
<td>Total: $116,300</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Dept. of Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Rehabilitation Sciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: H133G020218-04 (04062903-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Health Administration and Policy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bradford, W.</strong></td>
<td><strong>Principal Investigator</strong></td>
<td>DTC Advertising Effect on Adherence to Statin Therapy</td>
<td>Budget Dates: 07/01/04 - 05/31/05</td>
<td>Direct: $175,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: NIH/NHLBI</td>
<td>Project Dates: 07/01/04 - 05/31/07</td>
<td>F&amp;A: 80,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1 R01 HL077841-01 (03093014)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Impact of Direct to Consumer Pharmaceutical Marketing</td>
<td>Budget Dates: 07/01/04 - 06/30/06</td>
<td>Direct: $193,144</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: AHCPR/AHRQ</td>
<td>Project Dates: 07/07/03 - 06/30/06</td>
<td>F&amp;A: 63,595</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 5 R01 HS011326-02 (04022710)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Correcting Under-Reporting in HCUP Inpatient Data</td>
<td>Total: $68,493</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PI: Clara Dismuke</td>
<td>Sponsor: AHCPR/AHRQ</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Health Administration and Policy</td>
<td>Award: 1 R03 HS014075-01A1 (03112106-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dismuke, Clara</strong></td>
<td><strong>Principal Investigator</strong></td>
<td>Correcting Under-Reporting in HCUP Inpatient Data</td>
<td>Budget Dates: 09/30/04 - 02/28/06</td>
<td>Direct: $68,493</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: AHCPR/AHRQ</td>
<td>Project Dates: 09/30/04 - 02/28/06</td>
<td>F&amp;A: 31,507</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1 R03 HS014075-01A1 (03112106)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hoskins, Daniel</strong></td>
<td><strong>Co-Investigator</strong></td>
<td>Stroke Belt Elimination Initiative/Community Initiatives to Eliminate Stroke</td>
<td>Total: $421,972</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: DHHS/PHS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Medicine</td>
<td>Award: US2MP04001-01-0 (04062918-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Jones, Walter</strong></td>
<td><strong>Co-Investigator</strong></td>
<td>A New Method for Measuring the Public Health Impact of Increased Access to Potential Reduced Exposure Products</td>
<td>Total: $44,293</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Robert Wood Johnson Fdn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Health Administration and Policy</td>
<td>Award: 051622 (04030811-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lindrooth, Richard</strong></td>
<td><strong>Principal Investigator</strong></td>
<td>New Approaches to Identifying Market Power in Health Care</td>
<td>Budget Dates: 05/01/04 - 04/30/05</td>
<td>Direct: $15,138</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Northwestern Univ.</td>
<td>Project Dates: 05/04/05 - 04/30/06</td>
<td>F&amp;A: 1,362</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 0965400N217994 (04042203)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Is the Impact of Managed Care Decreasing?</td>
<td>Budget Dates: 10/01/04 - 03/31/06</td>
<td>Direct: $78,528</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Cornell Univ. Med. Center</td>
<td>Project Dates: 10/01/04 - 03/31/06</td>
<td>F&amp;A: 76,067</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 47326-7714 (040611101)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New Approaches to Identifying Market Power in Health Care</td>
<td>Budget Dates: 05/01/05 - 04/30/06</td>
<td>Direct: $11,339</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Northwestern Univ.</td>
<td>Project Dates: 05/04/05 - 04/30/06</td>
<td>F&amp;A: 1,021</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 0965 400 N217 994 (05042645)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Martin, Margaret</strong></td>
<td><strong>Co-Investigator</strong></td>
<td>ALLIANCEnet: Anytime/Anywhere Learning Linkages in Allied Health and Nursing Continuing Education</td>
<td>Total: $116,696</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sponsor: Duke Endowment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dept: Health Administration and Policy</td>
<td>Award: 5304-SP (03080601-2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Mcllwain, Thomas**

**Principal Investigator**

**Impact of Direct to Consumer Pharmaceutical Marketing**

- **PI:** W. Bradford
- **Dept:** Health Administration and Policy
- **Sponsor:** AHCPR/AHRQ
- **Award:** 5 R01 HS011326-02 (04022710-1)
- **Total:** $193,144

**Co-Investigator**

**Shilling, Lilless**

**A Program to Increase Living Donations in African Americans**

- **PI:** Prabhakar Baliga
- **Dept:** Surgery
- **Sponsor:** NIH/NIDDK
- **Award:** 5 R01 DK062596-03 (04043004-1)
- **Total:** $150,000

**Simpson, Kit**

**Principal Investigator**

**Targeting Acute HIV: Cost Effectiveness Modeling**

- **Sponsor:** Univ. of North Carolina
- **Award:** 5 R01 MH066866-02 5 (04091502)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $17,123
- **F & A:** 7,877

**Cost Effectiveness Modeling for Fixed Dose Combination Products (FDCs)**

- **Sponsor:** GlaxoSmithKline
- **Award:** GH0104011 (04120130)
- **Budget Dates:** 07/01/04 - 07/31/05
- **Direct:** $55,400
- **F & A:** 13,850

**Co-PI or Project Leader**

**Understanding and Eliminating Health Disparities in Blacks in South Carolina - Project 2: Economic Access to Antiretroviral (ARV) Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in SC**

- **Pl:** Barbara Tilley
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** AHCPR/AHRQ
- **Award:** 5 P01 HS010871-05 (04052807-6)
- **Total:** $119,440

**Co-Investigator**

**Schizophrenia Liability Genes Among African Americans**

- **Pl:** Alberto Santos
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIMH
- **Award:** 5 R01 MH066004-03 (04052810-1)
- **Total:** $451,529

**Terza, Joseph**

**Principal Investigator**

**A New Method for Measuring the Public Health Impact of Increased Access to Potential Reduced Exposure Products**

- **Sponsor:** Robert Wood Johnson Fdn.
- **Award:** 051622 (04030811)
- **Budget Dates:** 08/01/04 - 07/31/05
- **Direct:** $44,293
- **F & A:** 3,986

**Establishing the Value of Stable Prescription Coverage for Medicare Beneficiaries**

- **Sponsor:** Univ. of Maryland
- **Award:** 050399 (04041401)
- **Budget Dates:** 04/01/04 - 07/31/05
- **Direct:** $26,730
- **F & A:** 2,406

**West, Valerie**

**Co-Investigator**

**Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities**

- **Pl:** Alexander Chessman
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 1 D56 HP03357-01-00 (03110601-1)
- **Total:** $186,020

**White, Andrea**

**Principal Investigator**

**Health Administration Traineeship and Special Projects**

- **Sponsor:** HRSA/BHP/Assoc. Health Professions
- **Award:** 5 A19 HP10187-05-00 (03112201)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $36,610
- **F & A:** 0

**Co-Investigator**

**Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities**

- **Pl:** Alexander Chessman
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 1 D56 HP03357-01-00 (03110601-1)
- **Total:** $186,020
## Health Professions

### Ripich, Danielle
- **Co-Investigator**
- **SC Geriatric Education Centers**
- **PI:** Esther Forti
- **Dept:** Rehabilitation Sciences
- **Sponsor:** HRSA
- **Award:** 5 D31 HP70148-04-00 (04092106-1)
- **Total:** $279,549

### Shilling, Lilless
- **Co-Investigator**
- **ALLIANCEnet: Anytime/Anywhere Learning Linkages in Allied Health and Nursing Continuing Education**
- **PI:** Elizabeth Ricciardone
- **Dept:** Health Administration and Policy
- **Sponsor:** Duke Endowment
- **Total:** $116,696

### Taylor, Lloyd
- **Principal Investigator**
- **Cognitive Changes in Pediatric Brain Tumor Survivors**
- **Sponsor:** NIH/NINDS
- **Award:** 1 F32 NS046944-01A1 (03080106)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $42,976

## Rehabilitation Sciences

### Forti, Esther
- **Principal Investigator**
- **SC Geriatric Education Centers**
- **PI:** Esther Forti
- **Dept:** Rehabilitation Sciences
- **Sponsor:** HRSA
- **Award:** 5 D31 HP70148-04-00 (04092106)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $279,549

### Krause, James
- **Principal Investigator**
- **Research Development Core**
- **Dept of Education**
- **Sponsor:** SC Spinal Cord Injury Fund
- **Award:** (02100202)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $74,696

### Mitcham, Maralynne
- **Principal Investigator**
- **Community Connections: Partners for Service and Learning**
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** HRSA/BHP/Assoc. Health Professions
- **Award:** 5 D37 HP00876-03-00 (04082312)
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $110,519

### Norman, Michele
- **Co-PI or Project Leader**
- **SC Cooperative for Healthy Aging in Minority Populations: A Research Supplement for Under-Represented Minorities: Culturally Non-Baised Language Assessment in Geriatric Adults:DAT (Michele Norman Supplement)**
- **PI:** Barbara Tilley
- **Dept:** Biostatistics, Bioinformatics and Epidemiology
- **Sponsor:** NIH/NIA
- **Award:** 5 P30 AG021677-03 (04022401-7)
- **Total:** $74,371

### Saladin, Michael
- **Co-Investigator**
- **ORWH: SCOR on Sex and Gender Factors Affecting Women's Health - Project #2: Gender Difference in Response to Cues in Cocaine Dependence**
- **PI:** Kathleen Brady
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 P50 DA016511-03 (04043003-3)
- **Total:** $141,813

### ORWH: SCOR on Sex and Gender Factors Affecting Women's Health - Project #3: Gender, Menstrual Cycle, and Smoking Cue Reactivity
- **PI:** Kathleen Brady
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIDA
- **Award:** 5 P50 DA016511-03 (04043003-4)
- **Total:** $104,706
Wise, Holly

**Principal Investigator**

**Home Physical Activity Programs for the Promotion of Health and Wellness in Individuals with Spinal Cord Injury**

- **Sponsor:** SC Spinal Cord Injury Fund
- **Budget Dates:** 10/11/04 - 10/10/05
- **Direct:** $75,000

**Award:** SCIRF0304 (04031515)

**Project Dates:** 10/11/04 - 10/10/06

Yuen, Hon

**Co-PI or Project Leader**

**South Carolina COBRE for Oral Health - Project 3: Oral Health in African-American Adolescents with Diabetes**

- **PI:** Steven London
- **Sponsor:** NIH/NCRR
- **Total:** $107,535

**Dept:** Microbiology and Immunology - CODM

**Award:** 5 P20 RR017696-03 (04052806-2)
## Anesthesiology

### Reeves, Scott

**Principal Investigator**

**A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, when Administered with Intra**

**Sponsor:** GlaxoSmithKline  
**Award:** NKT102260 (04081704)

**Budget Dates:** 08/04/04 - 09/30/05  
**Direct:** $84,503  
**F & A:** $21,126

## Biochemistry and Molecular Biology

### Bastia, Depak

**Principal Investigator**

**Mechanism of Termination of DNA Replication**  
**Sponsor:** NIH/NIGMS  
**Award:** 5 R01 GM049264-13 (04122011)

**Budget Dates:** 02/01/05 - 01/31/06  
**Direct:** $240,000  
**F & A:** $30,554

**Mechanism of Replication of Drug Resistance Factors**  
**Sponsor:** NIH/NIAID  
**Award:** 5 R01 AI019881-23 (05030342)

**Budget Dates:** 05/01/05 - 04/30/06  
**Direct:** $314,299  
**F & A:** $144,578

### Bielawska, Alicja

**Principal Investigator**

**Molecular Pathogenesis of Apoptosis in Liver Cells**  
**Sponsor:** Univ. of North Carolina  
**Award:** 5 P01 DK69340-03 (03110305)

**Budget Dates:** 06/01/01 - 05/31/05  
**Direct:** $71,057  
**F & A:** $4,600

**Role of Ceramide Phosphate in Prostaglandin Synthesis**  
**Sponsor:** Virginia Commonwealth Univ.  
**Award:** 1 R01 HL072925-01A1 (04030805)

**Budget Dates:** 01/01/04 - 10/31/08  
**Direct:** $10,000  
**F & A:** $4,600

### Co-PI or Project Leader

**Sphingolipids in Cancer Therapy and Angiogenesis - Core B**  
**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 1 P01 CA97132-02 (01100808-10)

**Total:** $144,690

**SC Cobre in Lipidomics & Pathobiology: Core B - Lipidomics Core**  
**PI:** Lina Obeid  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 5 P20 RR017677-03 (03071704-21)

**Total:** $233,624

### Co-Investigator

**Ceramide Activated Protein Phosphatases**  
**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 3 R01 CA087584-04S1 (03041604-2)

**Total:** $24,762

**Alkaline Ceramidase and Sphingolipid Signaling**  
**PI:** Cungui Mao  
**Dept:** Medicine  
**Award:** 1 R01 CA104834-01A1 (03101602-1)

**Total:** $184,500

**MCRC in Rheumatoid Disease**  
**PI:** Richard Silver  
**Dept:** Medicine  
**Award:** 5 P60 AR049459-03 (05012859-1)

**Total:** $119,297

**NIAMS MCRC in Rheumatoid Disease - Project A: Sphingosine Kinase in Systemic Sclerosis**  
**PI:** Richard Silver  
**Dept:** Medicine  
**Award:** 5 P60 AR049459-03 (05012859-4)

**Total:** $134,930

### Co-Investigator

**Sphingolipids in Cancer Therapy and Angiogenesis - Core B**  
**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 1 P01 CA97132-02 (01100808-10)

**Total:** $144,690

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 2: Genesis of Bystander Activity in FasL Gene Therapy**  
**PI:** Yusuf Hannun  
**Dept:** Biochemistry and Molecular Biology  
**Award:** 1 P01 CA97132-02 (01100808-7)

**Total:** $156,685
<table>
<thead>
<tr>
<th>Name</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
<th>Dept</th>
<th>Award Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullesbach, Erika</td>
<td>Relaxin-Like Factor in Male Gonadal Development</td>
<td>Christian Schwabe</td>
<td>NIH/NICHD</td>
<td>$180,000</td>
<td>Biochemistry and Molecular Biology</td>
<td>5 R01 HD040406-05 (05011997-1)</td>
</tr>
<tr>
<td>Chao, Julie</td>
<td>Tissue Kallikrein, Oxidative Stress and Renal Fibrosis</td>
<td>Yusuf Hannun</td>
<td>NIH/NHLBI</td>
<td>$225,000</td>
<td>Biochemistry and Molecular Biology</td>
<td>5 R01 HL029397-22 (04033002)</td>
</tr>
<tr>
<td></td>
<td>Regulation and Function of Renal Kallikrein</td>
<td>Yusuf Hannun</td>
<td>NIH/NHLBI</td>
<td>$177,113</td>
<td>Biochemistry and Molecular Biology</td>
<td>1 R01 DK066350-01A1 (03101302)</td>
</tr>
<tr>
<td>Davies, Christopher</td>
<td>Penicillin-Resistant Neisseria Gonorrhoeae (CMRNG)</td>
<td>Depak Bastia</td>
<td>NIH/NIAID</td>
<td>$314,299</td>
<td>Biochemistry and Molecular Biology</td>
<td>1 R01 AI019881-23 (05030342-1)</td>
</tr>
<tr>
<td>Del Poeta, Maurizio</td>
<td>Roles for Inositol Phosphoryl Ceramide Synthase 1 (IPC1) in Fungal-Host Interaction</td>
<td>Lina Obeid</td>
<td>NIH/NCRR</td>
<td>$100,000</td>
<td>Biochemistry and Molecular Biology</td>
<td>1003642 (01103103)</td>
</tr>
<tr>
<td></td>
<td>3rd International Charleston Ceramide Conference 2005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 R01 AI056168-02 (04120994)</td>
</tr>
<tr>
<td></td>
<td>Sphingolipid-Mediated Fungal Pathogenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 R01 AI056168-02 (04120994)</td>
</tr>
<tr>
<td></td>
<td>Sphingolipid-Mediated Fungal Pathogenesis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 R01 AI056168-02 (04120994)</td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5 R01 AI056168-02 (04120994)</td>
</tr>
<tr>
<td></td>
<td>SC Cobre in Lipidomics &amp; Pathobiology: Core D - Protein Science Core</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1003642 (01103103)</td>
</tr>
<tr>
<td></td>
<td>SC Cobre in Lipidomics &amp; Pathobiology: Project 2 - Role of Lpc1 in the Regulation of Phagocytosis in C. Neoformans</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1003642 (01103103)</td>
</tr>
<tr>
<td></td>
<td>SC Cobre in Lipidomics &amp; Pathobiology: Core D - Protein Science Core</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1003642 (01103103)</td>
</tr>
<tr>
<td></td>
<td>SC Cobre in Lipidomics &amp; Pathobiology: Project 2 - Role of Lpc1 in the Regulation of Phagocytosis in C. Neoformans</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1003642 (01103103)</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
<td>F &amp; A</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------</td>
<td>---------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Fernandes, Daniel</td>
<td>Drug-Induced Destabilization of Bcl-2 mRNA</td>
<td>NIH/NCI</td>
<td>04/01/05 - 03/31/06</td>
<td>158,000</td>
<td>72,680</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>04/01/05 - 03/31/09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-PI or Project Leader</td>
<td>DOD Phase VI: Project 3- Stabilization of bcl-2 mRNA in Human Leukemia and Lymphoma</td>
<td>Geo-Centers, Inc.</td>
<td>04/01/05 - 03/31/09</td>
<td>$51,370</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Gross, Paul            | Analysis of a New and Potentially Multi-Functional Antimicrobial Peptide Family Identified in the Pacific White Shrimp, Litopenaeus Vannamei | USDA | 01/01/04 - 12/31/06 | 86,501 |
|                        | Identification and Functional Characterization of Toll-Like Family of Pathogen Receptors from the Pacific White Shrimp Litopenaeus Vannamei | USDA | 01/01/04 - 12/31/06 | 41,478 |
|                        | Shrimp Gene Discovery: Enlarging the EST Collection for the Pacific White Shrimp, Litopenaeus Vannamei | USDA | 01/01/04 - 12/31/06 | 502,178 |
|                        | Utilization of Reagents and Tools for Genomic Analysis Related to Shrimp Research | SC Dept. of Natural Resources | 01/01/04 - 12/31/06 | 39,539 |
|                        | Advancing Shrimp Genomics Research: A Workshop | USDA | 01/01/04 - 12/31/06 | 4,000 |

| Hama, Hiroko           | SC Cobre in Lipidomics & Pathobiology: Project 3 - Function and Regulation of Mammalian Fatty Acid Alphs Hydroxylase Gene | NIH/NCRR | 01/01/04 - 12/31/06 | 148,434 |

| Hannun, Yusuf          | Development of Structural and Chemical Biology | SC EPSCOR | 01/01/04 - 12/31/06 | 345,298 |
|                        | Sphingolipids in Cancer Therapy and Angiogenesis - Core B | NIH/NCI | 01/01/04 - 12/31/06 | 713,861 |
|                        | Development of Structural and Chemical Biology | SC Research Authority | 01/01/04 - 12/31/06 | 694,021 |
|                        | Ceramide Activated Protein Phosphatases | NIH/NCI | 01/01/04 - 12/31/06 | 24,762 |
|                        | Role and Regulation of Protein Kinase C Isoenzymes | NIH/NHLBI | 01/01/04 - 12/31/06 | 250,000 |
|                        | Molecular Pathogenesis of Apoptosis in Liver Cells | Univ. of North Carolina | 01/01/04 - 12/31/06 | 223,942 |

Annual Report for Research FY2005
Modeling and Analysis of Yeast Sphingolipid Metabolism
Sponsor: NIH/NIGMS  
Award: 5 R01 GM03265-04 (04012903)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/01 - 03/31/06  
Direct: $53,762  
F & A: $24,731

Ceramide Activated Protein Phophatases
Sponsor: NIH/NCI  
Award: 2 R01 CA087584-05A1 (04070208)  
Budget Dates: 04/01/05 - 03/31/10  
Project Dates: 04/01/01 - 03/31/10  
Direct: $225,000  
F & A: $103,500

3rd International Charleston Ceramide Conference 2005
Sponsor: SC EPSCOR  
Award: 0012 (04110338)  
Budget Dates: 01/01/05 - 04/30/05  
Project Dates: 01/01/05 - 04/30/05  
Direct: $10,000  
F & A: $0

Sphingomyelin Turnover and Cellular Regulation
Sponsor: NIH/NIGMS  
Award: 5 R01 GM43825-16 (04112203)  
Budget Dates: 07/01/97 - 12/31/06  
Project Dates: 07/01/97 - 12/31/06  
Direct: $235,000  
F & A: $108,100

Hsu, Yi-Te  
Principal Investigator  
Mechanisms of Apoptosis Inhibition by Bcl-XL  
Sponsor: NIH/NINDS  
Award: 5 R01 NS040932-05 (05030343)  
Budget Dates: 07/01/01 - 04/30/06  
Project Dates: 07/01/01 - 04/30/06  
Direct: $150,000  
F & A: $64,500

Krupenko, Sergey  
Principal Investigator  
FDH: A Novel Determinant of Tumor Suppression  
Sponsor: NIH/NCI  
Award: 1 R01 CA095030-01A3 (04031004)  
Budget Dates: 03/01/05 - 02/28/06  
Project Dates: 03/01/05 - 02/28/06  
Direct: $177,750  
F & A: $81,765

Mechanism of Action of a Major Folate Enzyme  
Sponsor: NIH/NIDDK  
Award: 5 R01 DK054388-09 (05032957)  
Budget Dates: 08/01/98 - 05/31/06  
Project Dates: 08/01/98 - 05/31/06  
Direct: $152,500  
F & A: $65,575

Luberto, Chiara  
Co-PI or Project Leader  
SC Cobre in Lipidomics & Pathobiology: Project 6 - Role and Function of Mammalian Sphingomyelin Synthases  
Pl: Lina Obeid  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCRR  
Total: $125,000  
Award: 5 P20 RR016434-04 (04050709-3)

Obeid, Lina  
Principal Investigator  
SC Cobre in Lipidomics and Pathobiology  
Sponsor: NIH/NCRR  
Award: 5 P20 RR017677-03 (03071704-17)  
Budget Dates: 09/26/02 - 06/30/07  
Project Dates: 09/26/02 - 06/30/07  
Direct: $1,480,519  
F & A: $674,139

Ogretmen, Besim  
Principal Investigator  
Regulation of Telomerase By Ceramide in Lung Cancer  
Sponsor: NIH/NCI  
Award: 5 R01 CA088932-04 (04011404)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/06  
Direct: $142,500  
F & A: $61,275

C18-Ceramide In Head and Neck Cancer Growth and Therapy  
Sponsor: NIH/NIDCR  
Award: 1 R01 DE016572-01 (04052605)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/06  
Direct: $218,250  
F & A: $89,240

Regulation of Telomerase by Ceramide in Lung Cancer - Supplement  
Sponsor: NIH/NCI  
Award: 3 R01 CA088932-04S1 (05012745)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/06  
Direct: $32,120  
F & A: $14,775

C18 Ceramide in Head and Neck Cancer Growth and Treatment: Research Supplement to Promote Diversity in Health-Related Research (Kesha Thomas, Candidate)  
Sponsor: NIH/NIDCR  
Award: 3 R01 DE016572-01S1 (05072585)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/06  
Direct: $39,537  
F & A: $18,187

---

30 Annual Report for Research FY2005
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ogretmen, Besim</td>
<td>Co-PI or Project Leader</td>
<td>Sphingolipids in Cancer Therapy and Angiogenesis - Project 1: Sphingolipids and Chemotherapy-Induced Apoptosis</td>
<td>NIH/NCI</td>
<td>07/01/04 - 06/30/05</td>
<td>$142,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DOD Phase VI: Project 7- Role of Ceramide in the Synergystic Actions of Anti-Cancer Chemotherapy and in the Pathogenesis of Human Lung and Head and Neck Cancers</td>
<td>Geo-Centers, Inc.</td>
<td>07/01/04 - 06/30/06</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DOD Phase VII: Comparative Analysis of Ceramide Analogs as Chemotherapeutic Agents with Gemcitabine/Doxorubicin in the Treatment of Head and Neck Cancers (HNC)</td>
<td>Geo-Centers, Inc.</td>
<td>07/01/04 - 06/30/06</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td>Spicer, Eleanor</td>
<td>Principal Investigator</td>
<td>Post-Transcriptional Regulation of Human BCL-2 Expression</td>
<td>NIH/NCI</td>
<td>07/01/04 - 06/30/05</td>
<td>$142,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug-Induced Destabilization of Bcl-2 mRNA</td>
<td>NIH/NCI</td>
<td>07/01/04 - 06/30/05</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td>Szulc, Zdzislaw</td>
<td>Co-Investigator</td>
<td>Sphingolipids in Cancer Therapy and Angiogenesis - Core B</td>
<td>NIH/NCI</td>
<td>07/01/04 - 06/30/05</td>
<td>$142,500</td>
<td></td>
</tr>
<tr>
<td>Warr, Gregory</td>
<td>Principal Investigator</td>
<td>Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp</td>
<td>NSF</td>
<td>07/01/04 - 06/30/05</td>
<td>$112,051</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Duck Antibody Genes: Unusual Organization Expression</td>
<td>NIH/NIAD</td>
<td>07/01/04 - 06/30/05</td>
<td>$125,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Subcontract to NOAA's Establishment of a National Oceanic and Atmospheric Administration Center of Excellence in Oceans and Human Health within the Hollings Marine Laboratory at Charleston, SC</td>
<td>NOAA</td>
<td>07/01/04 - 06/30/05</td>
<td>$211,567</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>FRD: Research Services Contract-Gregory Warr</td>
<td>Shrimp Improvement Systems</td>
<td>07/01/04 - 06/30/05</td>
<td>$55,008</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shrimp Disease and Immunity: Host, Pathogen, and Environment Interactions</td>
<td>SC Dept. of Natural Resources</td>
<td>07/01/04 - 06/30/05</td>
<td>$142,500</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NA03NM058245</td>
<td>07/01/04 - 06/30/05</td>
<td>$37,143</td>
<td></td>
</tr>
</tbody>
</table>

**Biostatistics, Bioinformatics and Epidemiology**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abell, Jill</td>
<td>Principal Investigator</td>
<td>Differences in Risk of Overweight and Obesity on Cardiovascular Outcomes for Blacks and Whites</td>
<td>Amer. Heart Assoc.</td>
<td>07/01/04 - 06/30/05</td>
<td>$20,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Training of Toolmakers for Bio-Medical Informatics (TTB*)</td>
<td>NIH/NLM</td>
<td>07/01/04 - 06/30/05</td>
<td>$456,789</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Army Unintended Pregnancy Study</td>
<td>Amer. Medical Assoc.</td>
<td>07/01/04 - 06/30/05</td>
<td>$170,475</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MM-0266-03/03</td>
<td>07/01/04 - 06/30/05</td>
<td>$18,381</td>
<td></td>
</tr>
<tr>
<td><strong>Almeida, Jonas</strong></td>
<td>Co-PI or Project Leader</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Proteomics Center - Administrative Core C: Bioinformatics Core Unit</td>
<td>Sponsor: NIH/NHLBI Total: $133,904</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI: Daniel Knapp</td>
<td>Dept: Cell and Molecular Pharmacology</td>
<td>Award: N01-HV-281-81-000 (02030610-34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Co-investigator</strong></th>
<th>Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Gregory Warr</td>
<td>Sponsor: NSF Total: $112,051</td>
</tr>
<tr>
<td>Dept: Biochemistry and Molecular Biology</td>
<td>Award: MCB-0315393 (03021801-2)</td>
</tr>
</tbody>
</table>

| National Heart, Lung and Blood Institute Proteomics Administrative Center | Sponsor: NIH/NHLBI Total: $330,814 |
| PI: Margaret Schachte | Dept: Library | Award: N01 HV 28181 (03042202-3) |

| South Carolina COBRE for Oral Health - Core B: Biostatistics Core | Sponsor: NIH/NHLBI Total: $159,910 |
| PI: Steven London | Dept: Microbiology and Immunology - CODM | Award: 5 P20 RR017696-03 (04052806-8) |

| DOD Phase VII: Prostate Cancer Proteomics in African-American Men | Sponsor: Geo-Centers, Inc. Total: $50,000 |
| PI: Andrew Kraft | Dept: Medicine | Award: GC-3609-04-43766CM (04113022-9) |

<table>
<thead>
<tr>
<th><strong>Carter, Rickey</strong></th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALS Creatine Study</strong></td>
<td>Sponsor: Carolinas Healthcare Budget Dates: 12/01/04 - 02/25/06 Direct: $7,969</td>
</tr>
<tr>
<td>Award: 30282 (03031102)</td>
<td>Project Dates: 12/01/02 - 02/25/06 F &amp; A: 4,050</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Co-PI or Project Leader</strong></th>
<th>Understanding and Eliminating Health Disparities: Biostatistics Core</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Barbara Tilley</td>
<td>Sponsor: AHCPR/AHRQ Total: $245,625</td>
</tr>
<tr>
<td>Dept: Biostatistics, Bioinformatics and Epidemiology</td>
<td>Award: 5 P01 HS010871-05 (04052807-4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Durkalski, Valerie</strong></th>
<th>Co-PI or Project Leader</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimization of TMS for Depression-Coordinating Center: Data Coordination Unit</td>
<td>Sponsor: NIH/NIMH Total: $75,473</td>
</tr>
<tr>
<td>PI: Mark George</td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hill, Elizabeth</strong></th>
<th>Co-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOD Phase VII: MALDI-TOF Prognostics in Esophageal Cancer</td>
<td>Sponsor: Geo-Centers, Inc. Total: $50,000</td>
</tr>
<tr>
<td>PI: Andrew Kraft</td>
<td>Dept: Medicine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Hoel, David</strong></th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savannah River Site Former Production Workers Medical Surveillance Program-Phase II Year 5</td>
<td>Sponsor: DOE Budget Dates: 09/01/03 - 11/30/05 Direct: $85,315</td>
</tr>
<tr>
<td>Award: DE-FC03-97SF21513 (03111404)</td>
<td>Project Dates: 09/25/97 - 11/30/05 F &amp; A: 36,685</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Knapp, Rebecca</strong></th>
<th>Co-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telepsychiatry Service Delivery to Trauma Victims</td>
<td>Sponsor: AHCPR/AHRQ Total: $166,387</td>
</tr>
<tr>
<td>PI: B. Frueh</td>
<td>Dept: Psychiatry and Behavioral Sciences</td>
</tr>
</tbody>
</table>

| Comparing Three Electrode Placements to Optimize ECT | Sponsor: Mayo Clinic Total: $17,123 |
| PI: Hilary Bernstein | Dept: Psychiatry and Behavioral Sciences | Award: 5 R01 MH62357-03 (04072303-1) |

| Comparing Three Electrode Placements to Optimize ECT | Sponsor: New Jersey Medical Scho Total: $67,808 |
| PI: Hilary Bernstein | Dept: Psychiatry and Behavioral Sciences | Award: R01 MH67201 (04072705-1) |

| CBT for PTSD Among Public Sector Consumers | Sponsor: NIH/NIMH Total: $195,500 |
| PI: B. Frueh | Dept: Psychiatry and Behavioral Sciences | Award: 5 R21 MH065248-03 (04102906-1) |

<table>
<thead>
<tr>
<th><strong>Lackland, Daniel</strong></th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black Pooling Project</td>
<td>Sponsor: NIH/NHLBI Budget Dates: 07/01/04 - 06/30/05 Direct: $150,000</td>
</tr>
<tr>
<td>Award: 1 R01 HL72377-02 (02020110)</td>
<td>Project Dates: 07/01/03 - 06/30/06 F &amp; A: 69,000</td>
</tr>
</tbody>
</table>
### Bench to Bedside Research on Type 1 Diabetes and Its Complications

**Sponsor:** Univ. of Oklahoma  
**Budget Dates:** 09/30/04 - 08/31/05  
**Direct:** $8,102  

### Apolipoprotein-Defined Plasma Lipoproteins in Type 1 Diabetic Subjects with Nephropathy

**Sponsor:** Oklahoma University Health Sc. Center  
**Budget Dates:** 04/01/04 - 09/29/04  
**Direct:** $4,051  

### Differences in Risk of Overweight and Obesity on Cardiovascular Outcomes for Blacks and Whites

**PI:** Jill Abell  
**Sponsor:** Amer. Heart Assoc.  
**Total:** $20,000  

### Markers and Mechanisms of Vascular Disease in Diabetes: Core B- Biostatistics and Epidemiology Core

**PI:** Maria Lopes-Virella  
**Sponsor:** NIH/NHLBI  
**Total:** $189,385  

### Dihidropyridine Calcium Channel Blockers, Blood Pressures and Serum Creatinine in Diabetic Hypertensives

**PI:** Brent Egan  
**Sponsor:** Pfizer, Inc.  
**Total:** $137,500  

### Lackland, Daniel

**Co-PI or Project Leader**  
**Differences in Risk of Overweight and Obesity on Cardiovascular Outcomes for Blacks and Whites**  
**PI:** Jill Abell  
**Sponsor:** Amer. Heart Assoc.  
**Total:** $20,000  

### Immune Mechanisms of Micro/Macrovascular Disease in Type 1 Diabetes

**PI:** Maria Lopes-Virella  
**Sponsor:** Juvenile Diabetes Fdn.  
**Total:** $232,261  

### Stroke Belt Elimination InitiativeCommunity Initiatives to Eliminate Stroke

**PI:** Brent Egan  
**Sponsor:** DHHS/PHS  
**Total:** $421,972  

### Lipsitz, Stuart

**Principal Investigator**  
**Statistical Methods for Cardiotoxicity Studies in Aids**  
**Sponsor:** NIH/NIAID  
**Budget Dates:** 12/01/04 - 11/30/05  
**Direct:** $200,000  

### Martin, Renee

**Co-Investigator**  
**Human Serum Albumin Therapy for Stroke**  
**PI:** Yuko Palesch  
**Sponsor:** Univ. of Miami  
**Total:** $39,222  

### McHenry, Brent

**Co-Investigator**  
**Markers and Mechanisms of Vascular Disease in Diabetes: Core B- Biostatistics and Epidemiology Core**  
**PI:** Maria Lopes-Virella  
**Sponsor:** NIH/NHLBI  
**Total:** $189,385  

### Nicholas, Joyce

**Principal Investigator**  
**The Effect of Statin Pre-Treatment on Infarct Volume and Clinical Outcome in Ischemic Stroke**  
**Sponsor:** Pfizer, Inc.  
**Budget Dates:** 08/31/04 - 03/30/06  
**Direct:** $75,338  

### Predictors of Skin Cancer in Commercial Airline Pilots

**Sponsor:** NIH/NCI  
**Budget Dates:** 05/01/05 - 04/30/06  
**Direct:** $50,000  

---

**Lackland, Daniel**  
**Co-PI or Project Leader**  
**Differences in Risk of Overweight and Obesity on Cardiovascular Outcomes for Blacks and Whites**  
**PI:** Jill Abell  
**Sponsor:** Amer. Heart Assoc.  
**Total:** $20,000  

**Smaller**  
**Comments**
Nicholas, Joyce

Co-Investigator
Population-Based Surveillance of Autism Spectrum Disorders
Pl: Jane Charles  Sponsor: CDC  Total: $ 272,434
Dept: Pediatrics  Award: UR3/CCU418882-05 (04042205-1)

Nietert, Paul

Co-Investigator
NIAMS MCRC in Rheumatoid Disease-Methodology Core
Pl: Richard Silver  Sponsor: NIH/NIAMS  Total: $ 137,437
Dept: Medicine  Award: 5 P60 AR049459-03 (05012859-2)

O'Rourke, Kathleen

Co-Investigator
Best Chance
Pl: Janice Key  Sponsor: DHHS  Total: $ 183,372
Dept: Pediatrics  Award: 5 APHPA002071-03-00 (04033009-1)

Palesch, Yuko

Principal Investigator
The ALIAS Trial (ALBUMIN IN ACUTE STROKE): A Phase II/III, Randomized, Multi-Center, Clinical Trial of High-Dose Albumin Therapy for Neuroprotection in Acute Ischemic Stroke
Sponsor: Univ. of Miami  Budget Dates: 04/01/04 - 03/31/05  Direct: $ 32,000
Award: 1 R34 NS048784-01 (03082001)  Project Dates: 04/01/04 - 03/31/05  F & A: 14,720

Interventional Management of Stroke III Planning Grant
Sponsor: Univ. of Cincinnati  Budget Dates: 09/24/04 - 08/31/05  Direct: $ 21,904
Award: R34-NS049722-01 (03121201)  Project Dates: 07/01/04 - 06/30/05  F & A: 10,076

PROfESS- Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis
Sponsor: Boehringer Ingelheim Pharmaceuticals  Budget Dates: 07/08/04 - 01/31/09  Direct: $ 133,120

SMC Statistical Services EFC5286
Sponsor: Sanofi Synthelabo, Inc.  Budget Dates: 05/01/04 - 12/31/06  Direct: $ 36,000
Award: 04070103  Project Dates: 05/01/04 - 12/31/06  F & A: 9,000

ALS Creatine Study
Sponsor: Avicena  Budget Dates: 05/01/04 - 10/01/05  Direct: $ 49,150
Award: 04082306  Project Dates: 05/01/04 - 10/01/05  F & A: 12,779

EKOS Contract
Sponsor: Ekos Corp.  Budget Dates: 08/12/04 - 08/13/05  Direct: $ 27,681
Award: 04082307  Project Dates: 08/12/04 - 08/13/05  F & A: 7,197

Human Serum Albumin Therapy for Stroke
Sponsor: Univ. of Miami  Budget Dates: 08/15/04 - 07/31/05  Direct: $ 39,222
Award: 04111272  Project Dates: 08/15/04 - 07/31/05  F & A: 18,742

Antihypertensive Treatment in Acute Cerebral Hemorrhage
Sponsor: New Jersey Medical School  Budget Dates: 09/15/04 - 05/31/05  Direct: $ 81,438
Award: 1 R01 NS044976-01A2 (04111278)  Project Dates: 09/15/04 - 05/31/07  F & A: 37,461

Pickelsimer, E.

Co-Investigator
The South Carolina Traumatic Brain Injury Registry & Surveillance of TBI in the ED
Pl: Anbesaw Selassie  Sponsor: CDC  Total: $ 490,304
Dept: Biostatistics, Bioinformatics and Epidemi  Award: U17/CCU421926-03 (04041602-1)

South Carolina Epidemiological Studies of Epilepsy and Seizure
Pl: Anbesaw Selassie  Sponsor: AAMC  Total: $ 242,632
Dept: Biostatistics, Bioinformatics and Epidemi  Award: U36/CCU319276 MM-0304-03/ (04050404-1)

South Carolina Health Outcome Project on Epilepsy
Pl: Anbesaw Selassie  Sponsor: AAMC  Total: $ 359,589
Dept: Biostatistics, Bioinformatics and Epidemi  Award: U36/CCU319276 (04080302-1)
Schwacke, John  
**Principal Investigator**

Marine Mammal Radio Tag Tracking Method Development  
Sponsor: NOAA  
Award: NCNS4000-5-00169 (05040175)  
Budget Dates: 04/01/05 - 06/30/05  
Direct: $ 5,295  
Project Dates: 04/01/05 - 06/30/05  
F & A: 2,436

Selassie, Anbesaw  
**Principal Investigator**

The South Carolina Traumatic Brain Injury Registry & Surveillance of TBI in the ED  
Sponsor: CDC  
Award: U17/CCU421926-03 (04041602)  
Budget Dates: 08/01/04 - 07/31/06  
Direct: $490,304  
Project Dates: 08/01/04 - 07/31/06  
F & A: 97,528

South Carolina Epidemiological Studies of Epilepsy and Seizure  
Sponsor: AAMC  
Award: U36/CCU319276 MM-0304-03/ (04050404)  
Budget Dates: 01/01/05 - 09/30/05  
Direct: $242,632  
Project Dates: 01/01/05 - 09/30/05  
F & A: 67,387

South Carolina Health Outcome Project on Epilepsy  
Sponsor: AAMC  
Award: U36/CCU319276 (04080302)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $165,411  
Project Dates: 07/01/04 - 06/30/05  
F & A: 0

SC Traumatic Brain Injury (TBI) Surveillance Program  
Sponsor: SC DHEC  
Award: CY-04-019 (04091504)  
Budget Dates: 08/01/04 - 07/31/05  
Direct: $38,039  
Project Dates: 08/01/04 - 07/31/05  
F & A: 9,890

Bridge Funding Support for the SC Statewide Traumatic Spinal Cord Injury Surveillance and Registry System and Participant Pool  
Sponsor: SC Spinal Cord Injury Fund  
Award: SCIRF 1004 (04100702)  
Budget Dates: 07/01/04 - 06/30/06  
Direct: $111,965  
Project Dates: 07/01/04 - 06/30/06  
F & A: 0

Sinha, Debajyoti  
**Principal Investigator**

Semiparametric Bayesian Survival Analysis  
Sponsor: NIH/NCI  
Award: 5 R01 CA069222-08 (04070115)  
Budget Dates: 09/01/04 - 08/31/06  
Direct: $125,000  
Project Dates: 09/01/04 - 08/31/06  
F & A: 36,340

Co-Investigator  
**Statistical Methods for Cardiotoxicity Studies in Aids**  
PI: Stuart Lipsitz  
Sponsor: NIH/NIAID  
Dept: Biostatistics, Bioinformatics and Epidemiology  
Award: 1 R01 AI060373-01A1 (04042603-1)

Slate, Elizabeth  
**Co-PI or Project Leader**

DOD Phase VI: Project 19  
PI: Carolyn Reed  
Sponsor: Geo-Centers, Inc.  
Dept: Surgery  
Award: GC-3532-03-42153CM (03080703-46)  
Total: $25,642

South Carolina COBRE for Oral Health - Core B: Biostatistics Core  
PI: Steven London  
Sponsor: NIH/NCRR  
Dept: Microbiology and Immunology - CODM  
Award: 5 P20 RR017696-03 (04052806-8)  
Total: $159,910

Co-Investigator  
**Undiagnosed Diabetes: Predictors and Comorbidities**  
PI: Richell Koopman  
Sponsor: NIH/NIDDK  
Dept: Family Medicine  
Award: 1 R21 DK067130-01A1 (04022401)  
Total: $100,000

Oral Health Infrastructure Development at MUSC  
PI: Steven London  
Sponsor: NIH/NIDCR  
Dept: Microbiology and Immunology - CODM  
Award: 1 U24 DE016508-01 (04051902-1)  
Total: $1,000,000

Tilley, Barbara  
**Principal Investigator**

SC Cooperative for Healthy Aging in Minority Populations  
Sponsor: NIH/NIA  
Award: 5 P30 AG021677-03 (04022401)  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $588,295  
Project Dates: 09/01/04 - 08/31/05  
F & A: 202,517

Parkinson's Disease Clinical Trial: Statistical Disease  
Sponsor: NIH/NINDS  
Award: 5 U01 NS043127-04 (04052717)  
Budget Dates: 08/01/04 - 07/31/05  
Direct: $282,689  
Project Dates: 08/01/04 - 07/31/05  
F & A: 107,961

Understanding and Eliminating Health Disparities in Blacks in South Carolina  
Sponsor: AHCPR/AHRQ  
Award: 5 P01 HS010871-05 (04052807)  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $1,617,984  
Project Dates: 09/01/04 - 08/31/05  
F & A: 638,925
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s Disease Clinical Trial: Statistical Center</td>
<td>NIH/NINDS</td>
<td>08/01/04 - 07/31/05</td>
<td>$27,521</td>
<td></td>
</tr>
<tr>
<td>Parkinson’s Disease Clinical Trial: Statistical Center - Administrative Supplement</td>
<td>NIH/NINDS</td>
<td>08/01/04 - 07/31/05</td>
<td>$48,530</td>
<td></td>
</tr>
<tr>
<td>t-PA Stroke Trial</td>
<td>NIH/NINDS</td>
<td>04/01/05 - 03/31/06</td>
<td>$42,209</td>
<td></td>
</tr>
<tr>
<td>t-PA Stroke Trial</td>
<td>NIH/NINDS</td>
<td>04/01/02 - 03/31/07</td>
<td>$18,150</td>
<td></td>
</tr>
<tr>
<td>t-PA Stroke Trial</td>
<td>NIH/NINDS</td>
<td>09/30/01 - 07/31/06</td>
<td>$12,660</td>
<td></td>
</tr>
<tr>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health - Administrative Core</td>
<td>NIH/NIHDA</td>
<td>03/03/09-01</td>
<td>$130,675</td>
<td></td>
</tr>
<tr>
<td>CBT and Modafinil for Cocaine Addiction</td>
<td>NIH/NID</td>
<td>04/03/03-06</td>
<td>$293,176</td>
<td></td>
</tr>
<tr>
<td>Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis</td>
<td>FDA</td>
<td>04/03/01-10</td>
<td>$234,434</td>
<td></td>
</tr>
<tr>
<td>Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis</td>
<td>FDA</td>
<td>04/03/02-11</td>
<td>$234,434</td>
<td></td>
</tr>
<tr>
<td>Understanding and Eliminating Health Disparities in Blacks in South Carolina - Project 3: An Exploration of Racial Differences in End-Of-Life Care Preferences Among Cancer and CHF Patients in South Carolina</td>
<td>AHCPR/AHRQ</td>
<td>04/03/04-07</td>
<td>$322,400</td>
<td></td>
</tr>
<tr>
<td>CBT and Modafinil for Cocaine Addiction</td>
<td>NIH/NID</td>
<td>04/03/03-06</td>
<td>$293,176</td>
<td></td>
</tr>
<tr>
<td>Clinical Investigation of Drug Abuse Disorders</td>
<td>NIH/NIDA</td>
<td>02/03/04-05</td>
<td>$137,624</td>
<td></td>
</tr>
<tr>
<td>Understanding and Eliminating Health Disparities in Blacks in South Carolina - Project 3: An Exploration of Racial Differences in End-Of-Life Care Preferences Among Cancer and CHF Patients in South Carolina</td>
<td>AHCPR/AHRQ</td>
<td>04/03/04-07</td>
<td>$322,400</td>
<td></td>
</tr>
<tr>
<td>Tobacco Prevention/Cessation Education: Medical Students</td>
<td>Boston Univ.</td>
<td>07/01/04 - 06/30/05</td>
<td>$20,863</td>
<td></td>
</tr>
<tr>
<td>Tobacco Prevention/Cessation Education: Medical Students</td>
<td>Boston Univ.</td>
<td>07/26/02 - 06/30/07</td>
<td>$1,669</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive Treatment in Acute Cerebral Hemorrhage</td>
<td>New Jersey Medical Scho</td>
<td>04/03/04-05</td>
<td>$81,438</td>
<td></td>
</tr>
<tr>
<td>Antihypertensive Treatment in Acute Cerebral Hemorrhage</td>
<td>New Jersey Medical Scho</td>
<td>04/03/04-05</td>
<td>$81,438</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: Molecular Profiling for Identification of Diagnostic and Prognostic Markers of Bladder Cancer</td>
<td>Geo-Centers, Inc.</td>
<td>04/03/04-04</td>
<td>$80,000</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: Molecular Profiling for Identification of Diagnostic and Prognostic Markers of Bladder Cancer</td>
<td>Geo-Centers, Inc.</td>
<td>04/03/04-04</td>
<td>$80,000</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: Proteomic Studies to Identify Novel Therapeutic Targets for Treatment of Kidney Cancers Involving VHL</td>
<td>Geo-Centers, Inc.</td>
<td>04/03/04-04</td>
<td>$85,765</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: Proteomic Studies to Identify Novel Therapeutic Targets for Treatment of Kidney Cancers Involving VHL</td>
<td>Geo-Centers, Inc.</td>
<td>04/03/04-04</td>
<td>$85,765</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: Ceramide Metabolizing Enzymes, Cancer Lipidomics and Gene Expression as a Function of Gleason Grade in Prostate Cancer</td>
<td>Geo-Centers, Inc.</td>
<td>04/03/04-04</td>
<td>$85,765</td>
<td></td>
</tr>
</tbody>
</table>
### Cell Biology and Anatomy

#### Argraves, Kelley

**Principal Investigator**

**The Role of Sphingosine-1-Phosphate in Vasculogenesis and Angiogenesis**

- **Sponsor:** Amer. Heart Assoc.
- **Budget Dates:** 01/01/05 - 12/31/05
- **Direct:** $59,091
- **Award:** 0230245N (01071302)

**Co-PI or Project Leader**

**SC Cobre in Lipidomics & Pathobiology: Project 1- Role of Sphingosine-1-Phosphate in Early Blood Vessel Formation**

- **PI:** Lina Obeid
- **Dept:** Biochemistry and Molecular Biology
- **Budget Dates:** 01/01/02 - 12/31/05
- **Total:** $139,538

**Co-Investigator**

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**

- **PI:** Yusuf Hannun
- **Dept:** Biochemistry and Molecular Biology
- **Budget Dates:** 01/01/02 - 12/31/05
- **Total:** $177,113

#### Argraves, W.

**Principal Investigator**

**Creating a Publicly Accessible Archive of Space Flight Transcriptomic Data (SC EPSCoR Program)**

- **Sponsor:** SC Research Authority
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $17,340
- **Award:** 0006 (04061701)

**Creating a Publicly Accessible Archive of Space Flight Transcriptomic Data**

- **Sponsor:** Coll. of Charleston
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $18,182
- **Award:** NCC5-575 (04090901)

**NASA REU in Bioastronautics at MUSC**

- **Sponsor:** Coll. of Charleston
- **Budget Dates:** 11/01/04 - 05/31/05
- **Direct:** $8,200
- **Award:** SCSGC-REU-NGT5-40099 (04110549)

**The Role of Megalin in Cranofacial Development**

- **Sponsor:** NIH/NIDCR
- **Budget Dates:** 02/01/05 - 01/31/06
- **Direct:** $200,000
- **Award:** 5 R01 DE014347-03 (04120670)

**Hollings Cancer Center Microarray Bioinformatics Facility**

- **Sponsor:** NIH/NICD
- **Budget Dates:** 05/01/03 - 01/31/07
- **Direct:** $89,700
- **Award:** 5 R24 CA095841-04 (04050709-13)

#### Bacro, Thierry

**Principal Investigator**

**GAANN in Cell and Neuro Biology**

- **Sponsor:** Dept. of Education
- **Budget Dates:** 08/15/04 - 08/14/05
- **Direct:** $207,555
- **Award:** P200A040143 (03111211)

#### Barth, Jeremy

**Principal Investigator**

**Travel Award to NASA**

- **Sponsor:** Coll. of Charleston
- **Budget Dates:** 03/01/04 - 02/28/05
- **Direct:** $1,000
- **Award:** NGTS-40099 (04110123)

**Co-Investigator**

**NASA REU in Bioastronautics at MUSC**

- **Sponsor:** Coll. of Charleston
- **Budget Dates:** 08/15/04 - 08/14/05
- **Direct:** $8,200
- **Award:** SCSGC-REU-NGT5-40099 (04110549-1)

**The Role of Megalin in Cranofacial Development**

- **Sponsor:** NIH/NIDCR
- **Budget Dates:** 05/01/03 - 01/31/07
- **Direct:** $200,000
- **Award:** 5 R01 DE014347-03 (04120670-1)
### Research Faculty Activity

#### Medical University of South Carolina

**Cell Biology and Anatomy**

**Hollings Cancer Center Microarray Bioinformatics Facility**

<table>
<thead>
<tr>
<th>PI: W. Argraves</th>
<th>Sponsor: NIH/NCI</th>
<th>Total: $ 166,305</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Cell Biology and Anatomy</td>
<td>Award: 5 R24 CA095841-04 (05030226-1)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Boockfor, Fredric**

**Principal Investigator**

**A Molecular Approach to GnRh Pulsatility**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NICHD</th>
<th>Budget Dates: 04/01/05 - 03/31/06</th>
<th>Direct: $ 180,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 HD037657-07 (05022809)</td>
<td>Project Dates: 01/05/05 - 03/31/07</td>
<td>F &amp; A: 82,800</td>
</tr>
</tbody>
</table>

---

**Drake, Christopher**

**Principal Investigator**

**Cytokine Regulation of Early Events in Blood Vessel Formation**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NHLBI</th>
<th>Budget Dates: 04/01/05 - 03/31/06</th>
<th>Direct: $ 150,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 HL057375-08 (05030227)</td>
<td>Project Dates: 01/01/99 - 03/31/07</td>
<td>F &amp; A: 69,000</td>
</tr>
</tbody>
</table>

---

**Co-Investigator**

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**

<table>
<thead>
<tr>
<th>PI: Yusuf Hannun</th>
<th>Sponsor: NIH/NCI</th>
<th>Total: $ 177,113</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Biochemistry and Molecular Biology</td>
<td>Award: 1 P01 CA97132-02 (01100808-8)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Tissue Reconstituting Potential of Human Stem Cells**

<table>
<thead>
<tr>
<th>PI: Makio Ogawa</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Total: $ 225,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Medicine</td>
<td>Award: 1 R01 HL075699-01A2 (04070111-1)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Transdifferentiation Potential of Bone Marrow Stem Cells**

<table>
<thead>
<tr>
<th>PI: Makio Ogawa</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Total: $ 250,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Medicine</td>
<td>Award: 5 R01 HL069123-03 (05021124-1)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Eisenberg, Leonard**

**Principal Investigator**

**Regulation of Heart Formation by Non-Canonical WNT Signal Transduction**

<table>
<thead>
<tr>
<th>Sponsor: Amer. Heart Assoc.</th>
<th>Budget Dates: 07/01/04 - 06/30/05</th>
<th>Direct: $ 60,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 0355766U (03011704)</td>
<td>Project Dates: 07/01/04 - 06/30/05</td>
<td>F &amp; A: 6,000</td>
</tr>
</tbody>
</table>

---

**Non-Canonical WNT Signal Transduction and Cardiogenesis**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NHLBI</th>
<th>Budget Dates: 04/01/05 - 03/31/06</th>
<th>Direct: $ 225,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 1 R01 HL073190-01A2 (04082301)</td>
<td>Project Dates: 04/01/05 - 03/31/09</td>
<td>F &amp; A: 95,220</td>
</tr>
</tbody>
</table>

---

**Co-Investigator**

**Patterning by Invasive Mesenchyme in the Embryonic Heart: Project 2-Induction and Pattern Formation in the cardiac His-Purkinje System**

<table>
<thead>
<tr>
<th>PI: Robert Gourdie</th>
<th>Sponsor: NIH/NICHD</th>
<th>Total: $ 140,920</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Cell Biology and Anatomy</td>
<td>Award: 5 P01 HD039946-05 (05040892-3)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Gourdie, Robert**

**Principal Investigator**

**Patterning of GAP Junction Coupling in Developing Heart**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NHLBI</th>
<th>Budget Dates: 07/01/04 - 06/30/05</th>
<th>Direct: $ 175,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 HL056728-08 (04050603)</td>
<td>Project Dates: 07/01/02 - 06/30/06</td>
<td>F &amp; A: 80,500</td>
</tr>
</tbody>
</table>

---

**Patterning by Invasive Mesenchyme in the Embryonic Heart**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NICHD</th>
<th>Budget Dates: 05/01/05 - 04/30/06</th>
<th>Direct: $ 1,015,167</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 P01 HD039946-05 (05040892)</td>
<td>Project Dates: 06/28/01 - 04/30/06</td>
<td>F &amp; A: 222,846</td>
</tr>
</tbody>
</table>

---

**Co-Investigator**

**SC 2004 Research Infrastructure Improvement Grant: MUSC Phenomics Center**

<table>
<thead>
<tr>
<th>PI: Mark Kindy</th>
<th>Sponsor: SC Research Authority</th>
<th>Total: $ 688,147</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: Task Order#0016 (04080503-1)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Kern, Michael**

**Co-PI or Project Leader**

**Characterizing Disease Implications of Translational Regulation of a Homeobox Gene in Cardiac Tissue**

<table>
<thead>
<tr>
<th>PI: Richard Peterson</th>
<th>Sponsor: Amer. Heart Assoc.</th>
<th>Total: $ 20,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Cell Biology and Anatomy</td>
<td>Award: 0315350U (03012111-2)</td>
<td></td>
</tr>
</tbody>
</table>

---

**SC COBRE for Cardiovascular Disease: Admin Core B - Transgenic Mouse Core**

<table>
<thead>
<tr>
<th>PI: Roger Markwald</th>
<th>Sponsor: NIH/NCCR</th>
<th>Total: $ 190,549</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dept: Cell Biology and Anatomy</td>
<td>Award: 5 P20 RR016434-04 (04050709-11)</td>
<td></td>
</tr>
</tbody>
</table>

---

---

38 Annual Report for Research FY2005
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Description</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total:</th>
<th>Dept</th>
<th>Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krug, Edward</td>
<td>Co-PI or Project Leader</td>
<td>Cardiovascular Proteomics Center - Project 2: Extracellular Matrix-Mediated Epithelial to Mesenchymal</td>
<td>Daniel Knapp</td>
<td>NIH/NHLBI</td>
<td>$122,230</td>
<td>Cell and Molecular Pharmacology</td>
<td>N01-HV-281-81-000 (02030610-27)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patterning by Invasive Mesenchyme in the Embryonic Heart: Project 4-Myocardial Induction of Epicardial Transformation</td>
<td>Robert Gourdie</td>
<td>NIH/NICHD</td>
<td>$118,609</td>
<td>Cell Biology and Anatomy</td>
<td>5 P01 HD039946-05 (05040892-5)</td>
</tr>
<tr>
<td>Kubalak, Steven</td>
<td>Co-PI or Project Leader</td>
<td>Patterning by Invasive Mesenchyme in the Embryonic Heart: Core C-Animal Core</td>
<td>Robert Gourdie</td>
<td>NIH/NICHD</td>
<td>$197,844</td>
<td>Cell Biology and Anatomy</td>
<td>5 P01 HD039946-05 (05040892-8)</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Patterning of GAP Junction Coupling in Developing Heart</td>
<td>Robert Gourdie</td>
<td>NIH/NHLBI</td>
<td>$175,000</td>
<td>Cell Biology and Anatomy</td>
<td>5 R01 HL056728-08 (04050603-1)</td>
</tr>
<tr>
<td>Markwald, Roger</td>
<td>Principal Investigator</td>
<td>Lineage Mapping Within the Mouse Outflow Tract</td>
<td>W. Argraves</td>
<td>NIH/NIDCR</td>
<td>$200,000</td>
<td>Cell Biology and Anatomy</td>
<td>5 R01 DE014347-03 (04120670-1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mucopolysaccharide Metabolism in Cardiac Anomalies</td>
<td>NIH/NHLBI</td>
<td></td>
<td></td>
<td></td>
<td>5 R01 HL033756-22 (04050708)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC COBRE for Cardiovascular Disease</td>
<td>NIH/NCRR</td>
<td></td>
<td></td>
<td></td>
<td>5 P20 RR016434-04 (04050709)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NASA/EPSCOR: Cardiovascular Tissue Engineering</td>
<td>Coll. of Charleston</td>
<td></td>
<td></td>
<td></td>
<td>NCC5-575 (04090902)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular Tissue Engineering</td>
<td>SC EPSCOR</td>
<td></td>
<td></td>
<td></td>
<td>NCC5-575 (04090903)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lineage Mapping within the Mouse Outflow Tract</td>
<td>Univ. of Indiana</td>
<td></td>
<td></td>
<td></td>
<td>R01 HL077342 (05060738)</td>
</tr>
<tr>
<td>McCarthy, Robert</td>
<td>Co-Investigator</td>
<td>The Role of Megalin in Cranofacial Development</td>
<td>W. Argraves</td>
<td>NIH/NIDCR</td>
<td>$200,000</td>
<td>Cell Biology and Anatomy</td>
<td>5 R01 DE014347-03 (04120670-1)</td>
</tr>
<tr>
<td>Mironov, Vladimir</td>
<td>Principal Investigator</td>
<td>Second International Workshop on Bioprinting, Biopatterning and Bioassembly</td>
<td>Univ. of South Carolina</td>
<td></td>
<td>$10,000</td>
<td></td>
<td>1 P20 RR16461-04/22050-FA (04120139)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Second International Workshop on Bioprinting, Biopatterning and Bioassembly</td>
<td>Whitaker Fdn.</td>
<td></td>
<td>$5,000</td>
<td></td>
<td>(04120666)</td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>SC COBRE for Cardiovascular Disease: Project 8- Engineered Vascularized Perfused Three-Dimensional Myocardial Tissue Construct</td>
<td>Roger Markwald</td>
<td>NIH/NCRR</td>
<td>$75,000</td>
<td>Cell Biology and Anatomy</td>
<td>5 P20 RR016434-04 (04050709-7)</td>
</tr>
</tbody>
</table>

Annual Report for Research FY2005 39
Misra, Suniti

**Principal Investigator**

**Hyaluronan and Drug Resistance**

**Sponsor:** Univ. of South Carolina  
**Award:** 1 P20 RR17698-02 (04110115)

**Budget Dates:** 09/01/04 - 08/31/05  
**Direct:** $ 53,957

**F & A:** $ 21,043

**Co-Investigator**

**Inhibition of Tumor Progression by Hyaluronan Oligomers**

**PI:** Bryan Toole  
**Sponsor:** NIH/NCI

**Budget Dates:** 06/01/03 - 05/31/06  
**Direct:** $ 2,400

**F & A:** $ 0

---

Mitchell, Jonathan

**Principal Investigator**

**NIH Predoctoral Dental Scientist Fellowship**

**Sponsor:** NIH/NIDCR  
**Award:** 1 F30 DE016776-01 (04080601)

**Budget Dates:** 04/01/05 - 03/31/06  
**Direct:** $ 39,331

**F & A:** $ 0

**Localization of the Two Prx1 Isoforms in Avian Mandibular Chondrogenesis**

**Sponsor:** Amer. Assoc. for Dental Research  
**Award:** (05011475)

**Budget Dates:** 06/01/05 - 05/31/06  
**Direct:** $ 200,000

**F & A:** $ 86,000

---

Mjaatvedt, Corey

**Principal Investigator**

**CSPG2 Gene and Cardiac Outlet Morphogenesis**

**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL066231-04 (04050501)

**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $ 200,000

**F & A:** $ 68,967

---

Muise-Helmericks, Robin

**Co-PI or Project Leader**

**SC COBRE for Cardiovascular Disease: Project 5 - Functional Role of ETS 1 and AKT in Angiogenesis**

**PI:** Roger Markwald  
**Sponsor:** NIH/NCRR

**Budget Dates:** 03/01/05 - 02/28/06  
**Direct:** $ 20,000

**F & A:** $ 0

---

Peterson, Richard

**Principal Investigator**

**Characterizing Disease Implications of Translational Regulation of a Homeobox Gene in Cardiac Tissue**

**Sponsor:** Amer. Heart Assoc.  
**Award:** 0315350U (03012111)

**Budget Dates:** 07/01/02 - 06/30/05  
**Direct:** $ 150,000

**F & A:** $ 0

---

Ramsdell, Ann

**Principal Investigator**

**Left-Right Axis Determination and Cardiac Development**

**Sponsor:** Univ. of South Carolina  
**Award:** 5 R01 HL73270-03 (04110116)

**Budget Dates:** 08/01/93 - 02/28/08  
**Direct:** $ 153,260

**F & A:** $ 68,967

**Co-Investigator**

**Non-Canonical WNT Signal Transduction and Cardiogenesis**

**PI:** Leonard Eisenberg  
**Sponsor:** NIH/NHLBI

**Budget Dates:** 09/01/02 - 07/31/05  
**Direct:** $ 225,000

**F & A:** $ 0

---

Sedmera, David

**Co-PI or Project Leader**

**SC COBRE for Cardiovascular Disease: Project 6 - Strategies for Prenatal Repair of Hypoplastic Myocardium**

**PI:** Roger Markwald  
**Sponsor:** NIH/NCRR

**Budget Dates:** 08/01/04 - 07/31/05  
**Direct:** $ 120,000

**F & A:** $ 0

---

Thattak, Shibanath

**Co-Investigator**

**Inhibition of Tumor Progression by Hyaluronan Oligomers**

**PI:** Bryan Toole  
**Sponsor:** NIH/NCI

**Budget Dates:** 06/01/03 - 05/31/06  
**Direct:** $ 180,000

**F & A:** $ 0

---

Thompson, Robert

**Principal Investigator**

**Myocyte Proliferation in Embryonic Chick Heart**

**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL050582-11 (05012532)

**Budget Dates:** 03/01/05 - 02/28/06  
**Direct:** $ 200,000

**F & A:** $ 92,000

**Co-PI or Project Leader**

**SC COBRE for Cardiovascular Disease: Admin Core C - Confocal Imaging Core**

**PI:** Roger Markwald  
**Sponsor:** NIH/NCRR

**Budget Dates:** 09/01/04 - 08/31/05  
**Direct:** $ 143,140

**F & A:** $ 0
<table>
<thead>
<tr>
<th>Role of Ets Genes in Transformation and Differentiation: Core C-Cellular Function Core</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Dennis Watson</td>
</tr>
<tr>
<td>Dept: Pathology and Laboratory Medicine</td>
</tr>
</tbody>
</table>

**Thompson, Robert**

Co-Investigator

Patterning of GAP Junction Coupling in Developing Heart

| PI: Robert Gourdie | Sponsor: NIH/NHLBI | Total: $ 175,000 |
| Dept: Cell Biology and Anatomy | Award: 5 R01 HL056728-08 (04050603-1) |

**Toole, Bryan**

Principal Investigator

Inhibition of Tumor Progression by Hyaluronan Oligomers

| Sponsor: NIH/NHLBI | Total: $ 75,000 |
| Project Dates: 05/01/05 - 03/31/06 | Direct: $ 8,406 |
| F & A: 3,867 |

Genetic Control of Limb Development: Project 1

| Sponsor: Univ. of Connecticut | Total: $ 97,938 |
| Project Dates: 05/01/05 - 03/31/10 | Direct: $ 180,000 |
| F & A: 82,800 |

**Visconti, Richard**

Co-PI or Project Leader

SC COBRE for Cardiovascular Disease: Project 7- Hematopoietic Stem Cells in Cardiovascular Regenerative Medicine

| PI: Roger Markwald | Sponsor: NIH/NCRR | Total: $ 75,000 |
| Dept: Cell Biology and Anatomy | Award: 5 P20 RR016434-04 (04050709-6) |

**Wessels, Arno**

Co-PI or Project Leader

Patterning by Invasive Mesenchyme in the Embryonic Heart: Core B - Morphology and Imaging Core

| PI: Robert Gourdie | Sponsor: NIH/NICHD | Total: $ 97,938 |
| Dept: Cell Biology and Anatomy | Award: 5 P01 HD039946-05 (05040892-7) |

**Cell and Molecular Pharmacology**

**Halushka, Perry**

Principal Investigator

Graduate Education at the Interface of Human Biology and New Technologies

| Sponsor: Dept. of Education | Total: $ 230,000 |
| Project Dates: 08/15/04 - 08/14/05 | Direct: $ 290,577 |
| F & A: 0 |

Training Program for Medical Scientists

| Sponsor: NIH/NIGMS | Total: $ 190,000 |
| Project Dates: 07/01/97 - 06/30/98 | Direct: $ 160,245 |
| F & A: 9,309 |

**Knapp, Daniel**

Principal Investigator

Cardiovascular Proteomics Center

| Sponsor: NIH/NHLBI | Total: $ 1,428,488 |
| Project Dates: 09/30/04 - 09/29/05 | Direct: $ 1,428,488 |
| F & A: 576,099 |

Guided and Biomimetic Bone Tissue Engineering

<p>| Sponsor: Clemson Univ. | Total: $ 27,680 |
| Project Dates: 07/09/04 - 07/08/06 | Direct: $ 27,680 |
| F &amp; A: 0 |</p>
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improving the Long-Term Survival and Functionality of the Transplanted Human Dopaminergic Neurons Based upon a Novel Tissue Engineering Approach</td>
<td>Clemson Univ.</td>
<td>01/16/05 - 01/15/06</td>
<td>$34,850</td>
<td>$79,744</td>
<td></td>
</tr>
<tr>
<td>Microfluidic System for Cancer Proteome Analysis</td>
<td>NIH/NCI</td>
<td>02/01/05 - 01/31/06</td>
<td>$173,357</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthetic Visual Pigments and Binding Proteins</td>
<td>NIH/NEI</td>
<td>04/01/05 - 03/31/06</td>
<td>$67,913</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Role of Retinal Pigment Epithelium in Choroidal Neovascularization</td>
<td>Amer. Health Assistance Fdn.</td>
<td>06/01/02 - 05/31/06</td>
<td>$205,015</td>
<td>$94,307</td>
<td></td>
</tr>
<tr>
<td>Histones as Antimicrobial Effectors in the Pacific White Shrimp, Lipoenaeus Vannamei</td>
<td>NSF</td>
<td>06/01/04 - 05/31/04</td>
<td>$225,000</td>
<td>$103,500</td>
<td></td>
</tr>
<tr>
<td>Determinants of Estramustine Resistance and Response</td>
<td>NIH/NCI</td>
<td>09/01/04 - 08/31/04</td>
<td>$174,890</td>
<td>$80,449</td>
<td></td>
</tr>
<tr>
<td>Preclinical Development of a Novel Glutathione Based Anticancer Drug</td>
<td>SC EPSCOR</td>
<td>09/01/04 - 08/31/04</td>
<td>$8,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione S-Transferases in Drug and Stress Response</td>
<td>NIH/NCI</td>
<td>06/01/04 - 05/31/04</td>
<td>$205,015</td>
<td>$94,307</td>
<td></td>
</tr>
<tr>
<td>Cross-Training Program for Undergraduates</td>
<td>NIH/NIGMS</td>
<td>05/01/05 - 04/30/06</td>
<td>$80,741</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Proteomics Center - Project 6: Intact Protein-Based Proteomic Analysis</td>
<td>NIH/NHLBI</td>
<td>05/01/04 - 04/30/04</td>
<td>$6,459</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Proteomics Center - Administrative Core B: Mass Spectrometry Core Unit</td>
<td>NIH/NHLBI</td>
<td>05/01/04 - 04/30/04</td>
<td>$6,459</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione S-Transferases in Drug and Stress Response</td>
<td>NIH/NCI</td>
<td>06/01/04 - 05/31/04</td>
<td>$225,000</td>
<td>$103,500</td>
<td></td>
</tr>
<tr>
<td>Preclinical Development of a Novel Glutathione Based Anticancer Drug</td>
<td>SC EPSCOR</td>
<td>09/01/04 - 08/31/04</td>
<td>$8,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione S-Transferases in Drug and Stress Response</td>
<td>NIH/NCI</td>
<td>06/01/04 - 05/31/04</td>
<td>$225,000</td>
<td>$103,500</td>
<td></td>
</tr>
<tr>
<td>Preclinical Development of a Novel Glutathione Based Anticancer Drug</td>
<td>SC EPSCOR</td>
<td>09/01/04 - 08/31/04</td>
<td>$8,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione S-Transferases in Drug and Stress Response</td>
<td>NIH/NCI</td>
<td>06/01/04 - 05/31/04</td>
<td>$225,000</td>
<td>$103,500</td>
<td></td>
</tr>
<tr>
<td>Preclinical Development of a Novel Glutathione Based Anticancer Drug</td>
<td>SC EPSCOR</td>
<td>09/01/04 - 08/31/04</td>
<td>$8,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Walle, Thomas
**Principal Investigator**
Flavonoid Bioavailability in Humans - Cellular Studies  
Sponsor: NIH/NIGMS  
Award: 5 R01 GM055561-07 (04052703)  
Budget Dates: 08/01/04 - 07/31/05  
Project Dates: 02/01/98 - 07/31/06  
Direct: $205,000  
F & A: $94,300

**Co-PI or Project Leader**
DOD Phase VI: Project 14- Ellagic Acid, an Esophageal Cancer Prevention Agent  
PI: Carolyn Reed  
Sponsor: Geo-Centers, Inc.  
Budget Dates: 09/01/04 - 08/28/05  
Direct: $1,349,415  
F & A: $468,136

---

## Webb, Jerry
**Principal Investigator**
Kinin/PGE Interaction in Control of Intracellular Pressure  
Sponsor: NIH/NEI  
Award: 1 R01 EY014653-01A2 (04070106)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/10  
Direct: $225,000  
F & A: $93,459

## Comparative Medicine

### Goodrich, James
**Principal Investigator**
The Yucatan Micropig Cardiovascular Model of Menopause  
Sponsor: NIH/NCRR  
Award: 5 R24 RR016535-04 (05031599)  
Budget Dates: 06/01/05 - 05/31/06  
Project Dates: 06/01/02 - 05/31/07  
Direct: $250,000  
F & A: $115,000

### Smith, Alison
**Principal Investigator**
Axonal Nerve Regeneration  
Sponsor: Organ Recovery Systems  
Award: 1 R43 HD047080-01 (04100803)  
Budget Dates: 09/23/04 - 09/30/05  
Project Dates: 09/23/04 - 09/30/05  
Direct: $8,700  
F & A: $4,002

### Swindle, M.
**Principal Investigator**
Vitrification for Tissue Engineered Blood Vessels  
Sponsor: Organ Recovery Systems  
Award: 1 R43 HL075876-01 (04110963)  
Budget Dates: 02/15/04 - 04/16/05  
Project Dates: 02/15/04 - 04/16/05  
Direct: $10,746  
F & A: $4,942

## Dean's Office - COM

### Browdy, Craig
**Co-Investigator**
Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp  
Pl: Gregory Warr  
Sponsor: NSF  
Budget Dates: 01/01/04 - 03/31/05  
Total: $112,051

### Cousineau, Edward
**Principal Investigator**
Integration of Physician Training and Biomedical Research in South Carolina  
Sponsor: Univ. of South Carolina  
Award: 04-0966/5205-SP (04072901)  
Budget Dates: 01/01/04 - 03/31/05  
Project Dates: 01/01/04 - 03/31/05  
Direct: $113,400  
F & A: $0

### Reed, Carolyn
**Principal Investigator**
Hollings Cancer Center Building Expansion  
Sponsor: Natl. Inst. of Standards and Technology  
Award: 60NANB00073 (03051603)  
Budget Dates: 01/01/04 - 12/31/04  
Project Dates: 09/01/00 - 12/31/05  
Direct: $1,850,000  
F & A: $0

DOD Phase VI  
Sponsor: Geo-Centers, Inc.  
Award: GC-3532-03-42153CM (03080703)  
Budget Dates: 09/01/04 - 08/28/05  
Project Dates: 09/02/03 - 08/28/05  
Direct: $1,349,415  
F & A: $468,136
Reves, Joseph

**Principal Investigator**

**General Clinical Research Center**

Sponsor: NIH/NCRR

Award: 5 M01 RR001070-29 (04113025)

Budget Dates: 03/01/05 - 02/28/06  Direct: $ 1,815,197

**F & A:** 248,038

Family Medicine

Blue, Amy

**Co-Investigator**

Faculty Development in Primary Care

**PI:** Paul Darden, Sponsor: HRSA/BHP/Medicine

**Dept:** Pediatrics, Award: 1 D14 HP00175-03-00 (02041704-4)

Faculty Development In Primary Care

**PI:** Arch Mainous, Sponsor: HRSA/BHP/Medicine

**Dept:** Family Medicine, Award: 5 D14 HP00161-03-00 (03121010-1)

Clinical Research Curriculum Award

**PI:** L. Key, Sponsor: NIH/NHLBI

**Dept:** Pediatrics, Award: 2 K30 HL004536-05 (04011407-1)

Carek, Peter

**Principal Investigator**

**Residency Training in Primary Care**

Sponsor: HRSA/BHP/Medicine

Award: 1 D58 HP03371-01-00 (03120112)

Budget Dates: 07/01/04 - 06/30/05  Direct: $ 167,560

**F & A:** 13,405

**Co-Investigator**

**Faculty Development In Primary Care**

**PI:** Arch Mainous, Sponsor: HRSA/BHP/Medicine

**Dept:** Family Medicine, Award: 5 D14 HP00161-03-00 (03121010-1)

Chessman, Alexander

**Principal Investigator**

**Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities**

Sponsor: HRSA

Award: 1 D56 HP03357-01-00 (03110601)

Budget Dates: 07/01/04 - 06/30/05  Direct: $ 186,020

**F & A:** 14,882

Diaz, Vanessa

**Principal Investigator**

**Evaluating the Relationship Between Race/Ethnicity and Cardiovascular Risk. What Is the Impact of Obesity, Diet and Physical Activity?**


Award: 051896 (04093008)

Budget Dates: 01/01/05 - 12/31/05  Direct: $ 83,808

**F & A:** 7,542

Dickerson, Lori

**Co-Investigator**

**Residency Training in Primary Care**

**PI:** Peter Carek, Sponsor: HRSA/BHP/Medicine

**Dept:** Family Medicine, Award: 1 D58 HP03371-01-00 (03120112-1)

Garr, David

**Principal Investigator**

**Bioterrorism Training and Curriculum Development Program**

Sponsor: HRSA/BHP/Medicine

Award: 5 T01HP01418-02-00 (03071106)

Budget Dates: 09/30/04 - 09/29/05  Direct: $ 1,008,618

**F & A:** 42,184

Gonsalves, Wanda

**Co-Investigator**

**Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities**

**PI:** Alexander Chessman, Sponsor: HRSA

**Dept:** Family Medicine, Award: 1 D56 HP03357-01-00 (03110601-1)

Hainer, Barry

**Co-Investigator**

**Academic Administrative Units In Primary Care**

**PI:** William Hueston, Sponsor: HRSA/BHP/Medicine

**Dept:** Family Medicine, Award: 5 D54 HP00023-05-00 (03121009-1)
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hueston, William</td>
<td>Principal Investigator</td>
<td>Academic Administrative Units In Primary Care</td>
<td>HRSA/BHP/Medicine</td>
<td>09/01/04 - 08/31/05</td>
<td>175,000</td>
<td>14,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Caring for the Future: A Collaborative Practice of Maternal and Infant Care in Rural Populations</td>
<td>Duke Endowment</td>
<td>05/15/04 - 03/31/07</td>
<td>20,535</td>
<td></td>
</tr>
<tr>
<td>Kern, Donna</td>
<td>Co-Investigator</td>
<td>Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities</td>
<td>HRSA</td>
<td>09/01/04 - 08/31/05</td>
<td>186,020</td>
<td></td>
</tr>
<tr>
<td>King, Dana</td>
<td>Principal Investigator</td>
<td>Dietary Fiber and Cardiovascular Inflammatory Markers</td>
<td>NIH/NHLBI</td>
<td>04/01/05 - 03/31/06</td>
<td>308,066</td>
<td></td>
</tr>
<tr>
<td>Koopman, Richell</td>
<td>Principal Investigator</td>
<td>Undiagnosed Diabetes: Predictors and Comorbidities</td>
<td>NIH/NIDDK</td>
<td>09/30/04 - 02/28/06</td>
<td>100,000</td>
<td>46,000</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Racial Disparities in Diabetes in the US and the UK</td>
<td>NIH/NIDDK</td>
<td>07/01/04 - 06/30/05</td>
<td>100,000</td>
<td></td>
</tr>
<tr>
<td>Mainous, Arch</td>
<td>Principal Investigator</td>
<td>Racial Disparities in Diabetes in the US and the UK</td>
<td>NIH/NIDDK</td>
<td>07/01/04 - 06/30/05</td>
<td>267,176</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>SC Cooperative for Healthy Aging in Minority Populations: Measurements and Methods Core</td>
<td>NIH/NIA</td>
<td>07/02/02 - 06/30/05</td>
<td>19,394</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Academic Administrative Units In Primary Care</td>
<td>HRSA/BHP/Medicine</td>
<td>07/01/04 - 06/30/05</td>
<td>175,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Undiagnosed Diabetes: Predictors and Comorbidities</td>
<td>NIH/NIDDK</td>
<td>07/02/02 - 06/30/05</td>
<td>100,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Dietary Fiber and Cardiovascular Inflammatory Markers</td>
<td>NIH/NHLBI</td>
<td>07/01/04 - 06/30/05</td>
<td>308,066</td>
<td></td>
</tr>
<tr>
<td>Mallin, Robert</td>
<td>Co-Investigator</td>
<td>Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities</td>
<td>HRSA</td>
<td>07/02/02 - 06/30/05</td>
<td>186,020</td>
<td></td>
</tr>
</tbody>
</table>
Ornstein, Steven

**Principal Investigator**

**Accelerating TRIP in a Practice Partner Research Network**

- **Sponsor:** Physician Micro Systems, Inc.
- **Award:** 5 U18 HS13716-02 (02101008)
- **Budget Dates:** 09/30/03 - 09/29/05
- **Direct:** $168,881
- **Project Dates:** 09/30/03 - 09/29/06
- **F & A:** $77,685

**Co-Investigator**

**Facilitating Alcohol Screening of Hypertensive Patients**

- **PI:** Peter Miller
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 1 R25 AA015066-01 (03092607-1)
- **Total:** $243,757

**DTC Advertising Effect on Adherence to Statin Therapy**

- **PI:** W. Bradford
- **Dept:** Health Administration and Policy
- **Sponsor:** NIH/NHLBI
- **Award:** 1 R01 HL077841-01 (03093014-1)
- **Total:** $175,000

**Residency Training in Primary Care**

- **PI:** Peter Carek
- **Dept:** Family Medicine
- **Sponsor:** HRSA/BHP/Medicine
- **Award:** 1 D58 HP03371-01-00 (03120112-1)
- **Total:** $167,560

Steyer, Terrence

**Principal Investigator**

**Leadership Seminar Series for Primary Care Residents and Faculty in Medicine and Dentistry**

- **Sponsor:** Amer. Medical Student Assoc.
- **Award:** (02100208)
- **Budget Dates:** 10/01/04 - 09/27/05
- **Direct:** $38,164
- **Project Dates:** 10/01/02 - 09/27/05
- **F & A:** $3,053

**Co-Investigator**

**DTC Advertising Effect on Adherence to Statin Therapy**

- **PI:** W. Bradford
- **Dept:** Health Administration and Policy
- **Sponsor:** NIH/NHLBI
- **Award:** 1 R01 HL077841-01 (03093014-1)
- **Total:** $175,000

**Correcting Under-Reporting in HCUP Inpatient Data**

- **PI:** Clara Dismuke
- **Dept:** Health Administration and Policy
- **Sponsor:** AHCPR/AHRQ
- **Award:** 1 R03 HS014075-01A1 (03112106-1)
- **Total:** $68,493

Thiedke, Carolyn

**Co-Investigator**

**Pre-doctoral Training in Primary Care: Systems Improvement to Reduce Health Disparities**

- **PI:** Alexander Chessman
- **Dept:** Family Medicine
- **Sponsor:** HRSA
- **Award:** 1 D56 HP03357-01-00 (03110601-1)
- **Total:** $186,020

Medicine

Afrin, Lawrence

**Principal Investigator**

**Anemia Training Grant/Fellowship**

- **Sponsor:** Amgen
- **Award:** (03010706)
- **Budget Dates:** 07/01/03 - 06/30/06
- **Direct:** $20,000
- **Project Dates:** 07/01/03 - 06/30/06
- **F & A:** $0

**Co-PI or Project Leader**

**Oncology Center: Informatics Support of HCC Clinical/Translational Research Development**

- **PI:** Carolyn Reed
- **Dept:** Surgery
- **Sponsor:** DOE
- **Award:** DE-FG02-01ER63121 (03051401-4)
- **Total:** $75,046

**Co-Investigator**

**Integration of Physician Training and Biomedical Research in South Carolina**

- **PI:** John Feussner
- **Dept:** Medicine
- **Sponsor:** Univ. of South Carolina
- **Award:** (05011045-1)
- **Total:** $7,500

Alele, Jimmy

**Co-Investigator**

**Clinical Utility of Caduet (R) in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population (CAPABLE)**

- **PI:** Peter Wilson
- **Dept:** Medicine
- **Sponsor:** Pfizer, Inc.
- **Award:** A3841025 (04061404-1)
- **Total:** $21,060

**A Phase III, Double-Blind, Randomized, Multi-Site Trial of the Efficacy, Safety and Tolerability of the Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily for 12 Months, Compared to Atorvastatin Alone, Titrated Based on NCEP ATP-III LDL-C Goals in Subjects with Fredrickson Types IIa and IIb Dyslipidemias**

- **PI:** Peter Wilson
- **Dept:** Medicine
- **Sponsor:** Icon Clinical Research
- **Award:** A5091019 (04111995-1)
- **Total:** $144,953
Arthur, John

Co-PI or Project Leader

Cardiovascular Proteomics Center - Project 4: Improved Methods for Separation and Identification of Protein

Pl: Daniel Knapp
Dept: Cell and Molecular Pharmacology
Sponsor: NIH/NHLBI
Award: N01-HV-281-81-000 (02030610-28)
Total: $ 155,823

Cardiovascular Proteomics Center - Administrative Core A-Gel Electrophoresis Core Unit

Pl: Daniel Knapp
Dept: Cell and Molecular Pharmacology
Sponsor: NIH/NHLBI
Award: N01-HV-281-81-000 (02030610-32)
Total: $ 82,770

Arthur, John

Co-Investigator

Nitric Oxide in Systemic Lupus Erythematosus

Pl: Gary Gilkeson
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 5 R01 AR045476-06 (05011146-1)
Total: $ 235,000

Awgulewitsch, Alexander

Co-PI or Project Leader

DOD Phase VI: Project 1- Hox Expression Profiles in Mammary Gland Tumors

Pl: Carolyn Reed
Dept: Dean's Office - COM
Sponsor: Geo-Centers, Inc.
Award: GC-3532-03-42153CM (03080703-26)
Total: $ 51,370

Roles of Ets Genes in Transformation and Differentiation: Core B-1b Vivo Experimentation Core

Pl: Dennis Watson
Dept: Pathology and Laboratory Medicine
Sponsor: NIH/NCI
Award: 2 P01 CA078582-06A2 (04060106-6)
Total: $ 120,372

Ball, Lauren

Principal Investigator

Role of the Hexosamine Pathway in Renal Vascular Complications of Diabetes

Sponsor: Juvenile Diabetes Fdn.
Budget Dates: 02/01/05 - 01/31/06
Direct: $ 47,296
Award: 3-2005-337 (04082315)
Project Dates: 02/01/05 - 01/31/07
F & A: 0

Bell, Norman

Principal Investigator

Regulation of Vitamin D Metabolism

Sponsor: DOD/US Army
Budget Dates: 09/13/04 - 10/12/06
Direct: $ 137,613
Award: DAMD17-01-1-0816 (00121502)
Project Dates: 09/13/04 - 10/12/06
F & A: 35,780

A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction with Monthly Dosed Ibandronate Therapy in Women with Postmenopausal Osteoporosis or Osteopenia Transitioned from Once-Weekly Alendronate or Risedronate

Sponsor: Roche Laboratories
Budget Dates: 11/30/04 - 11/30/05
Direct: $ 168,000
Award: ML18056B (04090804)
Project Dates: 02/01/05 - 01/31/06
F & A: 43,680

Bogatkevich, Galina

Principal Investigator

CTFG-Interacting Proteins in Scleroderma Lung Fibrosis

Sponsor: NIH/NIAMS
Budget Dates: 05/01/05 - 04/30/06
Direct: $ 105,429
Award: 1 K01 AR051052-01A1 (04062502)
Project Dates: 05/01/05 - 04/30/10
F & A: 8,434

Functional Proteomics of CTFG-Induced SSC Lung Fibroblasts

Sponsor: Scleroderma Fdn.
Budget Dates: 01/30/05 - 01/30/08
Direct: $ 138,888
Award: (04091303)
Project Dates: 01/30/05 - 01/30/08
F & A: 11,112

Bolster, Marcy

Principal Investigator

SONORA Study of New Onset Rheumatoid Arthritis

Sponsor: Knoll Pharmaceutical
Budget Dates: 10/01/00 - 05/16/05
Direct: $ 3,577
Award: (00100312)
Project Dates: 10/01/00 - 05/16/05
F & A: 823

Bone Mineral Density in African American Females with Scleroderma

Sponsor: Amgen
Budget Dates: 07/01/04 - 06/30/06
Direct: $ 25,000
Award: (04072101)
Project Dates: 07/01/04 - 06/30/06
F & A: 0
<table>
<thead>
<tr>
<th>Name</th>
<th>Role/Position</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolster, Marcy</td>
<td>Co-Investigator</td>
<td>MCRC in Rheumatoid Disease</td>
<td>Sponsor: NIH/NIAMS; Award: 5 P60 AR049459-03 (05012859-1)</td>
<td>Total: $ 119,297</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NIAMS MCRC in Rheumatoid Disease - Patient Resource Core</td>
<td>Sponsor: NIH/NIAMS; Award: 5 P60 AR049459-03 (05012859-3)</td>
<td>Total: $ 131,359</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boylan, Alice</td>
<td>Principal Investigator</td>
<td>A Prospective, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis</td>
<td>Sponsor: GlaxoSmithKline; Award: PROTOCOL EMD20001 (04090802)</td>
<td>Project Dates: 05/07/04 - 07/30/07</td>
<td>Direct: $ 154,571</td>
<td>F &amp; A:</td>
<td>38,642</td>
</tr>
<tr>
<td>Bradshaw, Amy</td>
<td>Principal Investigator</td>
<td>Role of Novel Oncogene in Mesothelioma</td>
<td>Sponsor: NIH/NIAMS; Award: 5 R01 ES011323-03 (05041919)</td>
<td>Project Dates: 05/07/04 - 07/30/07</td>
<td>Direct: $ 166,250</td>
<td>F &amp; A:</td>
<td>76,475</td>
</tr>
<tr>
<td>Brescia, Frank</td>
<td>Principal Investigator</td>
<td>A Phase III, Randomized, Multi-Center Study of Cetuximab, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Oxaliplatin, 5-Fluorouracil and Leucovorin in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma</td>
<td>Sponsor: PPD Development; Award: CA225-014 (04070209)</td>
<td>Project Dates: 07/07/04 - 07/06/06</td>
<td>Direct: $ 73,830</td>
<td>F &amp; A:</td>
<td>18,458</td>
</tr>
<tr>
<td>Budisavljevic, Milos</td>
<td>Principal Investigator</td>
<td>Detection and Characterization of Glomerulonephritis Associated Proteins</td>
<td>Sponsor: Dialysis Clinics, Inc.; Award: C-2340 (04111685)</td>
<td>Project Dates: 01/01/05 - 12/31/05</td>
<td>Direct: $ 100,000</td>
<td>F &amp; A:</td>
<td>0</td>
</tr>
<tr>
<td>Buse, Maria</td>
<td>Principal Investigator</td>
<td>Factors That Modify Insulin Action</td>
<td>Sponsor: NIH/NIDDK; Award: 5 R01 DK002001-46 (04120144)</td>
<td>Project Dates: 05/01/05 - 01/31/06</td>
<td>Direct: $ 174,376</td>
<td>F &amp; A:</td>
<td>80,213</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of the Hexosamine Pathway in Renal Vascular Complications of Diabetes</td>
<td>Sponsor: Juvenile Diabetes Fdn.; Award: 3-2005-337 (04082315-1)</td>
<td></td>
<td>Total: $ 47,296</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Medical University of South Carolina Research Faculty Activity

#### College of Medicine

<table>
<thead>
<tr>
<th>Name</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Total</th>
<th>Dept</th>
<th>Award</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Byeon, Mee</strong></td>
<td>Co-PI or Project Leader South Carolina COBRE for Oral Health - Project 10: Role of the Extracellular Matrix (ECM) in Oral Cancer</td>
<td>NIH/NCRR</td>
<td>$11,521</td>
<td>Microbiology and Immunology - CODM</td>
<td>5 P20 RR017696-03 (04052806-4)</td>
</tr>
<tr>
<td><strong>Cantey, J.</strong></td>
<td>Principal Investigator Ryan White CARE Act Title II Emerging Communities</td>
<td>SC DHEC</td>
<td>$214,315</td>
<td>Microbiology and Immunology - CODM</td>
<td>01-S3928-A6654 (05030869)</td>
</tr>
<tr>
<td></td>
<td>Ryan White CARE Act Title II-Trident</td>
<td>SC DHEC</td>
<td>$980,695</td>
<td>Microbiology and Immunology - CODM</td>
<td>01-S3928-A6654 (05030870)</td>
</tr>
<tr>
<td><strong>Chaudhary, Uzair</strong></td>
<td>Co-PI or Project Leader Molecular and Clinical Epidemiology of Antibiotic-Resistant Acinetobacter in New Jersey Hospitals</td>
<td>Merck</td>
<td>$1,096</td>
<td>Medicine</td>
<td>(02071604-2)</td>
</tr>
<tr>
<td><strong>Chiaramida, Salvatore</strong></td>
<td>Principal Investigator A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer</td>
<td>PPD Development</td>
<td>$115,217</td>
<td>Medicine</td>
<td>CA225-014 (04070209-1)</td>
</tr>
<tr>
<td></td>
<td>Phase II Study of PEG-Interferon, GM-CSF and Thalidomide in Metastatic Renal Cell Carcinoma</td>
<td>Berlex Laboratories</td>
<td>$60,000</td>
<td>Radiation Oncology</td>
<td>EFC 5512 (05031501-1)</td>
</tr>
<tr>
<td></td>
<td>A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine, and Bevacizumab Followed by Radical Cystectomy for Patients with Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder</td>
<td>Genentech, Inc.</td>
<td>$61,850</td>
<td>Medicine</td>
<td>AVF3312 (05061044)</td>
</tr>
<tr>
<td><strong>Church, L. W.</strong></td>
<td>Principal Investigator A 52-Week, Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy of Lotrel and Benazepril/Hydrochlorothiazide in the Regression of Left Ventricular Hypertrophy by Magnetic Resonance Imaging in Patients with High Risk Hypertension</td>
<td>Novartis Corp.</td>
<td>$67,145</td>
<td>Medicine</td>
<td>CCIB002FU316 (05012007)</td>
</tr>
<tr>
<td></td>
<td>A 12-Week, Prospective, Open Label, Multi-Center, Cohort Study to Assess HIV-Patient Quality of Life and Tolerability after Administration of Enfuvirtide-Containing HAART (QUALITE)</td>
<td>Roche Laboratories</td>
<td>$11,516</td>
<td>Medicine</td>
<td>ML 18018 (04111788)</td>
</tr>
<tr>
<td></td>
<td>A Phase IV, Multi-Center, Cross-Sectional Study to Evaluate the I50L Substitution among Subjects Experiencing Virologic Failure on a HAART Regimen Containing Atazanavir (ATV)</td>
<td>PPD Development</td>
<td>$6,000</td>
<td>Medicine</td>
<td>A424128 (05031181)</td>
</tr>
</tbody>
</table>

---

**Note:** The table continues with more projects, each with a unique identifier and sponsor, budget details, and departmental affiliation.
Clancy, Dawn
Co-PI or Project Leader
Understanding and Eliminating Health Disparities in Blacks in South Carolina - Pilot Project 1: Implementing Successful Managed Care Models of Healthcare Delivery in a Medically Underserved African American Patient Population with Type 2 Diabetes
PI: Barbara Tilley
Dept: Biostatistics, Bioinformatics and Epidemi
Award: 5 P01 HS010871-05 (04052807-9)

Clyburn, Ben
Principal Investigator
Resident and Faculty Practicum in Practice Based Learning and Improvement
Sponsor: American Board of Internal Medicine
Budget Dates: 07/01/04 - 12/31/05
Direct: $17,500

Colwell, John
Principal Investigator
Epidemiology of Diabetes Intervention and Complications (EDIC)
Sponsor: NIH/NIDDK
Budget Dates: 03/01/04 - 02/28/06
Direct: $122,615

Colwell, John
Co-Investigator
Undiagnosed Diabetes: Predictors and Comorbidities
PI: Richell Koopman
Dept: Family Medicine
Award: 1 R21 DK067130-01A1 (04022601-1)

Cooper, IV, George
Principal Investigator
Growth Regulation of Adult Cardiac Muscle Cells
Sponsor: VAMC
Budget Dates: 10/01/04 - 09/30/05
Direct: $140,000

Egan, Brent
Principal Investigator
Leveraging the Impact of the Clinical Hypertension Specialist in the Local Community
Sponsor: Duke Endowment
Budget Dates: 07/01/04 - 06/30/05
Direct: $161,186

Insulin Resistance and Cardiovascular Risk Factors
Sponsor: NIH/NHLBI
Budget Dates: 09/01/04 - 08/31/06
Direct: $138,666

Dihidropyridine Calcium Channel Blockers, Blood Pressures and Serum Creatinine in Diabetic Hypertensives
Sponsor: Pfizer, Inc.
Budget Dates: 04/07/05 - 04/06/06
Direct: $137,500

A 26 Week, Double-Blind, Randomized, Multi-Center, Parallel Group, Active-Controlled Study Comparing Aliskiren to Ramipril with Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-Blind, Randomized, Placebo-Controlled Withdrawal in Patients with Essential Hypertension
Sponsor: Novartis Corp.
Budget Dates: 01/01/05 - 09/01/06
Direct: $58,880

TROPHY Substudy
Sponsor: Astra Pharmaceuticals, L.P.
Budget Dates: 04/01/00 - 06/30/06
Direct: $53,234
<table>
<thead>
<tr>
<th>TROPHY: Trial of Preventing Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor:</strong> Astrazeneca</td>
</tr>
<tr>
<td><strong>Award:</strong> 197 (99061101)</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 04/01/99 - 06/30/06</td>
</tr>
<tr>
<td><strong>Direct:</strong> $53,235</td>
</tr>
<tr>
<td><strong>F &amp; A:</strong> $12,243</td>
</tr>
</tbody>
</table>

**Egan, Brent**

Co-PI or Project Leader

Understanding and Eliminating Health Disparities in Blacks in South Carolina - Project 1: Reducing the Racial Disparities in CV Disease through Better BP Control

**Pl:** Barbara Tilley

**Dept:** Biostatistics, Bioinformatics and Epidemiology

**Co-Investigator**

**Pl:** Sabra Slaughter

**Dept:** Family Medicine

**Award:** 5 R01 HL076271-02 (05012112-1)

### Principal Investigator

**Egege, Leonard**

**Principal Investigator**

**Collaborative Management of Diabetes in Blacks**

**Sponsor:** AHCPR/AHRQ

**Award:** 5 K08 HS011418-04 (04022610)

**Budget Dates:** 07/01/04 - 06/30/05

**Direct:** $90,950

**F & A:** $7,276

**Understanding Racial and Ethnic Variations in Health Outcomes for Chronic Diseases (TREP Award)**

**Sponsor:** VAMC

**Award:** TREP-824 (04063020)

**Budget Dates:** 04/01/04 - 06/30/06

**Direct:** $145,408

**F & A:** 0

### Principal Investigator

**Fernandes, Jyotika**

**Principal Investigator**

**Effect of Weight Loss Liquid Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on Body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes**

**Sponsor:** Abbott Labs

**Award:** SRDB30 (04062309)

**Budget Dates:** 06/25/04 - 06/24/09

**Direct:** $10,000

**F & A:** 2,500

**APIDRA (Insulin Glulisine) Administered Premeal vs. Postmeal in Adult Subjects with Type 2 Diabetes Mellitus Receiving LANTUS (Insulin Glargine) as Basal Insulin: A Multi-Center, Randomized, Parallel, Open-Label, Clinical Study**

**Sponsor:** Aventis Pharmaceutical, Inc.

**Award:** HMR1964A/3503 (04091603)

**Budget Dates:** 06/24/04 - 12/15/05

**Direct:** $59,800

**F & A:** 14,950

**Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)**

**Sponsor:** Amgen

**Award:** 20010184 (04091402)

**Budget Dates:** 09/28/04 - 09/27/08

**Direct:** $233,150

**F & A:** 58,287

**One Versus Two Versus Three Daily Rapid-Acting Insulin Injections of Apidra (Insulin Glulisine) as Add-On to Lantus and Oral Sensitizer Basal Therapy in Type 2 Diabetes: A Multi-Center, Randomized, Parallel, Open-Label Clinical Study**

**Sponsor:** Aventis Pharmaceutical, Inc.

**Award:** HMR1964A/3511 (05060626)

**Budget Dates:** 05/05/05 - 06/30/06

**Direct:** $98,000

**F & A:** 24,500

### Principal Investigator

**Feussner, John**

**Integration of Physician Training and Biomedical Research in South Carolina**

**Sponsor:** Univ. of South Carolina

**Award:** (050011045)

**Budget Dates:** 01/01/05 - 12/31/05

**Direct:** $7,500

**Integration of Physician Training and Biomedical Research in South Carolina**

**Sponsor:** Greenville Hospital System

**Award:** (050011887)

**Budget Dates:** 01/01/05 - 12/31/05

**Direct:** $7,500

### Principal Investigator

**Fitzgibbon, Wayne**

**Effect of Cox-2 Inhibitors on Renal Function**

**Sponsor:** Microbia, Inc.

**Award:** (04091402)

**Budget Dates:** 09/13/04 - 10/31/05

**Direct:** $15,222

**F & A:** 3,806
Fitzgibbon, Wayne  
Co-Investigator  
Renal Constitutive and Inducible Na+/Urea Transporters  
PI: David Ploth  
Dept: Medicine  
Sponsor: Dialysis Clinics, Inc.  
Award: C-2229 (03121013-2)  
Total: $ 33,450

Flume, Patrick  
Principal Investigator  
A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater than Twenty-Four Hours of Continuous Sedation  
Sponsor: Omni Care  
Award: 2001-001 (05041295)  
Budget Dates: 04/01/05 - 08/31/06  
Direct: $ 280,413  
F & A: 70,103

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects  
Sponsor: Chiron, Inc.  
Award: TIP002 (05042643)  
Budget Dates: 05/01/05 - 04/30/06  
Direct: $ 32,634  
F & A: 8,159

Frei-Lahr, Debra  
Principal Investigator  
A Randomized Open-Label Study of 400 mg Versus 800 mg of STI571 in Patients with Newly Diagnosed Chronic Myelogenous Leukemia (CML-CP) (CTO100908)  
Sponsor: Novartis Corp.  
Award: STI571K 2301-515 (05062951)  
Budget Dates: 04/30/05 - 06/30/12  
Direct: $ 163,118  
F & A: 40,779

Co-PI or Project Leader  
Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma  
Sponsor: Corixa Corp.  
Award: CP-98-020 (04092803-1)  
Budget Dates: 05/01/05 - 04/30/06  
Direct: $ 4,480  
F & A: 0

A Quality of Life Assessment in the Multi-Center, Randomized, Phase III Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tuxetan Therapeutic Regimen for Patients with Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma  
Sponsor: GlaxoSmithKline  
Award: SB-393229/BEX101662 (04101207-1)  
Budget Dates: 05/01/05 - 04/30/06  
Direct: $ 3,608  
F & A: 13,000

Gelasco, Andrew  
Principal Investigator  
Cellular Effects of Indoxyl Sulfate-A Uremic Toxin  
Sponsor: NIH/NIDDK  
Award: 5 K25 DK059950-04 (04043015)  
Budget Dates: 08/01/01 - 06/30/06  
Direct: $ 128,707  
F & A: 10,297

Gilkeson, Gary  
Principal Investigator  
Molecular and Structural Characteristics of Glomerulotrophic Antibodies  
Sponsor: VAMC  
Award: IMMU-010-00S (03063008)  
Budget Dates: 10/01/04 - 09/30/05  
Direct: $ 125,000  
F & A: 0

Kirkland Scholar Award  
Sponsor: Mary Kirkland Ctr. For Lupus Research  
Award: (03093006)  
Budget Dates: 10/01/04 - 09/30/05  
Direct: $ 60,000  
F & A: 0

LCTC Participating Center  
Sponsor: Lupus Clinical Trials Consortium  
Award: (03100207)  
Budget Dates: 10/01/04 - 09/30/05  
Direct: $ 100,000  
F & A: 0

Complement in the Pathogenesis of Autoimmune Arthritis  
Sponsor: Univ. of Colorado  
Award: FY05.090.002 (03121202)  
Budget Dates: 09/10/04 - 08/31/05  
Direct: $ 50,000  
F & A: 13,000

Lupus Community Awareness Seminars  
Sponsor: Department of the Interior  
Award: 04-04-PO-35528 (04041903)  
Budget Dates: 06/14/04 - 09/30/05  
Direct: $ 7,006  
F & A: 2,102
Histone Deacetylase Inhibitors for the Treatment of Lupus
Sponsor: Wake Forest University
Award: (04083002)

Role of PPARgamma and PPARgamma Agonists in Lupus Nephritis
Sponsor: NIH/NIAMS
Award: 5 R01 AR047451-05 (04092206)

Comparison of IV Cyclophosphamide to Mycophenolate Mofetil in SLE - Record Review for FDA Application
Sponsor: Aspreva Pharmaceuticals Corp.
Award: (04112209)

Comparison of IV Cyclophosphamide to Mycophenolate Mofetil in SLE - Minority Supplement for Chinedu Njoku
Sponsor: NIH/NIAMS
Award: 3 R01 AR045476-06S1 (05052340)

A Prospective, Randomized, Double-Blind, Active Controlled, Parallel Group, Multi-Center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Maintaining Remission and Renal Function in Subjects with Lupus Nephritis Who Underwent Successful Induction Therapy with Either MMF or Cyclophosphamide
Sponsor: Hoffman-Laroche, Inc.
Award: WX17801 (05031486)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II/III Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with Moderate to Severe Systemic Lupus Erythematosus
Sponsor: Genentech, Inc.
Award: U2971g (05031487)

Nitric Oxide in Systemic Lupus Erythematosus - Minority Supplement for Chinedu Njoku
Sponsor: NIH/NIAMS
Award: 3 R01 AR045476-06S1 (05052340)

Nitric Oxide in Systemic Lupus Erythematosus
Sponsor: NIH/NIAMS
Award: 5 K08 AR002193-05 (05011041)

Role of Nitric Oxide and Eicosanoids in Lupus Nephritis
Sponsor: NIH/NIAMS
Award: 5 P01 AR049459-03 (05012859)

MCRC in Rheumatoid Disease
Sponsor: NIH/NIAMS
Award: 5 P60 AR049459-03 (05012859)

MCRC in Rheumatoid Disease - Project C: Genetic and Environmental Influences on the Development and Progression of Lupus Nephritis
PI: Richard Silver
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 5 P60 AR049459-03 (05012859)

CLEAR Registry
PI: Edwin Smith
Dept: Medicine
Sponsor: Univ. of Alabama, Birmi
Award: N01-AR-0-2247 (00060609-5)

Role of Nitric Oxide and Eicosanoids in Lupus Nephritis
PI: James Oates
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 5 K08 AR002193-05 (05011041)

MCRC in Rheumatoid Disease
PI: Richard Silver
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 5 P60 AR049459-03 (05012859)

MCRC in Rheumatoid Disease - Undergraduate Student Supplement for Kristie Quarles
PI: Richard Silver
Dept: Medicine
Sponsor: NIH/NIAMS
Award: 3 P60 AR049459-03S1 (05050271)

AutoCapture vs. Capture Management Evaluation
Sponsor: St. Jude Medical, Inc.
Award: CRD #264 (04101402)

Resynchronization Hemodynamic Treatment for Heart Failure Management Study (Rhythm ICD)
Sponsor: St. Jude Medical, Inc.
Award: (02080610)

Study for Atrial Fibrillation Reduction Investigational Plan SAFARI
Sponsor: Vitatron
Award: SAFARI (02083007)
### Educational Grant in Support of an EP Fellowship

**Sponsor:** Medtronic, Inc.  
**Budget Dates:** 10/01/02 - 06/30/05  
**Direct:** $92,592  
**F & A:** $7,408

### Device Evaluation of Contak Renewal 2 and Easytrak 2: Assessment of Safety and Effectiveness, (Decrease-HF)

**Sponsor:** Guidant  
**Budget Dates:** 04/01/03 - 12/31/05  
**Direct:** $56,880  
**F & A:** $14,220

### The CRT Optimization Algorithm Validation Study

**Sponsor:** Guidant  
**Budget Dates:** 10/01/04 - 06/30/05  
**Direct:** $63,336  
**F & A:** $15,834

### Clinical Partners in Excellence Program

**Sponsor:** St. Jude Medical, Inc.  
**Budget Dates:** 09/09/04 - 09/08/06  
**Direct:** $34,000  
**F & A:** $8,500

### Device System Post-Approval Study

**Sponsor:** St. Jude Medical, Inc.  
**Budget Dates:** 10/01/05 - 12/31/07  
**Direct:** $10,000  
**F & A:** $2,500

### GDT 1000 Sensing Acute Study

**Sponsor:** Guidant  
**Budget Dates:** 03/01/05 - 03/01/07  
**Direct:** $18,000  
**F & A:** $4,500

### Multi-Center Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy (MADIT-CRT)

**Sponsor:** Univ. of Rochester  
**Budget Dates:** 03/01/05 - 03/01/07  
**Direct:** $94,572  
**F & A:** $23,643

### Asymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (with Evaluation of Mechanisms of AF)

**Sponsor:** St. Jude Medical, Inc.  
**Budget Dates:** 03/01/05 - 03/01/07  
**Direct:** $25,200  
**F & A:** $6,300

### Arrhythmia Management Clinical and Outcomes Research

**Sponsor:** Medtronic, Inc.  
**Budget Dates:** 03/01/05 - 03/01/07  
**Direct:** $9,644  
**F & A:** $2,411

### Optimal SVC Coil Usage in ICD Patients

**Sponsor:** CRD # 273 (05033062)  
**Budget Dates:** 03/01/05 - 12/31/06  
**Direct:** $17,200  
**F & A:** $4,300

---

**Gooz, Pal**  
**Co-Investigator**  
**PKC epsilon-Related Proteins in Lung Fibrosis**  
**PI:** Stanley Hoffman  
**Dept:** Medicine  
**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL073718-02 (04070122-1)  
**Total:** $250,000

**Gore, Jim**  
**Co-PI or Project Leader**  
**Bone Mineral Density in African American Females with Scleroderma**  
**PI:** Marcy Bolster  
**Dept:** Medicine  
**Sponsor:** Amgen  
**Award:** (04072101-1)  
**Total:** $25,000

**Hammad, Samar**  
**Principal Investigator**  
**Sphingolipid Signaling Response to Modified Low Density Lipoprotein-Immune Complexes in Human Macrophages**  
**Sponsor:** Amer. Heart Assoc.  
**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $59,091  
**F & A:** $9,909

**Harris, Brett**  
**Principal Investigator**  
**Molecular Development and Pathophysiology of the Atrio-Ventricular Conduction System**  
**Sponsor:** Amer. Heart Assoc./Mid-Atlantic  
**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $35,000  
**F & A:** $0

---

54 Annual Report for Research FY2005
<table>
<thead>
<tr>
<th>Name</th>
<th>Co-Investigator/Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hendrix, Katheine</td>
<td>Co-Investigator</td>
<td>Dihidropyride Calcium Channel Blockers, Blood Pressures and Serum Creatinine in Diabetic Hypertensives</td>
<td>Pfizer, Inc.</td>
<td>09/01/04 - 08/31/05</td>
<td>$250,000</td>
<td>$115,000</td>
<td>$365,000</td>
</tr>
<tr>
<td>Hermayer, Kathie</td>
<td>Co-Investigator</td>
<td>APIDRA (Insulin Glulisine) Administered Premeal vs. Postmeal in Adult Subjects with Type 2 Diabetes Mellitus Receiving LANTUS (Insulin Glargine) as Basal Insulin: A Multi-Center, Randomized, Parallel, Open-Label, Clinical Study</td>
<td>Aventis Pharmaceutical, Pfizer, Inc.</td>
<td>09/01/04 - 08/31/05</td>
<td>$250,000</td>
<td>$115,000</td>
<td>$365,000</td>
</tr>
<tr>
<td>Hildreth, Barbara</td>
<td>Co-Investigator</td>
<td>Surrogate Biomarkers of Micrometastatic Gastric Cancer</td>
<td>NIH/NCI</td>
<td>09/01/04 - 08/31/05</td>
<td>$250,000</td>
<td>$115,000</td>
<td>$365,000</td>
</tr>
<tr>
<td>Hoffman, Brenda</td>
<td>Co-Investigator</td>
<td>PKCepsilon-Related Proteins in Lung Fibrosis</td>
<td>NIH/NHLBI</td>
<td>04/01/05 - 03/31/06</td>
<td>$153,900</td>
<td>$0</td>
<td>$153,900</td>
</tr>
<tr>
<td>Hoffman, Stanley</td>
<td>Principal Investigator</td>
<td>The Effects of Insulin-Sensitizing Thiazolidinediones on the Stability of Atherosclerotic Plaque</td>
<td>VAMC</td>
<td>04/01/05 - 03/31/06</td>
<td>$153,900</td>
<td>$0</td>
<td>$153,900</td>
</tr>
<tr>
<td>Huang, Yan</td>
<td>Co-Investigator</td>
<td>A Placebo-and Active-Controlled (Ciclesonide metered-dose inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler) in Adult and Adolescent Patients with Persistent Asthma</td>
<td>PPD Development</td>
<td>04/01/05 - 03/31/06</td>
<td>$153,900</td>
<td>$0</td>
<td>$153,900</td>
</tr>
<tr>
<td>Huggins, John</td>
<td>Co-Investigator</td>
<td>A 6-Month, Double-Blind, Double-Dummy, Randomized, Parallel Group, Multi-Center, Efficacy and Safety Study of SYMBICORT pMDI 2 X 169/4.5 ug and 80/4.5 up bid Compared to Formoterol Turbuhaler, Budesonide pMDI and Placebo in Patients with COPD</td>
<td>AstraZeneca</td>
<td>04/01/05 - 03/31/06</td>
<td>$153,900</td>
<td>$0</td>
<td>$153,900</td>
</tr>
<tr>
<td>Principal Investigator</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates: 05/01/05 - 04/30/06</td>
<td>Direct: $</td>
<td>F &amp; A: $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-----------------------------------</td>
<td>------------</td>
<td>-----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaffa, Ayad</td>
<td>Short Term Research Training for Health Professional Students</td>
<td>NIH/NIDDK</td>
<td>02 T35 DK007431-21 (04020601)</td>
<td>142,718</td>
<td>11,417</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaffa, Ayad</td>
<td>Kinins Role in Mesangial Cell Fibrosis</td>
<td>NIH/NIDDK</td>
<td>05 R01 DK046543-10 (05030113)</td>
<td>175,000</td>
<td>75,250</td>
<td></td>
<td></td>
</tr>
<tr>
<td>John, Jr., Joseph</td>
<td>Molecular and Clinical Epidemiology of Antibiotic-Resistant Acinetobacter in New Jersey Hospitals</td>
<td>Merck</td>
<td>07/01/02 - 12/31/05</td>
<td>1,096</td>
<td>504</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Judson, Marc</td>
<td>Phase II, Pilot Trial of Thalidomide in Steroid-Dependent Pulmonary Sarcoidosis</td>
<td>Celgene Corp.</td>
<td>12/10/02 - 06/30/05</td>
<td>56</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keum, Joo-Seob</td>
<td>CHORD Fellowship</td>
<td>Arthritis Fdn.</td>
<td>07/01/03 - 06/30/05</td>
<td>1,310</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kio, Ebeneezer</td>
<td>A Phase II Study of Arsenic Trioxide in Combination with 5-Azacitidine in Myelodysplastic Syndromes</td>
<td>Cell Therapeutics, Inc.</td>
<td>07/01/03 - 06/30/05</td>
<td>194,219</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Klein, Richard</td>
<td>Interactions of Lipoproteins and Cells in Diabetes Mellitus</td>
<td>VAMC</td>
<td>10/01/04 - 09/30/05</td>
<td>174,184</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Kneuper-Hall, Rayna

Principal Investigator
Low-Fat Diet in Stage II Breast Cancer
Sponsor: Institute For Cancer Prevention
Award: 5 R01 CA45504-15 (04080203)
Budget Dates: 01/01/04 - 12/31/04
Project Dates: 01/01/03 - 12/31/04
Direct: $ 5,850
F & A: 2,691

A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (CTO 100881)
Sponsor: NSABP
Award: NSABP-B-35 (05050275)
Budget Dates: 05/01/05 - 04/30/08
Project Dates: 05/01/05 - 04/30/08
Direct: $ 20,103
F & A: 397

Kraft, Andrew

Principal Investigator
Oncology Center: Hollings Cancer Translational Research Core Development Grant
Sponsor: DOE
Award: DE FG02 01ER63121 (04042303)
Budget Dates: 07/01/04 - 06/30/05
Project Dates: 07/01/01 - 06/30/07
Direct: $ 232,878
F & A: 93,497

Hollings Cancer Center Planning Grant
Sponsor: NIH/NCI
Award: 3 P20 CA093282-03S1 (04051101)
Budget Dates: 08/01/04 - 07/31/05
Project Dates: 08/24/01 - 07/31/05
Direct: $ 181,480
F & A: 83,481

Hollings Cancer Center Building Addition
Sponsor: HRSA
Award: 1 C76HF03130-01-00 (04052001)
Budget Dates: 09/01/04 - 12/31/06
Project Dates: 09/01/04 - 12/31/06
Direct: $ 6,889,117
F & A: 0

Hollings Cancer Center Building Addition
Sponsor: Natl. Inst. of Standards and Technology
Award: 60NANB00073 (04060104)
Budget Dates: 09/01/04 - 12/31/05
Project Dates: 09/01/00 - 12/31/04
Direct: $ 13,852,684
F & A: 0

Pim 1 Protein Kinase as a Target for Drug Discovery
Sponsor: NIH/NCI
Award: 7 R21 CA095183-03 (04070203)
Budget Dates: 06/16/04 - 03/31/05
Project Dates: 06/16/04 - 03/31/05
Direct: $ 34,384
F & A: 15,816

Mechanisms by which Proteasome Enhance Apoptosis
Sponsor: NIH/NCI
Award: 7 R01 CA104710-01 (04070203)
Budget Dates: 06/15/04 - 02/28/05
Project Dates: 06/15/04 - 02/28/05
Direct: $ 164,000
F & A: 75,440

Overcoming Resistance of Prostate Cancer to TRAIL - Mediated Apoptosis
Sponsor: DOD
Award: DAMD17-01-1-0145 (04072703)
Budget Dates: 06/15/04 - 11/30/05
Project Dates: 06/15/04 - 11/30/05
Direct: $ 30,174
F & A: 13,880

Pim Protein Kinase-Levels Correlate with Prostate Tumor Growth and Chemo-Resistance - Potential Mechanisms of Pim Action
Sponsor: DOD/US Army
Award: W81XWH-05-1-0126 (04082311)
Budget Dates: 11/30/04 - 11/29/05
Project Dates: 11/30/04 - 11/29/05
Direct: $ 130,087
F & A: 59,840

VELCADE (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Sponsor: Millennium Pharmaceuticals
Award: 03-1218 (04092903)
Budget Dates: 08/01/04 - 12/31/07
Project Dates: 08/01/04 - 12/31/07
Direct: $ 163,310
F & A: 40,827

Proposal for Cancer Prevention and Control Program for Reducing Tobacco-Related Malignancies in South Carolina
Sponsor: CDC
Award: H75/CCH424532-01 (04093015)
Budget Dates: 09/01/04 - 08/31/06
Project Dates: 09/01/04 - 08/31/06
Direct: $ 2,103,489
F & A: 763,782

Phase I Trial of Bortezomib (VELCADE TM) and Celecoxib in Patients with Advanced Solid Tumors
Sponsor: Millennium Pharmaceuticals
Award: i605-341-03 (04111273)
Budget Dates: 11/15/04 - 11/15/07
Project Dates: 11/15/04 - 11/15/07
Direct: $ 143,263
F & A: 35,816

DOD Phase VII: Translational Research: Cancer Control Research Program
Sponsor: Geo-Centers, Inc.
Award: GC-3609-04-43766CM (04113002)
Budget Dates: 10/01/04 - 09/29/05
Project Dates: 10/01/04 - 09/29/06
Direct: $ 919,888
F & A: 75,440

Mechanisms by Which Proteasome Enhance Apoptosis
Sponsor: NIH/NCI
Award: 5 R01 CA104710-02 (05011903)
Budget Dates: 06/15/04 - 02/29/08
Project Dates: 06/15/04 - 02/29/08
Direct: $ 164,000
F & A: 75,440

A Randomized, Multi-Center, Open-Label Study of YONDELIS ET-743 (ecteinascidin) Administered by Two Different Schedules (Weekly for 3 or 4 Weeks vs. q3 Weeks) in Subjects with Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment with an Anthracycline and Ifosfamide
Sponsor: Johnson and Johnson
Award: ET743-STS-201 (05031588)
Budget Dates: 03/04/05 - 03/15/07
Project Dates: 03/04/05 - 03/15/07
Direct: $ 67,525
F & A: 7,050
## 2005 Supporting the Safety Net

**Sponsor:** Avon Foundation  
**Award:** (05040166)  
**Budget Dates:** 05/01/05 - 04/30/06  
**Direct:** $150,909  
**Project Dates:** 05/01/05 - 06/01/07  
**F & A:** 15,081

### Kuppuswamy, Dhandapani

**Principal Investigator**

#### S6K Activation in Hypertrophying Myocardium

**Sponsor:** VAMC  
**Award:** CARD-006-02S (03063011)  
**Budget Dates:** 10/01/04 - 09/30/05  
**Direct:** $180,344  
**Project Dates:** 10/01/02 - 09/30/06  
**F & A:** 0

**Co-PI or Project Leader**

**Load-Induced Cardiac Hypertrophy in the Adult Mammal: Project 5 - Integrin Signaling in Cardiac Hypertrophy**

**PI:** George Cooper, IV  
**Sponsor:** NIH/NHLBI  
**Total:** $166,497  
**Dept:** Medicine  
**Award:** 5 P01 HL048788-12 (04060211-10)

**Co-Investigator**

**Signaling Pathways Mediating NCX1 Expression**

**PI:** Donald Menick  
**Sponsor:** NIH/NHLBI  
**Total:** $250,000  
**Dept:** Medicine  
**Award:** 5 R01 HL066223-04 (04070118-1)

### Kwon, Soonho

**Co-Investigator**

**Effect of Weight Loss Liquid Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on Body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes**

**PI:** Jyotika Fernandes  
**Sponsor:** Abbott Labs  
**Total:** $10,000  
**Dept:** Medicine  
**Award:** SRDB30 (04062309-2)

### Leman, Robert

**Principal Investigator**

**A Multi-Center, 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 75 and 125mg Doses of Oral Azimilide Dihydrochloride in Patients with an Implantable Cardioverter Defibrillator for the Treatment of Ventricular Arrhythmia**

**Sponsor:** Procter and Gamble  
**Budget Dates:** 08/01/01 - 08/01/04  
**Direct:** $1,191  
**F & A:** 357

**Alternans Before Cardioverter Defibrillator Trial**

**Sponsor:** St. Jude Medical, Inc.  
**Budget Dates:** 02/01/05 - 12/31/08  
**Direct:** $27,200  
**F & A:** 6,800

**Pacing Evaluation - Atrial Support Study in Cardiac Resynchronization Therapy - PEGASUS CRT**

**Sponsor:** Guidant  
**Budget Dates:** 06/27/05 - 12/31/07  
**Direct:** $198,000  
**F & A:** 15,450

### Lopes-Virella, Maria

**Principal Investigator**

**Lipoprotein Metabolism and Lipoprotein-Cell Interaction in Diabetes Mellitus**

**Sponsor:** VAMC  
**Budget Dates:** 04/01/05 - 03/31/06  
**Direct:** $140,000  
**F & A:** 0

**Immune Mechanisms of Micro/Macrovacular Disease in Type I Diabetes**

**Sponsor:** Juvenile Diabetes Fdn.  
**Budget Dates:** 08/01/04 - 07/31/05  
**Direct:** $232,261  
**F & A:** 17,739

**Markers and Mechanisms of Vascular Disease in Diabetes**

**Sponsor:** NIH/NHLBI  
**Budget Dates:** 09/01/04 - 08/31/05  
**Direct:** $1,447,308  
**F & A:** 402,538

**Markers and Mechanisms of Vascular Disease in Diabetes**

**Sponsor:** Oklahoma University Health Sc. Center  
**Budget Dates:** 11/10/04 - 11/09/05  
**Direct:** $103,000  
**F & A:** 15,450

### Luttrell, Deirdre

**Co-Investigator**

**Tyrosine Kinases in G Protein Mediated Signaling**

**PI:** Louis Luttrell  
**Sponsor:** NIH/NIDDK  
**Total:** $198,000  
**Dept:** Medicine  
**Award:** 5 R01 DK055524-08 (04070603-1)
Luttrell, Louis

**Principal Investigator**

**Parathyroid Hormone and Osteoblast Mitogenesis**

Sponsor: NIH/NIDDK

Award: 5 R01 DK064353-04 (04070205)

Budget Dates: 09/01/04 - 08/31/05

Direct: $174,376

**Tyrosine Kinases in G Protein Mediated Signaling**

Sponsor: NIH/NIDDK

Award: 5 R01 DK055524-08 (04070603)

Budget Dates: 09/01/04 - 07/31/05

Direct: $198,000

Lyons, Timothy

**Co-PI or Project Leader**

Markers and Mechanisms of Vascular Disease in Diabetes: Project 1 - Lipoproteins and Oxidative Stress

Pl: Maria Lopes-Virella

Sponsor: NIH/NHLBI

Total: $254,039

Dept: Medicine

Award: 5 R01 DK064353-04 (04070205)

Project Dates: 09/15/02 - 08/31/06

F & A: $51,480

Markers and Mechanisms of Vascular Disease in Diabetes: Core A- Administrative and EDIC/VA Coordination

Pl: Maria Lopes-Virella

Sponsor: NIH/NHLBI

Total: $264,161

Dept: Medicine

Award: 5 P01 HL055782-09 (04063004-6)

Mao, Cungui

**Principal Investigator**

**Alkaline Ceramidase and Sphingolipid Signaling**

Sponsor: NIH/NCI

Award: 1 R01 CA104834-01A1 (03101602)

Budget Dates: 07/01/04 - 06/30/09

Direct: $184,500

Co-PI or Project Leader

SC Cobre in Lipidomics & Pathobiology: Project 5 - Human Alkaline Phytoceramidase Regulation of Angiogenesis

Pl: Lina Obeid

Sponsor: NIH/NCRR

Total: $50,000

Dept: Biochemistry and Molecular Biology

Award: 5 P20 RR017677-03 (03071704-16)

DOD Phase VI: Project 4- The Role of Human Alkaline Phytoceramidase in Tumor Growth

Pl: Carolyn Reed

Sponsor: Geo-Centers, Inc.

Total: $51,370

Dept: Dean's Office - COM

Award: GC-3532-03-42153CM (03080703-29)

Markiewicz, Margaret

**Principal Investigator**

**Role of TGF-Beta and CTGF in the Process of New Vessel Formation in Scleroderma**

Sponsor: Scleroderma Fdn.

Award: (04091304)

Budget Dates: 01/30/05 - 01/30/08

Direct: $138,888

Mayfield, Ronald

**Principal Investigator**

**A Phase IIIB, Multi-Center, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects with Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets with Insulin Therapy**

Sponsor: Amylin Pharmaceuticals

Award: 2993-115E (03043003)

Budget Dates: 05/21/03 - 06/01/06

Direct: $9,220

Glycemic Control and Complications in Diabetes Mellitus Type 2

Sponsor: VAMC

Award: (05060629)

Budget Dates: 10/01/04 - 09/30/05

Direct: $148,976

McDermott, Paul

**Co-PI or Project Leader**

Load-Induced Cardiac Hypertrophy in the Adult Mammal: Core D - Gene Transfer Core

Pl: George Cooper, IV

Sponsor: NIH/NHLBI

Total: $66,974

Dept: Medicine

Award: 5 P01 HL048788-12 (04060211-4)

Load-Induced Cardiac Hypertrophy in the Adult Mammal: Project 1 - Translational Regulation of Cardiac Protein Synthesis

Pl: George Cooper, IV

Sponsor: NIH/NHLBI

Total: $161,657

Dept: Medicine

Award: 5 P01 HL048788-12 (04060211-6)
Menick, Donald

Principal Investigator

Training to Improve Cardiovascular Drug Therapy
Sponsor: NIH/NHLBI
Award: 5 T32 HL007260-28 (03122202)
Budget Dates: 07/01/04 - 06/30/05
Direct: $ 443,375
F & A: 32,876

Signaling Pathways Mediating NCX1 Expression
Sponsor: NIH/NHLBI
Award: 5 R01 HL066223-04 (04070118)
Budget Dates: 09/30/01 - 01/31/06
Direct: $ 250,000
F & A: 107,500

Summer Research Program for Minority Medical Students
Sponsor: NIH/NHLBI
Award: 5 T35 HL007923-07 (04110118)
Budget Dates: 06/04/99 - 04/30/09
Direct: $ 54,912
F & A: 4,393

Co-PI or Project Leader

Load-Induced Cardiac Hypertrophy in the Adult Mammal: Project 3 - Cardiac Na-Ca Exchange Hypertrophic Regulation
PI: George Cooper, IV
Dept: Medicine
Award: 5 P01 HL048788-12 (04060211-8)
Total: $ 165,588

Mitchell, Holly

Co-Investigator

MCRC in Rheumatoid Disease
PI: Richard Silver
Dept: Medicine
Award: 5 P60 AR049459-03 (05012859-1)
Total: $ 119,297

NIAMS MCRC in Rheumatoid Disease - Patient Resource Core
PI: Richard Silver
Dept: Medicine
Award: 5 P60 AR049459-03 (05012859-3)
Total: $ 131,359

Morinelli, Thomas

Co-PI or Project Leader

Nuclear Trafficking of the Angiotensin II Type 1a Receptor
PI: Michael Ullian
Dept: Medicine
Award: C-2342 (Charleston-Magnol (04111684-1)
Total: $ 278,289

Mukhin, Yuri

Co-Investigator

Differential Signaling of Serotonin and Angiotensin II in Vascular Smooth Cells
PI: David Ploth
Dept: Medicine
Award: C-2288 (04072903-1)
Total: $ 76,860

Nelson, Kristine

Principal Investigator

Music Therapy for Cancer Patients at the End-Of-Life
Sponsor: NIH/NCI
Award: 7 R21 CA096516-03 (04080902)
Budget Dates: 09/10/04 - 04/30/06
Direct: $ 150,000
F & A: 69,000

Nielsen, Christopher

Principal Investigator

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
Sponsor: Boston Scientific Corp.
Award: ARRIVE - 2 (04111274)
Budget Dates: 12/02/04 - 12/31/07
Direct: $ 121,200
F & A: 30,300

Novgorodov, Sergei

Co-Investigator

Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis
PI: Lina Obeid
Dept: Medicine
Award: 5 R01 AG016583-07 (04062504-1)
Total: $ 175,000

O'Brien, Terrence

Principal Investigator

Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose-Comparative Study of the Efficacy, Tolerability and Safety of MCC-135 in Subjects with Chronic Heart Failure, NYHA II/III (VAMC)
Sponsor: Quintiles Pacific, Inc.
Award: MCC-135/G01 (01042007)
Budget Dates: 04/01/01 - 12/31/04
Direct: $ 32,362
F & A: 7,443

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation and Function in Patients with Heart Failure and Left Ventricular Systolic Dysfunction Protocol # 156-01-232
Sponsor: Cardiovascular Clinical Studies
Award: 156-01-232 (02080609)
Budget Dates: 08/01/02 - 12/31/04
Direct: $ 4,252
F & A: 1,063
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Cardiac Conduction System as Regulated by NKX2.5</strong></td>
<td>VAMC</td>
<td>10/01/04 - 09/30/05</td>
<td>$129,700</td>
<td></td>
</tr>
<tr>
<td><strong>A Phase 2, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide</strong></td>
<td>Fujisawa Healthcare, Inc.</td>
<td>04/15/04 - 10/31/05</td>
<td>$4,800</td>
<td></td>
</tr>
<tr>
<td><strong>A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to</strong></td>
<td>VAMC</td>
<td>10/01/02 - 09/30/05</td>
<td>$15,800</td>
<td></td>
</tr>
<tr>
<td><strong>The Cardiac Conduction System as Regulated by NKX2.5</strong></td>
<td>VAMC</td>
<td>10/01/02 - 09/30/05</td>
<td>$129,700</td>
<td></td>
</tr>
<tr>
<td><strong>A Phase 2, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide</strong></td>
<td>Fujisawa Healthcare, Inc.</td>
<td>04/15/04 - 10/31/05</td>
<td>$4,800</td>
<td></td>
</tr>
<tr>
<td><strong>A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Center Study to</strong></td>
<td>VAMC</td>
<td>10/01/02 - 09/30/05</td>
<td>$15,800</td>
<td></td>
</tr>
</tbody>
</table>

**O’Brien, Terrence**

- **Load-Induced Cardiac Hypertrophy in the Adult Mammal: Core E - Morphology and Molecular Imaging Core**
  - Sponsor: NIH/NHLBI
  - Budget Dates: 07/01/01 - 06/30/05
  - Total: $33,452

- **Patterning by Invasive Mesenchyme in the Embryonic Heart: Project 1 - The Genetic Origin of Structural and Functional Defects of Atrioventricular Conduction in Humans**
  - Sponsor: NIH/NICHD
  - Budget Dates: 04/15/04 - 10/31/05
  - Total: $178,602

**Oates, James**

- **The Role of Nitric Oxide and Eicosanoids in Lupus Nephritis**
  - Sponsor: Arthritis Fdn.
  - Budget Dates: 07/01/04 - 06/30/05
  - Total: $70,000

**Urbano, Francisco**

- **Regulation of Human Alkaline Ceramidases Role in Cancer Biology**
  - Sponsor: VAMC
  - Budget Dates: 01/01/05 - 12/31/05
  - Total: $150,000

**Obeid, Lina**

- **Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**
  - Sponsor: NIH/NCI
  - Project Dates: 07/01/98 - 08/31/05
  - Total: $177,113

**Obeid, Lina**

- **Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis**
  - Sponsor: NIH/NCI
  - Project Dates: 07/01/04 - 08/31/05
  - Total: $175,000

**Obeid, Lina**

- **Regulation of Human Alkaline Ceramidases Role in Cancer Biology**
  - Sponsor: VAMC
  - Project Dates: 07/01/04 - 08/31/05
  - Total: $150,000

**Obeid, Lina**

- **Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**
  - Sponsor: NIH/NCI
  - Project Dates: 07/01/98 - 08/31/05
  - Total: $177,113

**Co-Investigator**

- **MCRC in Rheumatoid Disease**
  - Sponsor: NIH/NIAMS
  - Project Dates: 07/01/04 - 06/30/05
  - Total: $119,297

**Obeid, Lina**

- **Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**
  - Sponsor: NIH/NCI
  - Project Dates: 07/01/98 - 08/31/05
  - Total: $177,113

**Co-Investigator**

- **MCRC in Rheumatoid Disease**
  - Sponsor: NIH/NIAMS
  - Project Dates: 07/01/04 - 06/30/05
  - Total: $119,297
## Ogawa, Makio

**Principal Investigator**

**Tissue Reconstituting Potential of Human Stem Cells**

Sponsor: NIH/NHLBI  
Award: 1 R01 HL075699-01A2 (04070111)

**Transdifferentiation Potential of Bone Marrow Stem Cells**

Sponsor: NIH/NHLBI  
Award: 5 R01 HL069123-03 (05021124)

**Sponsor:** NIH/NHLBI  
**Budget Dates:** 04/01/05 - 03/31/06  
**Direct:** $225,000  
**F & A:** $58,500  
**Award:** 1 R01 HL075699-01A2 (04070111)

**Project Dates:** 04/01/05 - 03/31/09  
**F & A:** $65,000  
**Award:** 5 R01 HL069123-03 (05021124)

## Pannu, Jaspreet

**Co-Investigator**

**TGF-Beta Receptor Signaling in Scleroderma**

PI: Maria Trojanowska  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Total: $173,000  
Award: 5 R01 AR044883-08 (05041510-1)

**Cloning and Characterization of Human CYP25**

PI: Norman Bell  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Total: $168,000  
Award: 5 R01 DK056603-05 (04112921-1)

## Patel, Shailendra

**Principal Investigator**

**The Role of Cholesterol in Development**

Sponsor: NIH/NHLBI  
Award: 5 R01 HL068660-03 (04050305)

**Co-Investigator**

**Cloning and Characterization of Human CYP25**

Pl: Adam Smolka  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Total: $184,343  
Award: 1 R01 DK064371-01A2 (04030305-1)

## Pereira, Naveen

**Principal Investigator**

**Randomized, Prospective, Multi-Center Comparison of Prograf, Cellcept and Steroids vs Cyclosporine, Cellcept and Steroids vs Prograf, Rapamune and Steroids in De Novo Cardiac Transplant Recipients**

Sponsor: Fujisawa Healthcare, Inc.  
Award: (02051606)

**A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients with Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy**

Sponsor: Cardiovascular Clinical Studies  
Award: CKI-202 (04091701)

**Pl: Wayne Fitzgibbon**  
**Dept: Medicine**  
**Sponsor: Microbia, Inc.**  
**Total:** $15,222  
**Award:** (04091402-1)

## Ploth, David

**Principal Investigator**

**Nephrology Fellows Education and Training in Anemia**

Sponsor: Amgen  
Award: (03091702)

**Renal Constitutive and Inducible Na+/Urea Transporters**

Sponsor: Dialysis Clinics, Inc.  
Award: C-2229 (03121013)

**Differential Signaling of Serotonin and Angiotensin II in Vascular Smooth Cells**

Sponsor: Dialysis Clinics, Inc.  
Award: C-2288 (04072903)

**Effect of Cox-2 Inhibitors on Renal Function**

Pl: Wayne Fitzgibbon  
Dept: Medicine  
Sponsor: Microbia, Inc.  
**Total:** $15,222  
**Award:** (04091402-1)

## Raymond, John

**Principal Investigator**

**G Protein Regulation of NHE-Activity: Minority Supplement #2**

Sponsor: NIH/NIDDK  
Award: 3 R01 DK052448-08S2 (04040604)

**Regulation of EGF Receptors by G Protein Receptor**

Sponsor: NIH/NIGMS  
Award: 5 R01 GM063909-04 (04042301)
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>G Protein Regulation of NHE Activity</td>
<td>NIH/NIDDK</td>
<td>04/01/05 - 03/31/06</td>
<td>$242,802</td>
<td>63,128</td>
</tr>
<tr>
<td>Inflammatory Mediators of Glomerular Disease (REAP)</td>
<td>VAMC</td>
<td>07/01/04 - 06/30/05</td>
<td>$139,500</td>
<td>0</td>
</tr>
<tr>
<td>Roles for Calmodulin in 5-HT Receptor Function</td>
<td>VAMC</td>
<td>07/01/04 - 06/30/05</td>
<td>$139,500</td>
<td>0</td>
</tr>
<tr>
<td>Training Grant in Glomerular Function and Disease</td>
<td>NIH/NIDDK</td>
<td>08/01/04 - 07/31/05</td>
<td>$108,569</td>
<td>7,854</td>
</tr>
<tr>
<td>A Comparison of the Safety and Efficacy of Two Doses of Peg-Interferon Alfa-2b</td>
<td>Schering-Plough Corp.</td>
<td>04/01/02 - 08/31/05</td>
<td>$1,800</td>
<td>450</td>
</tr>
<tr>
<td>Comparison of PEG-Intron 1.5 mcg/kw/wk Plus REBETOL vs PEG-Intron 1 mcg/kw/wk</td>
<td>Schering-Plough Corp.</td>
<td>04/12/04 - 08/31/04</td>
<td>$86,400</td>
<td>21,600</td>
</tr>
<tr>
<td>A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfa-1 plus Ribavirin in Hepatitis C Infected Patients Who Failed to Achieve Virologic Response after Previous Pegylated Interferon Alfa plus Ribavirin Therapy and During at Least 24 Weeks of No Treatment in IRHC-001</td>
<td>IRHC-002 (05011880)</td>
<td>01/01/05 - 01/31/08</td>
<td>$94,053</td>
<td>23,513</td>
</tr>
<tr>
<td>A Multi-Centered, Prospective, Randomized, Placebo-Controlled, Clinical Trial for the Treatment of Significant Steatosis or NASH with Xenical Followed by Treatment of Hepatitis C (HCV) with PEG-Interferon alpha-2a/Copemeg</td>
<td>Geneva Fdn.</td>
<td>06/02/05 - 06/30/08</td>
<td>$49,424</td>
<td>12,356</td>
</tr>
<tr>
<td>A 6-Month, Double-Blind, Double-Dummy, Randomized, Parallel Group, Multi-Center, Efficacy and Safety Study of SYMPLICITY pMDI 2 × 160/4.5 ug and 80/4.5 up bid Compared to Formoterol Turbuhaler, Budesonide pMDI and Placebo in Patients with COPD</td>
<td>Astrazeneca</td>
<td>04/01/05 - 05/31/07</td>
<td>$71,200</td>
<td>17,800</td>
</tr>
</tbody>
</table>

**Raymond, John**
- Co-Investigator
- **Cellular Effects of Indoxyl Sulfate-A Uremic Toxin**
  - PI: Andrew Gelasco
  - Sponsor: NIH/NIDDK
  - Total: $128,707
- **A Placebo-and Active-Controlled (Ciclesonide metered-dose inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler) in Adult and Adolescent Patients with Persistent Asthma**
  - Sponsor: PPD Development
  - Budget Dates: 03/30/05 - 05/31/07
  - Direct: $92,600
- **A 12 Week Treatment with 125 ug Roflumilast Versus 250 ug Roflumilast Versus Placebo in Patients with Asthma**
  - Sponsor: Covance, Inc.
  - Budget Dates: 11/01/01 - 12/31/04
  - Direct: $3,150

**Reuben, Adrian**
- **Principal Investigator**
- **Comparison of PEG-Intron 1.5 mcg/kw/wk Plus REBETOL vs PEG-Intron 1 mcg/kw/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1**
  - Sponsor: Schering-Plough Corp.
  - Budget Dates: 04/01/02 - 08/31/05
  - Direct: $86,400
- **A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Daily Interferon Alfacon-1 plus Ribavirin in Hepatitis C Infected Patients Who Failed to Achieve Virologic Response after Previous Pegylated Interferon Alfa plus Ribavirin Therapy and During at Least 24 Weeks of No Treatment in IRHC-001**
  - Sponsor: Intermune, Inc.
  - Budget Dates: 01/01/05 - 01/31/08
  - Direct: $94,053
- **A Multi-Centered, Prospective, Randomized, Placebo-Controlled, Clinical Trial for the Treatment of Significant Steatosis or NASH with Xenical Followed by Treatment of Hepatitis C (HCV) with PEG-Interferon alpha-2a/Copemeg**
  - Sponsor: Geneva Fdn.
  - Budget Dates: 06/02/05 - 06/30/08
  - Direct: $49,424

**Sahn, Steven**
- **Principal Investigator**
- **A Placebo-and Active-Controlled (Ciclesonide metered-dose inhaler), Randomized, Parallel-Group, Dose-Range Finding Study of Ciclesonide Administered by Dry Powder Inhaler (Ultrahaler) in Adult and Adolescent Patients with Persistent Asthma**
  - Sponsor: PPD Development
  - Budget Dates: 03/30/05 - 05/31/07
  - Direct: $92,600
- **A 6-Month, Double-Blind, Double-Dummy, Randomized, Parallel Group, Multi-Center, Efficacy and Safety Study of SYMPLICITY pMDI 2 × 160/4.5 ug and 80/4.5 up bid Compared to Formoterol Turbuhaler, Budesonide pMDI and Placebo in Patients with COPD**
  - Sponsor: Astrazeneca
  - Budget Dates: 04/01/05 - 05/31/07
  - Direct: $71,200

**Annual Report for Research FY2005**
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates:</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schweinfest, Clifford</td>
<td><strong>Models of DRA Growth Suppression in Colon Cancer</strong></td>
<td>NIH/NCI</td>
<td>07/01/04 - 06/30/05</td>
<td>$178,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Elucidation of a DRA Signaling Pathway in Colon Cancer</strong></td>
<td>NIH/NCI</td>
<td>04/01/05 - 03/30/06</td>
<td>$90,000</td>
<td></td>
</tr>
<tr>
<td>Sherman, Carol</td>
<td><strong>A Phase III Study of Delayed vs. Immediate Second-Line Therapy with Docetaxel After Gemcitabine + Carcobilatin in Advanced Non-Small Cell Lung Cancer</strong></td>
<td>Lilly Research Laboratories</td>
<td>03/01/02 - 12/31/05</td>
<td>$6,940</td>
<td></td>
</tr>
<tr>
<td>Shetye, Kedar</td>
<td><strong>Definity (Perflutren Lipid Microspheres) Enhanced Sonothrombolysis of Thrombosed Dialysis Grafts and Fistulae (Sonolysis)</strong></td>
<td>ImaRx Therapeutics</td>
<td>04/01/05 - 03/31/06</td>
<td>$873,846</td>
<td></td>
</tr>
<tr>
<td>Silver, Richard</td>
<td><strong>BUILD 2-OL: Long-Term, Open-Label Study in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis Who Completed the Protocol AC-052-330/BUUILD 2</strong></td>
<td>Actelion Pharmaceuticals</td>
<td>10/26/04 - 12/31/06</td>
<td>$14,848</td>
<td>$3,712</td>
</tr>
<tr>
<td></td>
<td><strong>MCRC in Rheumatoid Disease</strong></td>
<td>NIH/NIAMS</td>
<td>04/01/04 - 03/31/08</td>
<td>$6,567</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NIAMS MCRC in Rheumatoid Disease - Undergraduate Student Supplement for Kristie Quarles</strong></td>
<td>NIH/NIAMS</td>
<td>06/01/05 - 03/31/06</td>
<td>$6,567</td>
<td></td>
</tr>
<tr>
<td>Silvestri, Gerard</td>
<td><strong>Computer-Aided Cancer Management</strong></td>
<td>DOD</td>
<td>04/01/05 - 03/31/06</td>
<td>$2,519,875</td>
<td>$153,174</td>
</tr>
<tr>
<td>Smith, Edwin</td>
<td><strong>CLEAR Registry</strong></td>
<td>Univ. of Alabama, Birmingham</td>
<td>09/30/04 - 09/29/05</td>
<td>$21,843</td>
<td>$9,392</td>
</tr>
<tr>
<td></td>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients with Systemic Sclerosis</strong></td>
<td>Actelion Pharmaceuticals</td>
<td>10/01/03 - 06/30/05</td>
<td>$6,466</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Multi-Center, Phase II Trial of Oral Type 1 Bovine Collagen in Scleroderma-Extension Through 4/30/2005</strong></td>
<td>Univ. of Tennessee</td>
<td>05/01/04 - 04/30/05</td>
<td>$2,444</td>
<td>$856</td>
</tr>
<tr>
<td></td>
<td><strong>Multi-Center, Phase II Trial of Oral Type I Bovine Collagen in Scleroderma</strong></td>
<td>Univ. of Tennessee</td>
<td>05/01/04 - 04/30/05</td>
<td>$18,211</td>
<td>$5,989</td>
</tr>
</tbody>
</table>

**NIAMS MCRC in Rheumatoid Disease - Patient Resource Core**

- **PI:** Richard Silver  
- **Dept:** Medicine  
- **Award:** P60 AR049459-03 (05012859-3)  
- **Total:** $131,359
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Description</th>
<th>Sponsor</th>
<th>Total:</th>
<th>Dept:</th>
<th>Award:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith, Edwin</td>
<td>Co-Investigator</td>
<td>MCRC in Rheumatoid Disease</td>
<td>NIH/NIAMS</td>
<td>$119,297</td>
<td>Medicine</td>
<td>5 P60 AR049459-03 (05012859-1)</td>
</tr>
<tr>
<td>Smolka, Adam</td>
<td>Principal Investigator</td>
<td>Mechanisms of H. Pylori-Induced Hypochlorhydria</td>
<td>NIH/NIDDK</td>
<td>$184,343</td>
<td>Medicine</td>
<td>GC-3532-03-42153CM (03080703-40)</td>
</tr>
<tr>
<td>Strange, Charlie</td>
<td>Principal Investigator</td>
<td>Efficacy and Safety of Drotrecogin Alfa (Activated) F1K-MC-EVAD in Adult Patients with Early Stage Severe Sepsis</td>
<td>Eli Lilly</td>
<td>$3,200</td>
<td>Medicine</td>
<td>F1K-MC-EVCL (02101407)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phase II: Comparative, Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (Procrit) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days</td>
<td>Ortho Biotech</td>
<td>$498</td>
<td>Medicine</td>
<td>PR02-33-048 (04031501)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alpha-1 Foundation Research Registry</td>
<td>Alpha-1 Fdn.</td>
<td>$261,666</td>
<td>Medicine</td>
<td>(04100703)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Aquavan Injection Versus Midazolam HCL for Sedation in Patients Undergoing Flexible Bronchoscopy Procedures.</td>
<td>PPD Development</td>
<td>$32,176</td>
<td>Medicine</td>
<td>3000-0409 (04111789)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Prospective, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis</td>
<td>GlaxoSmithKline</td>
<td>$144,546</td>
<td>Medicine</td>
<td>PROTOCOL EMD20001 (04090802-1)</td>
</tr>
<tr>
<td>Stuart, Robert</td>
<td>Principal Investigator</td>
<td>A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations</td>
<td>Cephalon, Inc.</td>
<td>$66,631</td>
<td>Medicine</td>
<td>C0701A/204/ON/US (04072605)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flavorpiridol/Bortezomib in Myeloma/B-Cell Neoplasms</td>
<td>Virginia Commonwealth Univ.</td>
<td>$46,252</td>
<td>Medicine</td>
<td>520833/POP52789 (05040578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Phase II Study of Arsenic Trioxide in Combination with 5-Azacitidine in Myelodysplastic Syndromes</td>
<td>MDS2773 (05050274)</td>
<td>$194,219</td>
<td>Medicine</td>
<td>05050274</td>
</tr>
</tbody>
</table>

Annual Report for Research FY2005
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sturdivant, Rachel</td>
<td>Fellows Travel Award to the International Dialysis Conference</td>
<td>Ortho Biotech</td>
<td>01/01/04 - 12/31/05</td>
<td>$10,000</td>
<td>0</td>
</tr>
<tr>
<td>Thomas, James</td>
<td>MR11 2002 - A Double-Blind, Randomized, Dose Escalating, Efficacy and Safety Study of Implitapide at Daily Doses of 10mg, 15mg, 20mg, 25mg, 30mg and 40mg Compared with Placebo Patients with Heterozygous Familial Hypercholesterolemia (heFH) on Maximal, Tolerable, Concurrent Triglyceride-Lowering Therapy</td>
<td>PPD Development</td>
<td>05/11/04 - 02/01/06</td>
<td>$34,536</td>
<td>6,000</td>
</tr>
<tr>
<td>Tourkina, Elena</td>
<td>Caveolin-1 in Scleroderma Lung Disease</td>
<td>Scleroderma Fdn.</td>
<td>01/01/05 - 12/31/05</td>
<td>$69,444</td>
<td>5,556</td>
</tr>
<tr>
<td>Trojanowska, Maria</td>
<td>Fibrosis: Molecular Basis for Fibroblast Activation</td>
<td>NIH/NIAMS</td>
<td>04/01/05 - 03/31/06</td>
<td>$194,000</td>
<td>89,240</td>
</tr>
</tbody>
</table>

**Announcement**

Tourkina, Elena, PhD, has been awarded a 5 R01 HL073718-02 grant from NIH/NHLBI, totaling $250,000. This grant focuses on the role of PKCepsilon-related proteins in lung fibrosis.
Trojanowska, Maria

**Co-Investigator**

**VHL and FGFR Signaling In Angiogenesis**

PI: Tien Hsu  
Dept: Pathology and Laboratory Medicine  
Sponsor: NIH/NCI  
Award: 1 R01 CA109860-01 (03110302-1)  
Total: $205,000

**Mechanisms of H. Pylori-Induced Hypochlorhydria**

PI: Adam Smolka  
Dept: Medicine  
Sponsor: NIH/NIDDK  
Award: 1 R01 DK064371-01A2 (04030305-1)  
Total: $184,343

**MCRC in Rheumatoid Disease**

PI: Richard Silver  
Dept: Medicine  
Sponsor: NIH/NIAMS  
Award: 5 P60 AR049459-03 (05012859-1)  
Total: $119,297

Ullian, Michael

**Principal Investigator**

**Regulation of Angiotensin AT1 Receptors by Antioxidants**

Sponsor: Dialysis Clinics, Inc.  
Award: C-2246 (04043006)  
Budget Dates: 07/01/04 - 06/30/06  
Direct: $150,000  
F & A: 0

**Nuclear Trafficking of the Angiotensin II Type 1a Receptor**

Sponsor: Dialysis Clinics, Inc.  
Award: C-2342 (Charleston-Magnol (04111684)  
Budget Dates: 01/01/05 - 12/31/07  
Direct: $278,289  
F & A: 0

Van Bakel, Adrian

**Principal Investigator**

**A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Study of Oral Enoximone Versus Placebo in Advanced Chronic Heart Failure Subjects**

Sponsor: Myogen, Inc.  
Award: MY-021 (02071203)  
Budget Dates: 06/01/02 - 06/30/05  
Direct: $400  
F & A: 100

**A Multi-Center, Controlled Trial of the Orqis Medical Cancion - Cardiac Recovery System (CRS) for the Use in Treatment of Acute Decompensated Heart Failure in a Chronic Heart Failure Population Requiring Hospitalization and Intravenous Pharmacologic Intervention**

Sponsor: Orqis Medical  
Award: 2003-C REV 2 (03072504)  
Budget Dates: 08/01/03 - 12/31/07  
Direct: $55,600  
F & A: 13,900

**A Pilot Study to Assess Change in Exercise Heart Rate as a Dosing Strategy for Beta Blocker Therapy in Patients with Heart Failure due to Left Ventricular Systolic Dysfunction (TARGET-HR)**

Sponsor: Univ. of North Carolina  
Award: TARGET HR (05021532)  
Budget Dates: 03/11/05 - 03/10/06  
Direct: $13,200  
F & A: 3,300

Watson, Patricia

**Co-Investigator**

**Role of Novel Oncogene in Mesothelioma**

PI: Alice Boylan  
Dept: Medicine  
Sponsor: NIH/NIEHS  
Award: 5 R01 ES011323-03 (05041919-1)  
Total: $166,250

Wharton, J.

**Principal Investigator**

**Electrophysiology Conventional Case Retrospective Data Collection and Analysis**

Sponsor: Stereotaxis, Inc.  
Award: (05012009)  
Budget Dates: 02/02/05 - 02/01/06  
Direct: $2,800  
F & A: 700

**HEART Study: Helios Electrophysiology Ablation Remote Treatment Study**

Sponsor: Stereotaxis, Inc.  
Award: CLIN-012 (05042026)  
Budget Dates: 04/08/05 - 12/31/08  
Direct: $88,800  
F & A: 22,200

Wilson, Peter

**Principal Investigator**

**Improvement in Estimation of CHD Risk**

Sponsor: Donald W. Reynolds Fdn.  
Award: (03112502)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $243,699  
F & A: 29,496

**Plasminogen Activator Inhibitor (PAI-1) as a Risk Factor for Developing Vascular Disease**

Sponsor: Wyeth-Ayerst  
Award: (04031512)  
Budget Dates: 11/17/04 - 11/16/05  
Direct: $108,000  
F & A: 27,000
**Mechanisms and Strategies for Insulin Resistance in AIDS**
Sponsor: Massachusetts Institute of Technology  
Award: 5 R01 DK59535-04 (04031902)  
Budget Dates: 10/01/03 - 08/31/04  
Direct: $13,698  
F & A: $6,302

**Clinical Utility of Caduet (R) in Simultaneously Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population (CAPABLE)**
Sponsor: Pfizer, Inc.  
Award: A3841025 (04061404)  
Budget Dates: 07/01/04 - 07/01/05  
Direct: $21,632  
F & A: $5,408

**Inflammatory Markers and Improving CHD Risk Assessment**
Sponsor: NIH/NHLBI  
Award: 5 R01 HL073272-02 (04062201)  
Project Dates: 09/01/04 - 08/31/06  
F & A: $19,219

**Identification of Persons with Insulin Resistance and Its Impact on CVD in the Framingham Population**
Sponsor: GlaxoSmithKline  
Award: (04111686)  
Project Dates: 11/15/04 - 12/31/06  
F & A: $28,000

**A Phase III, Double-Blind, Randomized, Multi-Site Trial of the Efficacy, Safety and Tolerability of the Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily for 12 Months, Compared to Atorvastatin Alone, Titrated Based on NCEP ATP-III LDL-C Goals in Subjects with Fredrickson Types IIA and IIB Dyslipidemias**
Sponsor: Icon Clinical Research, Inc.  
Award: A5091019 (04111995)  
Project Dates: 11/19/04 - 12/31/05  
F & A: $36,238

---

**Yang, Qing**

**Novel AT1a Receptor Interaction Partners**
Sponsor: NIH/NIDDK  
Award: 5 K01 DK063252-03 (04110441)  
Project Dates: 01/01/03 - 12/31/05  
F & A: $7,308

---

**Young, M.**

**Blocking Angiogenesis by Targeting PP-2A Pathways**
Sponsor: NIH/NCI  
Award: 5 R01 CA097813-02 (04031907)  
Project Dates: 07/01/04 - 06/30/05  
F & A: $52,065

---

**Yu, Hongwei**

**Role of Lipid Raft Disorganization in Lung Hypoplasia of Dhc7 Null Mice**
Sponsor: Amer. Lung Assoc.  
Award: RG-11311-N (04083103)  
Project Dates: 07/01/05 - 06/30/06  
F & A: $0

---

**Zhang, John**

**Development of Novel Monoclonal Antibodies for the Diagnosis and Treatment of Cancer**
Sponsor: Neogenix Oncology, Inc.  
Award: (04081301)  
Project Dates: 08/15/04 - 11/15/05  
F & A: $39,100

---

**Zile, Michael**

**Phase II, Double-Blind, Randomized, Placebo-Controlled, Dose-Comparative Study of the Efficacy, Tolerability and Safety of MCC-135 in Subjects with Chronic Heart Failure, NYHA III/III (MUSC)**
Sponsor: Quintiles Pacific, Inc.  
Award: MCC-135/G01 (01041902)  
Project Dates: 04/01/01 - 12/31/04  
F & A: $4,319

**Clinical Study of the Medtronic Chronicle Implantable Hemodynamic Monitor System for Heart Failure Compass HF**
Sponsor: Medtronic, Inc.  
Award: (03050711)  
Project Dates: 05/01/03 - 12/31/07  
F & A: $20
## Diastolic Heart Failure: Role of the Extracellular Matrix

**Sponsor:** VAMC  
**Budget Dates:** 04/01/04 - 03/31/05  
**Direct:** $135,000

## A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients with Hypertension and Diastolic Dysfunction

**Sponsor:** Novartis Corp.  
**Budget Dates:** 06/09/04 - 12/14/06  
**Direct:** $89,083

### Microbiology and Immunology

#### Dong, Jianyun

**Persistent Adeno-EBV Vectors for Gene Therapy**  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 DK057997-04 (04051104)

**Personnel Agreement for Economic Development**  
**Sponsor:** Genphar, Inc.  
**Award:** (05032543)

#### Haque, Azizul

**Defective Antigen Presentation by Burkitt Lymphoma**  
**Sponsor:** Leukemia and Lymphoma Society  
**Award:** 3024-04 (04052816)

#### London, Lucille

**PKCepsilon-Related Proteins in Lung Fibrosis**  
**Sponsor:** NIH/NHLBI  
**Award:** 5 R01 HL073718-02 (04070122-1)

#### May, Harold

**A Polyphasic Approach to Assess the Fate of Polychlorinated Biphenyls (PCBs) in Coastal Sediments**  
**Sponsor:** DOD/ONR  
**Award:** N00014-03-1-0034 (02071702)

**An Anode Array Microbial Fuel Cell (MFC) for High Throughput MUFC Research**  
**Sponsor:** Clemson Univ.  
**Award:** 897-7557-223-2094553/01-0 (04111066)

**An Anode Array Microbial Fuel Cell (MFC) for High Throughput MUFC Research**  
**Sponsor:** SC EPSCOR  
**Award:** 900-7557-231-2004646 (05062410)
Norris, James

**Principal Investigator**

**Viral Vector Core Facility**

Sponsor: NIH/NCI  
Award: 5 R24 CA088163-05 (05012642)

**Co-PI or Project Leader**

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 2: Genesis of Bystander Activity in FasL Gene Therapy**

PI: Yusuf Hannun  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCI  
Award: 1 P01 CA97132-02 (01100808-7)

**DOD Phase VI: Project 6- Intervventional Pre-Clinical Studies of Prostate Cancer Xenograft Therapy with AdGFPFasL and Ceramidase Inhibitors**

PI: Carolyn Reed  
Dept: Dean's Office - COM  
Sponsor: Geo-Centers, Inc.  
Award: GC-3532-03-42153CM (03080703-31)

**DOD Phase VII: Ceramide Metabolizing Enzymes, Cancer Lipidomics and Gene Expression as a Function of Gleason Grade in Prostate Cancer**

PI: Andrew Kraft  
Dept: Medicine  
Sponsor: Geo-Centers, Inc.  
Award: GC-3609-04-43766CM (04113022-7)

**Co-Investigator**

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**

PI: Yusuf Hannun  
Dept: Biochemistry and Molecular Biology  
Sponsor: NIH/NCI  
Award: 1 P01 CA97132-02 (01100808-8)

Ohta, Rieko

**Principal Investigator**

**The Complement System and Immune Response to Breast Cancer**

Sponsor: DOD  
Award: DAMD17-03-1-0442 (02051703)

**Rubinchik, Semyon**

**Co-Investigator**

**Persistent Adeno-EBV Vectors for Gene Therapy**

PI: Jianyun Dong  
Dept: Microbiology and Immunology  
Sponsor: NIH/NIDDK  
Award: 6 R01 DK057997-04 (04051104-1)

**Viral Vector Core Facility**

PI: James Norris  
Dept: Microbiology and Immunology  
Sponsor: NIH/NCI  
Award: 5 R24 CA088163-05 (05012642-1)

Schmidt, Michael

**Principal Investigator**

**Administer and Manage the Nuclear Engineering/Health Physics Fellowship and Scholarship Program**

Sponsor: SCUREF  
Award: NEID-001 (01050803)

**Navy Nuclear Propulsion Graduate Fellowship Program**

Sponsor: SCUREF  
Award: NEID-005 (01061512)

**Radiochemistry Education Award Program-Phase III**

Sponsor: SCUREF  
Award: DE-FC09-00SR22184 (05062401)

**Management of the Nuclear Energy Research Advisory Committee (NERAC)**

Sponsor: SCUREF  
Award: NEID-002 (99042909)

Sutkowski, Natalie

**Principal Investigator**

**Role of HERV-K18 Superantigen in EBV Lymphomagenesis**

Sponsor: NIH/NCI  
Award: 7 K01 CA095443-03 (05042541)

Tomlinson, Stephen

**Principal Investigator**

**Target Complement of Inhibitors**

Sponsor: Arthritis Fdn.  
Award: (02082302)
The Component System as a Therapeutic Target for Lupus
Sponsor: Arthritis Fdn.  
Award: (03082801)
---

Complement Inhibitors and Immunotherapy
Sponsor: NIH/NCI  
Award: 5 R21 CA104579-02 (05031604)
---

Tomlinson, Stephen
Co-PI or Project Leader
DOD Phase VI: Project 10- Immune Modulation in Cancer Immunotherapy
Pl: Carolyn Reed  
Dept: Dean's Office - COM  
Award: GC-3532-03-42153CM (03080703-35)
---

Varela, Juan
Principal Investigator
Minority Predoctoral Fellowship Program
Sponsor: NIH/NCI  
Award: 1 F31 CA113269-01 (04042802)
---

Virella, Gabriel
Principal Investigator
Research and Development
Sponsor: VAMC  
Award: 534-D3597 (04032201)
---

Medical University of South Carolina AIDS Symposium
Sponsor: Gilead Sciences, Inc.  
Award: (05042753)
---

Voelkel-Johnson, Christina
Principal Investigator
TRAIL-Induced Apoptosis in Prostate Cancer
Sponsor: NIH/NCI  
Award: 5 R01 CA102218-02 (05012121)
---

Neurosciences
Bailey, Byron
Principal Investigator
A Phase II, Randomized, Pharmacokinetic, Dose Finding and Dose Frequency Determination Using rt-PA in Intraventricular Hemorrhage
Sponsor: Johns Hopkins Univ.  
Award: A2652/PO # 8410-68115-5 (05031819)
---

Bhat, Narayan
Principal Investigator
MAP Kinases in Oligodendrocyte Cell Signaling
Sponsor: NIH/NINDS  
Award: 5 R01 NS041396-04 (05062499)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Progesterone, Aging and Memory Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIA</td>
<td>Budget Dates: 05/15/05 - 06/15/05</td>
</tr>
<tr>
<td>Award: 5 R03 AG023925-02 (05030337)</td>
<td>Project Dates: 05/15/04 - 06/15/05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Ethanol and ERK/PKB Signaling in Brain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIAAA</td>
<td>Budget Dates: 05/01/05 - 04/30/06</td>
</tr>
<tr>
<td>Award: 5 R01 AA010983-09 (05031711)</td>
<td>Project Dates: 12/01/06 - 04/30/08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Role of Eicosanoids in Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIGMS</td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
</tr>
<tr>
<td>Award: 2 R01 GM027673-23 (04011304)</td>
<td>Project Dates: 04/01/05 - 06/30/08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>The Role of PPARg and PPARg Agonists in Septic Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Children's Hospital Medical Center</td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
</tr>
<tr>
<td>Award: 5 R01 GM067202-02 (04082402)</td>
<td>Project Dates: 07/01/03 - 06/30/07</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-PI or Project Leader</th>
<th>Mechanisms of Gram-Positive Bacterial Tolerance</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Octavia Peck</td>
<td>Sponsor: NIH/NIGMS</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 F31 GM067559-03 (04120884-1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Pharmacological Correlates of Aging and Brain Cell Grafts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Univ. of South Florida</td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
</tr>
<tr>
<td>Award: 6155-0032-00-B (04043007)</td>
<td>Project Dates: 07/01/01 - 06/30/06</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Aged Forebrain Cholinergic Neurons-Estrogen and NGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIA</td>
<td>Budget Dates: 09/01/04 - 08/31/06</td>
</tr>
<tr>
<td>Award: 5 R01 AG12122-10 (04070119)</td>
<td>Project Dates: 04/08/04 - 08/31/06</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Mechanisms of Neurotrophin Improved Cognition in Aging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIA</td>
<td>Budget Dates: 09/01/04 - 08/31/05</td>
</tr>
<tr>
<td>Award: 5 R01 AG010755-11 (04070125)</td>
<td>Project Dates: 09/29/91 - 08/31/08</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Serotonergic Agonists and Memory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Predix Pharmaceuticals, Inc.</td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
</tr>
<tr>
<td>Award: (04071612)</td>
<td>Project Dates: 07/01/04 - 06/30/05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Regulation and Cell Biology of Beta-Secretase</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Kumar Sambamurti</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 1 R01 AG023055-01A1 (03112401-1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Prefrontal Glutamate and Working Memory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIMH</td>
<td>Budget Dates: 09/30/04 - 09/29/05</td>
</tr>
<tr>
<td>Award: 5 F30 MH070194-02 (04063016)</td>
<td>Project Dates: 09/30/03 - 06/29/07</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Cocaine Regulation of Norepinephrine Transporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: NIH/NIDA</td>
<td>Budget Dates: 08/01/04 - 07/31/05</td>
</tr>
<tr>
<td>Award: 1 R03 DA16753-01A1 (03063004)</td>
<td>Project Dates: 08/01/04 - 07/31/06</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Neurobiology of Addiction Research Center: Project 3 - Changes in Expression and Regulation of Monoamine Transporters Associated with Drug Seeking Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI: Peter Kalivas</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 P50 DA015369-03 (05032959-4)</td>
</tr>
</tbody>
</table>
### Kalivas, Peter

**Principal Investigator**

**NIDA Invest International Visiting Scientists and Technical Exchange Program**

- **Sponsor:** NIH/NIDA
- **Award:** (03600201)
- **Budget Dates:** 10/01/04 - 09/30/05
- **Direct:** $36,000

**Glutamate and Craving for Cocaine**

- **Sponsor:** NIH/NIDA
- **Award:** 2 R01 DA012513-06 (04062905)
- **Budget Dates:** 04/01/05 - 03/30/06
- **Direct:** $175,000

**Cocaine, Opioids and Drug Abuse**

- **Sponsor:** NIH/NIDA
- **Award:** 4 R37 DA003906-22 (04083102)
- **Budget Dates:** 12/01/04 - 07/31/06
- **F & A:** $0

**NAC-1 A Cocaine Regulated mRNA in the Rat Brain**

- **Sponsor:** Univ. of Pennsylvania
- **Award:** 5 P50 DA015369-03 (05032959)
- **Budget Dates:** 04/01/05 - 03/30/06
- **Direct:** $863,592

**Neurobiology of Addiction Research Center (NARC)**

- **Sponsor:** NIH/NIDA
- **Award:** 5 R01 DA012513-06 (04062905)
- **Budget Dates:** 12/01/04 - 07/31/06
- **Direct:** $256,047

**Co-PI or Project Leader**

**Prefrontal Glutamate and Working Memory**

- **PI:** Mary Gregory
- **Dept:** Neurosciences
- **Sponsor:** NIH/NIMH
- **Award:** 5 F30 MH070194-02 (04063016-1)
- **Budget Dates:** 04/01/05 - 03/30/06
- **Direct:** $5,000

**Treatment and Gene/Protein Analysis of Ethanol Relapse**

- **PI:** Howard Becker
- **Dept:** Psychiatry and Behavioral Sciences
- **Sponsor:** NIH/NIAAA
- **Award:** 5 R01 AA013885-03 (05012858-1)
- **Budget Dates:** 04/01/05 - 03/30/06
- **Direct:** $250,000

### Kindy, Mark

**Principal Investigator**

**Neprilysin and Amyloid-Beta Degradation in Alzheimer’s Disease**

- **Sponsor:** VAMC
- **Award:** NEUD-021-01F (03063010)
- **Budget Dates:** 04/01/05 - 03/31/06
- **Direct:** $85,000

**Therapeutic Potential of Galantamine in Alzheimer’s Disease**

- **Sponsor:** Janssen Pharmaceutica
- **Award:** (04063008)
- **Budget Dates:** 09/01/04 - 08/31/05
- **Direct:** $13,000

**Oxidized Lipoproteins in Neurodegeneration**

- **Sponsor:** NIH/NINDS
- **Award:** 5 R01 NS039588-05 (04070206)
- **Budget Dates:** 08/15/04 - 08/31/05
- **Direct:** $227,088

**SC 2004 Research Infrastructure Improvement Grant: MUSC Phenomics Center**

- **Sponsor:** SC Research Authority
- **Award:** Task Order#0016 (04080503)
- **Budget Dates:** 06/01/05 - 05/31/06
- **Direct:** $688,147

**Neprilysin and Abeta Degradation in Alzheimer’s Disease**

- **Sponsor:** NIH/NIA
- **Award:** 5 R01 AG019323-04 (04100401)
- **Budget Dates:** 12/15/04 - 11/30/05
- **Direct:** $186,000

**Purification of Cord Blood Stem Cells**

- **Sponsor:** CureSource, Inc.
- **Award:** (05012005)
- **Budget Dates:** 01/15/05 - 12/31/05
- **Direct:** $9,600

**MUSC/NSF EPSCoR Minority Undergraduate Research Program**

- **Sponsor:** Univ. of South Carolina
- **Award:** (05022882)
- **Budget Dates:** 04/01/05 - 06/30/05
- **Direct:** $20,000

**Expectatory and Anticipatory Behavior in Natural Systems (BRIN)**

- **Sponsor:** Univ. of South Carolina
- **Award:** 1 P20 RR16461-01 (05022883)
- **Budget Dates:** 03/01/05 - 02/28/06
- **Direct:** $22,000

### Lavin, Antonieta

**Principal Investigator**

**Dopaminergic Modulation of Thalamocortical Circuits**

- **Sponsor:** NIH/NIDA
- **Award:** 5 R01 DA014698-04 (04120658)
- **Budget Dates:** 05/01/05 - 01/31/06
- **Direct:** $150,000
<table>
<thead>
<tr>
<th>Research Faculty Activity</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurosciences College of Medicine</td>
<td></td>
</tr>
<tr>
<td><strong>Lavin, Antonieta</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>Fast and Slow Dopamine Signaling in Prefrontal Cortex</td>
<td>PI: Jeremy Seamans</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Award: 5 R01 MH065924-03 (04061812-1)</td>
</tr>
<tr>
<td><strong>Total</strong>: $150,000</td>
<td></td>
</tr>
<tr>
<td><strong>Lokensgard, Rita</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Neural Bases of Drug Context-Induced Cocaine Seeking</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>PI: Ronald See</td>
<td>Award: 1 R01 DA017673-01A1 (04022305)</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Project Dates: 02/05/05 - 06/01/05</td>
</tr>
<tr>
<td><strong>Total</strong>: $150,000</td>
<td></td>
</tr>
<tr>
<td><strong>McFarland, Krista</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Stress-Induced Reinstatement of Cocaine-Seeking Behavior</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>PI: Peter Kalivas</td>
<td>Award: 5 R01 DA015851-02 (05021126)</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Budget Dates: 04/01/05 - 03/31/06</td>
</tr>
<tr>
<td><strong>Total</strong>: $63,100</td>
<td></td>
</tr>
<tr>
<td><strong>McGinty, Jacqueline</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Drug Abuse Training Program</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>PI: Howard Becker</td>
<td>Award: 5 T32 DA007288-13 (04030308)</td>
</tr>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Budget Dates: 07/01/04 - 06/30/05</td>
</tr>
<tr>
<td><strong>Total</strong>: $240,154</td>
<td></td>
</tr>
<tr>
<td>Telencephalic Opioid Neurons: Psychostimulant Effects</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>PI: Peter Kalivas</td>
<td>Award: 5 R01 DA003982-22 (05040787)</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Budget Dates: 06/01/05 - 05/31/06</td>
</tr>
<tr>
<td><strong>Total</strong>: $204,346</td>
<td></td>
</tr>
<tr>
<td><strong>Moran, Megan</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Preventing Cocaine Rooted Neuroplasticity</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>PI: Howard Becker</td>
<td>Award: 1 F31 DA018459-01A1 (04100710)</td>
</tr>
<tr>
<td>Dept: Psychiatry and Behavioral Sciences</td>
<td>Budget Dates: 05/01/05 - 04/30/06</td>
</tr>
<tr>
<td><strong>Total</strong>: $250,000</td>
<td></td>
</tr>
<tr>
<td><strong>Patel, Sunil</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>A Phase II, Randomized, Pharmacokinetic, Dose Finding and Dose Frequency Determination Using rt-PA in Intraventricular Hemorrhage</td>
<td>Sponsor: Johns Hopkins Univ.</td>
</tr>
<tr>
<td>PI: Byron Bailey</td>
<td>Award: A2652/PO # 8410-68115-5 (05031819-1)</td>
</tr>
<tr>
<td>Dept: Neurosciences</td>
<td>Total: $28,128</td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>Neurosciences</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td><strong>Peck, Octavia</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Principal Investigator</strong></td>
<td><strong>Mechanisms of Gram-Positive Bacterial Tolerance</strong></td>
</tr>
</tbody>
</table>
| Sponsor: NIH/NIGMS | Budget Dates: 03/01/05 - 08/31/05  Direct: $ 24,821  
| Award: 5 F31 GM067559-03 (04120884) | Project Dates: 03/12/03 - 08/31/05  
|  | F & A: 0 |
| **Peters, Jamie** |  |
| **Principal Investigator** | **Metabotropic Glutamate Receptors Mediate Cocaine Relapse** |
| Sponsor: NIH/NIDA | Budget Dates: 09/01/04 - 08/31/05  Direct: $ 32,127  
| Award: 1 F31 DA018486-01 (03121008) | Project Dates: 09/01/04 - 08/31/07  
|  | F & A: 0 |
| **Ramamoorthy, Sammanda** |  |
| **Principal Investigator** | **Serotonin Transporter Phosphorylation** |
| Sponsor: NIH/NIMH | Budget Dates: 12/01/04 - 11/30/05  Direct: $ 150,000  
| Award: 5 R01 MH062612-04 (04092806) | Project Dates: 12/07/01 - 11/30/05  
|  | F & A: 64,500 |
| **Co-PI or Project Leader** | Neurobiology of Addiction Research Center: Project 3 - Changes in Expression and Regulation of Monoamine Transporters Associated with Drug Seeking Behavior  
| PI: Peter Kalivas | Sponsor: NIH/NIDA  
| Dept: Neurosciences | Award: 5 P50 DA015369-03 (05032959-4) |
| **Rohrer, Baerbel** |  |
| **Principal Investigator** | **Rod Neurodegenerative and Protective-Genes** |
| Sponsor: NIH/NEI | Budget Dates: 08/01/04 - 07/31/06  Direct: $ 175,000  
| Award: 5 R01 EY013520-04 (04052501) | Project Dates: 08/01/01 - 07/31/06  
|  | F & A: 75,250 |
| **Sambamurti, Kumar** |  |
| **Principal Investigator** | **Regulation of BACE in DIGs** |
| Sponsor: Alzheimers Assoc. | Budget Dates: 04/01/04 - 03/31/05  Direct: $ 72,728  
| Award: IIIRG-01-3062 (02121708) | Project Dates: 12/15/02 - 03/31/05  
|  | F & A: 7,272 |
| **Regulation and Cell Biology of Beta-Secretase** |  
| Sponsor: NIH/NIA | Budget Dates: 09/30/04 - 06/30/05  Direct: $ 164,000  
| Award: 1 R01 AG023055-01A1 (03112401) | Project Dates: 09/30/04 - 06/30/09  
|  | F & A: 75,440 |
| **Effects of Cholinergic Drugs on APP Metabolism** |  
| Sponsor: Axonyx USA | Budget Dates: 04/01/05 - 10/31/05  Direct: $ 408,630  
| Award: (04010704) | Project Dates: 04/01/05 - 10/31/05  
|  | F & A: 153,470 |
| **Collaboration Account from Dr. Greig** |  
| Sponsor: NIH/NIA | Budget Dates: 09/09/04 - 09/08/05  Direct: $ 10,425  
| Award: 263-MA-321247 (04090102) | Project Dates: 09/09/04 - 09/08/06  
|  | F & A: 1,575 |
| **Effects of Cholinergic Agonists on APP Metabolism** |  
| Sponsor: Predix Pharmaceuticals, Inc. | Budget Dates: 04/01/05 - 03/31/06  Direct: $ 62,968  
| Award: (05041298) | Project Dates: 04/01/05 - 03/31/06  
|  | F & A: 28,966 |
| **Co-Investigator** | Mechanisms of Neurotrophin Improved Cognition in Aging  
| PI: Ann-Charlotte Granholm | Sponsor: NIH/NIA  
| Dept: Neurosciences | Award: 5 R01 AG010755-11 (04070125-1)  
|  | Total: $ 194,000 |
| **Seamans, Jeremy** |  |
| **Principal Investigator** | **Fast and Slow Dopamine Signaling in Prefrontal Cortex** |
| Sponsor: NIH/NIMH | Budget Dates: 08/01/04 - 05/31/05  Direct: $ 150,000  
| Award: 5 R01 MH065924-03 (04061812) | Project Dates: 08/01/02 - 05/31/07  
|  | F & A: 69,000 |
| **Dopamine and Ach Regulation of Inhibition in PFC** |  
| Sponsor: NIH/NIMH | Budget Dates: 02/01/05 - 01/31/06  Direct: $ 150,000  
| Award: 5 R01 MH064569-03 (04120880) | Project Dates: 02/07/03 - 01/31/06  
|  | F & A: 69,000 |
| **See, Ronald** |  |
| **Principal Investigator** | **Basolateral Amygdala - A Substrate for Relapse** |
| Sponsor: NIH/NIDA | Budget Dates: 06/01/05 - 05/31/06  Direct: $ 150,000  
| Award: 5 R01 DA010462-09 (05032328) | Project Dates: 04/10/97 - 05/31/07  
|  | F & A: 69,000 |

---

Annual Report for Research FY2005 75
See, Ronald

Co-PI or Project Leader
ORWH: SCOR on Sex and Gender Factors Affecting Women's Health - Project #1: Sex Differences in Animal Models of Relapse
PI: Kathleen Brady
Sponsor: NIH/NIDA
Total: $108,553
Dept: Psychiatry and Behavioral Sciences
Award: 5 P50 DA016511-03 (04043003-2)

Neurobiology of Addiction Research Center: Animal Core B
PI: Peter Kalivas
Sponsor: NIH/NIDA
Total: $221,932
Dept: Neurosciences
Award: 5 P50 DA015369-03 (05032959-7)

Co-Investigator
PGP Regulation of Antipsychotic Exposure and Effects
PI: C. Devane
Sponsor: NIH/NIMH
Total: $200,000
Dept: Psychiatry and Behavioral Sciences
Award: 1 R01 MH071811-01A1 (04062914-1)

Szumlinski, Karen

Principal Investigator
Homer Proteins in Alcohol Abuse
Sponsor: Scripps Research Inst.
Budget Dates: 09/01/04 - 03/31/05
Direct: $45,205
Project Dates: 09/01/03 - 03/31/05
F & A: $20,795
Award: 5 U01 AA013517-04 (04061501)

Tempel, George

Co-Investigator
Role of Eicosanoids in Shock
PI: James Cook
Sponsor: NIH/NIGMS
Total: $230,000
Dept: Neurosciences
Award: 2 R01 GM027673-23 (04011304-1)

The Role of PPARg and PPARg Agonists in Septic Shock
PI: James Cook
Sponsor: Children's Hospital Med
Total: $75,475
Dept: Neurosciences
Award: 5 R01 GM067202-02 (04082402-1)

Woodward, John

Principal Investigator
Alcohol Sensitivity of P2X Receptors
Sponsor: Univ. of Southern California
Budget Dates: 08/15/04 - 05/31/05
Direct: $8,219
Project Dates: 08/15/04 - 05/31/09
F & A: $3,781
Award: 1 R01 AA013022-01A2 (03102302)

Ethanol-Sensitivity-Native/Recombinant NMDA Receptors
Sponsor: NIH/NIAAA
Budget Dates: 08/01/05 - 03/31/06
Direct: $141,067
Project Dates: 08/01/05 - 03/31/09
F & A: $11,285
Award: 5 K02 AA000238-09 (04060204)

Training in Alcohol Research
Sponsor: NIH/NIAAA
Budget Dates: 04/01/05 - 03/31/06
Direct: $274,500
Project Dates: 09/30/05 - 03/31/06
F & A: $20,045
Award: 5 T32 AA007474-18 (04120246)

Neural Actions of Toluene
Sponsor: NIH/NIDA
Budget Dates: 03/01/05 - 02/28/06
Direct: $200,000
Project Dates: 03/01/05 - 02/28/06
F & A: $87,509
Award: 5 R01 DA013951-04 (05011258)

Ethanol Sensitivity of Native and Cloned NMDA Receptors
Sponsor: NIH/NIAAA
Budget Dates: 04/01/05 - 03/31/06
Direct: $137,500
Project Dates: 04/01/05 - 03/31/06
F & A: $63,250
Award: 5 R01 AA009986-11 (05011365)

Co-Investigator
Ethanol and ERK/PKB Signaling in Brain
PI: L. Chandler
Dept: Neurosciences
Sponsor: NIH/NIAAA
Total: $225,000
Award: 5 R01 AA010983-09 (05031711-1)

Obstetrics and Gynecology

Carter, James

Co-Investigator
Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety
PI: Steven Swift
Sponsor: Omni Care
Total: $13,120
Dept: Obstetrics and Gynecology
Award: PROTOCOL FIJ-US-SBCD (04012710-2)

An Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Vesicare (Solifenacin Succinate) in Patients Who Wish to Switch from Detrol LA (Tolterodine Tartrate Extended Release) For Treatment of Overactive Bladder Symptoms
PI: Steven Swift
Sponsor: Ingenix
Total: $17,200
Dept: Obstetrics and Gynecology
Award: PROTOCOL#905-US-006 (04062109-1)
A Phase 2, 8-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Tolerability and Safety of [S,S] - Reboxetine (PNU-165442G) for Stress Urinary Incontinence in Women

PI: Steven Swift  
Sponsor: Quintiles Pacific, Inc.  
Dept: Obstetrics and Gynecology  
Award: A6061023 (04111891-1)  
Total: $27,912

A Multi-Center, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Oxybutynin Vaginal Ring Releasing 4 Mg/Day versus 6 Mg/Day versus Placebo in Women Diagnosed with Overactive Bladder Who Have Symptoms of Predominant to Pure Urge Incontinence, Urgency and Frequency

PI: Steven Swift  
Sponsor: Duramed Research, Inc.  
Dept: Obstetrics and Gynecology  
Award: BR-OXY-202 (04121707-1)  
Total: $70,700

Creasman, William

Principal Investigator
An Open-Label, Multi-Center, Randomized, Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX Alone in Subjects with Advanced Relapsed Ovarian Cancer

Sponsor: PPD Development  
Budget Dates: 04/18/05 - 04/30/08  
Direct: $93,713  
F & A: 23,428

Johnson, Donna

Principal Investigator
A Parallel, Double-Blind, Placebo-Controlled, Randomized Comparison of Digibind versus Placebo for the Treatment of Antepartum Patients with Severe Preeclampsia

Sponsor: Glenveigh Research, LLC  
Budget Dates: 02/22/05 - 02/21/06  
Direct: $32,000  
F & A: 8,000

Co-Investigator
Evaluation of Vitamin D Requirements During Pregnancy
PI: Bruce Hollis  
Sponsor: NIH/NICHD  
Total: $362,514

Kohler, Matthew

Principal Investigator
A Phase III, Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian tube Carcinoma (d)

Sponsor: Eli Lilly  
Budget Dates: 10/15/04 - 10/15/06  
Direct: $30,011  
F & A: 7,503

Litts, Particia

Co-Investigator
Quidel OTC BV Test Field Study
PI: David Soper  
Sponsor: Quintiles Pacific, Inc.  
Total: $51,600

Newman, Roger

Principal Investigator
The Preterm Birth Prevention Project

Sponsor: March of Dimes  
Budget Dates: 04/01/05 - 03/31/06  
Direct: $47,500  
F & A: 0

Robinson, Christopher

Co-Investigator
A Parallel, Double-Blind, Placebo-Controlled, Randomized Comparison of Digibind versus Placebo for the Treatment of Antepartum Patients with Severe Preeclampsia

PI: Donna Johnson  
Sponsor: Glenveigh Research, LLC  
Total: $32,000

Soper, David

Principal Investigator
Assessment of the Clinical Performance of SYSCAN3 ELISA and CANDIA5 as Aids in the Diagnosis of Vulvovaginal Candidiasis

Sponsor: Rockeby Biomed, Inc.  
Budget Dates: 11/13/03 - 01/01/05  
Direct: $21,080  
F & A: 5,270
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>An Open-Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate, 1 mg/Ethinyl Estradiol 20 mcg Oral Tablets Administered for 24 days of a 28-day Cycle</td>
<td>Galen Holdings PLC</td>
<td>01/16/04 - 01/31/06</td>
<td>$22,916</td>
<td></td>
</tr>
<tr>
<td>Quidel OTC BV Test Field Study</td>
<td>Quintiles Pacific, Inc.</td>
<td>08/02/04 - 08/01/06</td>
<td>$51,600</td>
<td></td>
</tr>
<tr>
<td>A Phase 3, Randomized, Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled Treatment Trial of Bacterial Vaginosis with Tinidazole Oral Tablets</td>
<td>Presutti Laboratories</td>
<td>12/27/04 - 12/26/05</td>
<td>$36,100</td>
<td></td>
</tr>
<tr>
<td>QuickVue Advance pH and Amines gII Test Economic Study</td>
<td>Quidel Corp.</td>
<td>04/01/05 - 03/31/06</td>
<td>$24,450</td>
<td></td>
</tr>
<tr>
<td>Candida Test Evaluation</td>
<td>Quidel Corp.</td>
<td>05/01/05 - 07/31/06</td>
<td>$9,500</td>
<td></td>
</tr>
<tr>
<td>Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety</td>
<td>Omni Care</td>
<td>02/02/04 - 01/31/06</td>
<td>$13,120</td>
<td></td>
</tr>
<tr>
<td>An Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg Vesicare (Solifenacin Succinate) in Patients Who Wish to Switch from Detrol LA (Tolterodine Tartrate Extended Release) For Treatment of Overactive Bladder Symptoms</td>
<td>Presutti Laboratories</td>
<td>07/05/04 - 09/30/05</td>
<td>$17,200</td>
<td></td>
</tr>
<tr>
<td>A Phase 2, 8-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Tolerability and Safety of [S,S] - Reboxetine (PNU-165442G) for Stress Urinary Incontinence in Women</td>
<td>Ingenix</td>
<td>01/04/05 - 01/03/06</td>
<td>$27,912</td>
<td></td>
</tr>
<tr>
<td>A Multi-Center, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Oxybutynin Vaginal Ring Releasing 4 Mg/Day versus 6 Mg/Day versus Placebo in Women Diagnosed with Overactive Bladder Who Have Symptoms of Predominant to Pure Urge Incontinence, Urgency and Frequency</td>
<td>Duramed Research, Inc.</td>
<td>12/15/04 - 12/14/05</td>
<td>$70,700</td>
<td></td>
</tr>
<tr>
<td>The Preterm Birth Prevention Project</td>
<td>March of Dimes</td>
<td>04/01/05 - 03/31/06</td>
<td>$47,500</td>
<td></td>
</tr>
</tbody>
</table>
### Ophthalmology

**Crosson, Craig**

**Principal Investigator**

**Adenosine Agonists: Potential Antiglaucoma Agents**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 03/01/04 - 02/28/05
- **Direct:** $7,700

**Core Resources for Vision Research at MUSC**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 05/01/01 - 04/30/06
- **Direct:** $128,140

**Evaluation of Adenosine A1 Agonists as Ocular Hypotensive Agents**
- **Sponsor:** Aderis Pharmaceuticals
- **Budget Dates:** 01/15/05 - 04/15/05
- **Direct:** $35,159

**Adenosine Agonists: Potential Antiglaucoma Agents**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 03/01/05 - 02/28/06
- **Direct:** $200,000

**Kinin/PGE Interaction in Control of Intraocular Pressure**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 05/01/03 - 04/30/08
- **Direct:** $86,000

**Crouch, Rosalie**

**Principal Investigator**

**Synthetic Visual Pigments and Binding Proteins**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 04/01/05 - 03/31/06
- **Direct:** $250,000

**Koutalos, Yiannis**

**Principal Investigator**

**Transport Processes in Photoreceptors**
- **Sponsor:** NIH/NEI
- **Budget Dates:** 09/06/04 - 08/31/05
- **Direct:** $200,000

**Husain, Shahid**

**Principal Investigator**

**Effects of Some Alcon's Compound on MMP Secretion from Ciliary Muscle Cells**
- **Sponsor:** Alcon, Inc.
- **Budget Dates:** 03/25/05 - 12/31/05
- **Direct:** $20,000

**PGF 2a, Natriuretic Peptides and IOP**
- **Sponsor:** Amer. Health Assistance Fdn.
- **Budget Dates:** 04/01/05 - 03/31/06
- **Direct:** $35,000

**Peterseim, Mae**

**Principal Investigator**

**A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% Azasite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis**
- **Sponsor:** Ophthalmic Research Associates
- **Budget Dates:** 03/09/05 - 03/09/06
- **Direct:** $30,000

---

**Annual Report for Research FY2005**
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potter, David</td>
<td>Ocular Hydrodynamics: Modulation by Opioids</td>
<td>NIH/NEI</td>
<td>04/01/04 - 03/31/06</td>
<td>116,515</td>
<td>53,597</td>
</tr>
<tr>
<td>Rohrer, Baerbel</td>
<td>Transgenic Rod Development and Function</td>
<td>NIH/NEI</td>
<td>07/01/04 - 06/30/05</td>
<td>100,000</td>
<td>33,776</td>
</tr>
<tr>
<td>Sandoval, Helga</td>
<td>Clinical Evaluation of the Amadeus II Microkeratome</td>
<td>Advanced Medical Optics</td>
<td>08/23/04 - 07/31/05</td>
<td>10,952</td>
<td>2,738</td>
</tr>
<tr>
<td>Saunders, Richard</td>
<td>Early Treatment of Retinopathy of Prematurity, Phase II</td>
<td>Alcon, Inc.</td>
<td>11/15/04 - 06/30/07</td>
<td>60,000</td>
<td>15,000</td>
</tr>
<tr>
<td>Solomon, Kerry</td>
<td>Clinical Study of the ACRYSOF Angle-Supported Phakic Intraocular Lens</td>
<td>Alcon, Inc.</td>
<td>06/06/05 - 06/05/06</td>
<td>38,820</td>
<td>9,705</td>
</tr>
<tr>
<td>Vroman, David</td>
<td>AcrySof ReSTOR IOL Postmarket Evaluation of Clinical Outcomes and Life Style Visual Performance</td>
<td>Alcon, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wilson, M.</td>
<td>Infant Aphakia Treatment Study</td>
<td>Emory Univ.</td>
<td>07/01/04 - 05/30/05</td>
<td>9,650</td>
<td>4,439</td>
</tr>
<tr>
<td></td>
<td>Clinical Evaluation of the Safety and Efficacy of StablEyz Intraocular Irrigating Solution Compared to BSS PLUS for Use During Cataract Extraction and IOL Implantation</td>
<td>Alcon, Inc.</td>
<td>10/01/04 - 05/01/05</td>
<td>22,531</td>
<td>5,633</td>
</tr>
<tr>
<td></td>
<td>Research to Prevent Blindness</td>
<td>Research to Prevent Blindness</td>
<td>01/01/05 - 12/31/05</td>
<td>110,000</td>
<td>0</td>
</tr>
</tbody>
</table>
**Orthopaedic Surgery**

**Principal Investigator**

**Cryopreservation of Articular Cartilage by Vitrification (Phase II)**
- **Sponsor:** Organ Recovery Systems
- **Award:** 2 R44 AR47273-02 (01040502)
- **Budget Dates:** 11/01/03 - 12/30/04
- **Direct:** $79,065
- **F & A:** $34,789

**An In-Vivo Evaluation of Precipitated HA Coating With and Without OP-1 Using a Rabbit Femoral Defect Model (Phase II)**
- **Sponsor:** Howmedica, Inc.
- **Award:** NCS03-003 (03052312)
- **Budget Dates:** 06/30/03 - 12/31/05
- **Direct:** $4,802
- **F & A:** $2,208

**Evaluation of Composite Cement Consisting of Calcium Phosphate and Iliac Crest Autograft Bone in a Rabbit Radius Defect Model**
- **Sponsor:** Etex Corp.
- **Award:** (03062619)
- **Budget Dates:** 06/26/03 - 06/30/05
- **Direct:** $71,958
- **F & A:** $33,101

**Tolerance and Performance of Cross-Linked Hyaluronic Acid Pellets Implanted into Osteochondral Defects in the Patellar Groove: A Feasibility Study in the New Zealand White Rabbit**
- **Sponsor:** SCIL Technology
- **Award:** P012004E (04050306)
- **Budget Dates:** 07/01/03 - 06/30/04
- **Direct:** $359
- **F & A:** $166

**Processing of Materials for Improved Biocompatibility**
- **Sponsor:** Univ. of South Carolina
- **Award:** 1 R01 EB00552-03 (04080502)
- **Budget Dates:** 07/01/03 - 06/30/04
- **Direct:** $67,848
- **F & A:** $29,174

**The Osseointegration of Porous Materials Using a Rabbit Femoral Defect Model**
- **Sponsor:** Stryker Orthopaedics
- **Award:** NC504-009 (04113024)
- **Budget Dates:** 11/23/04 - 12/31/05
- **Direct:** $23,568
- **F & A:** $10,841

**Transdermal ComPreSs**
- **Sponsor:** Biomet, Inc.
- **Award:** (04120132)
- **Budget Dates:** 11/01/04 - 12/31/05
- **Direct:** $25,531
- **F & A:** $16,562

**Platelet-Rich and Platelet-Poor Plasma as Topical Hemostats**
- **Sponsor:** Cell Factor Technologies
- **Award:** (05041816)
- **Budget Dates:** 04/14/05 - 10/31/05
- **Direct:** $13,927
- **F & A:** $6,406

**Guided and Biomimetic Bone Tissue Engineering**
- **Pl:** Daniel Knapp
- **Dept:** Cell and Molecular Pharmacology
- **Sponsor:** Clemson Univ.
- **Award:** 832-7558-248-2004172 (04031514-1)
- **Total:** $27,680

**Otologyngology**

**Principal Investigator**

**Community Outreach for Arthritis and Total Joint Replacement Surgery**
- **Sponsor:** Aventis Pharmaceutical, Inc.
- **Award:** 8823 (05030223)
- **Budget Dates:** 01/12/05 - 11/05/05
- **Direct:** $5,000
- **F & A:** $0

**Auditory Analysis and Speech Recognition**
- **Pl:** Judy Dubno
- **Dept:** Otolaryngology
- **Sponsor:** NIH/NIDCD
- **Award:** 5 R01 DC000184-24 (04112315-1)
- **Total:** $227,500

**Implementing Oral, Head, and Neck Cancer Screening Education Programs for Health Care Providers**
- **Sponsor:** SC DHEC
- **Award:** 05-188 (05032126)
- **Budget Dates:** 01/01/05 - 08/01/05
- **Direct:** $53,617
- **F & A:** $3,400

**Auditory Analysis and Speech Recognition**
- **Pl:** Judy Dubno
- **Dept:** Otolaryngology
- **Sponsor:** NIH/NIDCD
- **Award:** 5 R01 DC000184-24 (04112315-1)
- **Total:** $227,500
Dubno, Judy

**Principal Investigator**

**Automated Test of Word Recognition -- Phase II**  
Sponsor: Audiology, Inc.  
Award: R42DC006509-02 (04081202)  
Budget Dates: 05/01/05 - 04/30/06  
F & A: 26,258

**Auditory Analysis and Speech Recognition**  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000184-24 (04112315)  
Budget Dates: 02/01/05 - 01/31/06  
Direct: $ 227,500

---

Gillespie, M.

**Principal Investigator**

**A Randomized Trial Comparing Preservation of Function Status after Either MedPulser Electroporation with Intratumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Anterior Oral Cavity, Soft Palate, and Tonsil that Have Failed Primary Curative Therapy**  
Sponsor: Genetronics, Inc.  
Award: HNBE-03-01 (05012424)  
Budget Dates: 01/20/05 - 12/31/08  
F & A: 20,650

**A Randomized Trial Comparing Preservation of Function Status after Either MedPulser Electroporation with Intratumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Base of the Tongue, Posterior lateral Pharyngeal Wall, Hypopharynx and Larynx that Have Failed Primary Curative Therapy**  
Sponsor: Genetronics, Inc.  
Award: HNBE-03-02 (05012425)  
Budget Dates: 01/20/05 - 12/31/08  
F & A: 20,650

---

He, Ning-Ji

**Co-Investigator**

**Auditory Analysis and Speech Recognition**  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000184-24 (04112315-1)

---

Horning, Joshua

**Co-PI or Project Leader**

**Radiation Therapy Oncology Group Protocol: A Phase II, Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide Plus Irinotecan for Glioblastoma Multiforme**  
Sponsor: Amer. Coll. of Radiolog  
Award: U10 CA21661 (05050587-3)

**Radiation Therapy Oncology Group Protocol: A Phase II, Study of Submandibular Salivary Gland Transfer to the Submental Space Prior to Start of Radiation Treatment for Prevention of Radiation-Induced Xerostomia in Head and Neck Cancer Patients**  
Sponsor: Amer. Coll. of Radiolog  
Award: U10 CA21661 (05050587-4)

---

Horwitz, Amy

**Co-Investigator**

**Auditory Analysis and Speech Recognition**  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000184-24 (04112315-1)

---

Lambert, Paul

**Co-PI or Project Leader**

**Experimental and Clinical Studies of Presbyacusis - Core B: Human Subjects**  
Sponsor: NIH/NIDCD  
Award: 5 P50 DC000422-18 (04042805-5)
**Lang, Hainan**  
Co-Investigator  
**Electrodes and Stimulators for Strial Presbyacusis**  
Pl: Richard Schmiedt  
Dept: Otolaryngology  
Sponsor: Advanced Cochlear Systems  
Award: R43DC005531 (03122901-1)  
Total: $ 33,737

**Lee, Fu-Shing**  
Co-Investigator  
**Automated Test of Word Recognition – Phase II**  
Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: Audiology, Inc.  
Award: R42DC006509-02 (04081202-1)  
Total: $ 57,082

**Martin-Harris, Bonnie**  
Principal Investigator  
**Standardized Assessment of Swallowing Impairment**  
Sponsor: NIH/NIDCD  
Award: 5 K23 DC005764-03 (05031608)  
Budget Dates: 05/01/05 - 04/30/06  
Project Dates: 07/01/03 - 04/30/08  
Direct: $ 182,916  
F & A: $ 13,609

**Matthews, Lois**  
Co-Investigator  
**Automated Test of Word Recognition – Phase II**  
Pl: Judy Dubno  
Dept: Otolaryngology  
Sponsor: Audiology, Inc.  
Award: R42DC006509-02 (04081202-1)  
Total: $ 57,082

**Mills, John**  
Principal Investigator  
**Experimental and Clinical Studies of Presbyacusis**  
Sponsor: NIH/NIDCD  
Award: 5 P50 DC000422-18 (04042805)  
Budget Dates: 07/01/04 - 06/30/05  
Project Dates: 07/01/02 - 06/30/07  
Direct: $ 1,081,773  
F & A: $ 497,616

**Schlosser, Rodney**  
Principal Investigator  
**Surfactant Proteins A and D in Chronic Sinusitis of Cystic Fibrosis**  
Sponsor: Cystic Fibrosis Fdn.  
Award: SCHLOS0510 (04083101)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/07  
Direct: $ 40,000  
F & A: $ 3,200

**Schmiedt, Richard**  
Principal Investigator  
**Electrodes and Stimulators for Strial Presbyacusis**  
Sponsor: Advanced Cochlear Systems  
Award: R43DC005531 (03122901)  
Budget Dates: 02/01/05 - 01/31/06  
Project Dates: 02/01/04 - 01/31/06  
Direct: $ 33,737  
F & A: $ 15,519

**Pathological and Laboratory Medicine**

**Brown, Erica**  
Principal Investigator  
**Mechanistic Studies of BRCA-RAD51 Mediated DNA Repair**  
Sponsor: NIH/NCI  
Award: 7 K01 CA096944-03 (04082602)  
Budget Dates: 09/01/04 - 08/31/05  
Project Dates: 09/01/04 - 08/31/07  
Direct: $ 127,849  
F & A: $ 9,650

**Dammari, Vincent**  
Co-PI or Project Leader  
**DOD Phase VII: Proteomic Studies to Identify Novel Therapeutic Targets for Treatment of Kidney Cancers Involving VHL**  
Pl: Andrew Kraft  
Dept: Medicine  
Sponsor: Geo-Centers, Inc.  
Award: GC-3609-04-43766CM (04113022-6)  
Total: $ 85,765

**Donald, Carlton**  
Principal Investigator  
**Functional Analysis of Human Beta Defensin Loss of Expression**  
Sponsor: NIH/NCI  
Award: 5 K22 CA096788-02 (05022892)  
Budget Dates: 05/01/05 - 04/30/06  
Project Dates: 05/01/04 - 04/30/07  
Direct: $ 144,951  
F & A: $ 11,596
<table>
<thead>
<tr>
<th>Research Faculty Activity</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathology and Laboratory Medicine</td>
<td>College of Medicine</td>
</tr>
</tbody>
</table>

### Fan, Weimin

#### Principal Investigator

**Hormonal Modulation of Taxol Action in Solid Tumors**

- **Sponsor:** NIH/NCI
- **Award:** 5 R01 CA092280-04 (05012115)
- **Budget Dates:** 04/14/05 - 03/31/06
- **Direct:** $178,000
- **Project Dates:** 04/01/02 - 03/31/06
- **F & A:** $76,540

### Fraig, Mostafa

#### Co-Investigator

**DOD Phase VII: Proteomic Studies to Identify Novel Therapeutic Targets for Treatment of Kidney Cancers Involving VHL**

- **PI:** Andrew Kraft
- **Dept:** Medicine
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $205,000
- **Award:** 1 R01 CA109860-01 (03110302)

**The Role of Thromboxane A2 in Bladder Cancer**

- **PI:** Dennis Watson
- **Dept:** Pathology and Laboratory Medicine
- **Budget Dates:** 04/01/02 - 03/31/06
- **Direct:** $190,000
- **Award:** 5 R01 CA106570-02 (05012748-1)

### Hazen-Martin, Debra

#### Co-PI or Project Leader

**Oncology Center: Human Tissue Procurement Service and Tumor Bank**

- **PI:** Carolyn Reed
- **Dept:** Surgery
- **Budget Dates:** 04/01/02 - 03/31/06
- **Direct:** $28,850
- **Award:** Department of Energy (DOE) (03051401-5)

**Oncology Center: Hollings Cancer Translational Research Core Development Grant**

- **PI:** Andrew Kraft
- **Dept:** Medicine
- **Budget Dates:** 07/01/04 - 06/30/09
- **Direct:** $232,878
- **Award:** Department of Energy (DOE) (04042303-1)

### Hsu, Tien

#### Principal Investigator

**VHL and FGFR Signaling In Angiogenesis**

- **Sponsor:** NIH/NCI
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $205,000
- **Award:** 1 R01 CA109860-01 (03110302)

**Control of Epithelial Morphogenesis in Drosophila Ovary**

- **Sponsor:** NIH/NIGMS
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $190,000
- **Award:** 5 R01 GM057843-06 (04050405)

### Kawamori, Toshihiko

#### Co-PI or Project Leader

**SC Cobre in Lipidomics & Pathobiology: Project 7 - Role of Sphingosine Kinase 1/Sphingosine-1-Phosphate Pathway in Colon Carcinogenesis**

- **PI:** Lina Obeid
- **Dept:** Biochemistry and Molecular Biology
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $125,000
- **Award:** 5 R01 CA102297-02 (04041601-1)

**DOD Phase VI: Project 18**

- **PI:** Carolyn Reed
- **Dept:** Dean's Office - COM
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $44,433
- **Award:** Department of Energy (DOE) (03080703-45)

**D609-A Novel Cytoprotectant and Selective Anti-Tumor Agent**

- **PI:** Daohong Zhou
- **Dept:** Pathology and Laboratory Medicine
- **Budget Dates:** 04/01/02 - 03/31/06
- **Direct:** $192,719
- **Award:** 5 R01 CA102558-02 (05012531-1)
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Project Title</th>
<th>PI Name</th>
<th>Sponsor</th>
<th>Total Funding</th>
<th>Dept</th>
<th>Award Numbers</th>
<th>Budget Dates</th>
<th>Direct Funding</th>
<th>F &amp; A Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lang, Hainan</td>
<td>Co-Investigator</td>
<td>Inner Ear Ion Transport Mechanisms</td>
<td>Bradley Schulte</td>
<td>NIH/NIDCD</td>
<td>$227,500</td>
<td>Pathology and Laboratory Medicine</td>
<td>5 R01 DC000713-15 (05013185-1)</td>
<td>07/15/04 - 06/30/05</td>
<td>$144,950</td>
<td>$11,596</td>
</tr>
<tr>
<td>Li, Runzhao</td>
<td>Principal Investigator</td>
<td>Modulation of EMT by ETS1 and EAPII</td>
<td>Bradley Schulte</td>
<td>NIH/NIC</td>
<td>$144,950</td>
<td>Medicine</td>
<td>1 K22 CA109577-01 (03100303)</td>
<td>07/15/04 - 06/30/07</td>
<td>F &amp; A:</td>
<td></td>
</tr>
<tr>
<td>Moussa, Omar</td>
<td>Co-Investigator</td>
<td>DOD Phase VII: Molecular Profiling for Identification of Diagnostic and Prognostic Markers of Bladder Cancer</td>
<td>Andrew Kraft</td>
<td>NIH/NIDCD</td>
<td>$80,000</td>
<td>Medicine</td>
<td>GC-3609-04-43766CM (04113022-4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schulte, Bradley</td>
<td>Principal Investigator</td>
<td>Interaction of Age-Related and Noise-Induced Hearing Loss</td>
<td>Bradley Schulte</td>
<td>Univ. of South Alabama</td>
<td>$329,248</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-3)</td>
<td>08/01/03 - 07/31/04</td>
<td>$35,195</td>
<td>$16,190</td>
</tr>
<tr>
<td></td>
<td>Co-PI or Project Leader</td>
<td>Experimental and Clinical Studies of Presbyacusis - Project 3: Morphologic and Molecular Changes in the Aging Human Cochlea</td>
<td>John Mills</td>
<td>NIH/NIDCD</td>
<td>$177,645</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-2)</td>
<td>08/01/03 - 05/31/05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Angiogenesis, Functional Recovery and TNF-Alpha After Stroke</td>
<td>Ling Wei</td>
<td>NIH/NINDS</td>
<td>$185,000</td>
<td>Pathology and Laboratory Medicine</td>
<td>1 R01 NS045810-01A1 (03110306-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Project 2: Speech Understanding in Realistic Environments</td>
<td>John Mills</td>
<td>NIH/NIDCD</td>
<td>$177,645</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-2)</td>
<td>08/01/03 - 05/31/05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core A: Administration</td>
<td>John Mills</td>
<td>NIH/NIDCD</td>
<td>$87,006</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-4)</td>
<td>08/01/03 - 05/31/05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Core B: Human Subjects</td>
<td>John Mills</td>
<td>NIH/NIDCD</td>
<td>$192,813</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-5)</td>
<td>08/01/03 - 05/31/05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Experimental and Clinical Studies of Presbyacusis - Project 1: Individual Differences in Age Related Hearing Loss</td>
<td>John Mills</td>
<td>NIH/NIDCD</td>
<td>$295,061</td>
<td>Otolaryngology</td>
<td>5 P50 DC000422-18 (04042805-6)</td>
<td>08/01/03 - 05/31/05</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shen, Zhijun</td>
<td>Co-Investigator</td>
<td>Inner Ear Ion Transport Mechanisms</td>
<td>Bradley Schulte</td>
<td>NIH/NIDCD</td>
<td>$227,500</td>
<td>Pathology and Laboratory Medicine</td>
<td>5 R01 DC000713-15 (05013185-1)</td>
<td>04/01/05 - 03/31/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singh, Avtar</td>
<td>Principal Investigator</td>
<td>Psychosine Mediated Pathogenesis in Globoid Cell Leukodystrophy</td>
<td>Avtar Singh</td>
<td>NIH/NINDS</td>
<td>$250,000</td>
<td>Pathology and Laboratory Medicine</td>
<td>5 R01 NS040810-05 (05020409)</td>
<td>04/01/05 - 03/31/06</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Singh, Avtar

Co-Investigator

Structure/Function of Peroxisomes in Neuroinflammation
PI: Inderjit Singh
Sponsor: NIH/NINDS
Total: $231,250
Dept: Pediatrics
Award: 2 R01 NS034741-09 (04110117-1)

Spyropoulos, Demetri

Principal Investigator

Use of HOXC6 Gene to Develop Novel Lung Chemopreventives
Sponsor: NIH/NCI
Budget Dates: 07/01/04 - 06/30/05
Direct: $50,000
F & A: $23,000
Award: 1 R03 CA109958-01 (03092905)
Project Dates: 07/01/04 - 06/30/06

Co-Investigator

Models of DRA Growth Suppression in Colon Cancer
PI: Clifford Schweinfest
Sponsor: NIH/NCI
Total: $178,000
Dept: Medicine
Award: 5 R01 CA095172-02 (04050402-1)

Steed, Lisa

Principal Investigator

ICU Surveillance Study: Incidence of Multiresistant Gram Negative Bacilli in ICU-2003
Sponsor: Merck
Budget Dates: 07/01/03 - 05/01/06
Direct: $5,000
F & A: $1,250
Award: (03060505)
Project Dates: 07/01/03 - 05/01/06

Watson, Dennis

Principal Investigator

Role of an Epithelial Ets factor in Breast Cancer
Sponsor: NIH/NCI
Budget Dates: 07/01/04 - 04/30/05
Direct: $222,500
F & A: $102,350
Award: 5 R01 CA102297-02 (04041601)
Project Dates: 07/01/03 - 04/30/05

Roles of Ets Genes in Transformation and Differentiation
Sponsor: NIH/NCI
Budget Dates: 04/01/05 - 03/31/06
Direct: $757,663
F & A: $340,168
Award: 2 P01 CA098582-06A2 (04060106)
Project Dates: 04/01/05 - 03/31/10

The Role of Thromboxane A2 in Bladder Cancer
Sponsor: NIH/NCI
Budget Dates: 04/01/05 - 03/31/06
Direct: $90,000
F & A: $41,400
Award: 5 R21 CA106570-02 (05012748)
Project Dates: 04/01/04 - 03/31/06

Wei, Ling

Principal Investigator

Angiogenesis, Functional Recovery and TNF-alpha After Stroke
Sponsor: NIH/NINDS
Budget Dates: 07/01/04 - 06/30/05
Direct: $185,000
F & A: $85,100
Award: 1 R01 NS045810-01A1 (03110306)
Project Dates: 07/01/04 - 06/30/09

Neuroprotective Effect of Merck Compounds In Ischemic Stroke Rats
Sponsor: Merck
Budget Dates: 02/16/05 - 02/15/06
Direct: $583,333
F & A: $116,667
Award: (04010502)
Project Dates: 02/16/05 - 02/15/06

Function Restoration by ES Cell Implant after Ischemia
Sponsor: NIH/NINDS
Budget Dates: 05/01/05 - 04/30/06
Direct: $213,750
F & A: $98,325
Award: 5 R01 NS045155-03 (05032329)
Project Dates: 05/15/03 - 04/30/07

Angiogenesis, Functional Recovery and TNF-a after Stroke
Sponsor: NIH/NINDS
Budget Dates: 04/01/05 - 03/31/06
Direct: $185,000
F & A: $85,100
Award: 5 R01 NS045810-02 (05032330)
Project Dates: 07/01/04 - 03/31/09
Wright, Cynthia  
Principal Investigator  
Short-Term Training for Minority Students  
Sponsor: NIH/NHLBI  
Award: 5 T35 HL07769-13 (04102502)  
Budget Dates: 05/01/05 - 04/30/06  
Direct: $ 100,576  
F & A: 8,046

Zhou, Daohong  
Principal Investigator  
D609-A Novel Cytoprotectant and Selective Anti-Tumor Agent  
Sponsor: NIH/NCI  
Budget Dates: 04/01/05 - 03/31/06  
Direct: $ 192,719  
Award: 5 R01 CA102558-02 (05012531)  
Project Dates: 04/01/04 - 03/31/08  
F & A: 64,958

Pediatrics

Anderson, Deborah  
Co-Investigator  
Cystic Fibrosis Center - MUSC  
PI: Michael Bowman  
Sponsor: Cystic Fibrosis Fdn.  
Dept: Pediatrics  
Award: C104-04 (03081503-1)  
Total: $ 53,476

Annibale, David  
Principal Investigator  
The South Carolina Neonatal Medicine Consortium  
Sponsor: March of Dimes  
Award: (04082310)  
Budget Dates: 04/01/05 - 03/31/06  
Direct: $ 23,500  
F & A: 0

Appiagyei-Dankah, Yaw  
Principal Investigator  
SEARCH Pediatric Diabetes Registry  
Sponsor: Univ. of South Carolina  
Award: U48/CCU419249-05 (04062101)  
Budget Dates: 09/30/04 - 09/29/05  
Direct: $ 81,765  
F & A: 37,612

External, Continuous, Subcutaneous Infusion of Insulin Aspart (NovoLog) versus Insulin Lispro (Humalog): An Open-Label, Randomized, Parallel-Group, Multi-Center Study in Children and Adolescents with Type 1 Diabetes  
Sponsor: Novo Nordisk Pharmaceuticals  
Award: ANA-2181 (05040685)  
Budget Dates: 04/11/05 - 04/10/06  
Direct: $ 26,779  
F & A: 6,695

Genentech National Cooperative Metabolic Study of Nutropin AQ [somatropin (rDNA origin) injection] and Nutropin [somatropin (rDNA origin) for injection] Replacement Therapy in Adults with Growth Hormone Deficiency  
Sponsor: Genentech, Inc.  
Award: L3339n (05051612)  
Budget Dates: 05/16/05 - 06/14/06  
Direct: $ 2,600  
F & A: 650

Atz, Andrew  
Principal Investigator  
Sponsor: Dartmouth Coll.  
Award: 20000354/5-38179-57 (02012808)  
Budget Dates: 07/01/03 - 06/30/04  
Direct: $ 6,424  
F & A: 1,606

A Pivotal, Phase 3 Study of MEDI-524 (Numax), An Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High Risk Children  
Sponsor: Medimmune, Inc.  
Award: MI-CP110 (04092809)  
Budget Dates: 06/01/04 - 09/09/06  
Direct: $ 79,716  
F & A: 19,929

Randomized, Double-Blind, Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age  
Sponsor: Medimmune, Inc.  
Award: MI-CP111 (04100601)  
Budget Dates: 10/01/04 - 09/30/05  
Direct: $ 97,464  
F & A: 24,366
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total:</th>
<th>Dept:</th>
<th>Award</th>
<th>Direct:</th>
<th>F &amp; A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atz, Andrew</td>
<td>Co-Investigator</td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>J. Saul</td>
<td>NIH/NHLBI</td>
<td>$24,237</td>
<td>Pediatrics</td>
<td>5 U01 HL068281-03 (03071403-2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>J. Saul</td>
<td>NIH/NHLBI</td>
<td>$407,290</td>
<td>Pediatrics</td>
<td>5 U01 HL068281-04 (04071605-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baatz, John</td>
<td>Principal Investigator</td>
<td>Role of Surfactant Protein B in Innate Airway Defense</td>
<td>J. Saul</td>
<td>NIH/NHLBI</td>
<td>$200,000</td>
<td>Pediatrics</td>
<td>5 R01 HL06606-04 (04051903)</td>
<td>86,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spectroscopy of Biomembrane Monolayers</td>
<td>Univ. of Georgia</td>
<td>NIH/NHLBI</td>
<td>$47,945</td>
<td>Pediatrics</td>
<td>RR68-552/6582647 (04061809)</td>
<td>22,055</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Surfactant Proteins A and D in Chronic Sinusitis of Cystic Fibrosis</td>
<td>Rodney Schlosser</td>
<td>Cystic Fibrosis Fdn.</td>
<td>$40,000</td>
<td>Otolaryngology</td>
<td>SCHLOS05/0 (04083101-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bandisode, Varsha</td>
<td>Principal Investigator</td>
<td>Closure of Perimembranous Ventricular Septal Defects with the AMPLATZER Membranous VSD Occluder</td>
<td>Aga Medical Corp.</td>
<td>NIH/NHLBI</td>
<td>$8,400</td>
<td>Pediatrics</td>
<td>(04011603)</td>
<td>2,100</td>
<td></td>
</tr>
<tr>
<td>Barredo, Julio</td>
<td>Principal Investigator</td>
<td>Children’s Oncology Chair Grant</td>
<td>National Childhood Cancer Fdn.</td>
<td>NIH/NHLBI</td>
<td>$10,989</td>
<td>Pediatrics</td>
<td>U10 CA98543-02 (03101505)</td>
<td>2,198</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children’s Oncology Group-Master</td>
<td>COG</td>
<td>NIH/NHLBI</td>
<td>$21,462</td>
<td>Pediatrics</td>
<td>U10CA98543-02/CFDA#93.395 (03112103)</td>
<td>4,292</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molecular Correlates of Methotrexate in Childhood ALL</td>
<td>Wayne State Univ.</td>
<td>NIH/NHLBI</td>
<td>$18,964</td>
<td>Pediatrics</td>
<td>5 R01 CA07664-01 (05022258)</td>
<td>8,724</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molecular Determinants of Methotrexate Metabolism in ALL</td>
<td>NIH/NCI</td>
<td>NIH/NHLBI</td>
<td>$205,000</td>
<td>Pediatrics</td>
<td>5 R01 CA098152-02 (05030331)</td>
<td>94,300</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pediatric Hydroxyurea Phase III Clinical Trial--Clinical Center</td>
<td>NIH/NHLBI</td>
<td>NIH/NHLBI</td>
<td>$64,410</td>
<td>Pediatrics</td>
<td>N01-HB-07154 (99100606)</td>
<td>27,697</td>
<td></td>
</tr>
<tr>
<td>Basco, William</td>
<td>Co-Investigator</td>
<td>Faculty Development in Primary Care</td>
<td>Paul Darden</td>
<td>HRSA/BHP/Medicine</td>
<td>$295,089</td>
<td>Pediatrics</td>
<td>1 D14 HP00175-03-00 (02041704-4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>J. Saul</td>
<td>NIH/NHLBI</td>
<td>$24,237</td>
<td>Pediatrics</td>
<td>5 U01 HL068281-03 (03071403-2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Randomized Clinical Trials for Pediatric Heart Disease</td>
<td>J. Saul</td>
<td>NIH/NHLBI</td>
<td>$407,290</td>
<td>Pediatrics</td>
<td>5 U01 HL068281-04 (04071605-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blaufox, Andrew</td>
<td>Co-Investigator</td>
<td>Cystic Fibrosis Center - MUSC</td>
<td>Cystic Fibrosis Fdn.</td>
<td>NIH/NHLBI</td>
<td>$53,476</td>
<td>Pediatrics</td>
<td>C104-04 (03081503)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

88 Annual Report for Research FY2005
<table>
<thead>
<tr>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Phase 3, Double-Blind, Multi-Center, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary <em>P. Aeruginosa</em> Requiring Frequent Antibiotics (AIR-CF2)</strong></td>
<td>Corus Pharma</td>
<td>04/18/05 - 12/31/05</td>
<td>$41,416</td>
<td>10,354</td>
</tr>
<tr>
<td><strong>Pediatric Asthma and Respiratory Disease</strong></td>
<td>GlaxoSmithKline</td>
<td>02/01/05 - 03/31/06</td>
<td>$5,000</td>
<td>0</td>
</tr>
<tr>
<td><strong>Optimizing Primary Stroke Prevention in SC Anemia Children-STOPII</strong></td>
<td>Medical Coll. of Georgia</td>
<td>07/01/04 - 06/30/05</td>
<td>$71,300</td>
<td>30,659</td>
</tr>
<tr>
<td><strong>Population-Based Surveillance of Autism Spectrum Disorders</strong></td>
<td>CDC</td>
<td>09/30/04 - 09/29/05</td>
<td>$272,434</td>
<td>117,146</td>
</tr>
<tr>
<td><strong>Advances in Autism Spectrum Disorders</strong></td>
<td>Janssen Pharmaceutica</td>
<td>12/01/04 - 11/30/05</td>
<td>$31,600</td>
<td>0</td>
</tr>
<tr>
<td><strong>African American Study of Kidney Disease and Hypertension (AASK) Cohort Study</strong></td>
<td>Lenox Hill Hosp.</td>
<td>07/01/03 - 06/30/07</td>
<td>$107,873</td>
<td>28,047</td>
</tr>
<tr>
<td><strong>Structure/Function of Peroxisomes in Neuroinflammation</strong></td>
<td>NIH/NINDS</td>
<td>Total: $231,250</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Faculty Development in Primary Care</strong></td>
<td>HRSA/BHP/Medicine</td>
<td>07/01/04 - 06/30/06</td>
<td>$295,089</td>
<td>19,639</td>
</tr>
<tr>
<td><strong>Evidence-Based Immunization Delivery: Education and Research APA-SAM-CDC Collaborative Project</strong></td>
<td>Ambulatory Pediatric Assoc.</td>
<td>09/30/04 - 09/29/05</td>
<td>$67,123</td>
<td>10,068</td>
</tr>
<tr>
<td><strong>Fellowship in Health Services Research</strong></td>
<td>AHCPR/AHRQ</td>
<td>07/01/04 - 06/30/05</td>
<td>$250,014</td>
<td>15,871</td>
</tr>
<tr>
<td><strong>Addressing Racial Disparities</strong></td>
<td>Assoc. of Teachers of Preventive Med.</td>
<td>09/30/04 - 09/29/05</td>
<td>$314,432</td>
<td>69,471</td>
</tr>
<tr>
<td><strong>MUSC Children's Care: Expanding Access to Medical Homes</strong></td>
<td>Duke Endowment</td>
<td>01/01/05 - 12/31/05</td>
<td>$103,192</td>
<td>0</td>
</tr>
<tr>
<td><strong>Mycocyte Proliferation in Embryonic Chick Heart</strong></td>
<td>NIH/NHLBI</td>
<td>Total: $200,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Medical University of South Carolina Research Faculty Activity**

**College of Medicine Pediatrics**

---

**Annual Report for Research FY2005** 89
Fowler, Sandra

**Principal Investigator**

**Clinical Trials for Antiviral Therapies**

- **Sponsor:** Univ. of Alabama
- **Award:** N01-AI-30025 (04032602)
- **Budget Dates:** 08/01/03 - 07/31/10
- **Direct:** $85,600

**Furlanetto, Richard**

**Principal Investigator**

**Recombinant Human Insulin-Like Growth Factor-1 (rhIGF-1) Treatment of Short Stature Associated with Primary IGF-1 Deficiency: A Multi-Center, Open-Label, Randomized, Concentration-Controlled Trial**

- **Sponsor:** Tercica, Inc.
- **Budget Dates:** 10/06/04 - 12/01/05
- **Direct:** $34,080
- **Award:** MS308 (04110556)

**The GH Monitor Registry**

- **Sponsor:** Serono Laboratories
- **Budget Dates:** 03/01/05 - 03/01/06
- **Direct:** $16,400
- **Award:** (05032960)

**Educational Grant for Endocrinology Fellowship Program**

- **Sponsor:** Serono Laboratories
- **Budget Dates:** 03/01/05 - 03/01/06
- **Direct:** $3,500
- **F & A:** 0
- **Award:** (05021429)

**Kabi International Growth Study**

- **Sponsor:** Pharmacia Upjohn
- **Budget Dates:** 10/01/97 - 06/30/06
- **Direct:** $1,382
- **Award:** 870545 (97100111)

**Habib, David**

**Principal Investigator**

**The Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics**

- **Sponsor:** Ino Therapeutics, Inc.
- **Budget Dates:** 03/28/03 - 07/01/06
- **Direct:** $62,584
- **Award:** INOT-11 (03041607)

**Multi-Disciplinary Crisis Prevention Program**

- **Sponsor:** Lowcountry Childrens Center
- **Budget Dates:** 10/01/03 - 09/30/05
- **Direct:** $30,000
- **F & A:** 0
- **Award:** 1995-JS-FX-0001 (03112009)

**Henshaw, Melissa**

**Principal Investigator**

**A Dose-Ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multi-Center, Randomized, Double-Blind Study with a 1-year Open-Label, Follow-Up Period**

- **Sponsor:** Astrazeneca
- **Budget Dates:** 12/07/04 - 12/31/05
- **Direct:** $30,800
- **Award:** D2451C00002 (04120351)

**SC Nutrition Research Consortium Palmetto Childhood Obesity Project**

- **Sponsor:** SC Research Authority
- **Budget Dates:** 04/01/05 - 06/30/05
- **Direct:** $5,000
- **Award:** Task Order #0013 (05062192)

**Co-Investigator**

**PEDS1: A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Epleronone in the Treatment of Hypertension in Children**

- **PI:** J. Saul
- **Sponsor:** Icon Clinical Research,
- **Total:** $24,140
- **Dept:** Pediatrics
- **Award:** A6141001 (04102201-1)

**Hollis, Bruce**

**Principal Investigator**

**Glucocorticoid-Induced Osteopenia in Children**

- **Sponsor:** Univ. of Pennsylvania
- **Budget Dates:** 09/01/04 - 08/31/05
- **Direct:** $8,855
- **Award:** 20573-03-02/DK60030-03 (03062702)

**Evaluation of Vitamin D Requirements During Pregnancy**

- **Sponsor:** NIH/NICHD
- **Budget Dates:** 08/01/04 - 07/31/05
- **Direct:** $362,514
- **Award:** 5 R01 HD043921-02 (04062908)

**Co-Investigator**

**Regulation of Vitamin D Metabolism**

- **PI:** Norman Bell
- **Sponsor:** DOD/US Army
- **Total:** $137,613
- **Dept:** Medicine
- **Award:** DAMD17-01-1-0816 (00121502-4)

**Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis**

- **PI:** L. Key
- **Sponsor:** FDA
- **Total:** $234,434
- **Dept:** Pediatrics
- **Award:** FD-R-001847-04 (04062308-1)
Cloning and Characterization of Human CYP25  
**PI:** Norman Bell  
**Sponsor:** NIH/NIDDK  
**Dept:** Medicine  
**Total:** $168,000  
**Award:** 5 R01 DK056603-05 (04112921-1)

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hoover, Michael</strong></td>
<td>Surfactant Protein Composition in Tracheal Aspirates of Common Neonatal Respiratory Disease States.</td>
<td>Forest Labs, Inc.</td>
<td>05/01/05 - 10/31/06</td>
<td>$7,500</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hulsey, Thomas</strong></td>
<td>Faculty Development in Primary Care</td>
<td>HRSA/BHP/Medicine</td>
<td>09/01/04 - 06/30/06</td>
<td>$116,482</td>
<td>$9,319</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jackson, Sherron</strong></td>
<td>A Phase III, Multi-Center, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell Disease Who Have Had &lt;2 Acute Sickle-Related Painful Crises within the Preceding 12 Months</td>
<td>Quintiles Pacific, Inc.</td>
<td>01/25/05 - 09/30/06</td>
<td>$157,006</td>
<td>$39,252</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Johnson, George</strong></td>
<td>SC Children's AIDS Care System</td>
<td>SC DHEC</td>
<td>08/01/03 - 07/31/05</td>
<td>$116,482</td>
<td>$9,319</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key, Janice</strong></td>
<td>The New Morning Foundation School/Community Health Promotion and Teen Pregnancy Prevention Initiative for the Charleston Sea Islands</td>
<td>New Morning Foundation</td>
<td>07/01/03 - 06/30/05</td>
<td>$183,524</td>
<td>$18,352</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Key, L.</strong></td>
<td>Clinical Research Curriculum Award</td>
<td>NIH/NHLBI</td>
<td>09/01/04 - 08/31/06</td>
<td>$185,185</td>
<td>$14,815</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis</strong></td>
<td>FDA</td>
<td>09/30/04 - 09/29/05</td>
<td>$234,434</td>
<td>$107,840</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>South Carolina Children’s Advocacy Medical Response System</strong></td>
<td>Univ. of South Carolina</td>
<td>12/02/03 - 06/30/05</td>
<td>$77,280</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genentech National Cooperative Growth Study Post-Marketing Surveillance Program for Protropin and Nutropin</strong></td>
<td>Genentech, Inc.</td>
<td>07/01/94 - 12/31/08</td>
<td>$5,610</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Award: 85-036 (95050104)</td>
<td>Project Dates: 07/01/94 - 12/31/08</td>
<td>F &amp; A: 1,290</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key, L.**

Co-Investigator

**Evaluation of Vitamin D Requirements During Pregnancy**

- **PI:** Bruce Hollis
- **Sponsor:** NIH/NICH
- **Total:** $362,514

**Dept:** Pediatrics

- **Award:** 5 R01 HD043921-02 (04062908-1)

---

**Kral, Mary**

Co-PI or Project Leader

**NIAMS MCRC in Rheumatoid Disease - Project B: Predictors of Adaptation and a Cognitive Behavioral Intervention for African-American Adolescents with Lupus**

- **PI:** Richard Silver
- **Sponsor:** NIH/NIAMS
- **Total:** $190,439

**Dept:** Medicine

- **Award:** 5 P60 AR049459-03 (05012859-5)

---

**Kraveka, Jacqueline**

Principal Investigator

**Children’s Oncology Chair Grant**

- **Sponsor:** National Childhood Cancer Fdn.
- **Budget Dates:** 03/01/04 - 02/28/05
- **Direct:** $15,450

**Role of Ceramide in Human Neuroblastoma Differentiation**

- **Sponsor:** NIH/NCI
- **Budget Dates:** 09/01/04 - 08/31/05
- **Direct:** $124,950

**Dept:** Biochemistry and Molecular Biology

- **Award:** 5 K01 CA100767-02 (04070105)

---

**Larosa, Angela**

Co-Investigator

**Promoting Happy and Healthy Youth**

- **PI:** Eve Spratt
- **Sponsor:** HRSA
- **Total:** $13,889

**Dept:** Pediatrics

- **Award:** 5 T21MC00123-02-00 (04051102-1)

---

**Leclerc, Guy**

Co-Investigator

**Molecular Determinants of Methotrexate Metabolism in ALL**

- **PI:** Julio Barredo
- **Sponsor:** NIH/NCI
- **Total:** $205,000

**Dept:** Pediatrics

- **Award:** 5 R01 CA098152-02 (05030331-1)

---

**Losek, Joseph**

Principal Investigator

**Prospective Epidemiologic Study of the Severity of Bronchiolitis in Infants Treated in Urgent/Emergent Care and Hospital Settings**

- **Sponsor:** Merck
- **Budget Dates:** 11/13/04 - 04/12/06
- **Direct:** $34,348

**Dept:** Pediatrics

- **Award:** 0000-016 (EPI7001.050) (04121709)

---

**Madyastha, Prema**

Co-PI or Project Leader

**Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis**

- **PI:** L. Key
- **Sponsor:** FDA
- **Total:** $234,434

**Dept:** Pediatrics

- **Award:** FD-R-001847-04 (04062308-1)

---

**Maria, Bernard**

Principal Investigator

**Neurobiology of Disease in Children Conference**

- **Sponsor:** NIH/NINDS
- **Budget Dates:** 04/01/04 - 03/31/05
- **Direct:** $384

**Dept:** Pediatrics

- **Award:** 5 R13 NS040925-06 (04021009)

---

**Joubert Syndrome and Related Disorders: Clinical Database**

- **Sponsor:** Univ. of California
- **Budget Dates:** 04/01/03 - 03/31/05
- **Direct:** $51,276

**Dept:** Pediatrics

- **Award:** 10240946 (04101202)

---

**Neurobiology of Disease in Children Conference**

- **Sponsor:** NIH/NINDS
- **Budget Dates:** 04/01/05 - 03/31/06
- **Direct:** $43,000

**Dept:** Pediatrics

- **Award:** 5 R13 NS040925-07 (05012851)

---

**Marsh, Linda**

Co-Investigator

**Best Chance**

- **PI:** Janice Key
- **Sponsor:** DHHS
- **Total:** $183,372

**Dept:** Pediatrics

- **Award:** 5 APHPA002071-03-00 (04033009-1)
Adolescent and Family Life Demonstration Project  
Pl: Janice Key  
Dept: Pediatrics  
Sponsor: DHHS  
Award: 5 APHPA002040-04-00 (04041507-1)  
Total: $ 179,625

McQuinn, Tim  
Principal Investigator  
Molecular Analysis of Pediatric Cardiovascular Disease  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL067135-04 (04101901)  
Budget Dates: 12/01/04 - 11/30/05  
F & A: 96,750

Pai, G.  
Principal Investigator  
Caring Connection  
Sponsor: SC DHEC  
Award: MC-5-026 (04070802)  
Budget Dates: 07/01/04 - 06/30/05  
F & A: 0

Reddy, Sakamuri  
Principal Investigator  
Project 3-Pittsburgh Program Project Grant-Pathology of Pagets Disease  
Sponsor: Univ. of Pittsburgh  
Award: P01 AR049363-01A1 (04061811)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $ 18,735

Project 3 - Pittsburgh Program Project Grant  
Sponsor: Univ. of Pittsburgh  
Award: 108156-5 (04062909)  
Budget Dates: 04/29/05 - 09/23/07  
F & A: 100,393

Inhibition of Osteoclast Activity by OIP-1/hSca1  
Sponsor: NIH/NIDCR  
Award: 2 R01 DE012603-06A2 (04062910)  
Budget Dates: 07/01/04 - 06/30/05  
F & A: 61,410

Measles Virus Nucleocapsid (MJVN) Gene Expression and RANK Receptor Signaling in Osteoclast Precursors. Osteoclast Inhibitors Peptide Therapy for Pagets Disease  
Sponsor: DOD  
Award: P00001/DAMD17-03-1-0763 (04102905)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $ 218,245

Distinguished Speaker Seminar Grant  
Sponsor: Abbott Labs  
Award: (04120882)  
Budget Dates: 07/01/04 - 06/30/05  
F & A: 3,000

Ringewald, Jeremy  
Principal Investigator  
An Ongoing Evaluation of the Safety and Efficacy of the CardioSEAL Septal Occlusion System with Qwik Load In Patients with Ventricular Septal Defect (*Post-Market VSD Follow-up Registry*)  
Sponsor: NMT Medical, Inc.  
Award: VSD2002 (05022359)  
Budget Dates: 02/24/05 - 02/23/06  
F & A: 1,300

Roberts, James  
Principal Investigator  
Incorporating Environmental Management of Asthma into Pediatric Medical and Nursing Education  
Sponsor: National Environmental Educ. and Training  
Award: (04050710)  
Budget Dates: 05/01/04 - 10/31/05  
F & A: 2,708

Education and Management of Lead Intoxication  
Sponsor: SC DHEC  
Award: WS-5-123 (04070901)  
Budget Dates: 07/01/04 - 06/30/05  
F & A: 0

Saul, J.  
Principal Investigator  
Randomized Clinical Trials for Pediatric Heart Disease  
Sponsor: NIH/NHLBI  
Award: 5 U01 HL068281-03 (03071403)  
Budget Dates: 09/01/04 - 08/31/05  
F & A: 26,031

Annual Report for Research FY2005  
93
Randomized Clinical Trials for Pediatric Heart Disease
Sponsor: NIH/NHLBI  
Award: 5 U01 HL099821-04 (04071605)  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $407,290  
F & A: $77,167

Peds1: A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Epleronone in the Treatment of Hypertension in Children
Sponsor: Icon Clinical Research, Inc.  
Award: A6141001 (04102201)  
Budget Dates: 09/24/04 - 09/24/05  
Direct: $24,140

Dose-Ranging, Pharmacodynamic Assessment of Platelet Aggregation Inhibition with Clopidogrel in Children of Blalock-Taussing Shunt Age Categories (Neonates and Infants/Toddlers)
Sponsor: Sanofi Research  
Award: PDY4422 (05010733)  
Budget Dates: 01/13/05 - 01/12/06  
Direct: $24,800

South Carolina Birth Defects Surveillance and Prevention Program
PI: Girish Shirali  
Sponsor: Greenwood Genetic Center  
Total: $22,072

Co-Investigator
Mechanisms of Myocardial Radiofrequency Scar Expansion
Pl: Rupak Mukherjee  
Sponsor: NIH/NHLBI  
Total: $175,000

Singh, Inderjit
Principal Investigator
Cytokines in Glial Cells and EAE Brain
Sponsor: NIH/NINDS  
Award: 2 R01 NS037766-06A2 (04030316)  
Budget Dates: 08/01/98 - 08/31/09  
Direct: $231,250  
F & A: $106,375

Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy
Sponsor: NIH/NINDS  
Award: 5 R37 NS022576-20 (04100101)  
Budget Dates: 09/09/85 - 11/30/06  
Direct: $313,214  
F & A: $134,682

Structure/Function of Peroxisomes in Neuroinflammation
Sponsor: NIH/NINDS  
Award: 2 R01 NS034741-09 (04110117)  
Budget Dates: 04/22/96 - 04/30/09  
Direct: $231,250  
F & A: $106,375

Southgate, William
Principal Investigator
Long-Term Outcomes of NO for Ventilated Premature Babies
Sponsor: Univ. of Pittsburgh  
Award: 106908 (05011473)  
Budget Dates: 12/01/03 - 11/30/04  
Direct: $5,200

Inhaled NO for the Prevention of Chronic Lung Disease
Sponsor: Univ. of Colorado  
Award: 2-58344 (99052411)  
Budget Dates: 09/01/00 - 08/31/05  
Direct: $24,607  
F & A: $545
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Award Number</th>
<th>Project Dates</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spratt, Eve</td>
<td>Promoting Happy and Healthy Youth</td>
<td>HRSA</td>
<td>07/01/04 - 06/30/05</td>
<td>$13,889</td>
<td></td>
<td>5 T21MC00123-02-00 (04051102)</td>
<td>07/01/03 - 06/30/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neurodevelopmental Biology of Neglected Children</td>
<td>NIH/NIMH</td>
<td>06/01/05 - 05/31/06</td>
<td>$163,940</td>
<td></td>
<td>5 K23 MH64111-03 (05042539)</td>
<td>06/01/05 - 05/31/08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virella-Lowell, Isabel</td>
<td>Anti-Antiflammatory Gene Therapy for Cystic Fibrosis</td>
<td>NIH/NHLBI</td>
<td>07/01/04 - 06/30/05</td>
<td>$114,273</td>
<td></td>
<td>5 K08 HL067260-05 (04070104)</td>
<td>05/01/03 - 06/30/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gene and Pharmacological Therapies for Cystic Fibrosis</td>
<td>Univ. of Florida</td>
<td>05/01/04 - 03/31/05</td>
<td>$41,750</td>
<td></td>
<td>UF05038 (04101103)</td>
<td>05/01/04 - 03/31/09</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wagner, Carol</td>
<td>Evaluation of Vitamin D Requirements During Pregnancy</td>
<td>NIH/NICH</td>
<td>10/01/04 - 09/30/05</td>
<td>$362,514</td>
<td></td>
<td>1 R02502 (04050702)</td>
<td>10/01/04 - 09/30/05</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Psychiatry and Behavioral Sciences**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
<th>Award Number</th>
<th>Project Dates</th>
<th>F &amp; A</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acierno, Ron</td>
<td>Sexual Assault and Domestic Violence Intervention: Training Program for Students in the Health Professions</td>
<td>SC Dept. of Public Safety</td>
<td>10/01/04 - 09/30/05</td>
<td>$53,585</td>
<td></td>
<td>1K02502 (04050702)</td>
<td>10/01/04 - 09/30/05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Florida Hurricanes and Older Adults: Outcome/Resiliency Factors</td>
<td>NIH/NIMH</td>
<td>03/04/05 - 02/28/06</td>
<td>$184,524</td>
<td></td>
<td>1 R21 MH074469-01 (04092819)</td>
<td>03/01/05 - 02/28/07</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disaster Research Education and Mentoring Center (DREM)</td>
<td>NIH/NIMH</td>
<td>10/01/04 - 09/30/05</td>
<td>$250,000</td>
<td></td>
<td>5 R25 MH070552-02 (04102773-1)</td>
<td>09/30/97 - 08/31/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anton, Jr., Raymond</td>
<td>Naltrexone/Acamprosate Plus CBT/MET Light for Alcoholism (The COMBINE Study)</td>
<td>NIH/NIAAA</td>
<td>07/15/04 - 08/31/04</td>
<td>$18,285</td>
<td></td>
<td>3 U10 AA011783-07S1 (02102213)</td>
<td>09/30/97 - 08/31/05</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Linkage Disequilibrium Studies of Alcohol Dependence</td>
<td>Yale Univ.</td>
<td>05/01/04 - 04/30/05</td>
<td>$95,411</td>
<td></td>
<td>5 R01 AA11330-06 (03010302)</td>
<td>05/01/02 - 04/30/07</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gabapentin as an Adjunct to Naltrexone for Alcoholism</td>
<td>NIH/NIAAA</td>
<td>09/01/04 - 08/31/05</td>
<td>$323,799</td>
<td></td>
<td>5 R01 AA009568-13 (04063017)</td>
<td>09/30/92 - 08/31/07</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Naltrexone/Acamprosate and CBT/MET Light for Alcoholism</td>
<td>NIH/NIAAA</td>
<td>09/01/04 - 08/31/06</td>
<td>$191,791</td>
<td></td>
<td>5 U10 AA011783-08 (04063018)</td>
<td>09/30/97 - 08/31/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alcohol Research Center-Treatment and Implications-Research Component 1</td>
<td>NIH/NIAAA</td>
<td>09/01/04 - 08/31/06</td>
<td>$190,967</td>
<td></td>
<td>5 P50 AA010761-10 (04110554-4)</td>
<td>09/30/97 - 08/31/06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Faculty Activity</td>
<td>Medical University of South Carolina</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatry and Behavioral Sciences</td>
<td>College of Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Alcohol Research Center-Treatment and Implications-Pilot Core**

**PI:** Carrie Randall  
**Sponsor:** NIH/NIAAA  
**Total:** $69,321  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5 P50 AA010761-10 (04110554-8)

### Anton, Jr., Raymond

**Co-Investigator**

**Facilitating Alcohol Screening of Hypertensive Patients**

**PI:** Peter Miller  
**Sponsor:** NIH/NIAAA  
**Total:** $243,757  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 1 R25 AA015066-01 (03092607-1)

**Naltrexone Treatment of Adolescent Alcoholics**

**PI:** Deborah Deas  
**Sponsor:** NIH/NIAAA  
**Total:** $285,116  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5 R01 AA013393-03 (04061503-1)

**Training in Alcohol Research**

**PI:** John Woodward  
**Sponsor:** NIH/NIAAA  
**Total:** $274,500  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5 T32 AA007474-18 (04120246-1)

### Barkley, Russell

**Co-Investigator**

**A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning**

**PI:** Markus Kruesi  
**Sponsor:** Eli Lilly  
**Total:** $177,316  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** B4Z-US-LYCW (04081701-1)

### Becker, Howard

**Principal Investigator**

**Repeated Ethanol Withdrawals: Subjective Effects and Ethanol Drinking**

**Sponsor:** VAMC  
**Budget Dates:** 10/01/04 - 09/30/05  
**Direct:** $124,400  
**Award:** ADRD-008-01S (03063005)

**Ethanol Dependence and Stress Effects on Ethanol Drinking**

**Sponsor:** NIH/NIAAA  
**Budget Dates:** 03/01/05 - 02/28/06  
**Direct:** $168,078  
**Award:** 5 U01 AA014095-03 (05011044)

**Ethanol Dependence and Stress Effects on Ethanol Drinking**

**Sponsor:** NIH/NIAAA  
**Budget Dates:** 03/01/04 - 02/28/05  
**Direct:** $199,621  
**Award:** 5 U01 AA014095-02 (03122902)

**Treatment and Gene/Protein Analysis of Ethanol Relapse**

**Sponsor:** NIH/NIAAA  
**Budget Dates:** 03/01/05 - 02/29/06  
**Direct:** $250,000  
**Award:** 5 R01 AA013885-03 (05012858)

### Co-PI or Project Leader

**Alcohol Research Center-Treatment and Implications-Research Component 4**

**PI:** Carrie Randall  
**Sponsor:** NIH/NIAAA  
**Total:** $158,518  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5 P50 AA010761-10 (04110554-7)

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health - Project #4: Gender Influence on Preclinical Alcohol Pharmacology**

**PI:** Kathleen Brady  
**Sponsor:** NIH/NIDA  
**Total:** $109,545  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 5 P50 DA016511-03 (04043003-5)

### Bernstein, Hilary

**Principal Investigator**

**Comparing Three Electrode Placements to Optimize ECT**

**Sponsor:** Mayo Clinic  
**Budget Dates:** 06/01/04 - 05/31/06  
**Direct:** $17,123  
**Award:** 5 R01 MH62357-03 (04072303)

**Comparing Three Electrode Placements to Optimize ECT**

**Sponsor:** New Jersey Medical School  
**Budget Dates:** 06/01/04 - 05/31/05  
**Direct:** $85,000  
**Award:** R01 MH67201 (04072705)

### Book, Sarah

**Principal Investigator**

**Training in Comorbidity of Alcoholism and Mental Illness**

**Sponsor:** NIH/NIAAA  
**Budget Dates:** 09/01/04 - 08/31/05  
**Direct:** $154,179  
**Award:** 5 K23 AA014430-02 (04062304)

**Adoption of Pharmacotherapy in Alcoholism Treatment**

**PI:** Peter Miller  
**Sponsor:** NIH/NIAAA  
**Total:** $143,750  
**Dept:** Psychiatry and Behavioral Sciences  
**Award:** 1 R21 AA015065-01 (03092606-1)
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrie Randall</td>
<td>Paroxetine for Social Anxiety Disorder and Alcoholism</td>
<td>NIH/NIAAA</td>
<td>04/123019-1</td>
<td>$ 257,809</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kathleen Brady</td>
<td>Open-Label Treatment with Duloxetine Hydrochloride Once-Daily Dosing</td>
<td>Eli Lilly</td>
<td>01/01/03 - 05/31/05</td>
<td>$ 57,400</td>
<td></td>
</tr>
<tr>
<td></td>
<td>for Evaluation of Stabilization in Patients with Major Depression</td>
<td></td>
<td>01/01/03 - 05/31/05</td>
<td>$ 14,350</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Investigation of Drug Abuse Disorders</td>
<td>NIH/NIDA</td>
<td>09/30/04 - 07/31/05</td>
<td>$ 137,624</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health</td>
<td>NIH/NIDA</td>
<td>07/01/04 - 06/30/05</td>
<td>$ 595,292</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant</td>
<td>Janssen</td>
<td>05/01/04 - 04/30/06</td>
<td>$ 17,800</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clinical Trials Network</td>
<td>Pharmaceutica</td>
<td>05/01/04 - 04/30/06</td>
<td>$ 221,066</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse:</td>
<td>Parexel Intl.</td>
<td>08/01/04 - 07/31/06</td>
<td>$ 194,330</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Randomized, Placebo-Controlled Trial</td>
<td>Corp.</td>
<td>08/01/04 - 07/31/06</td>
<td>$ 48,583</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CBT and Modafinil for Cocaine Addiction</td>
<td>NIH/NIDA</td>
<td>04/03040301</td>
<td>$ 293,176</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MST Services Consultation</td>
<td>MST Group, LLC</td>
<td>11/01/02 - 07/31/05</td>
<td>$ 58,809</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Differential Response to Evidenced-Based Treatment</td>
<td>NIH/NIMH</td>
<td>05/01/05 - 03/31/06</td>
<td>$ 381,805</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adherence to IDDM Regimen in Urban Youth</td>
<td>Wayne State Univ.</td>
<td>07/01/04 - 08/31/05</td>
<td>$ 26,204</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CBT for PTSD Among Public Sector Consumers</td>
<td>NIH/NIMH</td>
<td>04/080201</td>
<td>$ 195,500</td>
<td></td>
</tr>
</tbody>
</table>

**Brady, Kathleen**

**Principal Investigator**

Open-Label Treatment with Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization in Patients with Major Depression

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly</td>
<td>F13-US-HMBZ (02123003)</td>
<td>01/01/03 - 05/31/05</td>
<td>$ 57,400</td>
<td></td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>2 K24 DA000435-06 (03103009)</td>
<td>08/15/99 - 07/31/09</td>
<td>$ 11,010</td>
<td></td>
</tr>
</tbody>
</table>

**Clinical Investigation of Drug Abuse Disorders**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDA</td>
<td>5 P50 DA016511-03 (04043003)</td>
<td>09/30/02 - 06/30/07</td>
<td>$ 595,292</td>
<td></td>
</tr>
<tr>
<td>NIH/NIDA</td>
<td>5 U010 DA013727-05 (04063002)</td>
<td>09/30/00 - 08/30/05</td>
<td>$ 221,066</td>
<td></td>
</tr>
</tbody>
</table>

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIDA</td>
<td>5 R01 AA013379-04 (04123019-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Duloxetine Hydrochloride Once Daily Versus Placebo in the Treatment of Generalized Anxiety Disorder**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIMH</td>
<td>1 R01 MH068813-01A2 (04022613)</td>
<td>07/01/04 - 08/31/05</td>
<td>$ 26,204</td>
<td></td>
</tr>
</tbody>
</table>

**Adherence to IDDM Regimen in Urban Youth**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIMH</td>
<td>5 R01 DK059067-04 (04080201)</td>
<td>07/01/04 - 08/31/05</td>
<td>$ 11,268</td>
<td></td>
</tr>
</tbody>
</table>

**Cusack, Karen**

**Co-Investigator**

CBT for PTSD Among Public Sector Consumers

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Award</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F &amp; A</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH/NIMH</td>
<td>5 R21 MH065248-03 (04102906-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
De Arellano, Michael

**Principal Investigator**

**Child Treatment in Hispanic Migrant Populations**
Sponsor: NIH/NIMH  
Budget Dates: 09/01/04 - 08/31/06  
Direct: $ 103,752

**Coordinating Services for Child Sexual Assault Victims**
Sponsor: SC Dept. of Public Safety  
Budget Dates: 04/01/05 - 03/31/06  
Direct: $ 66,498

Deas, Deborah

**Principal Investigator**

**Naltrexone Treatment of Adolescent Alcoholics**
Sponsor: NIH/NIAAA  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $ 285,116

**A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg and 30mg) in the Treatment of Child and Adolescent Patients, Ages 10-17 Years, with Bipolar I Disorder, Manic, or Mixed Episode with or without Psychotic Features**
Sponsor: Ingenix  
Budget Dates: 04/15/05 - 06/30/07  
Direct: $ 207,248

Devane, C.

**Principal Investigator**

**PGP Regulation of Antipsychotic Exposure and Effects**
Sponsor: NIH/NIMH  
Budget Dates: 02/14/05 - 01/31/06  
Direct: $ 200,000

**In Vivo Interactions of Risperidone and Paliperidone with P-Glycoprotein in the Blood Brain Barrier**
Sponsor: Janssen Pharmaceutica  
Budget Dates: 07/15/04 - 04/15/06  
Direct: $ 34,246

**SCOR Medications in Pregnancy: Defining Exposure**
Sponsor: Emory Univ.  
Budget Dates: 08/01/04 - 07/31/05  
Direct: $ 113,744

**CBT and Modafinil for Cocaine Addiction**
Sponsor: NIH/NIDA  
Total: $ 293,176
<table>
<thead>
<tr>
<th>Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
<th>Dept</th>
<th>Award Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacokinetics and Drug Interactions with Milk Thistle</td>
<td>John Markowitz</td>
<td>NIH/NCCAM</td>
<td>$87,500</td>
<td>Pharmaceutical Sciences</td>
<td>1 R21 AT002817-01 (04052710-1)</td>
</tr>
<tr>
<td>Drug Interactions and Bioavailability of Cranberry</td>
<td>Jennifer Donovan</td>
<td>NIH/NCCAM</td>
<td>$125,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R21 AT002073-02 (04112207-1)</td>
</tr>
<tr>
<td>PGP Regulation of Antipsychotic Exposure and Effects</td>
<td>C. Devane</td>
<td>NIH/NIMH</td>
<td>$200,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>1 R01 MH071811-01A1 (04062914-1)</td>
</tr>
<tr>
<td>In Vivo Interactions of Risperidone and Paliperidone with P-Glycoprotein in the Blood Brain Barrier</td>
<td>C. Devane</td>
<td>Janssen Pharmaceutica</td>
<td>$34,246</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>RIS-EMR-4025 (04071611-1)</td>
</tr>
<tr>
<td>(SCOR) Medications in Pregnancy: Defining Exposure</td>
<td>C. Devane</td>
<td>Emory Univ.</td>
<td>$113,744</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 P50 MH068036-03 (04101403-1)</td>
</tr>
<tr>
<td>Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease</td>
<td>Faison, Warachal</td>
<td>Janssen Pharmaceutica</td>
<td>$26,800</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>GAL-ALZ-303 (04051901)</td>
</tr>
<tr>
<td>Telepsychiatry Service Delivery to Trauma Victims</td>
<td>B. Frueh</td>
<td>AHCPR/AHRQ</td>
<td>$166,387</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 HS011642-03 (04022615)</td>
</tr>
<tr>
<td>CBT for PTSD Among Public Sector Consumers</td>
<td>C. Devane</td>
<td>NIH/NIMH</td>
<td>$195,500</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R21 MH065248-03 (04102906)</td>
</tr>
<tr>
<td>A Multi-Center, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prothesis (NCP) System in Patients with Depression</td>
<td>M. George</td>
<td>Cyberonics, Inc.</td>
<td>$11,251</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>DO-2 (00061906)</td>
</tr>
<tr>
<td>Optimization of TMS for Depression-Coordinating Center</td>
<td></td>
<td>NIH/NIMH</td>
<td>$457,014</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>1 R01 MH069887-01 (03021403)</td>
</tr>
<tr>
<td>Optimization of TMS for Depression</td>
<td></td>
<td>NIH/NIMH</td>
<td>$225,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>1 R01 MH069896-01A1 (03110301)</td>
</tr>
<tr>
<td>Remediation of Motor Control Degradation via Application of rTMS to the Motor Cortex</td>
<td></td>
<td></td>
<td>$13,619</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>NCC5-575 (04052812)</td>
</tr>
<tr>
<td>Using Motor and Prefrontal Cortex Interleaved Transcranial Magnetic Stimulation (TMS) BOLD FMRI to Compare the Mechanism of Action of Lamotrigine to Valproic Acid in Normal Volunteers</td>
<td></td>
<td>GlaxoSmithKline</td>
<td>$330,520</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>RES102981 (05012528)</td>
</tr>
</tbody>
</table>
### Remediation of Motor Controls Degradation via Application of rTMS to the Motor Cortex
- **Sponsor:** SC Research Authority
- **Budget Dates:** 07/01/04 - 10/31/05
- **Direct:** $15,080

### A Study of Vagus Nerve Stimulation in Patients with Depression
- **Sponsor:** Cyberonics, Inc.
- **Budget Dates:** 06/01/98 - 12/31/07
- **Direct:** $9,017

### Gold, Paul
#### Community Integration of Persons with Mental Illness
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 08/01/04 - 07/31/06
- **Direct:** $127,380

### Gray, Kevin
#### Marijuana Cue-Reactivity and Medication in Adolescents
- **Sponsor:** Eli Lilly
- **Budget Dates:** 07/01/04 - 10/31/05
- **Direct:** $9,000

### Halliday-Boykins, Coleen
#### Substance Outcomes for Youth in Psychiatric Crisis
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $62,727

### Hamner, Mark
#### A Multi-Center, Open Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL tm) and Risperidone (RISPERDAL tm) in the Long-Term Treatment of Patients with Schizophrenia and Schizoaffective Disorder
- **Sponsor:** Astrazeneca
- **Budget Dates:** 01/30/04 - 01/29/06
- **Direct:** $35,600

### Hansen, Rochelle
#### Treating Child Sexual Abuse: Effectiveness Pilot Study
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 04/01/05 - 02/28/06
- **Direct:** $139,500

#### Youth Violence Exposure: A National Longitudinal Study
- **Sponsor:** NIH/NICHD
- **Budget Dates:** 04/01/05 - 02/29/08
- **Direct:** $64,170
**Henggeler, Scott**

**Principal Investigator**

**Substance Abusing Delinquents: 5-Year Outcomes of RCT**

Sponsor: NIH/NIDA  
Award: 2 R01 DA013066-06 (03012110)  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $294,672  
F & A: $135,549

**Randomized Clinical Trial of Juvenile Drug Court and MST**

Sponsor: NIH/NIDA  
Award: 5 R01 DA013066-05 (03061902)  
Budget Dates: 09/01/03 - 08/31/04  
Direct: $71,250  
F & A: $32,775

**Evidenced-Based Treatment in Juvenile Drug Court**

Sponsor: SAMHSA/CSAT  
Budget Dates: 09/30/04 - 10/31/05  
Direct: $273,972  
F & A: $135,549

**Implementing Evidenced-Based Treatment for Youth**

Sponsor: NIH/NIDA  
Budget Dates: 09/30/03 - 08/30/06  
Direct: $339,246  
F & A: $146,418

**Effectiveness Trial: MST with Juvenile Offenders**

Sponsor: NIH/NIDA  
Award: 3 R01 MH065414-02S1 (04042807)  
Project Dates: 09/30/04 - 08/31/05  
Direct: $41,297  
F & A: $18,997

**Adoption and Implementation of Adolescent EBT State-Wide**

Sponsor: NIH/NIDA  
Award: 5 R01 DA017487-02 (04062906)  
Project Dates: 09/30/04 - 08/31/05  
Direct: $339,246  
F & A: $146,418

**Effectiveness Trial: MST with Juvenile Offenders**

Sponsor: NIH/NIMH  
Award: 5 R01 DA015844-03 (0402807)  
Project Dates: 09/30/04 - 08/31/04  
Direct: $71,250  
F & A: $32,775

**Effectiveness Trial: MST with Juvenile Offenders - Minority Supplement**

Sponsor: NIH/NIMH  
Award: 5 R01 MH065414-03 (05011251)  
Project Dates: 03/14/03 - 02/29/08  
Direct: $68,995  
F & A: $31,738

**Kilpatrick, Dean**

**Principal Investigator**

**Youth Violence Exposure: A National Longitudinal Study**

Sponsor: NIH/NICHD  
Award: 1 R01 HD046830-01 (03062605)  
Budget Dates: 08/01/04 - 05/31/05  
Direct: $419,680  
F & A: $68,323

**Graduate Psychology Education Programs: Internship Training in Health and Community Psychology**

Sponsor: HRSA/BHP/Medicine  
Award: 5 D40 HP00017-03-00 (03121203)  
Project Dates: 09/30/04 - 04/30/07  
Direct: $130,253  
F & A: $10,420

---

**Hiott, Walter**

**Co-Investigator**

**Atomoxetine in Adolescents with Comorbid ADHD and Nicotine Dependence: A Pilot Study**

PI: Himanshu Upadhyaya  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Eli Lilly  
Total: $60,996

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg and 30mg) in the Treatment of Child and Adolescent Patients, Ages 10-17 Years, with Bipolar I Disorder, Manic, or Mixed Episode with or without Psychotic Features

PI: Deborah Deas  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Ingenix  
Total: $207,248

A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg - 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode

PI: Deborah Deas  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Ingenix  
Total: $89,648

---

**Kilpatrick, Therese**

**Co-PI or Project Leader**

**Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD**

PI: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Sponsor: Janssen Pharmaceutica  
Total: $17,800

---

**Kilpatrick, Dean**

**Principal Investigator**

**Youth Violence Exposure: A National Longitudinal Study**

Sponsor: NIH/NICHD  
Award: 1 R01 HD046830-01 (03062605)  
Budget Dates: 08/01/04 - 05/31/05  
Direct: $419,680  
F & A: $68,323

**Graduate Psychology Education Programs: Internship Training in Health and Community Psychology**

Sponsor: HRSA/BHP/Medicine  
Award: 5 D40 HP00017-03-00 (03121203)  
Project Dates: 09/30/04 - 04/30/07  
Direct: $130,253  
F & A: $10,420

---

**Annual Report for Research FY2005**

101
### Child and Adult Trauma Victims: A Training Program
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 07/01/04 - 06/30/05
- **Direct:** $210,810
- **Project Dates:** 01/01/08 - 06/30/08
- **F & A:** $15,401

### State of South Carolina Victim Assistance Academy
- **Sponsor:** SC State Office of Victim Assistance
- **Budget Dates:** 09/01/04 - 08/31/05
- **Direct:** $3,850
- **Project Dates:** 09/01/04 - 08/31/05
- **F & A:** $308

### Disaster Research Education and Mentoring Center (DREM)
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 01/01/05 - 12/31/05
- **Direct:** $250,000
- **Project Dates:** 04/14/04 - 12/31/08
- **F & A:** $10,096

### Florida Hurricanes and Older Adults: Outcome/Resiliency Factors
- **PI:** Ron Acierno
- **Sponsor:** NIH/NIMH
- **Total:** $184,524
- **Award:** 1 R21 MH074469-01 (04092819-1)

### Function Neuroanatomy of Maternal and Paternal Behavior
- **PI:** Jeffrey Lorberbaum
- **Sponsor:** NIH/NICHD
- **Total:** $50,000
- **Award:** 1 R03 HD049422-01 (04060201-1)

### Using BOLD fMRI to Detect Deception and Better Understand the Polygraph: Current Knowledge and a Focused, Applied Research Agenda
- **Pl.:** Raymond Anton, Jr.
- **Sponsor:** NIH/NIAAA
- **Total:** $323,799
- **Award:** 5 R01 AA009568-13 (04063017-1)

### A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention Deficit/Hyperactivity Disorder: with a Secondary Examination of Impact on Family Functioning
- **Pl.:** Eli Lilly
- **Sponsor:** Eli Lilly
- **Total:** $225,000
- **Award:** 1 R01 MH069896-01A1 (03110301-1)

### N-Acetylcysteine as Treatment in Cocaine Addiction
- **Pl.:** Raymond Anton, Jr.
- **Sponsor:** NIH/NIDA
- **Total:** $47,296
- **Award:** 1 F32 DA018501-01 (03120102)

### Using Motor and Prefrontal Cortex Interleaved Transcranial Magnetic Stimulation (TMS) BOLD fMRI to Compare the Mechanism of Action of Lamotrigine to Valproic Acid in Normal Volunteers
- **Pl.:** Mark George
- **Sponsor:** GlaxoSmithKline
- **Total:** $330,520
- **Award:** RES102981 (05012528-1)
### Lorberbaum, Jeffrey

**Principal Investigator**

**Function Neuroanatomy of Maternal and Paternal Behavior**

Sponsor: NIH/NICHD  
Budget Dates: 06/01/05 - 05/31/06  
Direct: $ 50,000  
Award: 1 R03 HD04922-01 (04060207)  
Project Dates: 06/01/05 - 05/31/07  
F & A: $ 23,000

### Magruder, Kathryn

**Co-Investigator**

**Southeastern Node of the Clinical Trials Network**

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 U01 DA013727-05 (04063002-1)

NIAMS MCRC in Rheumatoid Disease-Methodology Core

Pl: Richard Silver  
Dept: Medicine  
Award: 5 P60 AR049459-03 (05012859-2)

### Malcolm, Jr., Robert

**Principal Investigator**

**CBT and Modafinil for Cocaine Addiction**

Sponsor: NIH/NIDA  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $ 293,176  
Award: 5 R01 DA016368-02 (04043010)  
Project Dates: 09/30/03 - 06/30/07  
F & A: $ 114,127

**Co-PI or Project Leader**

**Alcohol Research Center-Treatment and Implications-Research Component 3**

Pl: Carrie Randall  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 P50 AA010761-10 (04110554-6)

### McLeod-Bryant, Stephen

**Co-Investigator**

**Schizophrenia Liability Genes Among African Americans**

Pl: Alberto Santos  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 R01 MH066004-03 (04052810-1)

### McRae, Aimee

**Principal Investigator**

**Career Training in Marijuana Dependence**

Sponsor: NIH/NIDA  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $ 109,040  
Award: 5 K23 DA015440-03 (04062901)  
Project Dates: 09/29/02 - 08/31/07  
F & A: $ 8,206

**Co-Investigator**

ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health - Project #2: Gender Difference in Response to Cues in Cocaine Dependence

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 P50 DA016511-03 (04043003-3)

Atomoxetine Treatment of Adults w/ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: B4Z-MC-LYBY (04080602-1)

### Middaugh, Lawrence

**Co-PI or Project Leader**

ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health - Project #4: Gender Influence on Preclinical Alcohol Pharmacology

Pl: Kathleen Brady  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 P50 DA016511-03 (04043003-5)

**Alcohol Research Center-Treatment and Implications-Research Component 2**

Pl: Carrie Randall  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 P50 AA010761-10 (04110554-5)

### Miller, Peter

**Principal Investigator**

**Adoption of Pharmacotherapy in Alcoholism Treatment**

Sponsor: NIH/NIAAA  
Budget Dates: 09/28/04 - 08/31/05  
Direct: $ 143,750  
Award: 1 R21 AA015065-01 (03092606)  
Project Dates: 09/28/04 - 08/31/06  
F & A: $ 66,125

**Facilitating Alcohol Screening of Hypertensive Patients**

Sponsor: NIH/NIAAA  
Budget Dates: 09/01/04 - 08/31/05  
Direct: $ 243,757  
Award: 1 R25 AA015066-01 (03092607)  
Project Dates: 09/01/04 - 08/31/07  
F & A: $ 19,501
Principal Investigator

**Mintzer, Jacobo**

**A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer's Type**

- **Sponsor:** Forest Labs, Inc.
- **Award:** MEM-MD-12 (02042505)
- **Budget Dates:** 04/01/02 - 12/31/05
- **Total:** $17,609

**Antipsychotic Discontinuation in Alzheimer's Disease**

- **Sponsor:** Research Fdn. For Mental Hygiene
- **Award:** 1003757/223532 (03052004)
- **Budget Dates:** 09/03/03 - 08/31/05
- **Total:** $129,477

**An Evaluation of the Long-Term Safety and Efficacy of Nervamexane in Patients with Moderate to Severe Dementia of the Alzheimer's Type**

- **Sponsor:** Forest Research Institute
- **Award:** NER-MD-03 (03101701)
- **Budget Dates:** 10/23/03 - 06/30/06
- **Total:** $1,143

**Administrative Supplement for PIP Study-68-00**

- **Sponsor:** Univ. of California, San Diego
- **Award:** 68-00/68PI (04040204)
- **Budget Dates:** 09/04/02 - 06/30/06
- **Total:** $28,356

**A Double-Blind, Phase II, Safety and Efficacy Evaluation of ONO-2506PO in Patients with Mild to Moderate Alzheimer's Disease**

- **Sponsor:** Pharmamet
- **Award:** ONO-2506POU010 (04081601)
- **Budget Dates:** 08/20/04 - 10/01/05
- **Total:** $389,166

**A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients with Mild-to-Moderate Dementia of the Alzheimer's Type**

- **Sponsor:** Sanofi Synthelabo, Inc.
- **Grant:** EFC2724 (04092808)
- **Budget Dates:** 08/20/04 - 10/01/05
- **Total:** $97,292

**A 1-Year, Double-Blind, Randomized, Placebo-Controlled Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients with Mild to Moderate Dementia of the Alzheimer's Type**

- **Sponsor:** Pharmaceutical Research Associates
- **Grant:** TVP-1012-A001-201 (04102701)
- **Budget Dates:** 10/26/04 - 10/31/06
- **Total:** $63,742

**A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effectiveness and Safety of Memantine in Nursing Home Residents with Moderate to Severe Alzheimer's Disease**

- **Sponsor:** Forest Research Institute
- **Award:** MEM-MD-22 (04112175)
- **Budget Dates:** 11/05/04 - 07/31/06
- **Total:** $129,553

**A Phase III Study of the Efficacy and Safety of Alzheimed in Patients with Mild to Moderate Alzheimer's Disease**

- **Sponsor:** Neurochem, Inc.
- **Grant:** CL-758007 (04111790)
- **Budget Dates:** 08/20/04 - 07/31/06
- **Total:** $193,514

**Depression in Alzheimer's Disease Study 2 (DIADS-2)**

- **Sponsor:** NIH/NIMH
- **Grant:** 5 U01 MH066176-03 (04123026)
- **Budget Dates:** 07/01/03 - 02/28/06
- **Total:** $49,979

**A 6-Month Safety Follow-up Study of Select Patients Previously Enrolled and Randomized to MKC-231 in Studies MKC-231/01, MKC-231/A02 or MKC-231/A03**

- **Sponsor:** Ingenix
- **Grant:** MKC-231 (05012006)
- **Budget Dates:** 01/20/05 - 09/30/05
- **Total:** $3,092

**Open Label Extension of a Double-Blind Placebo-Controlled Study of Leuprolide Acetate Depot in the Treatment of Alzheimer's Disease in Men**

- **Sponsor:** Voyager Pharmaceutical Corp.
- **Grant:** VP-AD-104E (05040579)
- **Budget Dates:** 04/05/05 - 11/04/05
- **Total:** $9,902

Co-Investigator

**Academic Administrative Units In Primary Care**

- **PI:** William Hueston
- **Dept:** Family Medicine
  - **Sponsor:** HRSA/BHP/Medicine
  - **Award:** 5 D54 HP00023-05-00 (03121009-1)
  - **Total:** $175,000

**Moak, Darlene**

**Naltrexone/Acamprosate Plus CBT/MET Light for Alcoholism (The COMBINE Study)**

- **PI:** Raymond Anton, Jr.
- **Dept:** Psychiatry and Behavioral Sciences
  - **Sponsor:** NIH/NIAAA
  - **Award:** 3 U10 AA011783-07S1 (02102213-2)
  - **Total:** $18,285
<table>
<thead>
<tr>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Total</th>
<th>Dept</th>
<th>Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBT and Modafinil for Cocaine Addiction</td>
<td>Robert Malcolm, Jr.</td>
<td>NIH/NIDA</td>
<td>$293,176</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 DA016368-02 (0403010-1)</td>
</tr>
<tr>
<td>Gabapentin as an Adjunct to Naltrexone for Alcoholism</td>
<td>Raymond Anton, Jr.</td>
<td>NIH/NIAAA</td>
<td>$323,799</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 AA009568-13 (04063017-1)</td>
</tr>
<tr>
<td>Naltrexone/Acamprosate and CBT/MET Light for Alcoholism</td>
<td>Raymond Anton, Jr.</td>
<td>NIH/NIAAA</td>
<td>$191,791</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 U10 AA011783-08 (04063018-1)</td>
</tr>
<tr>
<td>Gabapentin as an Adjunct to Naltrexone for Alcoholism</td>
<td>Raymond Anton, Jr.</td>
<td>NIH/NIAAA</td>
<td>$323,799</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 AA009568-13 (04063017-1)</td>
</tr>
<tr>
<td>Remediation of Motor Control Degradation via Application of rTMS to the Motor Cortex</td>
<td>Mark George</td>
<td>Coll. of Charleston</td>
<td>$13,619</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>NCC5-575 (04052812-1)</td>
</tr>
<tr>
<td>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability and Efficacy of L-000753721 in Maintaining Weight Loss Induced by a Very Low Calorie Diet in Obese Patients</td>
<td>Sanofi Synthelabo, Inc.</td>
<td>NIH/NIH</td>
<td>$10,849</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>ACT3 3801 (04071609)</td>
</tr>
<tr>
<td>Taurine Regulation of Alcohol-Seeking Behavior</td>
<td>NIH/NIAAA</td>
<td>$62,537</td>
<td></td>
<td>Psychiatry and Behavioral Sciences</td>
<td>7 R21 AA013276-04 (05011360)</td>
</tr>
<tr>
<td>Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Combination Therapy for Safety and Efficacy in Subjects with Uncomplicated Obesity</td>
<td>NIH/NIAAA</td>
<td>$162,841</td>
<td></td>
<td>Psychiatry and Behavioral Sciences</td>
<td>NB-201 (05042748)</td>
</tr>
<tr>
<td>Control of Ethanol Intake by mGluR5-PKCe Pathway</td>
<td>NIH/NIAAA</td>
<td>$175,000</td>
<td></td>
<td>Psychiatry and Behavioral Sciences</td>
<td>7 R01 AA013852-03 (05011359)</td>
</tr>
<tr>
<td>Taurine Regulation of Alcohol-Seeking Behavior</td>
<td>NIH/NIAAA</td>
<td>$62,537</td>
<td></td>
<td>Psychiatry and Behavioral Sciences</td>
<td>7 R21 AA013276-04 (05011360)</td>
</tr>
</tbody>
</table>

**Co-Investigators**

- Monnier, Jeannine
  - Telepsychiatry Service Delivery to Trauma Victims | B. Frueh | AHCPR/AHRQ | $166,387 | Psychiatry and Behavioral Sciences | 5 R01 HS011642-03 (04022615-1) |
- Myrick, Donald
  - CBT and Modafinil for Cocaine Addiction | Robert Malcolm, Jr. | NIH/NIDA | $293,176 | Psychiatry and Behavioral Sciences | 5 R01 DA016368-02 (0403010-1) |
- Nahas, Ziad
  - Interleaved Prefrontal TMS/fMRI in Schizophrenia | NIH/NIMH | $125,000 | Psychiatry and Behavioral Sciences | 5 R21 MH065630-03 (04112206) |
- O'Neil, Patrick
  - A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability and Efficacy of Rimonabant 20mg Versus Placebo on Weight Loss and Frequency of Binge Episodes In Obese Patients | Sanofi Synthelabo, Inc. | Merck | $10,849 | Psychiatry and Behavioral Sciences | 012-00 (03111304) |
- Olive, M.
  - Control of Ethanol Intake by mGluR5-PKCe Pathway | NIH/NIAAA | $175,000 | Psychiatry and Behavioral Sciences | 7 R01 AA013852-03 (05011359) |
  - Taurine Regulation of Alcohol-Seeking Behavior | NIH/NIAAA | $62,537 | Psychiatry and Behavioral Sciences | 7 R21 AA013276-04 (05011360) |
Randall, Carrie

**Principal Investigator**

**Mentoring and Career Development in Alcohol Research**
Sponsor: NIH/NIAAA  
Award: 5 K24 AA013314-04 (04061604)  
Budget Dates: 09/01/04 - 08/31/05  
Project Dates: 09/20/01 - 08/31/06  
Direct: $125,414  
F & A: $10,033

**Alcohol Research Center - Treatment and Implications**
Sponsor: NIH/NIAAA  
Award: 5 P50 AA010761-10 (04110554)  
Budget Dates: 01/01/05 - 12/31/05  
Project Dates: 12/10/04 - 12/31/05  
Direct: $1,266,442  
F & A: $533,558

**Paroxetine for Social Anxiety Disorder and Alcoholism**
Sponsor: NIH/NIAAA  
Award: 5 R01 AA013379-04 (04123019)  
Budget Dates: 03/01/05 - 02/28/06  
Project Dates: 03/01/02 - 02/28/06  
Direct: $257,809  
F & A: $110,858

**Co-PI or Project Leader**

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health - Administrative Core**
PI: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $130,675  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 P50 DA016511-03 (04043003-6)

**Naltrexone/Acamprosate Plus CBT/MET Light for Alcoholism (The COMBINE Study)**
PI: Raymond Anton, Jr.  
Sponsor: NIH/NIAAA  
Total: $18,285  
Dept: Psychiatry and Behavioral Sciences  
Award: 3 U10 AA011783-07S1 (02102213-2)

**Naltrexone Treatment of Adolescent Alcoholics**
PI: Deborah Deas  
Sponsor: NIH/NIAAA  
Total: $285,116  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 R01 AA013393-03 (04061503-1)

**Training in Comorbidity of Alcoholism and Mental Illness**
PI: Sarah Book  
Sponsor: NIH/NIAAA  
Total: $154,179  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 K23 AA014430-02 (04063004-1)

**Southeastern Node of the Clinical Trials Network**
PI: Kathleen Brady  
Sponsor: NIH/NIDA  
Total: $1,278,934  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 U01 DA013727-05 (04063027-1)

**Naltrexone/Acamprosate and CBT/MET Light for Alcoholism**
PI: Raymond Anton, Jr.  
Sponsor: NIH/NIAAA  
Total: $191,791  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 U10 AA011783-08 (04063018-1)

Randall, Jeff

**Principal Investigator**

**Multisystemic Therapy as a Residential Aftercare Model**
Sponsor: Univ. of Colorado  
Award: FY04.153.001 (02062803)  
Budget Dates: 09/30/04 - 09/29/05  
Project Dates: 02/01/04 - 09/29/05  
Direct: $8,338  
F & A: $3,836

Resnick, Heidi

**Co-Investigator**

**Youth Violence Exposure: A National Longitudinal Study**
PI: Dean Kilpatrick  
Sponsor: NIH/NICHD  
Total: $419,680  
Dept: Psychiatry and Behavioral Sciences  
Award: 1 R01 HD046830-01 (03062605-1)

**Florida Hurricanes and Older Adults: Outcome/Resiliency Factors**
PI: Ron Acierno  
Sponsor: NIH/NIMH  
Total: $184,524  
Dept: Psychiatry and Behavioral Sciences  
Award: 1 R21 MH074469-01 (04092819-1)

**Disaster Research Education and Mentoring Center (DREM)**
PI: Dean Kilpatrick  
Sponsor: NIH/NIMH  
Total: $250,000  
Dept: Psychiatry and Behavioral Sciences  
Award: 5 R25 MH070552-02 (04120773-1)

Rheingold, Alyssa

**Principal Investigator**

**Specialized Services for Homicide Survivors**
Sponsor: SC Dept. of Public Safety  
Award: 1V05115 (04111070)  
Budget Dates: 04/01/05 - 03/31/06  
Project Dates: 04/01/05 - 03/31/06  
Direct: $42,172  
F & A: $0

**Co-PI or Project Leader**

**Coordinating Services for Child Sexual Assault Victims**
PI: Michael De Arellano  
Sponsor: SC Dept. of Public Safety  
Total: $66,498  
Dept: Psychiatry and Behavioral Sciences  
Award: 1V05061 (04111582-1)
Robert, Sophie
Co-Investigator
A Multi-Center, Open Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL tm) and Risperidone (RISPERDAL tm) in the Long-Term Treatment of Patients with Schizophrenia and Schizoaffective Disorder
PI: Mark Hamner  Sponsor: Astrazeneca  Total: $ 35,600
Dept: Psychiatry and Behavioral Sciences  Award: PROTOCOL # 5077IL/0089 (04012914-2)

Roitzsch, John
Co-Investigator
Florida Hurricanes and Older Adults: Outcome/Resiliency Factors
PI: Ron Acierno  Sponsor: NIH/NIMH  Total: $ 184,524
Dept: Psychiatry and Behavioral Sciences  Award: 1 R21 MH074469-01 (04092819-1)

Rowland, Melisa
Co-PI or Project Leader
CRA for Substance Abusing Caregivers of Delinquent Youth
Sponsor: NIH/NIDA  Total: $ 125,000
Dept: Psychiatry and Behavioral Sciences  Award: 1 R21 DA017927-01 (03052908)

Ruggiero, Kenneth
Co-Investigator
Youth Violence Exposure: A National Longitudinal Study
PI: Dean Kilpatrick  Sponsor: NIH/NICHD  Total: $ 419,680
Dept: Psychiatry and Behavioral Sciences  Award: 1 R01 HD046830-01 (03062605-1)

Florida Hurricanes and Older Adults: Outcome/Resiliency Factors
PI: Rochelle Hanson  Sponsor: NIH/NIMH  Total: $ 139,500
Dept: Psychiatry and Behavioral Sciences  Award: 1 R34 MH071266-01A1 (04062917-1)

Saldana, Lisa
Co-PI or Project Leader
Understanding and Eliminating Health Disparities in Blacks in South Carolina - Pilot Project 5: Cost Analysis for Two Child Maltreatment Interventions
PI: Barbara Tilley  Sponsor: AHCPR/AHRQ  Total: $ 48,158
Dept: Biostatistics, Bioinformatics and Epidemi  Award: 5 P01 HS010871-05 (04052807-11)

Santos, Alberto
Principal Investigator
Schizophrenia Liability Genes Among African Americans
Sponsor: NIH/NIMH  Total: $ 451,529
Dept: Psychiatry and Behavioral Sciences  Award: 5 R01 MH066004-03 (04052810)

Co-PI or Project Leader
SC Cooperative for Healthy Aging in Minority Populations: Investigator Development Core
PI: Barbara Tilley  Sponsor: NIH/NIA  Total: $ 116,770
Dept: Biostatistics, Bioinformatics and Epidemi  Award: 5 P30 AG021677-03 (04022401-5)

Youth Violence Exposure - Core D: Investigator Development Core
PI: Barbara Tilley  Sponsor: AHCPR/AHRQ  Total: $ 56,944
Dept: Biostatistics, Bioinformatics and Epidemi  Award: 5 P01 HS010871-05 (04052807-2)

Saunders, Benjamin
Principal Investigator
Service System Models Intervention Development and Evaluation Center (SSM)
Sponsor: SAMHSA/CMHS  Total: $ 482,141
Dept: Psychiatry and Behavioral Sciences  Award: 5 UD1 SM56070-02 (04031506)

Co-Investigator
Youth Violence Exposure: A National Longitudinal Study
PI: Dean Kilpatrick  Sponsor: NIH/NICHD  Total: $ 419,680
Dept: Psychiatry and Behavioral Sciences  Award: 1 R01 HD046830-01 (03062605-1)

Schoenwald, Sonja
Principal Investigator
School as Context for Mental Health: Interdisciplinary Network
Sponsor: Univ. of Illinois, Chicago  Total: $ 18,374
Dept: Psychiatry and Behavioral Sciences  Award: 1 R21 MH067361-01 (02040907)
<table>
<thead>
<tr>
<th>Project Description</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct: $</th>
<th>Award:</th>
<th>Project Dates</th>
<th>F &amp; A:</th>
<th>Principal/Co-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebraska Center for K-3 Behavior and Reading Intervention Model</td>
<td>MST Group, LLC</td>
<td>06/01/02 - 07/31/05</td>
<td>9,163</td>
<td>02061905</td>
<td>06/01/02 - 07/31/05</td>
<td>2,382</td>
<td>Sheidow, Ashli</td>
</tr>
<tr>
<td>Testing EBP and Organization Effects in Rural Appalachia</td>
<td>Univ. of Tennessee</td>
<td>04/01/05 - 03/31/06</td>
<td>93,556</td>
<td>OR4175-001.01</td>
<td>07/01/03 - 06/30/08</td>
<td>43,036</td>
<td>Smith, Daniel</td>
</tr>
<tr>
<td>Linking Science and Practice to Improve Youth Mental Health Care: II Evidenced-based Practice in Clinics and Systems</td>
<td>Judge Baker Childrens Center</td>
<td>10/01/04 - 09/30/05</td>
<td>15,000</td>
<td>04032604</td>
<td>10/01/03 - 09/30/05</td>
<td>0</td>
<td>Sonne, Susan</td>
</tr>
<tr>
<td>Testing Context Effects on Treatment of Drug-Using Youth</td>
<td>NIH/NIDA</td>
<td>03/01/05 - 02/28/06</td>
<td>250,000</td>
<td>1 R01 DA018107-01A1 (04062306)</td>
<td>03/01/05 - 02/28/07</td>
<td>115,000</td>
<td>Swenson, Cynthia</td>
</tr>
<tr>
<td>Development of Outpatient MST for Dually Diagnosed Youth - Minority Supplement</td>
<td>NIH/NIDA</td>
<td>09/30/04 - 06/30/05</td>
<td>16,485</td>
<td>3 R21 DA017118-02S1 (04041901)</td>
<td>09/30/03 - 06/30/06</td>
<td>7,583</td>
<td>Thomas, Suzanne</td>
</tr>
<tr>
<td>Mentored Patient-Oriented Research Career Development</td>
<td>NIH/NIDA</td>
<td>07/01/04 - 06/30/05</td>
<td>110,960</td>
<td>5 K23 DA015658-02 (04042808)</td>
<td>09/30/03 - 06/30/08</td>
<td>8,877</td>
<td></td>
</tr>
<tr>
<td>Development of Outpatient MST for Dually Diagnosed Youth</td>
<td>NIH/NIDA</td>
<td>07/01/04 - 06/30/05</td>
<td>75,000</td>
<td>5 R21 DA017118-02 (04042809)</td>
<td>09/30/03 - 06/30/06</td>
<td>34,500</td>
<td></td>
</tr>
<tr>
<td>Sheidow, Ashli</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of Outpatient MST for Dually Diagnosed Youth - Minority Supplement</td>
<td>NIH/NIDA</td>
<td>09/30/04 - 06/30/05</td>
<td>16,485</td>
<td>3 R21 DA017118-02S1 (04041901)</td>
<td>09/30/03 - 06/30/06</td>
<td>7,583</td>
<td>Smith, Daniel</td>
</tr>
<tr>
<td>Mentored Patient-Oriented Research Career Development</td>
<td>NIH/NIDA</td>
<td>07/01/04 - 06/30/05</td>
<td>110,960</td>
<td>5 K23 DA015658-02 (04042808)</td>
<td>09/30/03 - 06/30/08</td>
<td>8,877</td>
<td>Sonne, Susan</td>
</tr>
<tr>
<td>Development of Outpatient MST for Dually Diagnosed Youth</td>
<td>NIH/NIDA</td>
<td>07/01/04 - 06/30/05</td>
<td>75,000</td>
<td>5 R21 DA017118-02 (04042809)</td>
<td>09/30/03 - 06/30/06</td>
<td>34,500</td>
<td>Swenson, Cynthia</td>
</tr>
<tr>
<td>Smith, Daniel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Youth Violence Exposure: A National Longitudinal Study</td>
<td>NIH/NICHD</td>
<td>09/30/04 - 06/30/05</td>
<td>419,680</td>
<td>1 R01 HD046830-01 (03062605-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treating Child Sexual Abuse: Effectiveness Pilot Study</td>
<td>NIH/NIMH</td>
<td>09/30/04 - 06/30/05</td>
<td>139,500</td>
<td>1 R34 MH071266-01A1 (04062917-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sonne, Susan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atomoxetine Treatment of Adults w/ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial</td>
<td>Parexel Intl. Corp.</td>
<td></td>
<td>194,330</td>
<td>B4Z-MC-LYBY (04080602-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swenson, Cynthia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MST Model with a Child Maltreatment</td>
<td>MST Group, LLC</td>
<td>02/01/04 - 06/30/05</td>
<td>70,187</td>
<td>04030311</td>
<td>02/01/04 - 06/30/05</td>
<td>17,546</td>
<td>Thomas, Suzanne</td>
</tr>
<tr>
<td>treating Child Sexual Abuse: Effectiveness Pilot Study</td>
<td>NIH/NIMH</td>
<td>02/01/04 - 06/30/05</td>
<td>139,500</td>
<td>1 R34 MH071266-01A1 (04062917-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas, Suzanne</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-PI or Project Leader</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol Research Center-Treatment and Implications-Shared Scientific Resource Core</td>
<td>Carrie Randall</td>
<td></td>
<td>358,018</td>
<td>5 P50 AA010761-10 (04110554-3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adotnation of Pharmacotherapy in Alcoholism Treatment</td>
<td>NIH/NIAAA</td>
<td></td>
<td>143,750</td>
<td>1 R21 AA015065-01 (03092606-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naltrexone Treatment of Adolescent Alcoholics</td>
<td>Deborah Deas</td>
<td></td>
<td>285,116</td>
<td>5 R01 AA013393-03 (04061503-1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Project Title</td>
<td>PI(s)</td>
<td>Sponsor</td>
<td>Total:</td>
<td>Dept</td>
<td>Award Number</td>
<td>Budget Dates</td>
<td>Direct:</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-----------------------</td>
<td>--------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>--------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Paroxetine for Social Anxiety Disorder and Alcoholism</td>
<td>Carrie Randall</td>
<td>NIH/NIAAA</td>
<td>$257,809</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 AA013379-04 (04123019-1)</td>
<td>07/01/04 - 06/30/05</td>
<td>225,000</td>
</tr>
<tr>
<td>Combined Pharmaco/Behavior Therapy in Adolescent Smokers</td>
<td>Himanshu Upadhyaya</td>
<td>NIH/NIDA</td>
<td>$225,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 R01 DA017460-02 (04042905)</td>
<td>08/01/04 - 07/31/06</td>
<td>60,996</td>
</tr>
<tr>
<td>Atomoxetine in Adolescents with Comorbid ADHD and Nicotine Dependence: A Pilot Study</td>
<td>Kevin Gray</td>
<td>Eli Lilly</td>
<td>$9,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>5 P50 DA016511-03 (04043003-4)</td>
<td>01/01/05 - 12/31/07</td>
<td>207,248</td>
</tr>
<tr>
<td>Repeated Ethanol Withdrawals: Disruption in Sleep Architecture</td>
<td>Lynn Veatch</td>
<td>VAMC</td>
<td>$125,000</td>
<td>Psychiatry and Behavioral Sciences</td>
<td>(04063025)</td>
<td>04/01/05 - 03/31/06</td>
<td>0</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>Joseph Jenrette</td>
<td>Amer. Coll. of Radiology</td>
<td>$154,964</td>
<td>Medicine</td>
<td>U10 CA21661 (05050587)</td>
<td>01/01/05 - 12/31/07</td>
<td>154,964</td>
</tr>
<tr>
<td>Radiation Oncology Group Protocols</td>
<td>Sebastiano Gattoni-Celli</td>
<td>Geo-Centers, Inc.</td>
<td>$50,000</td>
<td>Medicine</td>
<td>GC-3609-04-43766CM (04113022-9)</td>
<td>01/01/05 - 12/31/07</td>
<td>154,964</td>
</tr>
</tbody>
</table>
Marshall, David

Co-PI or Project Leader

Radiation Therapy Oncology Group Protocol: A Phase II Randomized Trial for Patients with Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and Bid Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed By Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy

PI: Joseph Jenrette
Sponsor: Amer. Coll. of Radiolog
Total: $ 18,391

Sharma, Anand

Principal Investigator

Phase III, Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer

Sponsor: Sanofi Synthelabo, Inc.
Budget Dates: 03/21/05 - 03/20/08
Direct: $ 166,300

Co-PI or Project Leader

Radiation Therapy Oncology Group Protocol: A Phase II, Randomized Trial of Surgery Followed by Chemoradiotherapy Plus C225 (Cetuximab) for Advanced Squamous Cell Carcinoma of the Head and Neck

PI: Joseph Jenrette
Sponsor: Amer. Coll. of Radiolog
Total: $ 32,290

Radiology

Ackerman, Susan

Principal Investigator

Multi-Center, Clinical Study to Determine the Effectiveness and Safety of HEDA in the Screening of Women for Breast Cancer

Sponsor: Z-Tech Corporation
Budget Dates: 07/01/03 - 06/30/05
Direct: $ 111,212

Bohning, Daryl

Co-Investigator

Remediation of Motor Control Degradation via Application of rTMS to the Motor Cortex

PI: Mark George
Sponsor: Coll. of Charleston
Total: $ 13,619

Conway, William

Principal Investigator

ACRIN Trials

Sponsor: Amer. Coll. of Radiology
Budget Dates: 01/01/04 - 12/31/10
Direct: $ 922,200

Costello, Philip

Principal Investigator

Volumetric Computed Tomography (VCT) Scanning

Sponsor: General Electric
Budget Dates: 09/01/04 - 08/31/09
Direct: $ 298,301

Gordon, Leonie

Principal Investigator

An Open-Label, Multi-Center, Phase 3 Study Evaluating the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects with Heart Failure Who Will Experience an Adverse Cardiac Event

Sponsor: Medi-Physics
Budget Dates: 05/18/05 - 12/31/08
Direct: $ 86,020

A Pilot Study Examining the Value of Combined Exercise and Adenosine Stress Myocardial Perfusion Imaging as Compared with Adenosine Testing Alone for the Evaluation of Women at Intermediate or High Likelihood for Coronary Artery Disease

Sponsor: Cardiovascular Clinical Studies
Budget Dates: 05/18/05 - 05/17/07
Direct: $ 8,200
### Hubbard, Josh
**Principal Investigator**

**The Effect of Transjugular Intrahepatic Porto-Systemic Shunts on Serum Serotonin Levels, and the Role of Serotonin as a Marker of Post-Procedure Complications**

- **Sponsor:** Radiological Soc. of No. America
- **Budget Dates:** 10/01/04 - 09/30/05
- **Direct:** $3,000

**Dept:** Pediatrics

**PI:** Kenneth Spicer

**Award:** MSD0411 (04102911)

### Mah, Eugene
**Co-PI or Project Leader**

**Effect of Collimator Type on I-131 Half-life Measurements**

- **Sponsor:** GlaxoSmithKline
- **Dept:** Radiology
- **Award:** BXR10477 (05012010-1)

**Total:** $10,808

### Mulvihill, Denise
**Co-Investigator**

**Randomized Clinical Trials for Pediatric Heart Disease**

- **Sponsor:** NIH/NHLBI
- **Dept:** Pediatrics
- **Award:** 5 U01 HL068281-04 (04071605-1)

**Total:** $407,290

### Ravenel, James
**Co-PI or Project Leader**

**ACRIN Trials**

- **Sponsor:** Amer. Coll. of Radiolog
- **Dept:** Radiology
- **Award:** CA80098 (02091903-4)

**Total:** $922,200

**Computer-Aided Cancer Management**

- **Sponsor:** DOD
- **Dept:** Medicine
- **Award:** W81XWH-05-1-0378 (04070160-1)

**Total:** $389,884

**Co-Investigator**

**Computer-Aided Cancer Management**

- **Sponsor:** DOD
- **Dept:** Medicine
- **Award:** W81XWH-05-1-0378 (04070160-1)

**Total:** $108,287

**Volumetric Computed Tomography (VCT) Scanning**

- **Sponsor:** General Electric
- **Dept:** Radiology
- **Award:** DAMD17-02-2-004 (04092807-1)

**Total:** $298,301

**Siemans Research Rotation**

- **Sponsor:** Siemans Medical Solutions USA
- **Dept:** Radiology
- **Award:** (05062719-1)

**Total:** $23,148

### Roberts, Donna
**Principal Investigator**

**Human Cerebral Cortex Plasticity in Response to Long-term Bedrest as an Analog to Microgravity**

- **Sponsor:** NASA
- **Dept:** Pediatrics
- **Award:** NNJ04HF70G (03081103)

**Total:** $287,215

### Schoepf, Uwe
**Principal Investigator**

**Multi-Detector Row CT Imaging of the Coronary Arteries**

- **Sponsor:** Siemans Medical Solutions USA
- **Dept:** Radiology
- **Award:** (04111996)

**Total:** $181,818

**Multi-Detector-Row CT Imaging of the Coronary Arteries**

- **Sponsor:** Medrad, Inc.
- **Dept:** Radiology
- **Award:** (04120878)

**Total:** $18,182

**Multi-Detector-Row CT Imaging of the Coronary Arteries**

- **Sponsor:** Bracco Diagnostics, Inc.
- **Dept:** Radiology
- **Award:** (04120879)

**Total:** $101,600

**Contrast Enhanced Multi-Detector-Row Computed Tomography (CT) of the Heart for Differentiating Cardiac and Non-Cardiac Sources of Acute Chest Pain in the Emergency Department**

- **Sponsor:** General Electric
- **Dept:** Radiology
- **Award:** 05-VIS-002 (05052337)

**Total:** $29,414
Schoepf, Uwe

Co-PI or Project Leader

Volumetric Computed Tomography (VCT) Scanning

Sponsor: General Electric  Total: $ 298,301

PI: Philip Costello  Award: DAMD17-02-2-004 (04092807-1)

Dept: Radiology

Siemens Research Rotation

Sponsor: Siemens Medical Solutions  Total: $ 23,148

PI: Leonie Gordon  Award: (08062719-1)

Dept: Radiology

Schoenholz, Claudio

Principal Investigator

Evaluation of the CardioMEMS EndoSensor System APEX Study (Acute Pressure Measurement to Confirm Aneurysm Sac Exclusion)

Sponsor: CardioMEMS, Inc.  Budget Dates: 02/01/05 - 03/01/10  Direct: $ 20,116

Award: CM-04-01 (05011369)

PI: Josh Hubbard

Dept: Radiology

Award: MSD0411 (04102911-1)

Co-Pl or Project Leader

The Effect of Transjugular Intrahepatic Portosystemic Shunts on Serum Serotonin Levels, and the Role of Serotonin as a Marker of Post-Procedure Complications

Sponsor: Radiological Soc. of No  Total: $ 3,000

PI: Josh Hubbard

Dept: Radiology

Award: MSD0411 (04102911-1)

Spicer, Kenneth

Principal Investigator

Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin’s Lymphoma

Sponsor: GlaxoSmithKline  Budget Dates: 07/31/04 - 07/31/15  Direct: $ 4,480

Award: AR#2202 (04092803)

PI: Claudio Schoenholz

Dept: Radiology

Award: CM-04-01 (05011369-1)

Uflacker, Renan

Principal Investigator

Effects of the Injection of DEAC-Glucosamine in High Flow Vessels

Sponsor: Marine Polymer Technologies  Budget Dates: 03/01/04 - 12/31/05  Direct: $ 530

Award: AR#2202 (04092803)

PI: Claudio Schoenholz

Dept: Radiology

Award: CM-04-01 (05011369-1)

Definity (Perflutren Lipid Microspheres) Enhanced Sonothrombolysis of Thrombosed Dialysis Grafts and Fistulae (Sonolysis)

Sponsor: ImRx Therapeutics  Budget Dates: 08/10/04 - 12/31/05  Direct: $ 530

Award: AR#2202 (04092803)

PI: Claudio Schoenholz

Dept: Radiology

Award: CM-04-01 (05011369-1)

Investigation of the Talent LPS

Sponsor: World Medical Manufacturing Corp.  Budget Dates: 03/01/99 - 02/28/05  Direct: $ 7,683

Award: AR#2202 (04092803)

Uflacker, Renan

Co-Investigator

Evaluation of the CardioMEMS EndoSensor System APEX Study (Acute Pressure Measurement to Confirm Aneurysm Sac Exclusion)

Sponsor: CardioMEMS, Inc.  Total: $ 20,116

PI: Claudio Schoenholz

Dept: Radiology

Award: CM-04-01 (05011369-1)

Surgery

Baliga, Prabhakar

Principal Investigator

An Open-Label, Concentration-Controlled, Randomized, 12-Month Study of Prograf Plus Rapamune Plus Corticosteroids Compared to Cyclosporine Capsules USP (Modified) Plus Rapamune Plus Corticosteroids in High Risk Renal Allograft Recipients

Sponsor: Wyeth, Inc.  Budget Dates: 08/30/02 - 06/15/06  Direct: $ 75,800

Award: 0468H1-101164 (02083006)

PI: Claudio Schoenholz

Dept: Radiology

Award: CM-04-01 (05011369-1)

A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment To Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy

Sponsor: Wyeth-Ayerst  Budget Dates: 11/02/02 - 08/31/06  Direct: $ 33,200
A Program to Increase Living Donations in African Americans

Sponsor: NIH/NIDDK
Award: 5 R01 DK062596-03 (04043004)
Budget Dates: 09/01/05 - 06/30/06
F & A: $69,000

A Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Early Calcineurin Inhibitor Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil; MMF (Cellcept) and Sirolimus (Rapamune)

Sponsor: Roche Laboratories
Award: ML17140 (04070701)
Budget Dates: 04/15/04 - 02/28/07
F & A: $48,365

A Three-Month, Open-Label, Two Cohort Study to Investigate the Safety and Tolerability of Myfortic in Combination with Neoral or Tacrolimus in Renal Transplant Recipients with GI Intolerance (MyTIME)

Sponsor: Wyeth, Inc.
Award: 0468H1-318-WW (05031180)
Budget Dates: 03/01/05 - 02/28/09
F & A: $58,059

A Randomized, Open-Label, Comparative Evaluation of the Safety and Efficacy of Sirolimus Versus Cyclosporine When Combined in a Regimen Containing Basiliximab. Mycophenolate Mofetil, and Corticosteroids in Primary De Novo Renal Allograft Recipients

Sponsor: Sangstat Medical Corp.
Award: TAILOR REGISTRY (04090803)
Budget Dates: 10/01/04 - 09/30/05
F & A: $12,500

The Hepatic Research Registry

Sponsor: CellzDirect, Inc.
Award: (04092001)
Budget Dates: 10/01/04 - 09/30/05
F & A: $50,000

Primal Testing of the GeneXpert System

Sponsor: Cepheid
Award: (05030224)
Budget Dates: 02/28/05 - 06/30/06
F & A: $0

A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node Positive Breast Cancer Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DDAC->P); DD AC Follow

Sponsor: NSABP
Award: TFED34-#381 (05042855)
Budget Dates: 02/01/05 - 01/31/08
F & A: $986
Investigator Salary Support for NSABP Member Industrial Master Purchased Services Treatment Protocols
Sponsor: NSABP
Award: (05050275)
Budget Dates: 05/01/05 - 04/30/08  Direct: $ 2,696
Project Dates: 05/01/05 - 04/30/08  F & A: 270

Cole, David
Co-PI or Project Leader
DOD Phase VI: Project 2- Novel Pancreatic Cancer Chemo/Gene Therapy Utilizing the Casm Oncogene
PI: Carolyn Reed  Sponsor: Geo-Centers, Inc.  Total: $ 51,370
Dept: Dean's Office - COM  Award: GC-3932-03-42153CM (03080703-27)

Investigator
Molecular Detection of Breast Cancer in Peripheral Blood
PI: William Gillanders  Sponsor: NIH/NCI  Total: $ 124,950
Dept: Surgery  Award: 5 K23 CA093419-03 (04050706-1)

Co-Investigator
Molecular Detection of Breast Cancer in Peripheral Blood
PI: William Gillanders  Sponsor: NIH/NCI  Total: $ 124,950
Dept: Surgery  Award: 5 K23 CA093419-03 (04050706-1)

Gillanders, William
Principal Investigator
Molecular Detection of Breast Cancer in Peripheral Blood
Sponsor: NIH/NCI  Award: 5 K23 CA093419-03 (04050706)
Budget Dates: 07/01/04 - 01/31/05  Direct: $ 124,950
Project Dates: 09/16/02 - 01/31/05  F & A: 9,996

Co-Investigator
Altering Post-Vaccination T Cell Contraction
PI: David Cole  Sponsor: NIH/NCI  Total: $ 180,000
Dept: Surgery  Award: 2 R01 CA083672-04A1 (03102901-1)

Ikonomidis, John
Principal Investigator
Extracellular Mechanisms for Thoracic Aortic Aneurysms
Sponsor: NIH/NHLBI  Award: 5 R01 HL075488-02 (04092817)
Budget Dates: 12/01/04 - 11/30/05  Direct: $ 250,000
Project Dates: 12/01/03 - 11/30/08  F & A: 103,500

A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Nesiritide Initiated Post-Induction of Anesthesia in the Management of Coronary Artery Bypass Graft (CABG) Patients Requiring Cardiopulmonary Bypass (CPB)
Sponsor: Scios, Inc.  Award: A014 (05041511)
Budget Dates: 03/11/05 - 06/30/06  Direct: $ 42,056
Project Dates: 03/11/05 - 06/30/06  F & A: 10,514

Lin, Angello
Principal Investigator
A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Induction Agents Alemtuzumab (Campath 1H), Basiliximab (Simulject) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin) in Combination with Tacrolimus (Prograf), Mycophenolate Mofetil (Cellcept) and a Rapid Steroid Withdrawal in Renal Transplant Recipients
Sponsor: Astellas Pharma US, Inc.  Award: 20-04-003 (05042230)
Budget Dates: 04/22/05 - 12/31/09  Direct: $ 434,640
Project Dates: 04/22/05 - 12/31/09  F & A: 108,660
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct Cost</th>
<th>F &amp; A Cost</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lindsey, Merry</td>
<td><strong>The Role of Macrophage-Derived MMP's in LV Remodeling</strong></td>
<td>NIH/NHLBI</td>
<td>07/01/04 - 06/30/05</td>
<td>$250,000</td>
<td></td>
<td>$101,200</td>
</tr>
<tr>
<td>Mikhitarian, Kaidi</td>
<td><strong>DOD Phase VI: Project 17</strong></td>
<td>Sponsor: Geo-Centers, Inc.</td>
<td>07/01/04 - 06/30/08</td>
<td>$10,400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitas, Michael</td>
<td><strong>Detection of Occult Mediastinal Lymph Node Metatases</strong></td>
<td>Mayo Clinic</td>
<td>05/11/04 - 11/30/04</td>
<td>$11,020</td>
<td></td>
<td>$5,069</td>
</tr>
<tr>
<td></td>
<td><strong>Detection of Occult Mediastinal Lymph Node Metatases</strong></td>
<td>Sponsor: Geo-Centers, Inc.</td>
<td>09/01/02 - 11/30/07</td>
<td>$143,974</td>
<td></td>
<td>$66,228</td>
</tr>
<tr>
<td></td>
<td><strong>Mechanisms of H. Pylori-Induced Hypochlorhydria</strong></td>
<td>NIH/NIDDK</td>
<td>02/04/05 - 11/30/05</td>
<td>$184,343</td>
<td></td>
<td>$43,750</td>
</tr>
<tr>
<td></td>
<td><strong>Plasma MMP/TIMP assays: MATCH</strong></td>
<td>Medtronic, Inc.</td>
<td>09/01/01 - 06/30/06</td>
<td>$1,000,000</td>
<td>$50,000</td>
<td>$1,050,000</td>
</tr>
<tr>
<td>Norcross, E.</td>
<td><strong>A Comprehensive Approach to Organ Donation by Incorporation of Family Support Counselors as Member of the Hospital Critical Care Team</strong></td>
<td>Life Point</td>
<td>09/01/04 - 06/30/06</td>
<td>$175,000</td>
<td>$75,250</td>
<td>$250,000</td>
</tr>
<tr>
<td>Norcross, E.</td>
<td><strong>Mechanisms of Myocardial Radiofrequency Scar Expansion</strong></td>
<td>NIH/NHLBI</td>
<td>07/01/04 - 06/30/06</td>
<td>$18,540</td>
<td>$4,635</td>
<td>$23,175</td>
</tr>
<tr>
<td></td>
<td><strong>A Comprehensive Approach to Organ Donation by Incorporation of Family Support Counselors as Member of the Hospital Critical Care Team</strong></td>
<td>Sponsor: Medtronic, Inc.</td>
<td>03/15/05 - 03/14/06</td>
<td>$4,480</td>
<td>$17,920</td>
<td>$22,400</td>
</tr>
<tr>
<td></td>
<td><strong>A One-Year, Multi-Center, Partially-Blinded, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined with Reduced-Dose or Full-Dose Neoral and Corticosteroids Versus Mycophenolate Mofetil (MMF, CellCept) Combined with Full Dose Neoral and Corticosteroids in De Novo Adult Renal Transplant Recipients</strong></td>
<td>Sponsor: Novartis Corp.</td>
<td>07/16/01 - 04/30/06</td>
<td>$18,540</td>
<td>$4,635</td>
<td>$23,175</td>
</tr>
<tr>
<td></td>
<td><strong>A One-Year, Multi-Center, Partially-Blinded, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined with Reduced-Dose or Full-Dose Neoral and Corticosteroids Versus Mycophenolate Mofetil (MMF, CellCept) Combined with Full Dose Neoral and Corticosteroids in De Novo Adult Renal Transplant Recipients</strong></td>
<td>Sponsor: Novartis Corp.</td>
<td>07/16/01 - 04/30/06</td>
<td>$76,747</td>
<td>$19,187</td>
<td>$95,934</td>
</tr>
<tr>
<td>Project Title</td>
<td>Principal Investigator</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct: $</td>
<td>F &amp; A: $</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>------------------------</td>
<td>-------------------------------------</td>
<td>-------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation</td>
<td>Reed, Carolyn</td>
<td>Novartis Corp.</td>
<td>02/17/04 - 10/15/05</td>
<td>12,610</td>
<td>3,152</td>
<td></td>
</tr>
<tr>
<td>Oncology Center: Informatics Support of HCC Clinical/Translational Research Development</td>
<td>Rogers, Jeffrey</td>
<td>DOE</td>
<td>07/01/04 - 06/30/05</td>
<td>103,896</td>
<td>47,791</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VI: Project 19</td>
<td>Salem, Mahamed</td>
<td>Geo-Centers, Inc.</td>
<td>09/01/04 - 08/28/05</td>
<td>25,642</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Computer-Aided Cancer Management</td>
<td>Salem, Mohamed</td>
<td>NIH/NCI</td>
<td>09/01/04 - 07/07/05</td>
<td>242,860</td>
<td>60,715</td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: PreClinical Assessment of the Novel Peptide-Based Cancer Vaccine F2 gel/CEA/IL-12</td>
<td>Spinale, Francis</td>
<td>NIH/NHLBI</td>
<td>02/01/05 - 01/31/06</td>
<td>225,000</td>
<td>96,750</td>
<td></td>
</tr>
<tr>
<td>Imaging of MMP Activation and Myocardial Fiber Strains</td>
<td>Urology</td>
<td>Yale Univ.</td>
<td>09/01/04 - 08/31/05</td>
<td>45,000</td>
<td>20,700</td>
<td></td>
</tr>
<tr>
<td>Protection of Myocyte Function after Cardioplegia</td>
<td></td>
<td>NIH/NHLBI</td>
<td>12/01/04 - 11/30/05</td>
<td>225,000</td>
<td>96,750</td>
<td></td>
</tr>
<tr>
<td>Endothelin Receptors and the Progression to Heart Failure</td>
<td></td>
<td>NIH/NHLBI</td>
<td>12/01/04 - 11/30/05</td>
<td>150,000</td>
<td>69,000</td>
<td></td>
</tr>
<tr>
<td>Load-Induced Cardiac Hypertrophy in the Adult Mammal: Project 2 - Mechanisms of Heterogeneous Remodeling in Myocardial Infarction</td>
<td></td>
<td>NIH/NHLBI</td>
<td>02/01/04 - 01/31/06</td>
<td>167,171</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOD Phase VII: A Clinical Assessment of Novel Urinary Markers for Diagnosis and Monitoring of Bladder Cancer Patients</td>
<td>Keane, Thomas</td>
<td>Geo-Centers, Inc.</td>
<td>09/01/04 - 07/07/05</td>
<td>85,765</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Keane, Thomas

Co-Investigator

DOD Phase VII: Molecular Profiling for Identification of Diagnostic and Prognostic Markers of Bladder Cancer
PI: Andrew Kraft
Dept: Medicine
Sponsor: Geo-Centers, Inc.
Award: GC-3609-04-43766CM (04113022-4)
Total: $ 80,000

DOD Phase VII: Ceramide Metabolizing Enzymes, Cancer Lipidomics and Gene Expression as a Function of Gleason Grade in Prostate Cancer
PI: Andrew Kraft
Dept: Medicine
Sponsor: Geo-Centers, Inc.
Award: GC-3609-04-43766CM (04113022-7)
Total: $ 85,765

Rames, Ross

Principal Investigator

Prospective, Open Label, Non-Comparative, Multi-Center Study to Evaluate the Efficacy and Safety of Ciprofloxacin Extended-Release (Cipro XR) 1000 mg Tablets Given Once Daily for 7 to 14 Days in the Treatment of Patients 18 Years or Older with Complicated Urinary Tract Infections Caused by Pseudomonas Aeruginosa and Other Common Uropathogens
Sponsor: Bayer Pharmaceuticals
Budget Dates: 11/01/04 - 03/14/06
Direct: $ 19,626
Award: 11490 (04110555)
Project Dates: 11/01/04 - 03/14/06
F & A: 4,906

Rovner, Eric

Principal Investigator

A Randomized, Evaluator-Blinded, Multi-Center Study Comparing the Efficacy and Safety of Zuidex with Contigen in Female Patients with Stress Urinary Incontinence
Sponsor: Q-Med AB
Budget Dates: 10/04/04 - 10/05/06
Direct: $ 82,039
Award: 33DS0201 (04072304)
Project Dates: 10/04/04 - 10/05/06
F & A: 20,510

A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, And Tolterodine ER Plus Tamsulosin) Study to Evaluate the Clinical Efficacy and Safety of Tolterodine ER 4 mg in Men Who Have Frequency and Urgency, With or Without Urinary Urge Incontinence, With or Without Bladder Outlet Obstruction
Sponsor: PPD Development
Budget Dates: 10/08/04 - 10/07/05
Direct: $ 23,500
Award: A6121120 (04091602)
Project Dates: 10/08/04 - 10/07/05
F & A: 5,875
**Nursing**

**Amella, Elaine**

Co-Investigator

**Advanced Education Nursing Grants: Adult Nurse Practitioner in Primary and Palliative Care**

PI: Barbara Edlund  
Dept: Nursing  
Sponsor: HRSA/BHP/Nursing  
Total: $201,830

Award: 1 D09 HP03381-01-00 (03112101-1)

**Barbosa, Gail**

Principal Investigator

**Domestic Violence Special Grant Program: An Education, Screening and Referral Program for Abuse among Pregnant Women**

Sponsor: Duke Endowment  
Award: 5387-SP (02041703)  
Budget Dates: 01/01/05 - 12/31/05  
Direct: $87,601  
F & A: 0

**Web-Based Learning, A Response to the Shortage of Baccalaureate and Advanced Practice Nurses in South Carolina**

Sponsor: Duke Endowment  
Award: 5334-SP (03071004)  
Budget Dates: 07/01/04 - 06/01/06  
Direct: $150,000  
F & A: 0

**Benedict, Susan**

Principal Investigator

**Innovative Alternatives for Women**

Sponsor: Bureau of Justice Assistance  
Award: 2001-DD-BX-0045 (04043005)  
Budget Dates: 05/01/01 - 08/31/05  
Direct: $82,244  
F & A: 16,704

**Edlund, Barbara**

Principal Investigator

**Advanced Education Nursing Grants: Adult Nurse Practitioner in Primary and Palliative Care**

Sponsor: HRSA/BHP/Nursing  
Award: 1 D09 HP03381-01-00 (03112101)  
Budget Dates: 07/01/04 - 07/01/05  
Direct: $201,830  
F & A: 16,147

**Francis-Baldesari, Catherine**

Principal Investigator

**Madre Y Nino (Mother and Child)**

Sponsor: The Community Fdn.  
Award: (04083001)  
Budget Dates: 11/18/04 - 11/17/05  
Direct: $3,263  
F & A: 0

**Grossman, Janet**

Co-PI or Project Leader

**Basic Nurse Education and Practice Program**

PI: Marilyn Laken  
Dept: Nursing  
Sponsor: HRSA/BHP/Nursing  
Total: $310,917

Award: 5 D11 HP00285-04-00 (04043017-1)

**Hulsey, Tara**

Co-Investigator

**Basic Nurse Education and Practice Program**

PI: Marilyn Laken  
Dept: Nursing  
Sponsor: HRSA/BHP/Nursing  
Total: $310,917

Award: 5 D11 HP00285-04-00 (04043017-1)

**Jenkins, Carolyn**

Principal Investigator

**Racial and Ethnic Approaches to Community Health 2010: Charleston and Georgetown Diabetes Coalition**

Sponsor: CDC  
Award: U50/CCU422184-03 (04043002)  
Budget Dates: 09/30/04 - 09/29/05  
Direct: $801,034  
F & A: 192,034

**Laken, Marilyn**

Principal Investigator

**Basic Nurse Education and Practice Program - Cost Share MUHA**

Sponsor: MUSC Hospital Authority  
Award: (01113009)  
Budget Dates: 07/01/04 - 06/30/06  
Direct: $100,000  
F & A: 0
Health-e-AME Faith Based Physical Activity Initiative
Sponsor: CDC
Budget Dates: 09/30/04 - 04/29/06
Direct: $374,695
Award: RO6/CCR421476-03 (04043016)
Project Dates: 09/30/02 - 04/29/06
F & A: $42,733

Basic Nurse Education and Practice Program
Sponsor: HRSA/BHP/Nursing
Budget Dates: 07/01/04 - 06/30/05
Direct: $310,917
Award: 5 D11 HP00285-04-00 (04043017)
Project Dates: 07/01/01 - 06/30/06
F & A: $24,873

Laken, Marilyn
Co-Investigator
Stroke Belt Elimination Initiative
Community Initiatives to Eliminate Stroke
PI: Brent Egan
Sponsor: DHHS/PHS
Total: $421,972
Dept: Medicine
Award: US2MP04001-01-0 (04062918-1)

Michel, Yvonne
Principal Investigator
Mathematics Science Partnership
Sponsor: SC Dept. of Education
Budget Dates: 12/01/04 - 06/30/05
Direct: $10,501
Award: 04 MS 306 (03090903)
Project Dates: 12/01/04 - 06/30/05
F & A: $840

Nickerson, Brenda
Co-PI or Project Leader
DOD Phase VI: Mobile Health Unit
Pl: Carolyn Reed
Sponsor: Geo-Centers, Inc.
Total: $204,791
Dept: Dean's Office - COM
Award: GC-3532-03-42153CM (03080703-38)

Olson, Melodie
Co-Investigator
Advanced Education Nursing Grants: Adult Nurse Practitioner in Primary and Palliative Care
Pl: Barbara Edlund
Sponsor: HRSA/BHP/Nursing
Total: $201,830
Dept: Nursing
Award: 1 D09 HP03381-01-00 (03112101-1)

Owens, Virginia
Co-Investigator
Adolescent and Family Life Demonstration Project
Pl: Janice Key
Sponsor: DHHS
Total: $179,625
Dept: Pediatrics
Award: 5 APHPA002040-04-00 (04041507-1)

Porcher, Frances
Principal Investigator
SC AHEC Award for Community Based Education
Sponsor: SC AHEC
Budget Dates: 09/30/04 - 09/29/05
Direct: $10,000
Award: (04121502)
Project Dates: 09/30/04 - 09/29/05
F & A: 0

Williamson, Deborah
Principal Investigator
Caring for the Future: A Collaborative Practice of Maternal and Infant Care in Rural Populations
Sponsor: Duke Endowment
Budget Dates: 07/01/04 - 12/31/05
Direct: $20,535
Award: 5281-SP (02082603)
Project Dates: 07/01/02 - 12/31/05
F & A: 0

Hispanic Health Initiative
Sponsor: Duke Endowment
Budget Dates: 01/05/05 - 01/04/06
Direct: $171,477
Award: 5395-SP (04061102)
Project Dates: 01/05/05 - 01/04/07
F & A: 0
**Pharmaceutical Sciences**

**Arrington, David**
Principal Investigator

*Identification of a Novel Mitochondrial Calpain*

**Sponsor:** NIH/NIEHS

**Award:** 5 F30 ES013083-02 (05012636)

**Budget Dates:** 04/01/05 - 03/31/06

**Direct:** $32,219

**Project Dates:** 04/01/04 - 03/31/07

**F & A:** 0

**Beeson, Craig**
Principal Investigator

*Beta Oxidation in Myotubes*

**Sponsor:** Seahorse Biosciences, Inc.

**Award:** (05031591)

**Budget Dates:** 03/14/05 - 11/30/05

**Direct:** $46,599

**Project Dates:** 03/14/05 - 11/30/05

**F & A:** 21,435

**Bosso, John**
Co-Investigator

*Cefepime-Ceftriaxone Switch Study in Adult Medicine Patients with CrCl <60 ml/min*

**PI:** Marlea Givens

**Dept:** Pharmacy and Clinical Services

**Sponsor:** Elan Pharmaceuticals

**Total:** $32,208

**Award:** (04091401-1)

**Dix, Thomas**
Principal Investigator

*Sponsored Research*

**Sponsor:** Argolyn Bioscience, Inc.

**Award:** (03092308)

**Budget Dates:** 10/01/04 - 09/30/05

**Direct:** $21,740

**Project Dates:** 10/01/04 - 03/30/05

**F & A:** 3,260

**Hallman, Mark**
Principal Investigator

*EGF Receptor as a Therapeutic Target in Renal Failure*

**Sponsor:** NIH/NIEHS

**Award:** 1 F30 ES013619-01 (04041202)

**Budget Dates:** 10/01/04 - 09/30/05

**Direct:** $33,234

**Project Dates:** 10/01/04 - 09/30/07

**F & A:** 0

**Markowitz, John**
Principal Investigator

*P-Glycoprotein and Disposition of Psychostimulants*

**Sponsor:** NIH/NICHD

**Award:** 1 R21 HD047810-01 (03093007)

**Budget Dates:** 07/01/04 - 06/30/05

**Direct:** $150,000

**Project Dates:** 07/01/04 - 06/30/06

**F & A:** 69,000

**Pharmacokinetics and Drug Interactions with Milk Thistle**

**Sponsor:** NIH/NCCAM

**Award:** 1 R21 AT002817-01 (04052710)

**Budget Dates:** 04/01/05 - 03/31/06

**Direct:** $175,000

**Project Dates:** 04/01/05 - 03/31/08

**F & A:** 80,500

**Co-Investigator**

*Drug Interactions and Bioavailability of Cranberry*

**PI:** Jennifer Donovan

**Dept:** Psychiatry and Behavioral Sciences

**Sponsor:** NIH/NCCAM

**Total:** $125,000

**Award:** 5 R21 AT002073-02 (04112207-1)
Patrick, Kennerly

**Co-Investigator**

Nitric Oxide in Systemic Lupus Erythematosus

PI: Gary Gilkeson  
Sponsor: NIH/NIAMS  
Total: $235,000

Dept: Medicine  
Award: 5 R01 AR045476-06 (05011146-1)

Schnellmann, Rick

**Principal Investigator**

Mitochondrial Calpain Mediated Renal Cell Death

Sponsor: NIH/NIHES  
Budget Dates: 09/30/04 - 07/31/05  
Direct: $190,000

Award: 1 R01 ES012239-01A1 (03022812)  
Project Dates: 09/30/04 - 07/31/08  
F & A: 87,400

Calpain Inhibition by AM-102 in Diverse in vitro Models

Sponsor: Auris Medical AG  
Budget Dates: 06/01/05 - 08/31/05  
Direct: $9,007

Award: (05050481)  
Project Dates: 06/01/05 - 08/31/05  
F & A: 2,252

Sweet, Douglas

**Principal Investigator**

Organic Anion Transporters 2 and 3 in Renal and CNS Toxicity

Sponsor: NIH/NIDDK  
Budget Dates: 01/05/05 - 11/30/05  
Direct: $211,500

Award: 1 R01 DK067216-01A1 (04030804)  
Project Dates: 01/05/05 - 11/30/08  
F & A: 97,290

VanWert, Adam

**Principal Investigator**

Murine Primary Renal Proximal Tubule Cells as a Model System to Study the Mechanism of Trichloroethylene Toxicity

Sponsor: Amer. Fdn. for Pharmaceutical Educ.  
Budget Dates: 09/01/05 - 08/31/06  
Direct: $6,000

Award: (04122114)  
Project Dates: 09/01/05 - 08/31/06  
F & A: 0

White, Roger

**Principal Investigator**

Use of Etest Values and the Geometric Mean to Assess the "MIC Creep" Effect with Fluoroquinolones Against S. pneumoniae

Sponsor: Bristol Myers Squibb  
Budget Dates: 02/20/04 - 09/30/05  
Direct: $15,000

Award: (04122115)  
Project Dates: 02/20/04 - 09/30/05  
F & A: 3,750

Assessment of Population Pharmacodynamic Profiles of Fluoroquinolones Against Common Nosocomial Pathogens Using Monte Carlo Analysis

Sponsor: Bristol Myers Squibb  
Budget Dates: 02/20/04 - 12/31/05  
Direct: $40,000

Award: (04122115)  
Project Dates: 02/20/04 - 12/31/05  
F & A: 10,000

Yu, Shan

**Co-Investigator**

Neuroprotective Effect of Merck Compounds In Ischemic Stroke Rats

PI: Ling Wei  
Sponsor: Merck  
Total: $583,333

Dept: Pathology and Laboratory Medicine  
Award: (04010502-2)

Wright, Gary

**Principal Investigator**

Prolyl Hydroxylase Oxygen-Sensing in Heart

Sponsor: NIH/NIHES  
Budget Dates: 03/09/05 - 02/28/06  
Direct: $100,000

Award: 5 K22 ES012261-02 (04123022)  
Project Dates: 05/07/04 - 02/28/07  
F & A: 8,000

**Co-Investigator**

Angiogenesis, Functional Recovery and TNF-Alpha After Stroke

PI: Ling Wei  
Sponsor: NIH/NINDS  
Total: $185,000

Dept: Pathology and Laboratory Medicine  
Award: 1 R01 NS045810-01A1 (03110306-1)
Function Restoration by ES Cell Implant after Ischemia
PI: Ling Wei  Sponsor: NIH/NINDS  Total: $ 213,750
Dept: Pathology and Laboratory Medicine  Award: 5 R01 NS045155-03 (05032329-1)

Angiogenesis, Functional Recovery and TNF-a after Stroke
PI: Ling Wei  Sponsor: NIH/NINDS  Total: $ 185,000
Dept: Pathology and Laboratory Medicine  Award: 5 R01 NS045810-02 (05032330-1)

Pharmacy and Clinical Services
Chumney, Elinor
Co-Investigator
Cost Effectiveness Modeling for Fixed Dose Combination Products (FDCs)
PI: Kit Simpson  Sponsor: GlaxoSmithKline  Total: $ 55,400
Dept: Health Administration and Policy  Award: GHO104011 (04120130-1)

Givens, Marlea
Principal Investigator
Cefepime-Ceftriaxone Switch Study in Adult Medicine Patients with CrCl <60 ml/min
Sponsor: Elan Pharmaceuticals  Budget Dates: 01/07/05 - 10/31/05  Direct: $ 32,208
Award: (04091401)  Project Dates: 01/07/05 - 10/31/05  F & A: 8,052

Lapointe, Marc
Co-PI or Project Leader
ICU Surveillance Study: Incidence of Multiresistant Gram Negative Bacilli in ICU-2003
PI: Lisa Steed  Sponsor: Merck  Total: $ 5,000
Dept: Pathology and Laboratory Medicine  Award: (03060505-2)

A Phase II, Randomized, Pharmacokinetic, Dose Finding and Dose Frequency Determination Using rt-PA in Intraventricular Hemorrhage
PI: Byron Bailey  Sponsor: Johns Hopkins Univ.  Total: $ 28,128
Dept: Neurosciences  Award: A2652/P0 # 8410-68115-5 (05031819-1)

Phase II, Randomized, Pharmacokinetic, Dose Finding and Dose Frequency Determination Using rt-PA in Intraventricular Hemorrhage
PI: Byron Bailey  Sponsor: Johns Hopkins Univ.  Total: $ 26,600
Dept: Neurosciences  Award: FD-R-001693 (05031823-1)

Mauldin, Patrick
Co-Investigator
Interventional Management of Stroke Ill Planning Grant
PI: Yuko Palesch  Sponsor: Univ. of Cincinnati  Total: $ 21,904
Dept: Biostatistics, Bioinformatics and Epidemi  Award: R34-NS049722-01 (03121201-1)

Cefepime-Ceftriaxone Switch Study in Adult Medicine Patients with CrCl <60 ml/min
PI: Marlea Givens  Sponsor: Elan Pharmaceuticals  Total: $ 32,208
Dept: Pharmacy and Clinical Services  Award: (04091401-1)

Mazyck, Pamela
Co-PI or Project Leader
Understanding and Eliminating Health Disparities in Blacks in South Carolina - Project 4: Improving Care for High Risk Minority Patients with Chronic Illnesses by Using Pharmacist Consultations to Follow-up on Missed Prescription Refills
PI: Barbara Tilley  Sponsor: AHCPR/AHRQ  Total: $ 161,000
Dept: Biostatistics, Bioinformatics and Epidemi  Award: 5 P01 HS010871-05 (04052807-8)

Ragucci, Kelly
Principal Investigator
Life after the WHI: Evaluation of Postmenopausal Symptoms and Use of Alternative Therapies After Discontinuation of Hormone Therapy
Sponsor: Procter and Gamble  Budget Dates: 04/01/05 - 12/31/05  Direct: $ 5,000
Award: (05061355)  Project Dates: 04/01/05 - 12/31/05  F & A: 0

Young, Vicki
Co-PI or Project Leader
Understanding and Eliminating Health Disparities in Blacks in South Carolina - Pilot Project 4: Pain Management of Elderly African American Patients with Cancer in the Community Setting
PI: Barbara Tilley  Sponsor: AHCPR/AHRQ  Total: $ 58,606
Dept: Biostatistics, Bioinformatics and Epidemi  Award: 5 P01 HS010871-05 (04052807-10)
University Centers

Investigators and Projects
### Center for Drug and Alcohol Programs

**Neurosciences**

Woodward, John  
*Training in Alcohol Research*

- **Sponsor:** NIH/NIAAA  
- **Award:** 5 T32 AA007474-18 (04120246)  
- **Budget Dates:** 04/01/05 - 03/31/06  
- **Project Dates:** 09/30/87 - 03/31/08  
- **Direct:** $274,500  
- **F & A:** 20,045

**Psychiatry and Behavioral Sciences**

Acrierno, Ron  
*Florida Hurricanes and Older Adults: Outcome/Resiliency Factors*

- **Sponsor:** NIH/NIMH  
- **Award:** 1 R21 MH074469-01 (04092819)  
- **Budget Dates:** 03/04/05 - 02/28/06  
- **Project Dates:** 03/01/05 - 02/28/07  
- **Direct:** $184,524  
- **F & A:** 31,402

Deas, Deborah  
*A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg and 30mg) in the Treatment of Child and Adolescent Patients, Ages 10-17 Years, with Bipolar I Disorder, Manic, or Mixed Episode with or without Psychotic Features*

- **Sponsor:** Ingenix  
- **Award:** 31-03-240 (05041306)  
- **Budget Dates:** 04/15/05 - 06/30/07  
- **Project Dates:** 04/15/05 - 06/30/07  
- **Direct:** $207,248  
- **F & A:** 51,812

Miller, Peter  
*Adoption of Pharmacotherapy in Alcoholism Treatment*

- **Sponsor:** NIH/NIAAA  
- **Award:** 1 R21 AA015065-01 (03092606)  
- **Budget Dates:** 09/28/04 - 08/31/05  
- **Project Dates:** 09/28/04 - 08/31/06  
- **Direct:** $143,750  
- **F & A:** 66,125

Randall, Carrie  
*Alcohol Research Center-Treatment and Implications-Pilot Core*

- **Sponsor:** NIH/NIAAA  
- **Award:** 5 K08 AA010761-10 (04110554)  
- **Budget Dates:** 01/01/05 - 12/31/05  
- **Project Dates:** 01/01/05 - 12/31/05  
- **Direct:** $1,266,442  
- **F & A:** 533,558

**Paroxetine for Social Anxiety Disorder and Alcoholism**

- **Sponsor:** NIH/NIAAA  
- **Award:** 5 R01 AA013379-04 (04123019)  
- **Budget Dates:** 03/01/02 - 02/28/06  
- **Project Dates:** 03/01/02 - 02/28/06  
- **Direct:** $257,809  
- **F & A:** 110,858

### Center for Health Care Research

**Medicine**

Egede, Leonard  
*Collaborative Management of Diabetes in Blacks*

- **Sponsor:** AHCPR/AHRQ  
- **Award:** 5 K08 HS011418-04 (04022610)  
- **Budget Dates:** 07/01/04 - 06/30/05  
- **Project Dates:** 07/01/04 - 06/30/06  
- **Direct:** $90,950  
- **F & A:** 7,276

### Center for the Study of Aging

**Neurosciences**

Granholm, Ann-Charlotte  
*Aged Forebrain Cholinergic Neurons-Estrogen and NGF*

- **Sponsor:** NIH/NIA  
- **Award:** 5 R01 AG12122-10 (04070119)  
- **Budget Dates:** 09/01/04 - 08/31/06  
- **Project Dates:** 09/01/04 - 08/31/06  
- **Direct:** $234,040  
- **F & A:** 60,217
**Neurosciences**

Granholm, Ann-Charlotte  
**Mechanisms of Neurotrophin Improved Cognition in Aging**  
Sponsor: NIH/NIA  
Award: 5 R01 AG010755-11 (04070125)  
Budget Dates: 09/01/04 - 08/31/05  
Project Dates: 09/29/01 - 08/31/08  
Direct: $194,000  
F & A: 89,240

Sambamurti, Kumar  
**Regulation and Cell Biology of Beta-Secretase**  
Sponsor: NIH/NIA  
Award: 1 R01 AG023055-01A1 (03112401)  
Budget Dates: 09/30/04 - 06/30/09  
Project Dates: 09/29/91 - 08/31/08  
F & A: 75,440

**Medicine**

Castell, Donald  
**Combined, Multichannel, Intraluminal Impedance and pH (MII-pH) Studies to Characterize Gastroesophageal Reflux on Acid Suppressive Therapy in Healthy Volunteers**  
Sponsor: AstraZeneca  
Award: IRUSESMO297 (05020912)  
Budget Dates: 02/01/05 - 01/31/06  
Project Dates: 02/01/05 - 01/31/06  
Direct: $68,988  
F & A: 17,247

**Does Administration of Standard Esomeprazole 40 mg Granules through a PEG Tube Effectively Suppress Gastric Acid Production?**  
Sponsor: AstraZeneca  
Award: 5 R21 DK065154-02 (05040888)  
Budget Dates: 05/01/05 - 04/30/06  
Project Dates: 05/01/05 - 04/30/06  
Direct: $100,000  
F & A: 44,620

Cotton, Peter  
**Planning Grant for SODIII Multi-Center Trial**  
Sponsor: NIH/NIDDK  
Award: 1 R03 DK069328-01 (04102002)  
Budget Dates: 09/30/04 - 01/31/06  
Project Dates: 09/30/04 - 01/31/06  
Direct: $100,000  
F & A: 0

**Boston Scientific Fellowship V**  
Sponsor: Boston Scientific Corp.  
Award: (04080504)  
Budget Dates: 08/01/04 - 07/31/05  
Project Dates: 08/01/04 - 07/31/05  
Direct: $46,296  
F & A: 3,704

Delegge, Mark  
**Comprehensive Management of Patients Diagnosed with Pancreatitis and Discharged from the Hospital on Home-Infusion Therapy**  
Sponsor: Coram Healthcare, Inc.  
Award: (04102002)  
Budget Dates: 11/01/04 - 10/31/05  
Project Dates: 11/01/04 - 10/31/05  
Direct: $9,206  
F & A: 2,302

Hoffman, Brenda  
**A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis**  
Sponsor: Otsuka Medical Research Inst.  
Award: 197-02-218 (03061206)  
Budget Dates: 03/28/03 - 06/03/06  
Project Dates: 03/28/03 - 06/03/06  
Direct: $20,896  
F & A: 5,224

**Endoscopic Clinical Research in Pancreatic and Biliary Diseases**  
Sponsor: Amer. College of Gastroenterology  
Award: (04012901)  
Budget Dates: 07/01/04 - 06/30/05  
Project Dates: 07/01/04 - 06/30/05  
Direct: $35,000  
F & A: 0

**A Phase III, Multi-Center, 52-Week, Open-Label, extension Study of the Safety and Efficacy of 25 mg or 50 mg of OPC-6535 Oral Tablets in the Treatment of Subjects with Ulcerative Colitis**  
Sponsor: SFBC Intl.  
Award: OPC-6535 (04102707)  
Budget Dates: 11/01/04 - 02/28/06  
Project Dates: 11/01/04 - 02/28/06  
Direct: $17,920  
F & A: 4,480

**A Phase III, Multi-Center, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn’s Disease Subjects Who Have Previously Participated in Natalizumab Crohn’s Disease Study CD351**  
Sponsor: Elan Pharmaceuticals  
Award: ELN100226-CD354 (05031074)  
Budget Dates: 02/23/05 - 08/31/07  
Project Dates: 02/23/05 - 08/31/07  
Direct: $24,048  
F & A: 6,012
Wilson, Frederick

A Phase III, Multi-National, Multi-Center, Open Label, 52 Week, Safety Study to Assess the Safety of Re-Exposure after a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc (dosed at weeks 0, 2 and 4 then 4-weekly to Week 48), in the Treatment of Patients with Active Crohn’s Disease Who Have Previously Been Withdrawn from Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn’s Disease

Sponsor: Icon Clinical Research, Inc.
Award: CDP870-033 (04012203)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN-002 (crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)

Sponsor: Trine Pharmaceuticals
Award: TRN-002 (04102706)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Nine Weeks Administration of Three Doses of SB-683699 in Subjects with Moderately-To-Severe Active Crohn’s Disease

Sponsor: Pharma Link FHI, Inc.
Award: SB-683699 (05020914)

Biochemistry and Molecular Biology

Del Poeta, Maurizio

Roles for Inositol Phosphoryl Ceramide Synthase 1 (IPC1) in Fungal-Host Interaction

Sponsor: Burroughs Wellcome Fdn.
Award: 1003642 (01103103)

Fernandes, Daniel

Drug-Induced Destabilization of Bcl-2 mRNA

Sponsor: NIH/NCI
Award: 1 R01 CA109254-01A1 (04062912)

Hannun, Yusuf

Sphingolipids in Cancer Therapy and Angiogenesis - Project 1: Sphingolipids and Chemotherapy-Induced Apoptosis

Sponsor: NIH/NCI
Award: 1 P01 CA97132-02 (01100808)

Development of Structural and Chemical Biology

Sponsor: SC Research Authority
Award: EPS-0132573 (02060503)

Ogretmen, Besim

Regulation of Telomerase By Ceramide in Lung Cancer

Sponsor: NIH/NCI
Award: 5 R01 CA088932-04 (04011404)

Cell and Molecular Pharmacology

Tew, Kenneth

Glutathione S-Transferases in Drug and Stress Response

Sponsor: NIH/NCI
Award: 2 R01 CA085660-06 (04062907)

Glutathione S-Transferases in Drug and Stress Response

Sponsor: NIH/NCI
Award: 7 R01 CA085660-06 (04072201)
# Cell and Molecular Pharmacology

**Determinants of Estramustine Resistance and Response**  
Tew, Kenneth  
**Sponsor:** NIH/NCI  
**Award:** 7 R01 CA083778-06 (04072202)  
**Budget Dates:** 05/01/04 - 02/28/06  
**Direct:** $174,890  
**F & A:** $80,449

**Preclinical Development of a Novel Glutathione Based Anticancer Drug**  
**Sponsor:** SC EPSCOR  
**Award:** TASK ORDER#0011 (04092102)  
**Budget Dates:** 09/01/04 - 11/30/04  
**Direct:** $8,000  
**F & A:** $0

---

# Dean's Office - COM

**Hollings Cancer Center Building Expansion**  
Reed, Carolyn  
**Sponsor:** Natl. Inst. of Standards and Techno  
**Award:** 60NANB00073 (03051603)  
**Budget Dates:** 01/01/04 - 12/31/04  
**Direct:** $1,850,000  
**F & A:** $0

**DOD Phase VI: Project 14- Ellagic Acid, an Esophageal Cancer Prevention Agent**  
**Sponsor:** Geo-Centers, Inc.  
**Award:** GC-3532-03-42153CM (03080703)  
**Budget Dates:** 09/02/03 - 08/28/05  
**Direct:** $1,349,415  
**F & A:** $468,136

---

# Medicine

**Role of Novel Oncogene in Mesothelioma**  
Boylan, Alice  
**Sponsor:** NIH/NIEHS  
**Award:** R01 ES011323-03 (05041919)  
**Budget Dates:** 06/01/05 - 05/31/06  
**Direct:** $166,250  
**F & A:** $76,475

**A Phase III, Randomized, Multi-Center Study of Cetuximab, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Oxaliplatin, 5-Fluorouracil and Leucovorin in Patients with Previously Treated Metastatic, EGFR-Positive Colorectal Carcinoma**  
Brescia, Frank  
**Sponsor:** PPD Development  
**Award:** CA225-014 (04070209)  
**Budget Dates:** 10/20/04 - 10/25/09  
**Direct:** $95,880  
**F & A:** $23,970

**Phase II Trial of Oxaliplatin and Gemcitabine in Patients with Unresectable Hepatocellular Carcinoma**  
**Sponsor:** Sanofi Synthelabo, Inc.  
**Award:** OX-03-088 (04102703)  
**Budget Dates:** 11/10/04 - 12/31/06  
**Direct:** $115,217  
**F & A:** $28,804

**A Phase II Study of XELOX in Locally Advanced or Metastatic Gastric Cancer**  
**Sponsor:** Sanofi Synthelabo, Inc.  
**Award:** OX-03-088 (04102702)  
**Budget Dates:** 11/10/04 - 12/31/06  
**Direct:** $61,850  
**F & A:** $15,463

**A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine, and Bevacizumab Followed by Radical Cystectomy for Patients with Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder**  
**Sponsor:** Genentech, Inc.  
**Award:** AVF3172 (05061044)  
**Budget Dates:** 04/30/05 - 06/30/10  
**Direct:** $61,850  
**F & A:** $15,463

**A Randomized Open-Label Study of 400 mg Versus 800 mg of STI571 in Patients with Newly Diagnosed Chronic Myelogenous Leukemia (CML-CP) (CTO100908)**  
**Sponsor:** Novartis Corp.  
**Award:** STI571K 2301-515 (05062951)  
**Budget Dates:** 04/30/05 - 06/30/10  
**Direct:** $61,850  
**F & A:** $15,463

**Low-Fat Diet in Stage II Breast Cancer**  
**Sponsor:** Institute For Cancer Prevention  
**Award:** CA45504-15 (04080203)  
**Budget Dates:** 01/01/04 - 12/31/04  
**Direct:** $5,850  
**F & A:** $2,691

**A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (CTO 100881)**  
**Sponsor:** NSABP  
**Award:** NSABP-B-35 (05050275)  
**Budget Dates:** 05/01/04 - 04/30/08  
**Direct:** $20,103  
**F & A:** $397
Medicine

Kraft, Andrew

Oncology Center: Hollings Cancer Translational Research Core Development Grant
Sponsor: DOE
Award: DE FG02 01ER63121 (04042303) Budget Dates: 07/01/04 - 06/30/05 Direct: $232,878
Project Dates: 07/01/04 - 06/30/07

Hollings Cancer Center Planning Grant
Sponsor: NIH/NCI
Award: 3 P20 CA093282-03S1 (04051101) Budget Dates: 08/01/04 - 07/31/05 Direct: $181,480
Project Dates: 08/24/04 - 07/31/05

Hollings Cancer Center Building Addition
Sponsor: HRSA
Award: 1 C76HF03130-01-00 (04052001) Budget Dates: 09/01/04 - 12/31/06 Direct: $6,889,117
Project Dates: 09/01/04 - 12/31/06

Hollings Cancer Center Building Addition
Sponsor: Natl. Inst. of Standards and Techno
Award: 60NANB00073 (04060104) Budget Dates: 09/01/04 - 12/31/05 Direct: $13,852,684
Project Dates: 09/01/04 - 12/31/05

Pim 1 Protein Kinase as a Target for Drug Discovery
Sponsor: NIH/NCI
Award: 7 R21 CA095183-03 (04070202) Budget Dates: 06/16/04 - 03/31/06 Direct: $34,384
Project Dates: 06/16/04 - 03/31/06

Mechanisms by which Proteasome Enhance Apoptosis
Sponsor: NIH/NCI
Award: 7 R01 CA104710-01 (04070203) Budget Dates: 06/15/04 - 02/29/06 Direct: $164,000
Project Dates: 06/15/04 - 02/29/08

Overcoming Resistance of Prostate Cancer to TRAIL - Mediated Apoptosis
Sponsor: DOD
Award: DAMD17-01-1-0045 (04072703) Budget Dates: 06/15/04 - 11/30/05 Direct: $30,174
Project Dates: 06/15/04 - 11/30/05

Pim Protein Kinase - Levels Correlate with Prostate Tumor Growth and Chemo-Resistance - Potential Mechanisms of Pim Action
Sponsor: DOD/US Army
Award: W81XWH-05-1-0126 (04082311) Budget Dates: 11/30/04 - 11/29/05 Direct: $130,087
Project Dates: 11/30/04 - 11/29/07

VELCADE (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer
Sponsor: Millennium Pharmaceuticals
Award: 00-1218 (04092903) Budget Dates: 08/01/04 - 12/31/07 Direct: $163,310
Project Dates: 08/01/04 - 12/31/07

Proposal for Cancer Prevention and Control Program for Reducing Tobacco-Related Malignancies in South Carolina
Sponsor: CDC
Award: H75/CCH424532-01 (04093015) Budget Dates: 03/01/05 - 08/30/06 Direct: $2,103,489
Project Dates: 09/01/05 - 08/31/06

Phase I Trial of Bortezomib (VELCADE TM) and Celecoxib in Patients with Advanced Solid Tumors
Sponsor: Millennium Pharmaceuticals
Award: i605-341-03 (04111273) Budget Dates: 11/15/04 - 11/15/07 Direct: $143,263
Project Dates: 11/15/04 - 11/15/07

DOD Phase VII: A Clinical Assessment of Novel Urinary Markers for Diagnosis and Monitoring of Bladder Cancer Patients
Sponsor: Geo-Centers, Inc.
Award: GC-3609-04-43766CM (04111322) Budget Dates: 10/01/04 - 09/29/05 Direct: $919,888
Project Dates: 10/01/04 - 09/29/06

Mechanisms by Which Proteasome Enhance Apoptosis
Sponsor: NIH/NCI
Award: 5 R01 CA104710-02 (05011903) Budget Dates: 03/01/05 - 02/28/06 Direct: $164,000
Project Dates: 06/15/04 - 02/29/08

A Randomized, Multi-Center, Open-Label Study of YONDELIS ET-743 (ecteinascidin) Administered by Two Different Schedules (Weekly for 3 or 4 Weeks vs. q3 Weeks) in Subjects with Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment with an Anthracycline and Ifosfamide
Sponsor: Johnson and Johnson
Award: ET743-STS-201 (05031588) Budget Dates: 03/04/05 - 03/15/07 Direct: $67,525
Project Dates: 03/04/05 - 03/15/07

2005 Supporting the Safety Net
Sponsor: Avon Foundation
Award: (05040166) Budget Dates: 05/01/05 - 04/30/06 Direct: $150,909
Project Dates: 05/01/05 - 06/01/07

Annual Report for Research FY2005 129
**Medicine**

**Nelson, Kristine**  
*Music Therapy for Cancer Patients at the End-Of-Life*  
Sponsor: NIH/NCI  
Award: 7 R21 CA096516-03 (04080902)  
Budget Dates: 09/10/04 - 04/30/06  
Direct: $150,000

**Schweinfest, Clifford**  
*Models of DRA Growth Suppression in Colon Cancer*  
Sponsor: NIH/NCI  
Award: 5 R01 CA095172-02 (04050402)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $178,000

**Silvestri, Gerard**  
*Computer-Aided Cancer Management*  
Sponsor: DOD  
Award: W81XWH-05-1-0376 (04070126)  
Budget Dates: 04/01/05 - 03/31/06  
Direct: $2,519,875

**Stuart, Robert**  
*A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations*  
Sponsor: Cephalon, Inc.  
Award: C0701A204/ON/US (04072605)  
Budget Dates: 08/02/04 - 07/31/06  
Direct: $66,631

**Microbiology and Immunology**

**Tomlinson, Stephen**  
*Complement Inhibitors and Immunotherapy*  
Sponsor: NIH/NCI  
Award: 5 R21 CA104579-02 (05031604)  
Budget Dates: 04/01/04 - 03/31/06  
Direct: $90,000

**Obstetrics and Gynecology**

**Creasman, William**  
*An Open-Label, Multi-Center, Randomized, Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX Alone in Subjects with Advanced Relapsed Ovarian Cancer*  
Sponsor: PPD Development  
Award: ET743-OVA-301 (05042023)  
Budget Dates: 04/18/05 - 04/30/08  
Direct: $93,713

**Kohler, Matthew**  
*A Phase III, Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian tube Carcinoma (d)*  
Sponsor: Eli Lilly  
Award: B9E-US-S302 (D) (04102202)  
Budget Dates: 10/15/04 - 10/15/06  
Direct: $30,011

**Pathology and Laboratory Medicine**

**Hsu, Tien**  
*VHL and FGFR Signaling In Angiogenesis*  
Sponsor: NIH/NCI  
Award: 1 R01 CA109860-01 (03110302)  
Budget Dates: 07/01/04 - 06/30/05  
Direct: $205,000

**Watson, Dennis**  
*Role of an Epithelial Ets factor in Breast Cancer*  
Sponsor: NIH/NCI  
Award: 5 R01 CA102297-02 (04041601)  
Budget Dates: 07/01/04 - 04/30/05  
Direct: $222,500
### Pathology and Laboratory Medicine

**Watson, Dennis**  
**The Role of Thromboxane A2 in Bladder Cancer**  
**Sponsor:** NIH/NCI  
**Award:** 5 R21 CA106570-02 (05012748)  
**Budget Dates:** 04/01/05 - 03/31/06  
**Direct:** $90,000  
**F & A:** 41,400

### Pediatrics

**Barredo, Julio**  
**Molecular Correlates of Methotrexate in Childhood ALL**  
**Sponsor:** Wayne State Univ.  
**Award:** 5 R01 CA076641-08 (05022258)  
**Budget Dates:** 01/01/05 - 12/31/05  
**Direct:** $18,964  
**F & A:** 8,724

**Molecular Determinants of Methotrexate Metabolism in ALL**  
**Sponsor:** NIH/NCI  
**Award:** 5 R01 CA098152-02 (05030331)  
**Budget Dates:** 05/01/05 - 04/30/06  
**Direct:** $205,000  
**F & A:** 94,300

### Pharmaceutical Sciences

**Hall, Philip**  
**Diphtheria Fusion Protein Therapy of AML**  
**Sponsor:** Wake Forest University  
**Award:** R01 CA76178 (05031712)  
**Budget Dates:** 01/01/03 - 12/31/05  
**Direct:** $5,890  
**F & A:** 2,710

**Targeting Protein Synthesis in AML**  
**Sponsor:** Wake Forest University  
**Award:** R01 CA90263 (05031713)  
**Budget Dates:** 03/01/04 - 02/28/06  
**Direct:** $6,705  
**F & A:** 3,085

### Radiation Oncology

**Jenrette, Joseph**  
**Radiation Therapy Oncology Group Protocol: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Vs Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer**  
**Sponsor:** Amer. Coll. of Radiology  
**Award:** U10 CA21661 (05050587)  
**Budget Dates:** 06/15/05 - 12/31/07  
**Direct:** $122,674  
**F & A:** 12,826

**Sharma, Anand**  
**Phase III, Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine (SR259075) Versus Concomitant Radiation and Cisplatin in Patients with Advanced Head and Neck Cancer**  
**Sponsor:** Sanofi Synthelabo, Inc.  
**Award:** EFC 5512 (05031501)  
**Budget Dates:** 03/21/05 - 03/20/08  
**Direct:** $166,300  
**F & A:** 41,577

### Radiology

**Conway, William**  
**ACRIN Trials**  
**Sponsor:** Amer. Coll. of Radiology  
**Award:** CA80098 (02091903)  
**Budget Dates:** 07/01/02 - 12/31/10  
**Direct:** $922,200  
**F & A:** 163,759

### Surgery

**Cole, David**  
**Altering Post-Vaccination T Cell Contraction**  
**Sponsor:** NIH/NCI  
**Award:** 2 R01 CA083672-04A1 (03102901)  
**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $180,000  
**F & A:** 82,800

**A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node Positive Breast Cancer Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DDAC->P); DD AC Follow**  
**Sponsor:** NSABP  
**Award:** TFED34-#361 (05042855)  
**Budget Dates:** 11/01/04 - 01/31/08  
**Direct:** $986  
**F & A:** 99

**Investigator Salary Support for NSABP Member Industrial Master Purchased Services Treatment Protocols**  
**Sponsor:** NSABP  
**Award:** (05050275)  
**Budget Dates:** 05/01/05 - 04/30/08  
**Direct:** $2,696  
**F & A:** 270
Surgery

Reed, Carolyn

**Oncology Center: Human Tissue Procurement Service and Tumor Bank**

**Sponsor:** DOE  
**Budget Dates:** 07/01/04 - 06/30/05  
**Direct:** $103,896

**DOD Phase VI: Project 19**

**Sponsor:** Geo-Centers, Inc.  
**Budget Dates:** 09/01/04 - 08/28/05  
**Direct:** $25,642

**Biochemistry and Molecular Biology**

Gross, Paul

**Analysis of a New and Potentially Multi-Functional Antimicrobial Peptide Family Identified in the Pacific White Shrimp, Litopenaeus Vannamei**

**Sponsor:** USDA  
**Budget Dates:** 01/01/04 - 12/31/06  
**Direct:** $86,501

**Identification and Functional Characterization of Toll-Like Family of Pathogen Receptors from the Pacific White Shrimp Litopenaeus Vannamei**

**Sponsor:** USDA  
**Budget Dates:** 01/15/04 - 01/14/06  
**Direct:** $41,478

**Utilization of Reagents and Tools for Genomic Analysis Related to Shrimp Research**

**Sponsor:** SC Dept. of Natural Resources  
**Budget Dates:** 09/01/04 - 08/31/06  
**Direct:** $142,857

**Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp**

**Sponsor:** NSF  
**Budget Dates:** 08/15/03 - 08/31/05  
**Direct:** $112,051

**Duck Antibody Genes: Unusual Organization Expression**

**Sponsor:** NIH/NIAID  
**Budget Dates:** 06/01/99 - 11/30/07  
**Direct:** $125,000

**Subcontract to NOAA’s Establishment of a National Oceanic and Atmospheric Administration Center of Excellence in Oceans and Human Health within the Hollings Marine Laboratory at Charleston, SC**

**Sponsor:** NOAA  
**Budget Dates:** 09/01/04 - 08/31/05  
**Direct:** $211,567

**Cell Biology and Anatomy**

Chapman, Robert

**Analysis of mtDNA and Microsatellite Data (Ann Chen contract)**

**Sponsor:** SC Dept. of Natural Resources  
**Budget Dates:** 04/01/05 - 07/31/05  
**Direct:** $7,176

Lacy, Eric

**Hollings Visiting Scholar Award**

**Sponsor:** Jardon and Howard Tech.  
**Budget Dates:** 05/17/05 - 09/30/05  
**Direct:** $45,286
### Cell Biology and Anatomy

**Lewitus, Alan**  
**Analysis of Algal Toxins (Wes Jackson)**  
- **Sponsor:** SC Dept. of Natural Resources  
- **Award:** 345704 (05031717)  
- **Budget Dates:** 03/01/05 - 06/30/05  
- **Direct:** $3,000

**Morris, Pamela**  
**Environmental Assessment of Bunker C Crude Oil Leaking from the USS Arizona**  
- **Sponsor:** National Park Service  
- **Award:** H1250020008-J7482040441 (04080505)  
- **Budget Dates:** 08/14/04 - 12/31/05  
- **Direct:** $34,777

### Dean’s Office - COM

**Chapman, Robert**  
**EPA Fellowship Award**  
- **Sponsor:** EPA  
- **Award:** U-91618501-1 (04061603)  
- **Budget Dates:** 08/01/04 - 08/01/05  
- **Direct:** $35,335

### Psychiatry and Behavioral Sciences

**De Arellano, Michael**  
**Coordinating Services for Child Sexual Assault Victims**  
- **Sponsor:** SC Dept. of Public Safety  
- **Award:** 1V05061 (04111582)  
- **Budget Dates:** 04/01/05 - 03/31/06  
- **Direct:** $66,498

**Henggeler, Scott**  
**Effectiveness Trial: MST with Juvenile Offenders - Minority Supplement**  
- **Sponsor:** NIH/NIMH  
- **Award:** 5 R01 MH065414-03 (05011251)  
- **Budget Dates:** 03/01/05 - 02/28/06  
- **Direct:** $68,995

**Kilpatrick, Dean**  
**Disaster Research Education and Mentoring Center (DREM)**  
- **Sponsor:** NIH/NIMH  
- **Award:** 5 R25 MH070552-02 (04120773)  
- **Budget Dates:** 01/01/05 - 12/31/05  
- **Direct:** $250,000

**Rheingold, Alyssa**  
**Specialized Services for Homicide Survivors**  
- **Sponsor:** SC Dept. of Public Safety  
- **Award:** 1V05115 (04111070)  
- **Budget Dates:** 04/01/05 - 03/31/06  
- **Direct:** $42,172

### Neurosciences

**Gregory, Mary**  
**Prefrontal Glutamate and Working Memory**  
- **Sponsor:** NIH/NIDA  
- **Award:** 5 F30 MH070194-02 (04063016)  
- **Budget Dates:** 09/30/03 - 06/29/07  
- **Direct:** $25,321

**Jayanthi, Lankupalle**  
**Cocaine Regulation of Norepinephrine Transporter**  
- **Sponsor:** NIH/NIDA  
- **Award:** 1 R03 DA16753-01A1 (03063004)  
- **Budget Dates:** 08/01/04 - 07/31/05  
- **Direct:** $50,000

**Kalivas, Peter**  
**NIDA Invest International Visiting Scientists and Technical Exchange Program**  
- **Sponsor:** NIH/NIDA  
- **Award:** (03100201)  
- **Budget Dates:** 10/01/04 - 09/30/05  
- **Direct:** $36,000

**Glutamate and Craving for Cocaine**  
- **Sponsor:** NIH/NIDA  
- **Award:** 2 R01 DA012513-06 (04062905)  
- **Budget Dates:** 02/01/05 - 03/31/10  
- **Direct:** $175,000
### Neurosciences

**Therapeutic Potential of Galantamine in Alzheimer's Disease**
- **Sponsor:** Janssen Pharmaceutica
- **Award:** (04063008)
- **Budget Dates:** 09/01/04 - 08/31/05
- **F & A:** $5,980

**Purification of Cord Blood Stem Cells**
- **Sponsor:** CureSource, Inc.
- **Award:** (05012005)
- **Budget Dates:** 01/17/05 - 12/31/05
- **F & A:** $2,400

**Neural Bases of Drug Context-Induced Cocaine Seeking**
- **Sponsor:** NIH/NIDA
- **Award:** 1 R01 DA017673-01A1 (04022305)
- **Budget Dates:** 02/05/05 - 06/01/05
- **F & A:** $17,420

**Metabotropic Glutamate Receptors Mediate Cocaine Relapse**
- **Sponsor:** NIH/NIDA
- **Award:** 1 F31 DA018486-01 (03121008)
- **Budget Dates:** 09/01/04 - 08/31/07
- **F & A:** 0

**Rod Neurodegenerative and Protective-Genes**
- **Sponsor:** NIH/NEI
- **Award:** 5 R01 EY013520-04 (04052501)
- **Budget Dates:** 08/01/04 - 07/31/06
- **F & A:** $75,250

**Regulation of BACE in DIGs**
- **Sponsor:** Axonyx USA
- **Award:** IIRG-01-3062 (02121708)
- **Budget Dates:** 04/01/04 - 03/31/05
- **F & A:** 7,272

**Effects of Cholinergic Drugs on APP Metabolism**
- **Sponsor:** NIH/NIAAA
- **Award:** 5 R01 AA009986-11 (05011365)
- **Budget Dates:** 04/01/05 - 10/31/05
- **F & A:** 63,250

### Ophthamology

**Transgenic Rod Development and Function**
- **Sponsor:** NIH/NEI
- **Award:** 5 R03 EY013728-02 (04042001)
- **Budget Dates:** 07/01/04 - 06/30/05
- **F & A:** $100,000

### Psychiatry and Behavioral Sciences

**Ethanol Dependence and Stress Effects on Ethanol Drinking**
- **Sponsor:** NIH/NIAAA
- **Award:** 5 U01 AA014095-02 (03122902)
- **Budget Dates:** 03/01/04 - 02/28/05
- **F & A:** 91,825

---

134 Annual Report for Research FY2005